A Pillai, MR, 1123(ab)
Abdel-Dayem, HM, 7
Abdi, H, 823(ab)
Abe, A, 948(ab), 959(ab), 1003(ab)
Abe, S, 1747
Abe, Y, 822(ab)
Abele, JT, 1200(ab)
Abend, M, 588(ab)
Abi-Dargham, A, 218(ab), 226(ab), 228(ab), 812(ab)
Abidov, A, 7(ab)
Aboul-Enein, FA, 743(ab)
Abourbeh, G, 161(ab)
Abraham, L, 828(ab)
Abramsky, O, 862(ab)
Abu Al-Huda, F, 909(ab)
Aburano, T, 475, 768(ab), 1207(ab), 1250(ab)
Acampa, W, 1023
Acar, P, 601(ab)
Accorsi, R, 1240(ab)
Acharya, KC, 449(ab)
Achong, DM, 1233(ab)
Achten, E, 63(ab)
Acil, Y, 557(ab)
Ackermann, RJ, 1264(ab)
Acton, P, 389(ab), 852(ab), 853(ab), 854(ab)
Acton, PD, 1890, 377(ab)
Adachi, H, 1604, 515(ab)
Adachi, I, 53(ab), 900(ab)
Adam, L-E, 1340
Adams, GP, 941(ab)
Adams, KH, 943(ab)
Adams, T, 1102(ab)
Adamson, KL, 490(ab)
Adelstein, JS, 111(ab)
Adelstein, SJ, 1083(ab), 1095(ab), 125(le), 1945
Adenis, A, 79(ab)
Adler, LP, 120(ab), 198(ab), 271(ab), 296(ab), 455(ab), 941(ab), 1026(ab), 1033(ab)
Adriaensen, T, 1007(ab)
Aerts, J, 533
Afroze, A, 159(ab)
Afroze, F, 1290(ab)
Agarval, AK, 1263
Agarwal, S, 1209(ab)
Agdeppa, ED, 222(ab)
Ageyeva, L, 89(ab), 150(ab), 156(ab), 1068(ab), 1073(ab), 1326(ab)
Agostini, D, 526, 1414(ab)
Agostini, J, 836(ab)
Agrawal, D, 383(ab)
Aguadé-Bruix, S, 1884
Ahamed, TB, 774(ab)
Ahn, BC, 758(ab)
Ahn, SH, 542(ab), 790(ab), 1060(ab), 1309(ab), 1410(ab)
Ahonen, AK, 1368(le)
Aicher, A, 6(ab)
Aide, N, 1397(ab), 1398(ab), 1414(ab)
Aides, N, 1392(ab)
Aikawa, T, 1339(ab)
Ak, İ, 658(le)
Akabani, G, 382(ab), 792, 1827
Akdemir, ÜÖ, 475(ab)
Akeboshi, M, 1381(ab)
Akhurst, T, 1290(ab)
Akhurst, TA, 424(ab)
Akhurst, TJ, 82(ab)
Akin, A, 1380(ab)
Akioka, K, 1030
Akita, Y, 49(ab), 864(ab)
Akkermans, J, 1007(ab)
Aktas, A, 763(ab), 1286(ab)
Al-Muqbel, K, 405(ab), 1418(ab)
Al-Shammeri, I, 1199(ab)
Ala, A, 409(ab)
Aladl, U, 743(ab)
Aladl, UE, 1156
Alauddin, MM, 168(ab), 1061(ab), 1079(ab), 1108(ab)
Alavi, A, 2000, 57(ab), 72(ab), 105(ab), 142(ab), 184(ab), 235(ab), 267(ab), 301(ab), 410(ab), 426(ab), 464(ab), 479(ab), 517(ab), 532(ab), 574(ab), 589(ab), 611(ab), 612(ab), 726(ab), 852(ab), 853(ab), 854(ab), 920(ab), 946(ab), 953(ab), 988, 1059(ab), 1081(ab), 1191(ab), 1196(ab), 1211(ab), 1231(ab), 1364(ab), 1366(ab), 1367(ab), 1390(ab), 1408(ab), 1409(ab), 1421(ab), 1451(ab), 1456(ab), 1478(ab), 1485(ab), 1486(ab), 1488(ab)
Alavi, AA, 503(ab), 604(ab)
Alazraki, N, 134
Alberini, J, 1081(ab)
Albers, FWJ, 341
Albers, P, 568(ab)
Aldegueri, EB, 1147(ab)
Alexander, M, 42(ab), 215(ab), 805(ab), 810(ab)
Alexanderson, E, 777(ab)
Alexoff, D, 798(ab), 800(ab), 802(ab)
Alexoff, DA, 1522
Alexoff, DL, 225(ab), 451(ab), 780(ab), 782(ab), 815, 1239(ab)
Aliaga, A, 1334(ab), 1655
Aliyari Zenooz, N, 1176(ab)
Allende, RH, 357(ab)
Allman, KC, 1194(le)
Almeida, O, 19(ab), 200(ab), 290(ab), 770(ab), 972(ab)
Almeida, OD, 1350, 773(ab)
Almo, K, 555(ab)
Alonso, O, 1561
Alpert, NM, 217(ab), 1012(ab)
AlSaadi, R, 909(ab)
Alsabeh, R, 440(ab), 1402(ab), 1496(ab)
Alsharif, A, 1468(ab)
Altes, TA, 1277(ab)
Altman, H, 1200
Altmann, A, 973, 1316(ab), 1319(ab), 1324(ab)
Amano, M, 974(ab)
Amendola, A, 1253
Ameshima, S, 540
Ametamey, SM, 1210
Amin, KC, 938(ab)
Amit, A, 421(ab)
Ammann, RW, 138(ab)
Amonchot, A, 1625
Ampela, K, 413(ab)
Amthauer, H, 394(ab), 876(ab)
Amyotte, G, 1200(ab)
Andel, M, 1218(ab)
Anderson, A, 1102(ab)
Anderson, CJ, 1284
Anderson, GS, 301(ab)
Anderson, J, 353(ab)
Anderson, ME, 31(ab)
Ando, A, 1717, 277(ab), 719(ab)
Andreadis, B, 1486(ab)
Andreev, O, 1105(ab)
Andrews, DA, 1258(ab)
Andrews, P, 324(ab)
Andriole, GL, 549
Ang, KK, 1157(ab)
Angileri, FF, 1566
Ansari, MS, 113(ab)
Anstett, F, 1039(ab)
Antich, PP, 523(ab), 528(ab)
Antoch, G, 75(ab), 270(ab), 561(ab), 933(ab), 986(ab), 1344(ab), 1354(ab)
Anton, M, 86(ab), 704(ab)
Antonini, A, 397(ab)
Antos, D, 1246(ab)
Aoyama, H, 883(ab)
Apostodidis, C, 579(ab)
Apostolidis, C, 588(ab)
Aquino, S, 1396(ab)
Arahata, Y, 822(ab)
Arai, H, 1010(ab), 1037(ab)
Arango, V, 1110(ab), 1111(ab)
Arano, Y, 4(ab), 1092(ab)
Arao, T, 1747
Aras, G, 1287(ab)
Araujo, LI, 726(ab)
Arcement, J, 1110(ab), 1111(ab)
Archer, CN, 1029(ab)
Archimandritis, S, 1028(ab)
Arena, V, 409(ab), 1213(ab)
Arevalo, S, 573(ab)
Arnold, R, 238(ab), 446(ab), 493(ab), 1362(ab)
Aronen, HJ, 487
Arrigoni, GL, 264(ab)
Artioli, D, 245(ab)
Asada, T, 1243, 830(ab)
Asano, D, 701(ab)
Asano, T, 842(ab)
Asenbaum, S, 806(ab)
Ash, S, 1243(ab), 1248(ab)
Ashby, SP, 352(ab)
Askienazy, S, 474(ab)
Askoxylakis, V, 1297(ab)
Assmus, B, 174(ab)
Aston, PJ, 392(ab)
Atilla, B, 1481(ab)
Atkinson, LA, 1066(ab)
Attie, S, 346(ab), 765(ab)
Atuahene, NF, 1323(ab)
Aubert, B, 492(ab), 1169(ab)
Audenaert, K, 163
Auerbach, M, 351(ab)
Augeri, C, 478(ab)
Austin-Seymour, MM, 1411(ab)
Avlonitis, V, 1171(ab)
Avogaro, A, 477(ab)
Axelrod, D, 7
Axworthy, D, 1292(ab)
Axworthy, DB, 1284, 437, 576(ab)
Azhdarinia, A, 319(ab), 322(ab), 1071(ab), 1077(ab), 1078(ab), 1082(ab), 1084(ab), 1158(ab)

Baas, J, 1007(ab)
Babich, JW, 154(ab), 162(ab), 164(ab), 166(ab), 703(ab), 774(ab), 1055(ab), 1090(ab), 1100(ab), 1128(ab)
Babin, E, 526
Bacetti, N, 280(ab)
Bacharach, SL, 201(ab), 266(ab)
Backer, JM, 1069(ab)
Backer, MV, 1069(ab)
Backus, WW, 1239(ab), 1522
Badawi, RD, 77(ab), 197(ab), 1014(ab)
Baden, M, 173(ab)
Bading, JR, 152(ab), 977(ab)
Badorf, C, 6(ab)
Bae, SA, 603(ab), 812(ab)
Bae, SK, 1437(ab)
Bae, YT, 1373(ab)
Baehre, M, 73(ab), 418(ab), 733(ab), 1023(ab), 1224(ab)
Baek, D, 1447(ab)
Baek, HJ, 1371(ab)
Baer, F, 1157(ab)
Baeuml, S, 897(ab)
Bagga, A, 1261(ab)
Baghaei, H, 1000(ab), 1015(ab), 1018(ab), 1019(ab)
Bagheri, B, 296(ab)
Bagnera, R, 606(ab)
Bagni, B, 1394(ab)
Bagni, I, 1394(ab)
Bahk, YW, 1182(ab), 1278(ab)
Bai, C, 194(ab), 970(ab), 1855
Bai, Y, 1294(ab)
Baidoo, KE, 321(ab)
Bailey, DL, 358(ab), 386(ab), 490(ab), 1046(ab)
Bailey, J, 1142(ab)
Baiocco, C, 409(ab), 1213(ab)
Baird, WH, 207(ab)
Bakale, G, 594(ab)
Bakchine, S, 1013
Baker, GE, 946(ab)
Bakker, PFA, 336
Bakker, WH, 442(ab), 1146(ab)
Bakthula, R, 299(ab)
Bal, CS, 383(ab), 486(ab), 1209(ab), 1242(ab)
Bal, H, 369(ab)
Balatoni, J, 150(ab), 156(ab), 1068(ab), 1073(ab), 1326(ab)
Balbach, T, 21(ab)
Baldari, S, 1566
Baldessarini, RJ, 166(ab), 1055(ab)
Baldwin, RM, 119(ab), 220(ab)
Ballangrud, AM, 260
Ballani, N, 909(ab), 1199(ab)
Ballanrud,AM, 1543(le)
Ballardin, M, 1164(ab)
Ballinger, JR, 11, 1037
Balogh, JM, 244(ab)
Balogh, LP, 1094(ab)
Balogh, P, 1094(ab)
Balon, H, 299(ab)
Balon, HR, 848(ab), 1218(ab)
Balter, HS, 1368(le)
Baltuch, G, 389(ab)
Bander, NH, 101(ab), 429(ab), 430(ab), 610, 1093(ab), 1155(ab), 1167(ab), 1173(ab), 1385(ab)
Bandopadhayaya, GP, 383(ab), 1209(ab), 1261(ab)
Banerjee, D, 93(ab)
Banerjee, SR, 154(ab), 162(ab), 164(ab), 1100(ab)
Bang, HY, 1399(ab)
Banzo, I, 357(ab)
Bao, A, 1097(ab), 1992
Bar-Haim Erez, A, 862(ab)
Bar-Sever, Z, 1243(ab), 1248(ab)
Bar-Shalom, R, 1200, 65(ab), 242(ab), 421(ab), 436(ab), 1214(ab)
Barale, R, 1164(ab)
Bardiès, M, 1163(ab)
Bardou, V-J, 1232
Bares, R, 114(ab), 191(ab), 212(ab), 438(ab), 563(ab), 1304(ab)
Barker, D, 1475(ab)
Barnden, LR, 206(ab)
Baron, JC, 833(ab)
Barquero, R, 1172(ab)
Barranger, E, 407(ab)
Barrett, HH, 58, 525(ab), 705(ab), 1307(ab)
Barrio, JR, 222(ab), 333(ab), 431(ab), 1325(ab)
Barron, BJ, 1818
Bars, E, 1101(ab)
Bart, J, 801(ab)
Bartel, T, 139(ab), 473(ab), 1244(ab)
Bartenstein, P, 109, 493(ab), 595(ab), 929(ab), 939(ab), 1184(ab), 1424(ab)
Barth, I, 1170(ab)
Barth, RF, 110(ab)
Bartlett, JC, 823(ab)
Bartlett, RM, 230(ab)
Bartolomei, M, 444(ab)
Bartsch, P, 1386(ab)
Basdemir, G, 1394
Bash, S, 1190(ab)

Bass, CS, 1406(ab)
Bass, L, 22(ab), 1206(ab), 1862
Bastidas, D, 610, 1093(ab), 1173(ab)
Bateman, TM, 279(ab), 356(ab), 507(ab)
Batra, SK, 1970
Batraki, M, 101(ab)
Battelli, LA, 484(le)
Battmann, A, 551(ab)
Baud, M, 485(le)
Bauer, A, 1682
Bauer, B, 107(ab)
Bauer, S, 75(ab)
Bauhofer, A, 551(ab)
Baulieu, J-L, 663
Baum, RP, 1156, 203(ab), 400(ab), 484(ab)
Baumert, BG, 24
Baumstark, JM, 345(ab)
Bax, J, 10(ab), 11(ab)
Bax, JJ, 127, 140, 877
Bayés-Genís, A, 179(ab)
Bayhan, H, 1024(ab)
Beanlands, RS, 169(ab), 714(ab)
Beattie, B, 378(ab), 424(ab), 1308(ab), 1845
Beauchemin, D, 1240(ab)
Beaulieu, S, 882(ab), 913(ab), 1044, 1389(ab)
Beaumont, J, 1483(ab)
Bebi, M, 413(ab)
Becherer, A, 234(ab), 567(ab)
Beck, D, 421(ab)
Beck, S, 1335(ab)
Becker, G, 114(ab)
Becker, GA, 117
Becker, K, 1336(ab)
Becker, KF, 579(ab), 588(ab)
Becker, W, 1298(ab)
Bedoucha, P, 55(ab)
Beekman, FJ, 522(ab)
Beer, A, 1336(ab)
Begleiter, H, 213(ab)
Behe, M, 1298(ab)
Béhé, M, 28(ab), 91(ab), 317(ab), 446(ab), 1320(ab)
Béhé, MP, 238(ab), 448(ab), 551(ab), 869(ab), 1425(ab), 1461(ab)
Behr, TM, 28(ab), 91(ab), 238(ab), 317(ab), 446(ab), 448(ab), 551(ab), 739(ab), 869(ab), 1298(ab), 1320(ab), 1362(ab), 1425(ab), 1461(ab)
Beiline, D, 1026(ab)
Belakhlef, A, 961
Belanger, MJ, 1021(ab)
Belhocine, T, 1386(ab)
Bell, T, 1047(ab)
Bellò, M, 409(ab), 1213(ab)
Bellandi, F, 746(ab)
Bellaviti, N, 406(ab)
Bellemann, ME, 966(ab)
Beller, GA, 1092
Bellon, N, 492(ab)
Bělohlávek, O, 1784
Ben-David, I, 161(ab)
Ben-Haim, S, 183(ab), 355(ab), 996(ab)
Ben-Nun, A, 242(ab), 436(ab)
Benada, A, 176(ab), 178(ab), 734(ab), 767(ab), 771(ab)
Bénard, F, 285(ab), 565(ab), 985(ab), 1225, 1334(ab), 1390(ab), 1655
Bencherif, B, 211(ab)
Bencivelli, V, 1008(ab)
Bender, BR, 1141(ab)
Bender, D, 1359(ab)
Bendriem, B, 360(ab), 452(ab)
Benelhadj, S, 181(ab)
Bengel, F, 21(ab)
Bengel, FM, 704(ab)
Benjamin, C, 505(ab)
Benkelfat, C, 895(ab)
Bennaghmouch, A, 5(ab)
Benninga, MA, 1099
Bennink, RJ, 136(ab), 140(ab), 1099
Bensadoun, H, 1414(ab)
Benti, R, 397(ab), 889(ab)
Bentourkia, M, 285(ab), 1655
Benveniste, H, 1522
Benveniste, HD, 1239(ab)
Benya, FF, 977(ab)
Bequignon, A, 526
Bereliani, A, 8(ab)
Beresten, T, 150(ab), 156(ab), 1068(ab)
Berezov, A, 1081(ab)
Bergara, F, 94(ab), 97(ab)
Berger, F, 1135(ab)
Berger, ML, 167(ab), 504(ab), 1132(ab)
Bergsneider, M, 384(ab), 885(ab), 1709
Bergstrom, JO, 1136(ab)
Berman, DS, 7(ab), 743(ab), 1633
Bernal, P, 573(ab)
Bernard, BF, 98
Bernard, F, 411(ab)
Bernardo, M, 887(ab)
Bernd, L, 257(ab), 258(ab)
Berndt, W, 987(ab)
Berner, U, 1065, 174(ab)
Bernik, S, 7
Berry, M, 169(ab)
Bertagna, F, 175(ab)
Bertrand, ME, 60(ab)
Beryt, M, 1333(ab)
Besch, OF, 559
Besenfelder, H, 1304(ab)
Best, AL, 242(ab)
Betman, L, 242(ab)
Bettan, M, 1307(ab)
Bettinsoli, G, 1198(ab)
Bettman, L, 470(ab)
Beu, M, 618
Beuter, D, 551(ab)
Bevilacqua, G, 501(ab)
Beyer, T, 360(ab), 561(ab), 933(ab), 986(ab), 1344(ab)
Beylin, D, 455(ab)
Beysens, AJ, 5(ab)
Bezard, E, 663
Bhargava, KK, 147(ab)
Bhargava, P, 184(ab), 589(ab), 726(ab), 1196(ab), 1364(ab), 1390(ab), 1486(ab), 1488(ab)
Bhat, S, 1284(ab)
Bhatnagar, V, 1209(ab)
Bhattachayra, M, 1411(ab)
Bhaumik, S, 1329(ab)
Bhutani, C, 184(ab), 589(ab), 726(ab), 1364(ab), 1488(ab)
Bianchi, F, 562(ab)
Bianco, JA, 1872(le)
Bibat, G, 47(ab)
Biegon, A, 809(ab)
Bielack, S, 997(le)
Bien-Aime, W, 751(ab)
Biermann, M, 476(ab)
Biersack, HJ, 568(ab), 572(ab), 1072(ab), 1460(ab), 1815
Bigner, DD, 382(ab)
Bijan, B, 135(ab)
Bijl, M, 146(ab)
Bilger, K, 1340
Bilir, E, 475(ab)
Bird, NJ, 1037
Bischof Delaloye, A, 71(ab), 349(ab), 351(ab)
Bishop, HA, 484(le)
Bisi, G, 409(ab), 1213(ab)
Bjelke, D, 961
Blagosklonov, O, 485(le)
Blahd, WH, 988
Blair, J, 814(ab)
Blake, GM, 490(ab), 891
Blanco, HP, 1113
Blankenberg, F, 587(ab)
Blankenberg, FG, 92, 501(ab), 582(ab), 583(ab), 783(ab), 1069(ab)
Blasberg, R, 89(ab), 93(ab), 108(ab), 150(ab), 156(ab), 1308(ab), 1845
Blasberg, RG, 85(ab), 1326(ab)
Bläuenstein, P, 71(ab), 1210, 1649
Blaufox, MD, 404(ab)
Bleeker-Rovers, CP, 144(ab), 1118(ab)
Bleichrodt, RP, 578(ab)
Blend, MJ, 961(ab), 1300(ab)
Blevis, I, 602
Blezer, EL, 522(ab)
Block, S, 33
Blond, S, 1413(ab)
Blondel, A, 157(ab), 318(ab)
Bloomfield, PM, 992(ab), 1047(ab)
Bluemke, DA, 463(ab)
Blumenfeld, H, 836(ab)
Blumenthal, R, 353(ab)
Blumenthal, RD, 67
Blumstein, N, 252(ab), 403(ab)
Blumstein, NM, 432(ab), 433(ab)
Boada, M, 835(ab)
Bocher, M, 862(ab), 1260(ab)
Bockisch, A, 75(ab), 270(ab), 561(ab), 933(ab), 1166(ab), 1344(ab), 1354(ab)
Bodei, L, 444(ab), 1164(ab)
Bodenstein, C, 86(ab)
Boecker, H, 856(ab)
Boeckxstaens, GE, 1099
Boehm, H, 484(ab)
Boekstegers, P, 339(ab)
Boellaard, R, 936(ab), 967(ab), 1271, 1663
Boening, G, 530(ab)
Boerman, OC, 102(ab), 103(ab), 316(ab), 317(ab), 400, 498(ab), 499(ab), 500(ab), 559(ab), 578(ab), 853(le), 1087, 1118(ab), 1502, 1663, 1690, 1707(le)
Boerner, AR, 1445(ab), 1473(ab)
Boersma, E, 140
Boersma, HH, 5(ab), 391, 509(ab)
Boggi, U, 134(ab)
Bohnen, NI, 50(ab), 398(ab), 837(ab)
Bohuslavizki, KH, 930
Boisgard, R, 157(ab), 318(ab)
Bok, B, 657(le)
Bokemeyer, C, 567(ab)
Bolch, WE, 774, 1113
Boles Ponto, LL, 1141(ab)
Bolzati, C, 806
Bom, HS, 323(ab), 401(ab), 485(ab), 487(ab), 496(ab), 508(ab), 571(ab), 1087(ab), 1139(ab)
Bomanji, J, 81(ab)
Bomanji, JB, 420(ab), 1178(ab), 1400(ab)
Bommer, M, 614(ab)
Bonab, AA, 217(ab), 1012(ab), 1109(ab), 1313(ab)
Bonaduce, D, 1023
Boni, G, 134(ab), 562(ab), 1008(ab), 1443, 1468(ab)
Bonte, FJ, 826(ab), 832(ab)
Bontron, R, 981
Bonuccelli, U, 396(ab)
Bonvin, F, 71(ab), 1649
Bonyadlou, S, 1186(ab)
Boobis, AR, 483(le)
Booker, JA, 1262(ab)
Booltink, E, 103(ab)
Bora, NS, 1122(ab)
Borbély, K, 817(ab), 839(ab)
Boreham, DR, 154(ab), 1100(ab)
Borg, M, 55(ab)
Borges-Neto, S, 134
Borgognoni, L, 548(ab)
Börjesson, PKE, 1690
Bormans, G, 613(ab)
Bormans, GM, 269, 1075, 1086(ab), 1973
Bornmann, W, 424(ab), 1068(ab), 1073(ab)
Borowitz, MJ, 273(ab)
Boschi, A, 806
Boschi, S, 134(ab), 396(ab), 1422(ab)
Bossuyt, A, 286(ab), 459(ab), 993(ab), 1013(ab), 1489
Botkin, N, 987(ab)
Bottet, P, 1414(ab)
Bottlaender, M, 596, 708(ab)
Botvinick, EH, 748(ab)
Boucher, L, 565(ab)
Bouchet, LG, 1113
Boudousq, V, 1013
Bouma, HM, 437(ab)
Bounds, MC, 521(ab), 975(ab)
Bountioukos, MA, 877
Bourdeau, I, 128(ab), 471(ab)
Bouterfa, H, 493(ab), 1464(ab), 1556
Bouvard, G, 1414(ab)
Bouvet, F, 1274(ab), 1275(ab)
Bowman, R, 778(ab)
Bowman, RR, 599(ab)
Bowsher, JE, 583
Boy, C, 1682
Bozkurt, A, 119(ab)
Bozkurt, MF, 1185(ab), 1377(ab)
Bozluolcay, S, 1368(ab)
Bozorgzadeh, MH, 152(ab)
Bradshaw, J, 56(ab)
Bradshaw, ML, 1029(ab)
Brady, RO, 1253
Brandman, S, 429(ab), 430(ab), 1155(ab)
Brandt-Mainz, K, 1166(ab)
Brasic, J, 215(ab)
Brasic, JR, 42(ab), 47(ab), 805(ab), 810(ab)
Brasse, D, 364(ab), 1855
Brechbiel, MW, 577(ab), 632, 1105, 1330(ab)
Breeman, WAP, 98, 1315
Brefel-Courbon, C, 847(ab)
Breithardt, G, 510(ab)
Breitz, H, 494(ab)
Breitz, HB, 453(ab)
Bremner, JD, 855
Brenner, A, 67, 2000
Brenner, AI, 1220(ab)
Brenner, W, 6(ab), 247, 315(ab), 489(ab), 559, 930, 1217(ab)
Brenot-Rossi, I, 1232
Breton, V, 1032(ab), 1048(ab)
Breuer, R, 202(ab)
Breyer, RJ, 1221(ab)
Breyholz, HJ, 709(ab)
Bridwell, RS, 1361(ab), 1427(ab)
Brill, AB, 335(ab)
Bristow, R, 1404(ab)
Bristow, RE, 422(ab), 423(ab)
Britten, M, 174(ab)
Britton, KE, 317(le), 658(le), 944(ab), 955(ab)
Britz-Cunningham, SH, 1945
Broft, A, 214(ab)
Broisat, A, 981
Bronfman, F, 269
Brooks, DJ, 386(ab)
Brouwers, AH, 103(ab), 559(ab)
Brown, KM, 970(ab)
Brown, ML, 1234(ab)
Brown, PH, 1544(le)
Brown, RP, 463(ab)
Brown-Proctor, C, 814(ab)
Bruckbauer, T, 360(ab)
Bruehlmeier, M, 1210
Bruland, OS, 252
Brümmer, C, 247
Brunken, RC, 938(ab)

Brunkhorst, T, 1445(ab)
Bruyant, PP, 1038(ab)
Bryan, R, 481(ab), 1030(ab)
Bryant, J, 1077(ab)
Bryant, JL, 319(ab), 1071(ab), 1082(ab), 1084(ab), 1158(ab)
Bublitz, T, 484(le), 993(le)
Bublitz, TP, 205(ab), 511(ab), 518(ab)
Buchegger, F, 71(ab), 1649
Buchert, R, 375, 902(ab)
Buchheimer, N, 814(ab)
Buchheimer, NC, 521(ab), 715(ab), 975(ab)
Buchholz, H-G, 109
Buchholz, HG, 493(ab), 595(ab), 939(ab)
Buchsbaum, DJ, 434
Buchwald, DS, 816(ab)
Buck, A, 732
Buck, AK, 252(ab), 403(ab), 432(ab), 614(ab), 1426
Budach, V, 875(ab)
Budach, W, 563(ab)
Budak-Alpdogan, T, 93(ab)
Budinger, TF, 809(ab)
Buell, U, 33, 274(ab), 592(ab)
Buffoni, F, 1253
Buhtani, C, 426(ab)
Buijs, WC, 102(ab), 103(ab), 559(ab)
Buijs, WCAM, 1690, 1707(le)
Bujenovic, LS, 1482(ab)
Bülow, H, 21(ab)
Bulte, JW, 710(ab)
Burak, Z, 1394
Burger, C, 78(ab), 146, 732
Burgess, AW, 100(ab)
Burggasser, G, 1547
Burnette, J, 134
Burrows, W, 1335(ab)
Burt, RW, 700
Burton, J, 2000
Bury, T, 1386(ab)
Buscombe, JR, 1, 237(ab), 445(ab), 539(ab), 1263(ab), 1465(ab), 1466(ab), 1474(ab)
Bushnell, D, 1244(ab), 1464(ab), 1495(ab), 1556
Bushnell, DL, 232(ab)
Bussone, R, 409(ab)
Buursma, AR, 106(ab), 1700
Buus, S, 1359(ab)
Buvat, I, 1184, 40(ab), 55(ab), 125(ab), 201(ab), 1032(ab)
Buxton-Thomas, MS, 963(ab)
Buyukasik, Y, 1481(ab)
Byas-Smith, MG, 855
Byck, C, 169(ab)

Cabrejas, ML, 994(ab)
Cachin, F, 411(ab), 1625
Cadenas, J, 349(ab)
Cadorette, J, 1655
Cahill, JM, 727(ab)
Cai, S, 378(ab)
Calcagni, M, 203(ab)
Caldwell, CB, 122(ab), 244(ab)
Camacho, V, 179(ab), 1283(ab), 1372(ab)
Cameron, R, 1469
Camici, PG, 510(ab), 1662
Camin, L, 482(ab)
Camp, VM, 151(ab)
Campbell, GT, 1544(le)
Campbell, Jr, PD, 199(ab), 590(ab)
Campbell, SK, 405(ab), 1418(ab)
Canclini, S, 175(ab)
Candell-Riera, J, 731(ab)
Caner, B, 1377(ab)
Cangemi, V, 1219
Cano, C, 446
Canpolat, NA, 1024(ab)
Canter, RJ, 410(ab)
Cao, B, 580(ab)
Cao, Z, 27(ab)
Capello, A, 98
Caplin, ME, 1, 237(ab), 445(ab), 1465(ab), 1474(ab)
Capoccetti, F, 1040(ab)
Caporizzo, E, 264(ab)
Cappele, O, 1414(ab)
Caraccio, N, 1164(ab)
Carasquillo, JA, 201(ab)
Caravaglia, GM, 408(ab)
Cardali, S, 1566
Cardi, C, 532(ab), 946(ab), 953(ab), 1890
Cardi, CA, 1340
Cardillo, T, 575(ab)
Cardot, J-C, 485(le)
Carey, M, 94(ab), 97(ab), 98(ab)
Carletto, M, 406(ab)
Carlin, S, 1827
Carlisle, T, 1464(ab), 1556
Carlsen, IC, 192(ab)
Carney, J, 360(ab), 364(ab), 983(ab), 991(ab)
Carpenter, M, 1159(ab)
Carpentier, P, 79(ab)
Carrasquillo, JA, 266(ab), 1091(ab), 1112(ab)
Carreras, JL, 1301
Carretta, R, 735(ab), 741(ab), 742(ab)
Carretta, RF, 754(ab)
Carrió, I, 179(ab), 1283(ab), 1372(ab)
Carril, JM, 357(ab)
Carroll, MJ, 944(ab), 955(ab)
Carroll, RG, 451
Carson, JM, 201(ab), 266(ab)
Carson, RE, 35(ab), 62(ab), 1330
Carter, EA, 1109(ab), 1313(ab)
Carter, P, 1239(ab), 1522
Carty, J, 1101(ab)
Casadevall, A, 481(ab), 1030(ab)
Casara, D, 477(ab), 1181(ab), 1183(ab), 1443
Case, JA, 279(ab), 356(ab), 507(ab)
Caselles, O, 1044(ab)
Casey, ME, 360(ab)
Casolo, A, 1394(ab)
Castagnoli, A, 548(ab)
Castell-Conesa, J, 1884
Castellani, M, 406(ab)
Castellon, SA, 828(ab)
Castellone, P, 245(ab)
Castellucci, P, 1422(ab)
Castiglioni, I, 245(ab)
Castrillon, J, 226(ab)
Cataldo, D, 533, 1386(ab)
Cattaneo, M, 245(ab)
Caussin, C, 761(ab)
Caveliers, V, 1013(ab), 1489
Ceballos-Baumann, A, 856(ab)
Cebon, J, 100(ab)
Ceravolo, R, 396(ab)
Ceresoli, GL, 245(ab)
Cerfolio, RJ, 1269(ab), 1406(ab)
Cerqueira, M, 134
Cerquerra, AM, 573(ab)
Cerulli-Switzer, J, 499
Cerveri, G, 889(ab)
Ceylan, E, 1267(ab)
Ceyssens, S, 947
Chacko, A, 166(ab)
Chacko, TK, 142(ab), 1211(ab)
Chae, WS, 1103(ab)
Chai, L, 937(ab), 984(ab)
Chakrabarti, A, 915
Chalabi, I, 1335(ab)
Chalam, G, 84(ab)
Chalon, S, 219(ab), 663
Chaly, T, 961
Cham, D, 241(ab)
Chan, A, 1402(ab)
Chan, DC, 441(ab)
Chan, P, 770(ab)
Chan, WS, 978(ab)
Chandrashekar, N, 383(ab)
Chang, CH, 575(ab), 1293(ab)
Chang, CP, 172(ab), 380(ab), 419(ab), 1416(ab)
Chang, CW, 155(ab), 544(ab)
Chang, HM, 1432(ab)
Chang, KH, 1006, 874(ab)
Chang, S, 346(ab), 765(ab)
Chang, SM, 1133(ab)
Chang, T, 1429(ab)
Chang, TC, 1387(ab)
Chang, Y, 1429(ab)
Chang, YS, 1054(ab)
Channing, M, 1152(ab)
Channing, MA, 1056(ab)
Chao, C, 1045(ab)
Chao, CK, 1082(ab)
Chao, EH, 123(ab)
Chapman, JD, 1153(ab)
Chapman, N, 499
Chapman, SB, 832(ab)
Chappell, B, 100(ab)
Charania, M, 1396(ab)
Charon, Y, 407(ab)
Charron, M, 1240(ab), 1247(ab), 1254(ab), 1257(ab), 1586, 1855
Charron, MJ, 702(ab)
Chatal, J-F, 2000
Chatal, JF, 1076(ab)
Chattopadhyay, S, 229(ab), 606(ab), 608(ab), 811(ab), 1051(ab)
Chatziioannou, AF, 1962
Chaudakshetrin, P, 1161(ab)
Che, J, 89(ab)
Cheema, A, 132(ab), 133(ab)
Chella, A, 562(ab)
Chen, CC, 1544(le)
Chen, CH, 370(ab), 932(ab)
Chen, CY, 844(ab)
Chen, FD, 544(ab)
Chen, H, 290(ab), 972(ab)
Chen, IY, 2(ab), 337(ab)
Chen, J-T, 1775
Chen, JC, 155(ab), 313(ab), 370(ab), 544(ab), 932(ab), 999(ab)
Chen, JH, 313(ab)
Chen, JT, 1430(ab)
Chen, K, 1083(ab), 1095(ab)
Chen, LB, 1321(ab)
Chen, M, 452(ab), 982(ab)
Chen, MN, 1145(ab)
Chen, MY, 348(ab), 727(ab)
Chen, P, 1469
Chen, S, 910(ab), 1220(ab)
Chen, SL, 104(ab), 804(ab), 1255(ab)
Chen, W, 52(ab), 341(ab), 857(ab), 1121(ab)
Chen, X, 152(ab)
Chen, Y, 525(ab), 1153(ab)
Chen, YJ, 1412(ab)
Cheng, C-Y, 999
Cheng, HW, 1106(ab), 1133(ab)
Cheng, KY, 1204(ab)
Cheng, PM, 415(ab)
Cheng, Z, 320(ab)
Cheon, GJ, 542(ab), 790(ab), 1309(ab), 1371(ab), 1388(ab), 1399(ab), 1453(ab), 1472(ab)
Cheon, JH, 1103(ab)
Cheon, KA, 891(ab), 893(ab)
Cherry, SR, 1027(ab)
Chesnay, E, 526
Cheung, NK, 576(ab), 1301(ab)
Chevalier, X, 1225(ab)
Chi, DY, 808(ab), 1054(ab), 1060(ab), 1126(ab), 1140(ab)
Chiacchio, S, 1468(ab)
Chiang, S, 267(ab), 532(ab)
Chiang, Y-H, 999
Chida, Y, 1228(ab)
Chilvers, ER, 11
Chin, BB, 273(ab), 309(ab), 710(ab)
Chinol, M, 444(ab), 478(ab)
Chiou, YH, 1256(ab)
Chisin, R, 161(ab), 202(ab), 470(ab), 862(ab), 1260(ab)
Chitambar, CR, 943
Chiti, A, 871(ab), 1149(ab), 1407(ab)
Chitimus, B, 961(ab)
Chittenden, S, 1044(ab)
Chiu, SB, 832(ab)
Cho, BK, 535(ab)
Cho, CS, 1125(ab), 1129(ab)
Cho, I, 1337(ab)
Cho, S, 861(ab)
Cho, SB, 1440(ab)
Cho, SC, 892(ab)
Cho, SS, 819(ab), 892(ab)
Cho, YS, 542(ab), 1309(ab)
Choe, YS, 66(ab), 67(ab), 513(ab), 819(ab), 870, 1099(ab), 1126(ab), 1226(ab), 1345(ab)
Choi, C-W, 347
Choi, CW, 542(ab), 790(ab), 1060(ab), 1309(ab), 1371(ab), 1388(ab), 1399(ab), 1453(ab), 1472(ab)
Choi, HK, 921(ab)
Choi, JY, 67(ab), 870, 1345(ab)
Choi, KY, 1006
Choi, S, 1360(ab)
Choi, S-C, 347
Choi, S-R, 1890
Choi, SR, 325(ab)
Choi, TH, 1212(ab)
Choi, Y, 66(ab), 67(ab), 513(ab), 819(ab), 870, 992(ab), 1099(ab), 1126(ab), 1226(ab), 1345(ab)
Choi, YS, 66(ab)
Choi, YY, 861(ab)
Chollet, F, 847(ab)
Chong, G, 100(ab)
Choong, WS, 454(ab)
Chotipanich, C, 426(ab), 1254(ab), 1408(ab)
Chou, H-H, 1775
Chou, HH, 1387(ab)
Chou, KL, 313(ab), 419(ab), 932(ab)
Chou, Y-H, 999
Chou, YH, 794(ab)
Choudhury, SK, 762(ab)
Chow, BJ, 744(ab), 772(ab)
Christian, B, 606(ab)
Christian, BT, 811(ab), 1051(ab)
Christodoulidou, I, 413(ab)
Chrousos, GP, 813(ab)
Chroustova, D, 1218(ab)
Chu, D, 1433(ab)
Chu, KW, 469(ab)
Chu, LS, 172(ab), 419(ab), 1251(ab), 1416(ab)
Chu, YK, 172(ab), 419(ab), 1416(ab)
Chugani, DC, 39(ab), 373(ab)
Chugani, HT, 39(ab), 373(ab)
Chun, H, 200(ab), 480(ab), 1387
Chun, K, 1337(ab)
Chun, KH, 1099(ab)
Chun, KS, 1060(ab)
Chung, CK, 1006
Chung, H-W, 316(le), 1874(le)
Chung, HK, 790(ab)
Chung, J-K, 1006, 1435, 1735, 2033
Chung, JK, 12(ab), 16(ab), 46(ab), 58(ab), 61(ab), 87(ab), 88(ab), 90(ab), 130(ab), 401(ab), 535(ab), 540(ab), 571(ab), 602(ab), 737(ab), 808(ab), 818(ab), 841(ab), 868(ab), 874(ab), 892(ab), 957(ab), 1054(ab), 1117(ab), 1130(ab), 1197(ab), 1203(ab), 1205(ab), 1342(ab), 1350(ab), 1457(ab)
Chung, JW, 2033
Chung, KY, 1440(ab)
Chung, SK, 821(ab), 851(ab), 1182(ab), 1278(ab)
Chung, WS, 790(ab), 1060(ab)

Chung, YA, 821(ab), 851(ab), 1182(ab), 1278(ab)
Chuttani, K, 1076(ab)
Cinca, J, 179(ab)
Cisar, A, 1102(ab)
Civelek, AC, 353(ab)
Clairand, I, 1113
Clark, DP, 273(ab)
Clark, JC, 483(le)
Clark, PB, 814(ab), 1026(ab), 1175(ab)
Clark, TW, 574(ab)
Clarke, E, 992(le)
Clausen, M, 375
Clavien, PA, 138(ab)
Cleland, JG, 494
Clement, A, 1271(ab)
Clement, L, 1252(ab)
Clermont, DA, 1141(ab)
Cliche, JP, 77(ab)
Coaguila, C, 155, 176(ab), 177(ab), 178(ab), 734(ab), 767(ab), 771(ab)
Cobben, DC, 240(ab), 547(ab)
Cobben, DCP, 1927
Cody, D, 1045(ab)
Cody, DD, 981(ab)
Coel, M, 978(ab)
Coenen, HH, 483(le), 873(ab), 879(ab), 881(ab), 1682
Cohade, C, 128(ab), 170, 199(ab), 240, 243(ab), 273(ab), 295(ab), 310(ab), 412, 422(ab), 423(ab), 471(ab), 590(ab), 1241(ab), 1267, 1341(ab), 1403(ab), 1404(ab), 1797
Cohen, A, 862(ab)
Cohen, I, 1633
Cohen, MH, 7(ab)
Colak, T, 1286(ab)
Colas-Linhart, N, 657(le)
Colcher, D, 1433(ab)
Coleman, RE, 247(ab), 583, 926(ab), 996(ab)
Colijn, AP, 522(ab)
Colin, P, 176(ab), 177(ab), 178(ab), 181(ab), 767(ab)
Collier, AC, 1303(ab)
Collier, BD, 775(ab), 1232(ab)
Collier, TL, 1323(ab)
Collins, DA, 602
Collins, JM, 1328(ab)
Comans, EF, 554(ab), 1022(ab)
Comas, L, 485(le)
Comess, KA, 354(ab)
Comtat, C, 276, 915(ab), 1855
Comte, F, 1761
Cone, L, 271(ab), 296(ab)
Connolly, LP, 599(ab), 909
Connolly, M, 1464(ab), 1556
Connolly, SA, 909
Conrad, B, 856(ab)
Conrad, E, 882(ab)
Conrad, EU, 1340(ab)
Constans, JM, 526
Constantinescu, CC, 32(ab)
Contag, CH, 582(ab)
Conte, M, 207
Conti, M, 982(ab)
Conti, P, 241(ab), 556(ab), 1441(ab)
Conti, PS, 152(ab), 168(ab), 949(ab), 977(ab), 1061(ab), 1108(ab)
Contoreggi, C, 813(ab)
Contreras, PA, 977(ab)
Cook, AT, 1094(ab)
Cook, G, 1044(ab), 1470(ab)
Cook, GJ, 490(ab)
Cook, JL, 1510
Cook, M, 781(ab)
Cooke, CD, 278(ab), 731(ab)
Cooper, JA, 132(ab), 133(ab)
Cooper, LB, 1335(ab)
Cooper, RG, 1046(ab)
Cooper, W, 43(ab), 45(ab)
Copello, F, 1253
Coppes, RP, 801(ab)
Coppola, A, 746(ab)
Corbett, JR, 456(ab), 727(ab), 730(ab), 747(ab), 755(ab)
Corbitt, BD, 536(ab)
Corbus, HF, 1543(le)
Corcoran, B, 963(ab)
Cordes, M, 1440
Correa, R, 537(ab)
Corstens, FH, 102(ab), 103(ab), 144(ab), 316(ab), 317(ab), 427(ab), 498(ab), 499(ab), 500(ab), 559(ab), 1118(ab)
Corstens, FHM, 400, 853(le), 1087, 1502
Corvin, S, 191(ab)
Cosentino, S, 1566
Coss, R, 1293
Costa, DC, 80(ab), 81(ab), 392(ab), 420(ab), 1178(ab), 1400(ab)
Coukos, G, 1059(ab)
Coulon, C, 596
Coulot, J, 492(ab), 1169(ab)
Coupal, JJ, 1148(ab)
Courbon, F, 1044(ab)
Crabb, AH, 30(ab), 42(ab)
Crawford, JA, 1258(ab)
Cremer, M, 1682
Crémieux, A-C, 319(le), 920
Cresi, F, 1253(ab)
Cresti, N, 1468(ab)
Cristofani, R, 1164(ab)
Croasdale, IR, 81(ab)
Croasdale, J, 1465(ab)
Cross, DJ, 31(ab), 59(ab)
Cross, ME, 1179(ab), 1494(ab)
Croteau, E, 285(ab), 565(ab), 985(ab), 1655
Crow, D, 1296(ab)
Crow, JP, 1258(ab)
Crowe, RJ, 543(ab), 1156(ab)
Cruz, JM, 1122(ab)
Cuccia, C, 175(ab)
Cullom, SJ, 356(ab)
Culp, RF, 362(ab)
Cundu, B, 1277(ab)
Cuocolo, A, 1023
Curry, S, 228(ab)
Czech, N, 247, 489(ab), 559, 1217(ab)
Czech, NJ, 141(ab), 538(ab), 557(ab)
Czerniecki, BJ, 410(ab)
Czernin, J, 52(ab), 246(ab), 248(ab), 260(ab), 303(ab), 402(ab), 431(ab), 615(ab), 857(ab), 950(ab), 1016(ab), 1025(ab), 1064(ab), 1190(ab), 1238, 1325(ab), 1333(ab), 1355(ab), 1497(ab)
Czirják, S, 817(ab)
Czuczman, MS, 2000

D'Agnolo, A, 441(ab), 555(ab), 1402(ab)
D'Agnpolo, A, 440(ab)
D'Asseler, Y, 1048(ab)
D'Agnolo, A, 1369(le)
d'Hemecourt, PA, 909
Da Cunha, M, 411(ab)
Da Silva, AJ, 970(ab)
Dadachova, E, 1707(le), 481(ab), 1030(ab)
Dadparvar, S, 235(ab), 301(ab), 426(ab), 464(ab), 611(ab), 612(ab), 1408(ab)
Daftary, A, 836(ab)
Dahlberg, ST, 987(ab), 1038(ab), 1725
Dahlbom, M, 52(ab), 283(ab), 293(ab), 333(ab), 360(ab), 431(ab), 756(ab), 945(ab), 950(ab), 1016(ab), 1025(ab), 1238, 1355(ab)
Dahlerup, JF, 1359(ab)
Dai, W, 1330(ab)
Dai, ZJ, 877(ab)
Daimaru, O, 1487(ab)
Dakhel, M, 7
Dalipaj, MM, 744(ab), 772(ab)
Dalrymple, S, 585(ab)
Dam, HQ, 1265(ab)
Dambrin, G, 761(ab)
Daniela, S, 1755
Danieli, R, 359, 1040(ab)
Daniels, TM, 1277(ab)
Danjoux, CE, 122(ab), 244(ab)
Dannals, RF, 115(ab), 160(ab), 211(ab), 281(ab), 463(ab), 584(ab), 585(ab), 805(ab), 1312(ab)
Daou, D, 155, 176(ab), 177(ab), 178(ab), 181(ab), 734(ab), 767(ab), 771(ab)
Darcourt, J, 40(ab), 55(ab), 1184
Dardano, A, 1164(ab)
Darush, A, 722(ab)
Das, BK, 1202(ab)
Das, SS, 317(le)
Dasai, R, 1845
Dasan, JB, 1209(ab), 1215(ab)
DaSilva, JN, 714(ab)
Daube-Witherspoon, ME, 1340
Dauplat, J, 411(ab)
Davis, JG, 50(ab), 398(ab), 837(ab)
Davis, MR, 855
Davis, PB, 1276(ab)
Davison, A, 320(ab)
Dawant, B, 113(ab)
Day, J, 34N(4)
De Barsy, C, 596(ab), 1237(ab)
de Boer, JR, 341
De Bondt, P, 967
De Boni, D, 1561
de Bree, R, 1690
De Divitiis, O, 1566
de Dreuille, O, 125(ab)
De Filippi, PG, 1574
De Freitas, D, 411(ab)
de Geus-Oei, LF, 427(ab)
de Groot, M, 102(ab)
de Groot, TJ, 269, 1075, 1973
de Jong, IJ, 331
de Jong, LC, 1146(ab)
De Jong, M, 330(ab)
de Jong, M, 98
de Jonge, WJ, 140(ab), 1099
De Keizer, B, 1177(ab), 1188(ab)
de Keizer, B, 472(ab)
De Klerk, JM, 1177(ab), 1188(ab)
de Klerk, JM, 472(ab)
de Klerk, JMH, 336
de Labriolle Vaylet, C 657(le)
De Latour, M, 411(ab)
De León, A, 1561
De Lorenzo, A, 1633
De Meerleer, G, 1531
De Mulder, PH, 103(ab), 559(ab)
De Neve, W, 1531
De Notaris, R, 397(ab)
De Reuck, J, 63(ab)
De Rosa, V, 1761
De Santis, M, 567(ab)
De Sutter, J, 967, 1531
De Vos, F, 63(ab)
de Vries, EF, 106(ab)
de Vries, EFJ, 1700
de Vries, EGE, 184
De Winter, F, 1219(ab)
De Winter, O, 967, 1531
de Witte, PA, 1086(ab)
De Wolf-Peeters, C, 613(ab)
De, A, 97(ab), 337(ab)
Dearnaley, DP, 1470(ab)
Debatin, JF, 75(ab), 561(ab), 1344(ab), 1354(ab)
deBruine, A, 509(ab)
Debruin, SW, 961(ab)
Debruyne, J, 63(ab)
Decker, M, 112(ab)
Deckersbach, T, 894(ab)
Decristoforo, C, 708, 1375(ab)
Dede, F, 1024(ab)
Defebvre, L, 391(ab)
Defrise, M, 993(ab), 1855
Dehdashti, F, 192, 428(ab), 549, 700
Deichen, JT, 284(ab), 1315(ab)
DeJesus, OT, 230(ab)
deKemp, RA, 169(ab), 772(ab)
Dekker, B, 586(ab)
DeKosky, ST, 50(ab), 398(ab), 837(ab)
Del Guerra, A, 1008(ab)
del Mar Matarín, M, 1884
Del Vecchio, S, 1369(le)
deLabriolle-Vaylet, C, 474(ab)
Delahaye, N, 749(ab), 920
Delaloye, AB, 1649
DeLano, DA, 345(ab)
Delbeke, D, 222
Delforge, J, 706(ab)
Delgado, L, 1561
Delgado-Bolton, RC, 1301
Dell, MA, 1137(ab)
Delle Fave, G, 359
Delpon, G, 1163(ab)
Delsarte, P, 724(ab)
Delzescaux, T, 193(ab)
Demetri, GD, 77(ab)
Demmelmair, J, 1246(ab)
Demura, Y, 540
DeNardo, GL, 495(ab), 1322
DeNardo, SJ, 495(ab), 988, 1322
Dence, C, 428(ab)
Dence, CS, 367(ab), 1062(ab)
Dence/Carmen, CS, 262(ab)
Deng, HF, 1096(ab), 1107(ab), 1469(ab), 1471(ab)
Deng, WP, 1327(ab)
DeNucci, C, 119(ab)
Depas, G, 596(ab), 1237(ab)
DePuey, EG, 766(ab)
Depuey, G, 1039(ab)
DeRook, FA, 354(ab)
Destee, A, 391(ab)
Deussen, A, 641
Deutsch, G, 536(ab), 867(ab), 1353(ab)
Deverre, JR, 706(ab), 708(ab), 711(ab)
Devlin, AL, 962(ab), 964(ab)
Devous, MD, 45(ab)
Devous, Sr, MD, 43(ab), 823(ab)
Dewaraja, Y, 457
Dewey, SL, 225(ab), 802(ab)
Dewitt, JM, 74(ab)
Dey, D, 1156
Dhar, SC, 1633
Dhawale, P, 1136(ab)
Dhawan, V, 961
Di Bella, EV, 976(ab)
Di Carli, MF, 728(ab)
Di Domenico, G, 806
Di Leo, C, 1394(ab)
DiBella, EV, 369(ab), 769(ab)
Dibos, PE, 1014(ab)
DiCarli, MF, 170(ab), 756(ab)
Dichgans, M, 862
Dick, D, 230(ab)
Dickinson, C, 299(ab)
Dickinson-Rowe, KL, 56(ab)
Dickson, JC, 539(ab)
Dickson, R, 1374(ab)
Diehl, M, 572(ab), 940(ab), 1065, 1193(ab), 1460(ab), 1463(ab)
Diener, J, 940(ab), 1463(ab)
Dierckx, R, 1531
Dierckx, RA, 63(ab), 163, 1219(ab)
Dietlein, M, 255(ab)
Dietz, L, 1168(ab)
Díez-Castro, MJ, 1884
DiFilippo, FP, 359(ab), 938(ab)
Dijkgraaf, I, 316(ab)
Dijkhuizen, RM, 522(ab)
Diksic, M, 895(ab)
Dillenburg, W, 595(ab)
Dillon, MS, 119(ab)
Dilsizian, V, 280(ab), 741(ab), 774(ab)
Dimeglio, A, 1761

Dimitrakopoulou-Strauss, A, 78(ab), 203(ab), 257(ab), 258(ab), 381(ab), 556, 880(ab), 935(ab), 1319(ab), 1933
Dimitrijevic, S, 77(ab)
Dimmeler, S, 6(ab)
Dinanian, S, 749(ab)
Dinelle, KP, 1047(ab)
Ding, H, 300(ab)
Ding, HL, 1331(ab)
Ding, YS, 117(ab), 165(ab), 213(ab), 216(ab), 798(ab), 800(ab), 898(ab), 1052(ab)
Dirkmorfeld, LM, 1362(ab)
Disley, L, 586(ab)
Dispensieri, A, 569(ab)
Dittmann, H, 191(ab), 438(ab)
Dittmar, C, 107(ab), 545(ab)
Dittrich, C, 567(ab)
Divgi, C, 105(ab), 573(ab), 1478(ab)
Divgi, CR, 101(ab), 260, 1161(ab), 1543(le)
Dizendorf, E, 732
Dizendorf, EV, 24
Djang, D, 882(ab)
Dobbeleir, AA, 724(ab)
Döbert, N, 174(ab), 468(ab), 940(ab), 1065, 1193(ab), 1424(ab)
Dogan, AS, 47(ab)
Dogan, S, 42(ab), 215(ab)
Dohmen, BM, 114(ab), 438(ab), 563(ab), 567(ab)
Doi, R, 1356(ab), 1357(ab)
Dollé, F, 596, 749(ab)
Dolle, F, 157(ab), 706(ab), 708(ab), 711(ab)
Doman, FE, 1322(ab)
Donnarieix, D, 1032(ab)
Donnemiller, E, 708
Donohoe, KJ, 846
Doorn, JJ, 522(ab)
Dopichaj-Menge, U, 1180(ab)
Dorbala, S, 728(ab)
Doria, R, 478(ab)
Dorn, R, 451
Doronila, AT, 84(ab), 1220(ab)
Doss, D, 271(ab)
Doss, M, 120(ab), 198(ab), 296(ab), 455(ab), 941(ab), 1033(ab)
Dou, S, 326(ab), 1070(ab)
Doubrovin, M, 89(ab), 93(ab), 150(ab), 156(ab), 1068(ab), 1073(ab)
Doubrovin, MM, 85(ab), 1326(ab)
Doubrovina, ES, 85(ab)
Dougherty, DD, 217(ab), 894(ab)
Douglas, KA, 1328(ab)
Dourvos, O, 73(ab)
Dove, D, 84(ab)
Draghici, S, 39(ab)
Dragotakes, SD, 217(ab)
Dresel, S, 70(ab), 116(ab), 143(ab), 1347(ab), 1384(ab)
Dresse, MF, 596(ab), 1237(ab)
Dreyfuss, D, 1274(ab), 1275(ab)
Drubach, LA, 909
Drucker, W, 552(ab)
Drzezga, A, 54(ab), 856(ab), 897(ab)
Du, Y, 208(ab), 971(ab)
Duan, J, 334(ab)
Duatti, A, 806
Dubay, JW, 1492(ab)
Dubois, F, 1413(ab)
Dubois-Randé, J-L, 1459
Dudczak, R, 567(ab), 806(ab), 1741
Duet, M, 1767
Dufort, P, 53(ab), 900(ab)
Dufour, L, 506(ab)
Duhamel, A, 391(ab)
Dujardin, K, 391(ab)
Dumont, EA, 5(ab), 338(ab), 509(ab)
Dumont, F, 163
Dundar, S, 1481(ab)
Dunkelmann, S, 131(ab)
Dunnwald, LK, 249(ab), 250(ab), 594, 913(ab), 1044, 1310(ab), 1806
Dunphy, MP, 185(ab)
Dunsche, A, 557(ab)
Dupont, P, 1973, 613(ab)
Durack, LD, 1467(ab)
Durakovic, A, 1168(ab)
Durie, BGM, 1369(le)
Duysinx, B, 533, 1386(ab)
Dworkin, H, 299(ab)
Dworkin, HJ, 33N(1), 1475(ab)
Dy, CJ, 828(ab)
Dynes, A, 963(ab)
Dyszlewski, M, 149(ab)

Earle, DC, 1221(ab)
Eary, JF, 315(ab), 882(ab), 930, 1467(ab)
Ebel, G, 28(ab)
Eberl, S, 40
Eberlé, MC, 1761
Ece, T, 1368(ab)
Eckelman, W, 1333(ab)
Eckelman, WC, 62(ab), 779(ab), 784(ab), 813(ab), 1056(ab), 1152(ab), 1330
Eckerle, S, 733(ab)
Eckey, T, 6(ab)
Edell, SL, 742(ab)
Edelman, MJ, 447(ab)
Edet-Sanson, A, 598(ab)
Edvinsson, JM, 920(ab)
Edwards, DS, 316(ab), 498(ab), 1087, 1131(ab)
Eftekhari, M, 1176(ab)
Egert, S, 702(ab)
Egert, SM, 339(ab)
Eggers, B, 393(ab)
Ehrlich, LE, 244(ab)
Ehsani, AA, 345(ab)
Eicher, U, 252(ab)
Eichhorn, KW, 191(ab)
Eichhorn, W, 929(ab), 1184(ab)
Eidelberg, D, 961
Eikman, EA, 960(ab)
Eiselen, GK, 1208(ab)
Eisenbeis, PE, 367(ab)
Eisenhut, M, 1075(ab), 1113(ab), 1297(ab)
Eisner, RL, 3(ab), 776(ab)
El Fakhri, G, 197(ab), 210(ab), 973(ab)
El-Sheemy, M, 1383(ab)
Elahi, D, 1012(ab)
Elbaz, N, 1459
Elgazzar, AH, 775(ab)
Elghany, HEA, 368(ab)
Elhendy, A, 10(ab), 11(ab), 127, 877
Ell, PJ, 80(ab), 81(ab), 420(ab), 788(ab), 917(ab), 1178(ab), 1400(ab)
Ella, AL, 29(ab)
Ellars, CE, 1087
Elliott, G, 1159(ab)
Ellis, GK, 249(ab), 250(ab), 1411(ab), 1806
Ellis, JK, 1310(ab)
Ellis, PR, 700
Ellmann, A, 437(ab)
Ellner, SJ, 308(ab)
Elmaleh, DR, 502(ab)
Elsinga, PH, 223(ab), 240(ab), 331, 547(ab), 1927
Elstrom, RL, 1485(ab)
Emancipator, SN, 650
Emmanouilides, C, 615(ab), 1479(ab), 1497(ab)
Emond, P, 219(ab)
Endou, H, 244
Endres, C, 215(ab), 805(ab)
Endres, CJ, 33(ab), 34(ab)
Enezi, F, 909(ab)
Engdahl, JC, 456(ab), 747(ab)
Engel, A, 1214(ab)
Engel, M, 1249(ab)
Engeland, U, 28(ab)
Engenhart-Cabillic, R, 869(ab), 1425(ab)
Englander, S, 953(ab)
Engles, J, 295(ab)
Enmon, R, 497(ab)
Enmon, RM, Jr., 1148
Epstein, A, 556(ab)
Epstein, AL, 1079(ab)
Erba, P, 478(ab), 1253, 1443
Erbas, B, 1267(ab)
Erdi, Y, 424(ab)
Erdi, YE, 124(ab), 527(ab), 968(ab), 969(ab), 1644, 1940
Erdogan, D, 136(ab)
Erelel, M, 1368(ab)
Eremin, O, 1383(ab)
Erhardt, W, 339(ab)
Erickson, LC, 1065(ab)
Eriksson, L, 360(ab)
Eriksson, T, 1136(ab)
Erlandsson, K, 788(ab), 917(ab)
Erlank, P, 437(ab)
Ernst, M, 215(ab)
Eroglu, A, 475(ab)
Erozan, YS, 273(ab)
Erritzoe, D, 231(ab), 1053(ab)
Ersoy, Ö, 1394
Erwin, WD, 453(ab), 465, 1034(ab), 1157(ab)
Esaki, T, 779(ab), 781(ab), 784(ab)
Escanilla, E, 835(ab)
Eschmann, SM, 191(ab), 563(ab), 1304(ab)
Eschner, W, 1189(ab)
Esguerra, R, 573(ab)
Eskandar, Y, 480(ab), 1387
Eskerski, H, 1316(ab)
Espasandín, J, 1561
Esquerre, JP, 847(ab)
Esquerré, J-P, 663
Esser, PD, 1021(ab)
Essman, SC, 1510
Essner, R, 549(ab)
Estorch, M, 179(ab), 1283(ab), 1372(ab)
Eubank, WB, 1411(ab)
Evangelista, E, 1225(ab)
Evans, JW, 11
Eve, D, 961(ab)
Even-Sapir, E, 470(ab), 1413
Everaert, H, 286(ab), 1013(ab), 1489
Ewald, E, 1725
Eyrich, GK, 1382(ab)
Ezuddin, S, 751(ab)
Ezzati, M, 1176(ab)
Ezziddin, S, 568(ab), 572(ab), 1072(ab)

Faber, TL, 278(ab), 731(ab), 855
Facta, A, 289(ab)
Facta, A, 293(ab), 756(ab)
Facta, AD, 349(ab), 351(ab), 945(ab)
Faggiano, A, 492(ab)
Fagret, D, 981
Fahey, FH, 521(ab), 715(ab), 975(ab)
Faintuch, BL, 1147(ab)
Falchi, A, 359
Fan, H, 607(ab)
Fan, ML, 439(ab)
Fang, P, 604(ab), 1890
Fang, W, 180(ab), 469(ab)
Fang, YH, 911(ab)
Fanti, S, 1422(ab)
Fard Esfahani, A, 1176(ab)
Farde, L, 219(ab)
Faria, SC, 268(ab), 269(ab)
Faries, MB, 549(ab)
Farrell, R, 1000(ab), 1015(ab), 1018(ab), 1019(ab)
Farsad, M, 1422(ab)
Fassotte, M-F, 533
Fassotte, MF, 596(ab), 1237(ab)
Faulhaber, PF, 964(ab)
Fauroux, B, 1271(ab)
Fava, M, 894(ab)
Favre, C, 720(ab)
Fawwaz, R, 1323(ab)
Fazio, F, 245(ab), 264(ab)
Fei, X, 158(ab), 1065(ab)
Feigl, F, 433(ab)
Feinendegen, LE, 125(le)
Felix, R, 394(ab), 876(ab)
Feng, D, 910(ab)
Feng, H, 1862
Feng, L, 770
Feng, Q, 503(ab), 1059(ab), 1191(ab), 1409(ab)
Fenig, E, 1243(ab)
Ferdeghini, M, 1164(ab)
Fernández-Pérez, C, 1301
Fernando, GP, 958(ab)
Ferrannini, E, 682
Ferrante, S, 1208(ab)
Ferrer, L, 1163(ab)
Ferrieri, R, 800(ab), 802(ab)
Fesler, L, 525(ab)
Feußner, A, 876(ab)
Feuardent, J, 125(ab)
Feustel, PJ, 132(ab), 133(ab)
Fey, G, 1152(ab)
Feyes, DK, 650
Ficaro, EP, 456(ab), 730(ab), 747(ab), 755(ab)
Fiedelak, JI, 816(ab)
Fiedler, EM, 1423(ab)
Fielding, HW, 1232(ab)
Fietz, T, 1065
Fig, LM, 84(ab)
Fijibayashi, Y, 1305(ab)
Filocamo, M, 1253
Fimm, B, 671
Fimmers, R, 568(ab)
Fink-Bennett, D, 299(ab)
Finn, R, 101(ab), 108(ab), 150(ab), 156(ab), 378(ab), 424(ab), 1153(ab), 1326(ab), 1845
Finn, RD, 260, 1543(le), 1962
Finn, RL, 1148
Fischer, KC, 549
Fischman, A, 1396(ab)
Fischman, AJ, 217(ab), 502(ab), 894(ab), 973(ab), 1012(ab), 1109(ab), 1197, 1313(ab), 1982
Fischman, M, 214(ab)
Fishbein, MC, 337(ab)
Fisher, DR, 77, 252, 494(ab)
Fisher, RS, 302(ab)
Fishman, EK, 412
Fissekis, JD, 1061(ab), 1108(ab)
Fitschen, L, 1473(ab)
Flege, S, 997(le)
Fletcher, JW, 74(ab)
Fliss, DM, 1413
Floeth, F, 879(ab), 881(ab)
Flores, LG, 230(ab)
Floresca, J, 232(ab)
Flotats, A, 179(ab), 1283(ab), 1372(ab)
Flux, G, 1044(ab)
Foehrenbach, H, 193(ab)
Foerster, GF, 493(ab)
Fogel, EL, 74(ab)
Fogelman, I, 490(ab), 891
Foidart, J, 533, 596(ab), 1237(ab)
Folks, R, 1282(ab), 1288(ab)
Folks, RD, 278(ab), 279(ab), 356(ab), 507(ab), 731(ab)
Foltin, R, 214(ab)
Font, M, 887(ab)
Fontes, F, 1561
Fontes, FG, 392(ab)
Fontes, FR, 1178(ab)
Foo, SS, 435(ab)
Forero, A, 334(ab), 447(ab), 494(ab)
Forget, PP, 1249(ab)
Formiconi, AR, 371(ab)

Forster, A, 1227(ab)
Förster, GJ, 1292(ab)
Forster, K, 981(ab)
Forster, KM, 1045(ab)
Forster, M, 723(ab), 1245(ab)
Forstrom, LA, 1138(ab)
Forte, LR, 1074(ab)
Forutan, F, 618
Fourme, T, 155, 177(ab), 178(ab), 767(ab)
Fournier, C, 79(ab)
Fowler, JS, 117(ab), 213(ab), 216(ab), 227(ab), 780(ab), 782(ab), 798(ab), 800(ab), 815, 890(ab), 898(ab), 1052(ab), 1239(ab), 1522
Fracassi, S, 871(ab)
Fraker, DL, 410(ab)
Franceschetto, A, 1394(ab)
Franceschi, D, 38(ab)
Franchi, R, 1422(ab)
Francis, DL, 80(ab), 81(ab)
Francis, IR, 457
Frank, H, 1741
Frank, R, 181(ab), 749(ab)
Franke, W-G, 953
Franken, P, 286(ab)
Franken, PR, 459(ab), 993(ab), 1013(ab), 1489
Frankle, WG, 218(ab), 228(ab)
Franquiz, JM, 457(ab)
Franzius, C, 550(ab), 997(le), 1238(ab), 1379(ab)
Fraser, C, 62(ab)
Freedman, M, 1374(ab)
Freedman, N, 161(ab), 202(ab), 862(ab)
Freeman, A, 80(ab)
Freeman, LM, 137(ab)
Freer, G, 501(ab)
Freifelder, R, 1340
Freiman, AH, 185(ab)
Freimanis, RI, 1026(ab)
Freimanis, RL, 455(ab)
Frenkel, A, 481(ab), 1030(ab), 1200
Freudenberg, L, 933(ab), 986(ab), 1166(ab)
Freudenberg, LS, 75(ab), 270(ab), 561(ab), 1354(ab)
Frey, EC, 23(ab), 195(ab), 207(ab), 208(ab), 366(ab), 461(ab), 971(ab), 997(ab), 1042(ab)
Frey, KA, 1264(ab), 846
Friedel, G, 563(ab)
Friedman, J, 743(ab)
Friedman, JD, 7(ab), 1633
Frielink, C, 316(ab), 499(ab)
Frilling, A, 1166(ab)
Fritzberg, AR, 1284
Frodl, T, 116(ab)
Froehlich, F, 1375(ab)
Froelich, L, 833(ab)
Front, A, 355(ab)
Frost, JJ, 160(ab), 211(ab), 281(ab), 584(ab), 585(ab), 1312(ab)
Frostfeldt, G, 1176
Frouin, V, 193(ab)
Frusciante, V, 207
Fu, IY, 1106(ab)
Fu, YK, 1327(ab)
Fu, ZL, 1294(ab)
Fuechsel, FG, 956(ab)
Fueger, B, 806(ab)
Fuertes, J, 179(ab), 1283(ab), 1372(ab)
Fujibayashi, Y, 254(ab), 791(ab), 815(ab), 1080(ab), 1671, 1875
Fujihara, K, 565
Fujii, H, 1005(ab)
Fujikawa, I, 329(ab)
Fujimori, K, 1273(ab)
Fujimoto, J, 924(ab)
Fujimoto, K, 1356(ab), 1357(ab)
Fujimoto, T, 1228(ab), 1415(ab)
Fujioka, Y, 1092(ab)
Fujita, M, 119(ab), 512, 917(ab)
Fujita, S, 820(ab), 827(ab), 870(ab)
Fujita, T, 864(ab), 901(ab), 990(ab), 1356(ab), 1357(ab)
Fukuchi, K, 171(ab), 707(ab), 740(ab), 753(ab), 759(ab), 1582
Fukuchi, T, 843(ab)
Fukuda, H, 265(ab), 690
Fukui, M, 173(ab), 757(ab), 764(ab)
Fukumitsu, N, 221(ab)
Fukumoto, S, 534(ab)
Fukushima, K, 707(ab), 760(ab)
Fuller, C, 440(ab), 441(ab), 1402(ab)
Funk, G, 1378(ab)
Furenlid, LR, 525(ab), 705(ab), 1307(ab)
Furukawa, T, 254(ab), 815(ab), 1305(ab)
Furumoto, S, 265(ab), 1311(ab)
Fuster, D, 235(ab), 426(ab), 1367(ab), 1408(ab), 1451(ab), 1486(ab), 1488(ab)
Futami, S, 820(ab), 827(ab), 870(ab)
Futatsubashi, M, 1051, 1346(ab), 1435(ab)

Gabram, SG, 408(ab)
Gabriel, M, 708, 1375(ab)
Gacinovic, S, 392(ab), 420(ab), 1178(ab), 1400(ab)
Gaetani, P, 871(ab)
Gage, HD, 455(ab), 521(ab), 814(ab), 975(ab)
Gage, Jr, HD, 715(ab)
Gagnon, A, 505(ab), 506(ab)
Gagnon, MK, 1128(ab)
Gaitini, D, 1200, 65(ab), 421(ab)
Gali, H, 823, 1074(ab), 1102(ab)
Galitzky, M, 847(ab)
Gallazzi, F, 1318(ab)
Galldiks, N, 107(ab)
Galli, L, 1468(ab)
Galt, JR, 279(ab), 356(ab), 507(ab), 1195(ab)
Gambhir, S, 1280(ab), 1285(ab)
Gambhir, SS, 1962, 2(ab), 94(ab), 95(ab), 96(ab), 97(ab), 98(ab), 149(ab), 337(ab), 1135(ab), 1296(ab), 1329(ab)
Gamie, S, 241(ab)
Gamliel, Z, 1335(ab)
Gangloff, A, 1064(ab), 1333(ab)
Ganguli, SN, 1483(ab)
Gangwar, PK, 1480(ab)
Gansbacher, B, 86(ab), 704(ab)
Ganz, PA, 828(ab)
Garayoa, EG, 1649
Garcés, ME, 1561
Garcia Flores L, II, 625
Garcia Garayoa, E, 71(ab)
Garcia III, LB, 751(ab)
Garcia, EV, 278(ab), 279(ab), 356(ab), 507(ab), 731(ab)
Garfinkel, A, 8(ab)
Gargari, H, 321(ab)
Garlip, G, 545(ab)
Garner, J, 170(ab)
Garrigues, V, 446
Garza, V, 800(ab), 1052(ab)
Gasaway, P, 1148(ab)
Gaspar, T, 183(ab), 436(ab)
Gasser, T, 387(ab)
Gaston, I, 1479(ab)
Gates, V, 1475(ab)
Gatley, SJ, 117(ab), 165(ab), 213(ab), 216(ab), 227(ab), 898(ab), 1052(ab), 1082
Gatsonis, CG, 247(ab)
Gatti, R, 1253
Gauger, PA, 297(ab)
Gaut, AW, 1322(ab)
Gauthier, H, 79(ab)
Gauthier, JP, 411(ab)
Gauthier, M, 1655
Gay, DJ, 158(ab), 1065(ab)
Gay, E, 409(ab), 1213(ab)
Gefter, WB, 1390(ab)
Gehan, E, 1374(ab)
Geisler, F, 682
Geissler, B, 411(ab), 1625
Gelaw, B, 271(ab)
Gelbard-Stokes, I, 218(ab)
Gelernter, J, 220(ab)
Gelfand, MJ, 36N(6)
Geliebter, A, 890(ab)
Gelovani Tjuvajev, J, 93(ab), 150(ab), 156(ab), 1068(ab), 1073(ab)
Gelovani Tjuvajev, JG, 1326(ab)
Gelovani-Tjuvajev, J, 89(ab), 1308(ab)
Gemmel, F, 1219(ab)
Génin, R, 920
Georgiou, MF, 1281(ab)
Gerard, SK, 852(le), 1194(le), 2039(le)
Gerasimov, MR, 802(ab)
Gerasimov, T, 815
Gerbaudo, VH, 846
Gerber, B, 276(ab)
Gerl, J, 418(ab)
Germano, A, 943, 1566
Germano, G, 7(ab), 743(ab)
Gerrits, MA, 522(ab)
Gershenson, DM, 700
Gertz, MA, 569(ab)
Gerundini, P, 397(ab), 406(ab), 756, 889(ab)
Geworski, L, 875(ab), 1041(ab)
Geyer, C, 1245(ab)
Geyser-Stoops, SM, 1150(ab)
Gheri, GR, 1057
Ghezzi, C, 981
Ghostine, S, 761(ab)
Giacomelli, F, 1495
Giani, R, 409(ab)
Gianolli, L, 264(ab)
Gianoukakis, AG, 132(ab), 133(ab)
Giblin, MF, 1074(ab)
Gielow, P, 1473(ab)
Gietema, JA, 76(ab)
Gifford, AN, 165(ab), 227(ab), 1052(ab)
Giganti, M, 806
Giglioni, B, 264(ab)
Gilbert, N, 263(ab)
Gilbert, R, 1014(ab)
Gildehaus, FJ, 112(ab), 541(ab)
Gildersleeve, DL, 341(ab), 1121(ab)
Gilissen, C, 269
Gilland, D, 27(ab)
Gilland, KL, 366(ab), 461(ab), 997(ab)
Gillet, M, 71(ab)
Gillies, JM, 1142(ab)
Gillispie, SB, 520(ab)
Gimbergues, P, 411(ab)
Gimsing, P, 177
Giokaris, N, 1028(ab), 1032(ab)
Giona, F, 1253
Giorgetti, A, 720(ab)
Giors, M, 409(ab)
Giovacchini, G, 62(ab)
Gips, S, 355(ab)
Giraudeau, B, 663
Giubbini, RM, 175(ab), 558(ab), 1198(ab)
Giuliano, AE, 1443
Giuliano, P, 351(ab), 1497(ab)
Gjedde, A, 810(ab), 922(ab)
Glass, E, 549(ab)
Glass, EC, 352(ab)
Glass, J, 165(ab)
Glatting, G, 252(ab), 433(ab), 434(ab), 614(ab), 965(ab), 966(ab), 1426
Glekas, A, 1073(ab)
Glenn, TC, 384(ab), 885(ab), 1709
Globits, S, 1741
Glover, DK, 1092
Godbersen, GS, 559
Goebel, H, 538(ab)
Goeke, B, 493(ab)
Goerges, R, 270(ab)
Goerres, GW, 272(ab), 417(ab), 1227(ab), 1382(ab)
Goertzen, AL, 1027(ab)
Goethals, I, 163, 1531
Goetz, C, 541(ab)
Goetz, S, 112(ab)
Gogami, A, 1080(ab), 1671
Goins, B, 1097(ab), 1992
Gold, DV, 575(ab)
Gold, HK, 1(ab)
Gold, PW, 813(ab)
Goldenberg, DM, 67, 77, 84(ab), 102(ab), 324(ab), 575(ab), 578(ab), 1057(ab), 1220(ab), 1258(ab), 1293(ab), 2000
Goldsmith, S, 99(ab)
Goldsmith, SJ, 105(ab), 224, 236(ab), 429(ab), 430(ab), 610, 1093(ab), 1155(ab), 1167(ab), 1173(ab), 1222(ab), 1351(ab), 1385(ab), 1478(ab)
Goldstein, DS, 1599
Golosovker, O, 1351(ab)
Gonen, M, 465(ab), 1349(ab), 1417(ab), 1489(ab), 1789
Gonzalez Trotter, DE, 82(ab), 198(ab), 941(ab), 1033(ab)
González-Maté, A, 1301
Goodbody, AE, 774(ab)
Goodman, MM, 151(ab), 153(ab), 543(ab), 605(ab), 855, 1050(ab), 1156(ab)
Gopinath, G, 237(ab), 1474(ab)
Gordon, L, 127(ab)
Gordon, LI, 1479(ab)
Gorey, JG, 224(ab)
Görg, T, 1461(ab)
Gorges, R, 1166(ab)
Goris, ML, 458(ab), 783(ab), 1031(ab), 657(le)
Gorman, JM, 109(ab)
Gosink, HJ, 1023(ab)
Gossmann, J, 468(ab)
Goto, Y, 753(ab)
Gotoh, Y, 740(ab)
Gottfried, HW, 432(ab), 433(ab)
Gotthardt, M, 238(ab), 446(ab), 448(ab), 551(ab), 739(ab), 869(ab), 1298(ab), 1362(ab), 1425(ab), 1461(ab)
Goudy, GH, 127(ab)
Govindan, SV, 77, 324(ab)
Gowda, NK, 383(ab)
Goyenechea, M, 992(le)
Grünwald, F, 174(ab), 468(ab), 572(ab), 1193(ab), 1424(ab)
Graetz, KW, 1382(ab)
Graf, S, 1741
Grafton, ST, 855
Graham, KA, 1075(ab), 1113(ab)
Graham, M, 616(ab), 1464(ab), 1495(ab)
Graham, MM, 139(ab), 232(ab), 473(ab), 988, 1244(ab), 1322(ab), 1378(ab), 1419(ab)
Graham-Coco, WA, 703(ab)
Grahek, D, 1392(ab), 1397(ab), 1398(ab)
Gralow, JR, 249(ab), 250(ab), 412(ab), 1310(ab), 1411(ab), 1806
Gramegna, G, 406(ab)
Grana, C, 444(ab)
Grass, J, 238(ab)
Grazioso, R, 1004(ab)
Grebe, G, 1041(ab)
Green, AM, 947
Green, G, 353(ab)
Green, KM, 44(ab)
Green, MA, 700, 795(ab)

Green, MV, 529(ab), 779(ab), 781(ab), 784(ab)
Green, TD, 251(ab)
Greenberg, JH, 604(ab), 1890
Greenwald, B, 1335(ab)
Greer, KL, 583, 1036(ab)
Greifeneder, M, 1547
Grekowicz, B, 123(ab)
Greskovich, JP, 964(ab)
Grevera, G, 953(ab)
Grewal, RK, 552(ab), 1349(ab), 1789
Grierson, J, 1482
Grierson, JR, 878(ab), 1340(ab), 2027
Gries, JM, 810(ab)
Griesinger, F, 400(ab)
Griffeth, LK, 1477(ab)
Griffiths, GL, 77, 324(ab), 1057(ab)
Griffiths, PA, 1383(ab)
Grigsby, PW, 192
Grimm, F, 138(ab)
Grimmer, T, 54(ab)
Gropler, RJ, 345(ab), 347(ab), 367(ab)
Gross, K, 752(ab)
Gross, MD, 580(ab)
Gross, MW, 869(ab), 1425(ab)
Gross, WL, 733(ab)
Grossman, GB, 278(ab), 279(ab), 356(ab), 731(ab)
Grosso, M, 134(ab), 562(ab), 1468(ab)
Groth, P, 131(ab)
Gruenwald, F, 1460(ab), 1463(ab)
Gründer, G, 109
Grunder, G, 115(ab)
Grunwald, F, 940(ab)
Grünwald, F, 996(le), 1065
Gschwend, JE, 434(ab)
Guan, HY, 439(ab), 877(ab)
Guan, L, 142(ab), 235(ab), 426(ab), 464(ab), 479(ab), 517(ab), 920(ab), 1081(ab), 1211(ab), 1366(ab), 1421(ab), 1485(ab), 1486(ab), 1488(ab)
Guay, C, 1225
Gueret, P, 899(ab)
Guerrero, T, 1045(ab)
Guhlke, S, 568(ab), 1072(ab)
Guichard, J-P, 1767
Guilbert, B, 709(ab)
Guillem, J, 82(ab)
Guilloteau, D, 219(ab), 663
Guiterrez, C, 573(ab)
Gulec, SA, 307(ab), 451, 549(ab), 1185(ab), 1443, 2040(le)
Gullberg, GT, 204(ab), 369(ab), 460(ab), 997(ab), 657(le)
Gulrajani, R, 1444(ab)
Gulyas, B, 219(ab)
Gulyas, G, 1098(ab)
Gunther, I, 424(ab)
Guo, F, 189(ab), 350(ab)
Guo, HF, 576(ab)
Guo, J, 1376(ab), 1442(ab)
Guo, LH, 1321(ab)
Guo, N, 812(ab), 1049(ab)
Gupta, A, 1280(ab), 1285(ab)
Gupta, AK, 1480(ab)
Gupta, N, 1405(ab)
Gupta, NC, 484(le), 1491(ab)
Gupta, NK, 1390(ab)
Gupta, S, 163(ab), 1070(ab), 1124(ab), 1295(ab)
Gur, E, 1413
Guralnik, L, 242(ab), 436(ab), 470(ab), 1200
Gustafson, MF, 580(ab)
Gutman, F, 598(ab)

Haberal, M, 1286(ab)
Haberkorn, U, 78(ab), 257(ab), 258(ab), 381(ab), 880(ab), 935(ab), 973, 1075(ab), 1113(ab), 1297(ab), 1316(ab), 1319(ab), 1324(ab), 1332(ab), 1933
Habte, F, 450(ab), 1006(ab)
Hachamovitch, R, 7(ab), 1633
Hackett, E, 109(ab), 226(ab), 228(ab)
Hackett, L, 214(ab)
Haddad, B, 1374(ab)
Hadi, M, 762(ab), 1215(ab)
Häfeli, UO, 650
Hagen, PJ, 739
Hagg, SA, 896(ab)
Hahn, H, 1279(ab)
Hahn, J, 255(ab)
Hahn, K, 70(ab), 116(ab), 143(ab), 597(ab), 1246(ab), 1347(ab), 1384(ab)
Haider, N, 1(ab), 338(ab)
Haim, N, 436(ab)
Hain, SF, 490(ab), 891
Hajjar, G, 2000
Hakim, SG, 1224(ab)
Halama, JR, 361(ab)
Halders, SG, 1249(ab)
Haley, RW, 826(ab)
Halkar, RK, 278(ab), 356(ab), 543(ab), 1156(ab), 1195(ab)
Hall, C, 1105
Hallaj, I, 474(ab)
Halldin, C, 219(ab)
Halling, H, 1682
Halpern, B, 1190(ab), 1325(ab), 1355(ab), 1497(ab)
Halpern, J, 101(ab)
Halter, G, 1426
Ham, HR, 659(le), 1707(le)
Hamacher, K, 483(le), 618, 873(ab), 879(ab), 881(ab)
Hamacher, KA, 1155(ab), 1167(ab)
Hämäläinen, MM, 1368(le)
Hamaloglu, E, 1185(ab)
Hamann, C, 918(ab)
Hamann, CS, 372(ab), 942(ab)
Hambye, AS, 724(ab)
Hamidzadeh, A, 1067(ab)
Hamill, J, 982(ab)
Hamlin, DK, 437, 1085(ab)
Hammer, HF, 305(ab), 306(ab)
Hammerschmidt, F, 167(ab), 504(ab), 1132(ab)
Hammoud, D, 243(ab)
Hamscho, N, 174(ab), 468(ab), 940(ab), 996(le), 1065, 1193(ab)
Han Liem, I, 391
Han, ES, 1091(ab), 1112(ab)
Han, L, 92(ab)
Hankins, D, 135(ab)
Hankins, J, 105(ab), 1478(ab)
Hannequin, D, 1013
Hannequin, P, 458(ab)
Hannequin, PP, 729(ab)
Hannink, M, 1318(ab)
Hanrahan, SM, 809(ab)
Hansen, HJ, 324(ab), 575(ab), 1057(ab), 1293(ab)
Hantschmann, P, 1384(ab)
Hany, TF, 272(ab), 417(ab), 732
Hapdey, S, 40(ab), 201(ab), 1184
Hara, T, 265(ab), 379(ab), 1452(ab)
Hara, TE, 379(ab)
Harada, N, 223(ab)
Hardenbergh, PH, 583
Hardoff, R, 1243(ab), 1272(ab)
Harduf, R, 1248(ab)
Hare, JM, 281(ab)
Hareyama, M, 1273(ab)
Harf, A, 1271(ab)
Haridas, KK, 18(ab)
Harmer, L, 574(ab)
Harmon, WE, 599(ab)
Harpf, AE, 283(ab)
Harris, RS, 1982
Harris, TD, 316(ab), 498(ab), 1087
Harris, TS, 43(ab), 45(ab), 826(ab), 832(ab)
Harris-Brandts, T, 1047(ab)
Hart, R, 169(ab)
Hartmann Siantar, CL, 495(ab), 1322
Hartmann, IJC, 739
Hartung, D, 1(ab)
Harwood, SJ, 84(ab), 1171(ab)
Hasebe, N, 768(ab)
Hasebe, S, 988(ab)
Hasegawa, B, 291, 321(le)
Hasegawa, BH, 998(ab), 1004(ab)
Hasegawa, H, 4(ab)
Hasegawa, Y, 560(ab)
Hashikawa, K, 49(ab)
Hashimoto, J, 385
Hashimoto, N, 864(ab)
Hasizume, T, 560(ab)
Hassan, A, 170(ab), 756(ab)
Hassan-Sebbag, N, 1232
Hasselbalch, SG, 943(ab)
Hastings, D, 586(ab)
Hastings, DL, 44(ab)
Hata, M, 385(ab), 884(ab)
Hataji, O, 1381(ab)
Hatano, K, 787(ab), 796(ab), 822(ab), 947(ab)
Hatazawa, J, 505
Hatton, RL, 206(ab), 994(ab)
Hattori, N, 384(ab), 885(ab), 1709
Haubner, R, 86(ab), 148(ab), 704(ab)
Hauff, W, 1547
Hauser, T, 728(ab)
Haussermann, P, 856(ab)
Hautmann, H, 433(ab)
Hawk, TC, 363(ab)
Hawkins, DS, 1467(ab)
Hawkins, R, 321(le)
Hawman, EG, 456(ab), 747(ab)
Hay, ID, 1402
Hay, RV, 580(ab)
Hayashi, A, 1080(ab), 1671
Hayashi, K, 838(ab)
Hayashi, T, 40, 565, 906(ab)
Hayashida, K, 906(ab), 1582
Hayden, C, 980(ab)
Hayem, G, 920
Hayes, DL, 823
Hayes, SW, 7(ab), 743(ab), 1633
Haynor, D, 26(ab), 1918
Hazra, DK, 1480(ab)
He, H, 1134(ab)
He, J, 326(ab), 1070(ab), 1115(ab), 1116(ab), 1295(ab), 1331(ab)
He, W, 1023
He, X, 366(ab), 461(ab)
He, ZX, 9(ab), 13(ab), 15(ab), 180(ab), 189(ab), 287(ab), 350(ab), 365(ab), 469(ab), 1002(ab)
Healy, E, 1725
Heckemann, RA, 956(ab)
Hedenstierna, G, 1176
Heiba, SI, 7
Heidendal, GA, 5(ab), 509(ab)
Heidendal, GAK, 391
Heidenreich, P, 451
Heijnen, BH, 136(ab)
Heinrich, MC, 77(ab)
Heinz, A, 212(ab)
Heinze, A, 538(ab)
Heinze-Kuhn, K, 538(ab)
Heiss, WD, 29(ab), 107(ab), 533(ab), 545(ab), 831(ab)
Hekman, A-M, 1105
Helisch, A, 493(ab), 595(ab), 939(ab)
Heller, GV, 356(ab), 507(ab)
Heller, S, 481(ab), 1030(ab)
Hellweg, L, 489(ab)
Helmberger, T, 1347(ab)
Helms, G, 252(ab)
Hendel, HW, 177
Hendel, R, 134
Henderson, BL, 1037
Henderson, RW, 1186(ab)
Hendrickson, R, 50(ab), 398(ab)
Hendrikse, NH, 801(ab)
Henkin, RE, 361(ab), 408(ab)
Henriksen, G, 252
Henze, E, 6(ab), 141(ab), 247, 489(ab), 538(ab), 557(ab), 559, 1217(ab)
Henze, M, 381(ab), 880(ab)
Henzel, M, 869(ab), 1425(ab)
Heo, YJ, 323(ab), 485(ab), 487(ab), 508(ab), 571(ab), 1087(ab), 1139(ab)
Her, D, 85
Herder, GJ, 554(ab)
Herholz, K, 51(ab), 545(ab), 831(ab), 833(ab)
Herman, P, 1767
Hermann, S, 1238(ab)
Hernandez Pampaloni, M, 349(ab)
Hernandez, I, 835(ab)
Herolz, K, 29(ab)
Herrero, P, 345(ab), 347(ab), 367(ab)
Herrmann, W, 855(ab)
Herscovitch, P, 62(ab), 1152(ab), 1330
Hersel, U, 148(ab)
Hertenstein, B, 1473(ab)
Herz, M, 233(ab)
Herzog, H, 879(ab), 881(ab), 939(ab)
Herzog, HR, 863(ab)
Hesse, B, 19, 177
Hesse, S, 393(ab), 849(ab), 855(ab)
Hetzel, M, 403(ab), 1426
Heufelder, AE, 91(ab)
Heute, D, 1375(ab)
Heydari, B, 1547
Hichwa, RD, 1141(ab), 1144(ab)
Hicks, RJ, 30
Hiemke, C, 109
Higano, S, 565
Higashi, K, 1376(ab), 1442(ab)
Higashi, N, 908(ab)
Higashi, T, 901(ab), 1314(ab), 1356(ab), 1357(ab), 1358(ab), 1369(ab)
Higashikubo, R, 1306(ab)
Higashikubo/Ryuji, R, 262(ab)
Higazi, MM, 368(ab)
Higuchi, T, 288(ab), 342(ab), 736(ab), 1376(ab), 1436(ab)
Hikosaka, K, 1168
Hildebrandt, I, 98(ab)
Hildebrandt, J, 94(ab)
Hill, EA, 1475(ab)
Hill, P, 353(ab)
Hilson, AJ, 237(ab), 445(ab), 1465(ab), 1474(ab)
Hilson, AJW, 1
Hilton, J, 42(ab), 160(ab), 281(ab), 463(ab)
Hiltunen, J, 219(ab)
Hindie, E, 474(ab)
Hindorf, C, 491(ab)
Hinkel, R, 339(ab)
Hinkle, GH, 110(ab)
Hinnen, F, 157(ab), 596
Hipp, P, 381(ab), 880(ab)
Hiraga, T, 325
Hirai, M, 277(ab)
Hirakawa, K, 1839
Hirata, K, 129(ab), 1192(ab), 1201(ab)
Hirata, M, 534(ab), 923(ab), 1454(ab)
Hirayama, H, 277(ab)
Hiroe, M, 4(ab)
Hirosaka, A, 1618
Hirotani, A, 325
Hisada, K, 275(ab), 799(ab)
Hitzel, A, 598(ab), 1013
Hliscs, R, 953
Hnatowich, DJ, 163(ab), 326(ab), 1070(ab), 1089(ab), 1115(ab), 1116(ab), 1124(ab), 1295(ab), 1331(ab)
Ho, C, 910(ab)
Ho, C-L, 213
Ho, YY, 1449(ab)
Hoare, T, 1252(ab)
Hock, J, 1101(ab)

Hocke, C, 1315(ab)
Hoeffken, H, 238(ab), 448(ab), 739(ab), 869(ab)
Hoekstra, A, 472(ab)
Hoekstra, HJ, 240(ab), 547(ab), 1927
Hoekstra, OS, 554(ab), 739, 936(ab), 1022(ab)
Hoffend, J, 1332(ab)
Hoffman, A, 1214(ab)
Hoffman, E, 100(ab)
Hoffman, H, 1378(ab)
Hoffman, JM, 855
Hoffman, TJ, 581(ab), 823, 1066(ab)
Hofland, LJ, 1315
Hofmann, M, 1445(ab), 1473(ab)
Hofstra, L, 5(ab), 338(ab), 391, 509(ab)
Hogan, RE, 60(ab)
Hoh, C, 1114(ab)
Hoh, CK, 196(ab), 308(ab), 1006(ab), 1009(ab), 1677
Holder, LE, 988
Holdsworth, CH, 197(ab)
Holmes, C, 1599
Holschbach, MH, 1682
Holthoff, V, 833(ab)
Holthusen, H, 863(ab)
Holtmannspoetter, M, 36(ab), 862
Holtz, D, 1059(ab)
Holy, R, 848(ab)
Homs, CJ, 1443(ab), 1444(ab)
Honda, G, 253(ab), 1311(ab)
Honda, H, 838(ab)
Honda, N, 37(ab), 842(ab), 1339(ab)
Hong, MK, 1117(ab), 1130(ab)
Hong, SB, 819(ab)
Hong, SW, 542(ab), 790(ab), 1309(ab), 1371(ab), 1388(ab), 1399(ab), 1453(ab), 1472(ab)
Honma, T, 1747
Hopkins, W, 100(ab)
Horak, I, 324(ab)
Horak, ID, 1057(ab)
Horev, G, 1243(ab), 1248(ab)
Hori, M, 505
Horsman, MR, 1302(ab)
Hoshizaki, H, 515(ab), 1604
Hosoi, R, 796(ab)
Hosokawa, M, 92
Hosokawa, R, 14(ab), 750(ab)
Hosono, M, 37(ab), 842(ab), 1076(ab), 1339(ab)
Hospers, GA, 106(ab)
Hou, C, 377(ab), 1890
Houghton, JH, 1116(ab)
Houle, S, 714(ab), 1047(ab)
Houvenaeghel, G, 1232
Hovda, DA, 1709
Howard, TJ, 74(ab)
Howarth, DM, 1262(ab)
Howe, J, 473(ab)
Howell, R, 1293
Howell, RW, 331(ab), 2019
Howey, S, 494
Howman-Giles, R, 384(ab), 570, 885(ab), 1235(ab), 1871(le)
Hoyos, M, 446
Hoyoux, C, 596(ab), 1237(ab)
Hruska, CB, 712(ab)
Hsaio, MC, 888(ab)
Hsieh, HJ, 1412(ab), 1416(ab)
Hsieh, J, 123(ab)
Hsu, P, 1633
Hsueh, S, 1387(ab), 1428(ab), 1430(ab), 1431(ab), 1455(ab), 1775
Hsueh, W, 349(ab)
Hsueh, WA, 1333(ab)
Hu, J, 168(ab)
Hu, MC, 1067(ab)
Hu, MK, 803(ab)
Hu, P, 1079(ab)
Hu, S, 1096(ab), 1107(ab)
Hu, SS, 15(ab)
Hu, Z, 126(ab)
Hua, CF, 439(ab)
Hua, W, 180(ab)
Huang, F, 1321(ab)
Huang, KG, 1430(ab), 1431(ab), 1455(ab)
Huang, LJ, 287(ab)
Huang, S, 931(ab)
Huang, S-C, 1709
Huang, SC, 222(ab), 384(ab), 885(ab), 907(ab), 951(ab)
Huang, W-S, 999
Huang, WS, 110(ab), 794(ab), 844(ab)
Huang, Y, 109(ab), 118(ab), 214(ab), 218(ab), 226(ab), 228(ab), 231(ab), 603(ab), 807(ab), 812(ab), 1049(ab), 1053(ab)
Huang, YY, 1450(ab)
Hubbs, AF, 484(le)
Huber, R, 579(ab), 588(ab)
Hubert, L, 985(ab)
Huberty, J, 321(le)
Hubner, KF, 405(ab), 914(ab), 928(ab), 1418(ab)
Huesman, RH, 121(ab), 282(ab)
Hughes, JA, 770
Hughes, S, 1400(ab)
Hughes, SJ, 420(ab), 1178(ab)
Hughetti, R, 482(ab)
Huh, WS, 1226(ab)
Humm, J, 424(ab)
Humm, JL, 124(ab), 378(ab), 527(ab), 968(ab), 969(ab), 1153(ab), 1644, 1940
Hummell, SM, 415(ab)
Humplik, BI, 1180(ab), 1268(ab)
Hung, JC, 1138(ab)
Hunhold, A, 1238(ab)
Hunsche, A, 467(ab), 731(ab), 1282(ab), 1288(ab), 1289(ab)
Hunt, J, 307(ab)
Hunter, DH, 166(ab), 1128(ab)
Hunter, KM, 405(ab), 1418(ab)
Huppa, C, 1245(ab)
Hur, K, 1205(ab)
Hur, MG, 1060(ab)
Hurh, P, 1257(ab)
Hurley, D, 124(ab), 449(ab), 968(ab)
Hurtig, H, 389(ab), 852(ab), 853(ab), 854(ab)
Hurtl, I, 1547
Hurwitz, GA, 512(ab), 725(ab)
Hurwitz, MM, 725(ab)
Hustinx, R, 533, 596(ab), 1237(ab)
Hutchins, GD, 158(ab), 375(ab), 376(ab), 795(ab), 797(ab), 952(ab), 1035(ab), 1065(ab)
Huten, D, 920
Hutton, BF, 206(ab), 994(ab)
Huy, PTB, 1767
Huyghe, D, 1086(ab)
Hwang, AB, 998(ab)
Hwang, BT, 1251(ab)
Hwang, CH, 1435
Hwang, DF, 313(ab)
Hwang, DR, 109(ab), 214(ab), 218(ab), 226(ab), 228(ab), 231(ab), 603(ab), 807(ab), 812(ab), 1049(ab), 1053(ab)
Hwang, JJ, 1327(ab)
Hwang, KH, 892(ab), 957(ab)
Hwang, WT, 790(ab)
Hwang, YS, 602(ab)
Hyde, N, 420(ab)

Ichikawa, S, 884
Ichise, M, 35(ab), 53(ab), 781(ab)
Ichise, R, 105, 1119(ab), 1516
Ide, M, 1338(ab)
Ido, T, 265(ab), 690
Idy-Peretti, I, 176(ab), 177(ab), 178(ab), 734(ab), 767(ab), 771(ab)
Ienuso, R, 1755
Ihara, M, 417
Iida, H, 40, 512, 701(ab), 745, 906(ab), 947(ab), 992(ab)
Iida, Y, 1088(ab)
Iimuro, Y, 924(ab)
Ikeda, M, 288(ab), 719(ab), 736(ab), 1436(ab), 1717
Ikeda, T, 1005(ab)
Ikezoe, J, 534(ab), 923(ab), 1454(ab)
Ikle, D, 1433(ab)
Ilgin, N, 475(ab)
Im, KC, 182(ab)
Im, SH, 540(ab)
Imabayashi, E, 37(ab), 830(ab), 840(ab), 886(ab), 1243
Imai, N, 1487(ab)
Imaizumi, M, 505
Imamura, M, 1356(ab), 1357(ab)
Imanaka-Yoshida, K, 4(ab)
Imperiale, A, 1057, 1755
Inaoka, Y, 904(ab)
Inatomi, J, 244
Iñiguez, MP, 1172(ab)
Innis, RB, 35(ab), 119(ab), 220(ab), 512, 529(ab), 781(ab), 917(ab)
Ino, H, 1612
Inoue Tomio, T, 1266(ab)
Inoue, H, 792(ab)
Inoue, O, 796(ab)
Inoue, T, 20(ab), 1003(ab), 1452(ab)
Inoue, Y, 1592
Inouye, S, 836(ab)
Intenzo, CM, 1265(ab)
Inubishi, M, 289(ab)
Inubushi, M, 283(ab), 293(ab), 349(ab), 351(ab), 945(ab)
Invernizzi, I, 889(ab)
Ioannidis, JPA, 717
Iozzo, P, 682
Irie, A, 1391(ab)
Irie, T, 4(ab), 343(ab)
Irimajiri, M, 795(ab), 952(ab)
Isaacs, C, 1374(ab)
Isaacs, JT, 584(ab)
Isaacs, TD, 585(ab)
Isabey, D, 1271(ab)
Ishida, Y, 171(ab), 707(ab), 740(ab), 753(ab), 759(ab), 1582
Ishiguchi, T, 908(ab)
Ishihata, T, 1618
Ishii, K, 221(ab), 843(ab)
Ishikawa, N, 244, 625
Ishikawa, Y, 475, 768(ab), 1207(ab), 1250(ab)
Ishill, M, 920(ab)
Ishimori, T, 901(ab), 1314(ab), 1356(ab), 1357(ab), 1358(ab), 1369(ab)
Ishino, S, 701(ab)
Ishiwata, K, 221(ab), 223(ab), 843(ab), 1839
Ishizaki, T, 540
Ishizu, K, 49(ab), 417, 864(ab), 901(ab), 1356(ab), 1357(ab), 1358(ab)
Isidoro, FP, 928(ab)
Isobe, N, 515(ab), 1604
Isobe, S, 277(ab), 719(ab), 1717
Israel, DA, 77(ab)
Israel, O, 65(ab), 183(ab), 242(ab), 421(ab), 436(ab), 470(ab), 1200, 1214(ab)
Ito, H, 520, 834(ab)
Ito, K, 787(ab), 796(ab), 822(ab), 947(ab)
Ito, M, 253(ab), 325, 1452(ab)
Ito, S, 1104(ab), 1104(ab), 1104(ab)
Itoh, H, 785(ab)
Itoh, M, 799(ab), 1228(ab), 1311(ab), 1415(ab)
Itoh, S, 1487(ab), 1487(ab)
Itokazu, N, 827(ab)
Itti, E, 899(ab), 1225(ab), 1271(ab), 1543 (le)
Ivanco, LS, 50(ab), 398(ab)
Iwado, H, 291(ab)
Iwado, Y, 291(ab)
Iwai, K, 822(ab)
Iwasa, M, 829(ab)
Iwasaka, T, 173(ab), 757(ab), 764(ab)
Iwata, K, 998(ab), 1031(ab)
Iwata, R, 265(ab), 1311(ab)
Iyer, M, 94(ab), 97(ab), 98(ab)
Izawa, H, 719(ab), 1717

Jääskeläinen, P, 487
Jabour, BA, 352(ab)
Jacene, HA, 309(ab)
Jacob, J, 466(ab)
Jacob, JS, 751(ab)
Jacob, T, 1392(ab)
Jacobs, A, 533(ab)
Jacobs, AH, 107(ab), 545(ab)
Jacobs, MP, 1545(le)
Jacobsen, LK, 220(ab)
Jacobson, AE, 813(ab)
Jacobson, AF, 735(ab), 741(ab), 742(ab), 754(ab)
Jacquemier, J, 1232
Jadvar, H, 556(ab), 949(ab), 1441(ab)
Jaeger, CB, 795(ab)
Jaffe, R, 355(ab)
Jagadeesan, B, 762(ab)
Jager, PL, 76(ab), 146(ab), 184, 240(ab), 547(ab), 1154(ab), 1927
Jaggi, J, 497(ab)
Jagoda, E, 779(ab)
Jagoda, EM, 813(ab)
Jahan, SA, 333(ab), 431(ab)
Jahn, M, 117, 314(ab)
Jain, D, 722(ab), 735(ab), 754(ab)
Jain, M, 1970
Jalali, A, 920(ab)
Jamar, F, 443(ab)
James, S, 1090(ab)
Jana, S, 7, 404(ab)
Janabi, M, 166(ab)
Janes, ML, 520(ab)
Jang, HJ, 66(ab), 67(ab), 513(ab), 718(ab), 1226(ab), 1345(ab)
Jang, JW, 1410(ab)
Jang, S, 72(ab), 953(ab), 1456(ab)
Janicek, MJ, 77(ab)
Janssen, PJ, 1146(ab)
Jarkas, N, 153(ab)
Jasinski, D, 215(ab)
Jaszczak, RJ, 583, 1036(ab)
Jayne, M, 117(ab), 890(ab), 898(ab)
Jenicke, L, 375
Jenkin, BA, 239(ab)
Jennings, D, 388(ab), 859(ab)
Jeon, TJ, 891(ab)
Jeong, H, 1125(ab), 1129(ab)
Jeong, J, 1360(ab)
Jeong, JM, 87(ab), 88(ab), 90(ab), 401(ab), 535(ab), 540(ab), 808(ab), 874(ab), 1054(ab), 1117(ab), 1125(ab), 1129(ab), 1130(ab), 1197(ab), 1203(ab), 1205(ab), 1342(ab), 1350(ab)
Jeong, M, 1311(ab)
Jeong, MH, 508(ab)
Jeong, SY, 758(ab)
Jerusalem, G, 533, 596(ab), 1237(ab)
Jha, N, 1200(ab)
Jhiang, SM, 110(ab)
Jia, F, 1318(ab)
Jiang, S, 1319(ab)
Jiang, SB, 1096(ab), 1107(ab)
Jiang, SL, 287(ab)
Jiang, XJ, 469(ab)
Jimbo, M, 1003(ab)
Jin, YJ, 365(ab), 1002(ab)
Jo, MK, 1453(ab)
Joe, A, 568(ab)
Joe, CW, 1493(ab)
Johnson, BG, 797(ab)

Johnson, CA, 529(ab)
Johnson, G, 611(ab), 612(ab), 1367(ab), 1451(ab), 1465(ab)
Jokura, H, 565
Jones, AG, 320(ab)
Jones, DA, 1263
Jones, DW, 224(ab)
Jones, HA, 483(le)
Jones, JR, 1466(ab)
Jønsson, V, 177
Jordan, R, 2027
Jorna, FH, 1187(ab)
Joseph, K, 1362(ab)
Joshi, S, 1123(ab)
Joshi, U, 554(ab), 1022(ab)
Joyce, M, 429(ab), 430(ab), 1385(ab)
Juarez, U, 777(ab)
Juengling, FD, 956(ab)
Juergens, H, 1238(ab)
Juh, RH, 821(ab), 851(ab)
Juhasz, C, 39(ab), 373(ab)
Julyan, PJ, 44(ab)
Jun, N-L, 725
Jung, G, 1360(ab)
Jung, H, 954(ab)
Jung, HE, 540(ab)
Jung, JH, 1371(ab)
Jung, YW, 341(ab), 1121(ab)
Junginger, T, 1424(ab)
Junila, JA, 1368(le)
Junqué, C, 1884
Jürgens, H, 997(le)
Juweid, M, 139(ab), 232(ab), 473(ab), 616(ab), 1244(ab), 1378(ab), 1495(ab)

Kachi, T, 822(ab)
Kaciroti, N, 915
Kadalie, C, 929(ab)
Kadrmas, DJ, 126(ab), 531(ab), 769(ab), 976(ab)
Kagana, O, 436(ab)
Kagawa, K, 373(ab)
Kahn, D, 1495(ab)
Kaiboriboon, K, 60(ab)
Kaim, A, 1227(ab)
Kaiser, H-J, 33
Kaiser, HJ, 274(ab)
Kaiser, LR, 1390(ab)
Kaji, T, 385(ab), 792(ab), 884(ab), 934(ab), 1168, 1192(ab), 1201(ab)
Kakiuchi, T, 223(ab)
Kalaigian, H, 969(ab), 1940
Kalapparambath, A, 566(ab)
Kalapparambath, TP, 1195(le)
Kalbe, E, 831(ab)
Kalff, V, 1484(ab)
Kalnischke, H, 1041(ab)
Kam, BLR, 140
Kambara, N, 14(ab), 750(ab)
Kamel, EM, 1911
Kameyama, K, 564(ab)
Kameyama, M, 948(ab), 959(ab)
Kaminski, M, 99(ab), 105(ab)
Kaminski, MS, 457, 1541(le)
Kampen, WU, 6(ab), 141(ab), 247, 489(ab), 538(ab), 557(ab), 559, 1217(ab)
Kanai, Y, 244
Kanamaru, R, 690
Kanayama, S, 275(ab)
Kaneko, K, 838(ab)
Kaneta, T, 745(ab)
Kanetaka, H, 825(ab), 830(ab), 840(ab), 1243
Kang, D, 846(ab), 1360(ab), 1447(ab)
Kang, E, 46(ab), 61(ab), 818(ab), 861(ab), 892(ab), 1435
Kang, H, 61(ab)
Kang, JH, 87(ab), 88(ab), 90(ab), 130(ab), 1197(ab), 1203(ab), 1205(ab)
Kang, W, 725
Kang, WJ, 12(ab), 58(ab), 401(ab), 602(ab), 808(ab), 1342(ab), 1350(ab), 1735
Kang, WS, 954(ab)
Kang, X, 7(ab), 743(ab), 1633
Kang, YK, 1432(ab)
Kanja, J, 75(ab), 1344(ab)
Kanno, T, 1051, 1346(ab), 1435(ab)
Kantar, M, 1394
Kantor, S, 302(ab)
Kantorová, I, 1784
Kao, CK, 813(ab)
Kao, CM, 999(ab)
Kao, MS, 1450(ab)
Kao, P, 860(ab), 1429(ab)
Kao, PF, 1387(ab), 1428(ab)
Kao, T, 911(ab)
Kapelanski, DP, 1009(ab)
Kaplan, HJ, 1122(ab)
Kappes, R, 1443(ab), 1444(ab)
Kara, G, 1267(ab), 1377(ab), 1380(ab), 1481(ab)
Karacay, H, 575(ab), 1057(ab), 1293(ab)
Karak, PK, 591(ab)
Karam, M, 132(ab), 133(ab)
Karamoskos, P, 239(ab)
Karanikas, G, 234(ab), 567(ab)
Karelin, Y, 1105(ab)
Karlsson, A, 1324(ab)
Karp, JS, 25(ab), 532(ab), 1340, 1890
Karthikeyan, G, 762(ab)
Karvelis, KC, 1234(ab)
Karwal, M, 1464(ab), 1556
Karwath, P, 1072(ab)
Kasai, S, 1207(ab)
Kasai, T, 766(ab)
Kasama, S, 884
Kasamatsu, S, 254(ab), 1305(ab)
Kashimada, A, 842(ab), 1339(ab)
Kashiwagi, T, 924(ab), 1001(ab)
Kasperbauer, JL, 1402
Kasperek, A, 1142(ab)
Kassaee, A, 72(ab), 1456(ab)
Kassis, AI, 111(ab), 1083(ab), 1095(ab), 1479
Kastis, GA, 705(ab), 1307(ab)
Katafuchi, T, 759(ab)
Kataria, R, 774(ab)
Katayama, Y, 843(ab)
Kato, K, 719(ab), 1717
Kato, M, 157(ab), 318(ab)
Kato, R, 947(ab)
Kato, T, 787(ab), 796(ab), 822(ab), 947(ab)
Katoh, C, 129(ab), 291(ab), 292(ab), 294(ab), 385(ab), 414(ab), 516(ab), 524(ab), 721(ab), 883(ab), 884(ab), 934(ab), 1010(ab), 1037(ab), 1192(ab)
Katoh, N, 883(ab)
Katsifis, A, 56(ab)
Katuta, T, 560(ab)
Katz, N, 862(ab)
Katzenellenbogen, JA, 428(ab)
Kaufer, DI, 50(ab), 398(ab), 837(ab)
Kauffmann, P, 411(ab)
Kaufmann, PA, 146
Kawabe, J, 353
Kawagoe NM Study Group, 37(ab)
Kawai, K, 244, 625, 815(ab)
Kawai, M, 707(ab)
Kawakami, Y, 190(ab), 1270(ab)
Kawamoto Masami, M, 1266(ab)
Kawamura, K, 223(ab)
Kawano, M, 187(ab), 369, 1612
Kawano, T, 1452(ab)
Kawashima, A, 342(ab)
Kawashima, H, 83(ab)
Kawashima, S, 707(ab)
Kawasumi, Y, 796(ab)
Kawata, T, 834(ab)
Kawatsu, S, 787(ab), 822(ab), 947(ab)
Kazama, T, 268(ab), 269(ab), 610(ab)
Keane, MJ, 484(le)
Keech, F, 38N(6)
Keen, H, 586(ab)
Kegeles, LS, 226(ab), 228(ab), 807(ab)
Keidar, Z, 65(ab), 421(ab), 436(ab), 470(ab), 1200, 1214(ab)
Keiding, S, 22(ab), 1206(ab), 1302(ab), 1359(ab), 1862
Keiper, D, 251(ab)
Keith, D, 703(ab), 1055(ab)
Keith, RA, 607(ab)
Kelley, DE, 896(ab)
Kelly, MJ, 1484(ab)
Kelly, R, 85
Kelly, S, 728(ab)
Kelsch, DN, 359(ab)
Kema, IP, 184
Kemerink, G, 391
Kemerink, GJ, 5(ab), 947
Kemna, L, 863(ab)
Kemp, A, 1244(ab)
Kemp, BJ, 903(ab)
Kenk, M, 714(ab)
Kennel, SJ, 792
Kent, PJ, 186(ab)
Kepe, V, 222(ab)
Keppel, C, 251(ab)
Keppens, J, 63(ab)
Kerger, J, 425(ab)
Kerrou, K, 1392(ab), 1397(ab), 1398(ab)
Kerrouche, N, 51(ab)
Kerwin, RW, 788(ab)
Kesmodel, SB, 410(ab)
Kesner, AL, 1064(ab), 1333(ab)
Kessler, H, 148(ab)
Kessler, RM, 113(ab)
Khafif, A, 1413
Khalil, MM, 368(ab)
Khan, MA, 1300(ab)
Khan, MK, 1094(ab)
Khanna-Hazra, P, 1480(ab)
Khatibi, B, 248(ab), 857(ab)
Khaw, P, 435(ab)
Khawli, LA, 1079(ab)
Khazaeli, MB, 334(ab), 494(ab), 1159(ab)
Kherbache, H, 1441(ab)
Khorsand, A, 1741
Khoury, JD, 352(ab)
Kibel, AS, 549
Kiblawi, S, 457(ab)
Kieffer, D, 947
Kieffer, V, 752(ab)
Kiemeney, LA, 427(ab)
Kies, P, 510(ab), 1379(ab)
Kiesewetter, DO, 1330, 1333(ab)
Kietselaer, BL, 509(ab)
Kiffel, T, 474(ab)
Kijewski, MF, 24(ab), 197(ab), 973(ab)
Kikuchi, K, 534(ab), 768(ab), 1454(ab)
Kilts, CD, 153(ab), 855
Kim, AY, 1432(ab)
Kim, BG, 487(ab)
Kim, BI, 1371(ab), 1388(ab), 1399(ab), 1453(ab), 1472(ab)
Kim, BN, 892(ab)
Kim, BS, 1432(ab)
Kim, BT, 66(ab), 67(ab), 513(ab), 819(ab), 1099(ab), 1126(ab), 1226(ab), 1345(ab)
Kim, C, 1071(ab), 1078(ab)
Kim, CK, 19(ab), 200(ab), 290(ab), 480(ab), 508(ab), 770(ab), 773(ab), 972(ab), 992(le), 1125(ab), 1129(ab), 1387
Kim, CS, 1435
Kim, DG, 540(ab)
Kim, DH, 954(ab)
Kim, DK, 244
Kim, E, 1077(ab), 1078(ab), 1125(ab), 1129(ab)
Kim, EE, 319(ab), 322(ab), 508(ab), 789(ab), 1067(ab), 1071(ab), 1082(ab), 1084(ab), 1157(ab), 1158(ab), 1818
Kim, ES, 496(ab)
Kim, GE, 1439(ab)
Kim, H, 525(ab), 818(ab), 1447(ab)
Kim, HC, 1493(ab)
Kim, HH, 1387
Kim, HJ, 891(ab), 893(ab), 954(ab)
Kim, HS, 1091(ab), 1112(ab)
Kim, HW, 808(ab), 1054(ab)
Kim, IJ, 1373(ab), 1395(ab)
Kim, J, 846(ab)
Kim, J-W, 1435
Kim, JD, 1437(ab)
Kim, JH, 344(ab), 487(ab), 850(ab), 1212(ab), 725
Kim, JJ, 182(ab)
Kim, JS, 182(ab), 496(ab), 851(ab), 915(ab), 1393(ab), 1432(ab), 1448(ab)
Kim, JY, 571(ab), 1140(ab), 1395(ab)
Kim, K, 947(ab)
Kim, K-B, 1735
Kim, KB, 12(ab), 16(ab), 737(ab)
Kim, KH, 874(ab)
Kim, KI, 87(ab), 88(ab), 90(ab), 1197(ab), 1203(ab), 1205(ab)
Kim, KJ, 602(ab), 1278(ab)
Kim, KM, 512, 906(ab), 992(ab)
Kim, KS, 725
Kim, M, 1360(ab)
Kim, M-H, 347
Kim, MW, 1210(ab)
Kim, NB, 344(ab), 850(ab), 1212(ab)
Kim, S, 130(ab), 540(ab), 571(ab), 874(ab)
Kim, S-K, 1006
Kim, SE, 66(ab), 67(ab), 513(ab), 819(ab), 1099(ab), 1126(ab), 1226(ab), 1345(ab), 870
Kim, SH, 821(ab), 851(ab), 1182(ab), 1278(ab)
Kim, SJ, 1373(ab)
Kim, SK, 303(ab), 535(ab)
Kim, SM, 485(ab), 487(ab), 508(ab), 571(ab), 1087(ab), 1139(ab), 1265(ab)
Kim, SW, 1060(ab)
Kim, SY, 1393(ab)
Kim, W, 508(ab)
Kim, Y, 1365(ab)
Kim, YB, 1370(ab)
Kim, YH, 66(ab), 67(ab), 87(ab), 90(ab), 513(ab), 718(ab), 819(ab), 1226(ab), 1345(ab)
Kim, YJ, 1054(ab), 1117(ab), 1130(ab)
Kim, YK, 211(ab), 1006, 1373(ab), 1395(ab)
Kim, YT, 401(ab)
Kimes, A, 215(ab)
Kimiaei, S, 209(ab)
Kimura, T, 14(ab), 750(ab)
Kimura, Y, 221(ab), 223(ab), 843(ab)
Kinahan, P, 594, 1044
Kinahan, PE, 276, 415(ab), 520(ab), 913(ab), 915(ab), 1855
King, MA, 987(ab), 1038(ab), 1725
King, P, 780(ab), 1239(ab), 1522
Kinney, G, 348(ab)
Kinney, NM, 1144(ab)
Kino, S, 475, 1207(ab)
Kinoshita, Y, 277(ab)
Kinscherf, R, 1332(ab)
Kinuya, K, 1043(ab)
Kinuya, S, 288(ab), 329(ab), 475, 736(ab), 1291(ab), 1436(ab), 1476(ab)
Kir, KM, 1287(ab), 1380(ab)
Kiratli, PO, 1267(ab)

Kirch, D, 484(le), 993(le)
Kirch, DL, 205(ab), 511(ab), 518(ab)
Kirichian, AM, 111(ab)
Kirrstetter, M, 733(ab)
Kishibe, Y, 866(ab)
Kiso, K, 740(ab), 753(ab), 759(ab)
Kisrieva-Ware, Z, 347(ab), 367(ab)
Kissel, M, 973
Kisselgoff, D, 1260(ab)
Kita, T, 14(ab), 750(ab)
Kitabatake, A, 292(ab), 294(ab), 516(ab), 713(ab)
Kitada, S, 325
Kitagawa, K, 505
Kitagawa, Y, 198, 1005(ab)
Kitajima, M, 1005(ab)
Kitamura, K, 904(ab), 974(ab)
Kitamura, S, 843(ab)
Kitani, H, 1001(ab)
Kitano, H, 49(ab), 417, 864(ab)
Kitapci, MT, 926(ab)
Kitsos, T, 1235(ab)
Kjaer, A, 19
Klaffke, S, 394(ab)
Klein, G, 899(ab)
Klein, GJ, 460(ab)
Klein, R, 169(ab)
Klein, RL, 1258(ab)
Klemm, E, 572(ab)
Kletter, K, 1741
Klingelhöfer, J, 671
Klipper, R, 1097(ab), 1992
Kloos, RT, 110(ab)
Klose, KJ, 551(ab)
Kloska, S, 873(ab)
Kluge, R, 188(ab), 723(ab)
Knapp, FF (Russ), Jr., 953
Knapp, WH, 1445(ab), 1473(ab)
Knesaurek, K, 19(ab), 200(ab), 290(ab), 773(ab), 972(ab)
KneŠaurek, K, 1350
Knight, LC, 302(ab)
Knight, S, 435(ab)
Knight, Y, 422
Knudsen, BS, 580(ab)
Knudsen, GM, 943(ab)
Knuuti, J, 682
Kobayashi, H, 577(ab), 760(ab)
Kobayashi, K, 1421, 1476(ab)
Kobayashi, M, 520
Kobayashi, S, 843(ab)
Kobayashi, T, 223(ab)
Koca, G, 1287(ab)
Koch, A, 131(ab)
Koch, H, 306(ab)
Koch, K-C, 33
Koch, W, 36(ab), 372(ab), 390(ab), 862, 918(ab), 942(ab)
Koczan, D, 257(ab), 258(ab)
Kodama, C, 825(ab)
Kodama, Y, 1376(ab), 1442(ab)
Kodimer, K, 1137(ab)
Koepfli, P, 146
Koeppe, RA, 31(ab), 915
Koepsell, H, 1075, 1973
Koga, H, 838(ab)
Kohanim, S, 319(ab), 1067(ab), 1071(ab), 1077(ab), 1078(ab), 1158(ab)
Kohlmyer, S, 362(ab), 449(ab), 527(ab), 1011(ab), 1045(ab)
Kohlmyer, SG, 363(ab)
Kohno, M, 291(ab)
Kohya, T, 516(ab), 713(ab)
Kolbert, K, 1543(le)
Kolbert, KS, 260, 784, 1148, 1940
Koletzko, S, 1246(ab)
Kolodgie, F, 1(ab)
Komaki, R, 1045(ab)
Komatsu, N, 1618
Komeda, M, 17(ab), 745
Komori, T, 53(ab), 900(ab)
Komuro, I, 4(ab), 343(ab)
Kondo, T, 379(ab)
Konijnenberg, MW, 330(ab), 1146(ab)
Konishi, J, 14(ab), 17(ab), 49(ab), 417, 738(ab), 745, 750(ab), 864(ab), 912(ab), 1314(ab), 1357(ab), 1358(ab), 1369(ab)
Konishi, S, 1093(ab), 1173(ab)
Konishi, T, 429(ab), 430(ab), 1385(ab)
Kononov, Y, 440(ab)
Konstan, MW, 594(ab)
Koo, J, 1435
Kooij, PP, 330(ab), 442(ab), 1146(ab)
Koole, M, 1048(ab)
Koparal, H, 1287(ab)
Kopin, IJ, 1599
Kopka, K, 709(ab)
Kopp, J, 451
Koppe, MJ, 578(ab)
Koral, KF, 457, 1541(le)
Koren, P, 742(ab)
Korf, J, 63(ab)
Kornhuber, J, 824(ab)
Kornmehl, E, 465
Kosaka, N, 379(ab)
Kosinski, M, 1649, 71(ab)
Koss, J, 484(le), 993(le)
Koss, JE, 205(ab), 511(ab), 518(ab)
Kostakoglu, L, 105(ab), 224, 236(ab), 429(ab), 430(ab), 1155(ab), 1167(ab), 1222(ab), 1351(ab), 1385(ab)
Kosuda, S, 1426(ab), 385
Kothari, KK, 1123(ab)
Kothari, P, 429(ab), 430(ab), 1093(ab), 1173(ab), 1385(ab)
Kotzerke, J, 434(ab), 1426
Kotzki, P-O, 1013
Koulibaly, PM, 40(ab), 55(ab), 1184
Koutcher, JA, 784, 1148
Koutsikos, J, 413(ab)
Kovacs, Z, 1098(ab)
Koyama, K, 353
Koyuncu, A, 763(ab)
Kracht, L, 545(ab)
Kracht, LW, 533(ab)
Kraeber-Bodere, F, 2000
Krais, R, 202(ab)
Kraitchman, DL, 710(ab)
Krak, NC, 936(ab)
Kraly, BM, 962(ab), 964(ab)
Kramer, K, 1301(ab)
Kramer, MR, 1272(ab)
Kranert, WT, 1065
Krasna, MJ, 1335(ab)
Krause, T, 956(ab)
Krausz, Y, 470(ab), 1260(ab), 1272(ab)
Krawczynska, E, 134
Krenning, EP, 98, 140, 330(ab), 442(ab), 443(ab), 877, 1146(ab), 1315
Krishnamurthy, GT, 499, 1544(le)
Krishnamurthy, S, 499
Kritzman, JN, 456(ab), 730(ab), 747(ab), 755(ab)
Krohn, KA, 31(ab), 412(ab), 415(ab), 416(ab), 786(ab), 872(ab), 878(ab), 1340(ab), 1482, 2027
Kroll, S, 99(ab)
Kronauge, JF, 703(ab)
Kropp, J, 953
Krynyckyi, B, 19(ab), 290(ab), 770(ab), 972(ab)
Krynyckyi, BR, 200(ab), 327(ab), 480(ab), 773(ab), 992(le), 1350, 1387
Kuang, AR, 300(ab), 937(ab), 984(ab)
Kuang, L, 1289(ab)
Kuang, RA, 1194(ab)
Kübler, W, 973
Kubo, A, 385, 1005(ab), 1089(ab)
Kubo, N, 524(ab), 1010(ab), 1037(ab)
Kubo, S, 234(ab), 567(ab), 738(ab), 745, 750(ab), 1873(le)
Kubodera, A, 625
Kubota, I, 1747
Kubota, K, 265(ab), 690
Kubota, N, 625
Kubota, T, 1421
Kucuk, NO, 1287(ab)
Kudo, G, 1446(ab)
Kudoh, K, 1201(ab)
Kudomi, N, 701(ab), 906(ab)
Kuehl, H, 274(ab), 1344(ab)
Kuenstner, H, 131(ab)
Kuesters, B, 316(ab)
Kugaya, A, 119(ab)
Kuge, Y, 92, 256(ab), 292(ab), 294(ab), 385(ab), 414(ab), 516(ab), 524(ab), 583(ab), 587(ab), 713(ab), 721(ab), 792(ab), 883(ab), 884(ab), 934(ab), 1120(ab), 1168, 1192(ab), 1467
Kuikka, JT, 487
Kuji, I, 793(ab)
Kula, NS, 166(ab), 1055(ab)
Kulkarni, PV, 523(ab), 528(ab)
Kull, T, 965(ab)
Kumabe, T, 565
Kumagai, H, 1273(ab)
Kumakura, H, 884
Kumakura, Y, 948(ab), 959(ab)
Kumar, A, 486(ab), 1242(ab)
Kumar, D, 1235(ab)
Kumar, JSD, 1110(ab), 1111(ab), 1127(ab)
Kumar, R, 7, 762(ab), 1209(ab), 1215(ab), 1261(ab)
Kumar, V, 1235(ab)
Kummer, C, 107(ab)
Kundra, V, 92(ab), 1034(ab)
Kunert, P, 671
Kung, H, 389(ab), 852(ab), 853(ab), 854(ab)
Kung, HF, 1890, 325(ab), 377(ab)
Kung, MP, 377(ab)
Kunjummen, BD, 726(ab)
Kunjummun, BD, 184(ab)
Kunjunmen, BD, 1191(ab)
Kupsch, A, 394(ab)
Kupzov, E, 183(ab)
Kurabayashi, M, 884
Kurami, M, 707(ab)
Kurdziel, KA, 1152(ab), 1330
Kurihara, H, 173(ab), 745(ab), 757(ab), 764(ab)
Kuroda, A, 609(ab)
Kuroda, K, 1352(ab)
Kuroiwa, T, 1839
Kuroki, K, 1510
Kurz, A, 54(ab)
Kusakabe, K, 760(ab)
Kusano, S, 1426(ab)
Kusuhara, T, 865(ab)
Kuten, A, 1200
Kuusisto, J, 487
Kuwahara, H, 41(ab), 42(ab), 47(ab), 215(ab), 810(ab)
Kuwabara, Y, 838(ab)
Kuwert, T, 284(ab), 824(ab), 1315(ab), 1423(ab)
Kuyvenhoven, JD, 659(le)
Kvaternik, H, 504(ab)
Kvols, L, 443(ab)
Kwack, HS, 542(ab), 1309(ab)
Kwak, HS, 1373(ab)
Kwekkeboom, DJ, 442(ab), 1146(ab)
Kwong, KF, 1335(ab)
Kyme, AZ, 206(ab), 994(ab)

La Cava, G, 371(ab), 1057, 1755
Laakso, M, 487
Lac, S, 797(ab)
Lacan, G, 1064(ab)
Lackner, K, 533(ab)
Lacy, MQ, 569(ab)
Ladas, TP, 962(ab)
Ladu, C, 1057
Laforest, R, 519(ab), 1017(ab)
laFougere, C, 143(ab)
Lago, G, 1561
Laboutte, T, 286(ab), 459(ab), 993(ab), 1013(ab), 1489
Lai, C, 1429(ab)
Lai, C-H, 1775
Lai, CH, 1387(ab), 1428(ab), 1430(ab), 1431(ab), 1455(ab)
Lai, PH, 1133(ab)
Lai, WF, 1327(ab)
Lajeunesse, S, 505(ab)
Lam, MG, 1177(ab), 1188(ab)
Lam, PT, 995(le)
Lamberts, SWJ, 1315
Lammertsma, AA, 936(ab), 967(ab), 1663
Lamon, A, 1169(ab)
Lamonica, D, 2000
Lampl, Y, 1898
Lancelin, B, 761(ab)
Landaw, EM, 951(ab)
Landi, A, 397(ab)
Landoni, C, 245(ab), 264(ab)
Lang, L, 62(ab), 1056(ab)
Lang, M, 1690
Lang, O, 848(ab), 1218(ab)
Langen, KJ, 873(ab), 879(ab), 881(ab)
Långström, B, 1176
Lanza, RC, 1240(ab)
Larikka, MJ, 1368(le)
Larisch, R, 618
Larsen, RH, 252
Larson, S, 1068(ab)
Larson, SM, 82(ab), 101(ab), 124(ab), 159(ab), 185(ab), 260, 378(ab), 424(ab), 465(ab), 527(ab), 552(ab), 570(ab), 576(ab), 968(ab), 969(ab), 988, 1073(ab), 1148, 1153(ab), 1290(ab), 1292(ab), 1349(ab), 1407, 1417(ab), 1420(ab), 1489(ab), 1543(le), 1644, 1789, 1940, 1962
Lartizien, C, 276, 915(ab)
Laruelle, M, 33(ab), 34(ab), 109(ab), 118(ab), 214(ab), 218(ab), 220(ab), 226(ab), 228(ab), 231(ab), 603(ab), 807(ab), 812(ab), 1049(ab), 1053(ab)
Latteri, F, 871(ab)
Lattimer, J, 1510
Lau, J, 717
Lauckner, K, 455(ab)
Lauer, I, 1224(ab)
Lauer, MS, 134
Lauer, T, 641
Lauerma, K, 487
Laurier, L, 708(ab)
Lavallee, E, 985(ab)
Laverman, P, 317(ab)
Lawson, S, 898
Lawton, TJ, 250(ab), 1310(ab), 1806
Layfield, D, 1982
Laymon, CM, 364(ab), 983(ab)
Lazaris, D, 413(ab)
Lazaro, D, 1032(ab)
Lazarova, N, 162(ab)
Lazzeri, E, 478(ab), 1164(ab)
Le Bars, D, 1495
Le Bouedec, G, 411(ab)
Le Cloirec, J, 1767
Le Guludec, D, 155, 319(le), 176(ab), 177(ab), 178(ab), 181(ab), 708(ab), 734(ab), 749(ab), 767(ab), 771(ab), 920, 1274(ab), 1275(ab)
Le, K, 94(ab)
Leal, J, 1797
Leal, JP, 240, 422(ab), 927(ab)
Leb, G, 305(ab), 306(ab)
Lebellec, Y, 920
LeBlanc, JK, 74(ab)
Lebtahi, R, 155, 176(ab), 177(ab), 178(ab), 734(ab), 767(ab), 771(ab), 920, 1274(ab), 1275(ab)

Lecomte, R, 285(ab), 985(ab), 1334(ab), 1655
Lecouffe, P, 391(ab)
Lee, B, 1408(ab)
Lee, BC, 730(ab), 1126(ab), 1388(ab)
Lee, BI, 921(ab), 957(ab)
Lee, CC, 549(ab)
Lee, CH, 542(ab), 1309(ab)
Lee, CM, 323(ab), 1139(ab)
Lee, D, 155(ab), 544(ab)
Lee, DS, 12(ab), 16(ab), 46(ab), 58(ab), 61(ab), 87(ab), 88(ab), 90(ab), 130(ab), 401(ab), 535(ab), 540(ab), 571(ab), 602(ab), 737(ab), 808(ab), 818(ab), 841(ab), 861(ab), 868(ab), 874(ab), 892(ab), 921(ab), 957(ab), 1006, 1054(ab), 1117(ab), 1130(ab), 1197(ab), 1203(ab), 1205(ab), 1342(ab), 1350(ab), 1435, 1457(ab), 1641, 1735
Lee, EJ, 66(ab), 67(ab), 513(ab), 718(ab), 1226(ab), 1345(ab)
Lee, F, 100(ab)
Lee, F-T, 1105
Lee, FT, 1282
Lee, GH, 1432(ab)
Lee, H, 1337(ab)
Lee, HK, 182(ab), 725
Lee, HM, 1453(ab)
Lee, HY, 16(ab), 535(ab), 808(ab), 841(ab), 868(ab), 1457(ab)
Lee, J, 758(ab), 1003(ab), 1117(ab)
Lee, JC, 790(ab)
Lee, JD, 891(ab), 893(ab), 954(ab), 1365(ab), 1370(ab), 1410(ab), 1439(ab), 1440(ab)
Lee, JI, 1399(ab)
Lee, JJ, 496(ab), 602(ab)
Lee, JS, 41(ab), 42(ab), 46(ab), 58(ab), 215(ab), 841(ab), 861(ab), 906(ab), 921(ab), 957(ab), 1435
Lee, JW, 732(ab)
Lee, K, 520(ab)
Lee, K-H, 347
Lee, KB, 758(ab)
Lee, KH, 66(ab), 67(ab), 513(ab), 718(ab), 819(ab), 1099(ab), 1126(ab), 1226(ab), 1236(ab), 1345(ab)
Lee, KS, 224(ab), 851(ab)
Lee, KY, 323(ab), 1087(ab), 1139(ab)
Lee, MC, 12(ab), 13N(5) 16(ab), 46(ab), 58(ab), 61(ab), 87(ab), 88(ab), 90(ab), 130(ab), 401(ab), 535(ab), 540(ab), 571(ab), 602(ab), 737(ab), 808(ab), 818(ab), 841(ab), 868(ab), 874(ab), 892(ab), 957(ab), 1006, 1054(ab), 1117(ab), 1130(ab), 1197(ab), 1203(ab), 1205(ab), 1342(ab), 1350(ab), 1435, 1457(ab), 1641, 1735, 2033
Lee, MH, 1493(ab)
Lee, MJ, 813(ab)
Lee, MM, 737(ab)
Lee, MS, 844(ab)
Lee, SG, 1448(ab)
Lee, SH, 513(ab), 954(ab)
Lee, SK, 61(ab), 808(ab), 841(ab), 1006
Lee, SO, 1210(ab)
Lee, SY, 725, 1099(ab), 1278(ab)
Lee, TS, 462(ab), 790(ab), 1060(ab)
Lee, TW, 1299(ab)
Lee, U, 850(ab)
Lee, VW, 1179(ab), 1494(ab)
Lee, WW, 1448(ab)
Lee, WY, 870
Lee, Y-S, 2033
Lee, YJ, 87(ab), 88(ab), 90(ab), 1197(ab), 1203(ab), 1205(ab)
Lee, YS, 1388(ab)
Lee, Z, 594(ab), 1276(ab)
Leenders, WP, 316(ab)
Leenhardt, A, 181(ab), 749(ab)
Leeper, DL, 1293
Leeuw de, K, 146(ab)
Lehman, GA, 74(ab)
Lehmann, J, 812(ab)
Lehner, T, 702(ab), 704(ab)
Lehnhardt, FG, 533(ab)
Lehovich, A, 525(ab)
Lehrer, D, 811(ab)
Lei, Y, 1096(ab), 1107(ab)
Leiderman, M, 65(ab)
Leigh, B, 465
Leinsinger, G, 597(ab)
Lejeune-Prigent, F, 1413(ab)
Lemahieu, I, 919(ab), 1048(ab)
Lemaire, C, 533
Lemstra, C, 1187(ab)
Leonardi, L, 871(ab)
Leoncini, M, 746(ab)
Leonidas, JC, 1072
Leopold, N, 852(ab), 853(ab)
Lépine, M, 1225
Leppo, JA, 987(ab), 1038(ab), 1725
Lerman, H, 1413
Lesko, NM, 455(ab), 1026(ab)
Leslie, F, 606(ab)
Lester, H, 161(ab), 862(ab)
Leucht, S, 897(ab)
Levadala, MK, 154(ab), 162(ab), 164(ab), 1100(ab)
Leveillee, RJ, 1281(ab)
Lever, SZ, 1318(ab)
Levin, CS, 196(ab), 450(ab), 1006(ab), 1009(ab)
Levin, DP, 1252(ab)
Levine, EA, 455(ab), 1026(ab)
Levitzki, A, 161(ab)
Levkau, B, 709(ab)
Levy, AV, 38(ab)
Lewellen, B, 872(ab), 1044
Lewellen, BL, 31(ab), 59(ab)
Lewellen, TK, 520(ab), 915(ab)
Lewis, BS, 355(ab)
Lewis, DH, 354(ab), 537(ab), 816(ab)
Lewis, JS, 254(ab), 1305(ab), 1306(ab)
Lewis, MA, 523(ab), 528(ab)
Lewis, MR, 1284, 1318(ab)
Lewis, PJ, 1379
Lewis, X, 94(ab), 97(ab), 1329(ab)
Lewis, XZ, 2(ab)
Leyton, M, 895(ab)
Lhommel, R, 276(ab)
Li, H, 1000(ab), 1015(ab), 1018(ab), 1019(ab), 1116(ab)
Li, J, 457, 815
Li, L, 300(ab), 937(ab), 984(ab), 1296(ab), 1469(ab)
Li, MH, 496(ab), 571(ab)
Li, R, 113(ab), 335(ab)
Li, S-T, 1599
Li, T, 137(ab), 481(ab), 979(ab), 995(ab), 1030(ab)
Li, XF, 1291(ab)
Li, Z, 165(ab), 949(ab), 1052(ab), 1165(ab), 1243
Lian, CH, 1251(ab)
Liang, L, 1408(ab)
Liang, Z, 979(ab), 995(ab)
Liao, SQ, 172(ab), 419(ab), 1251(ab), 1416(ab)
Liao, WH, 885(ab)
Liao, YC, 858(ab)
Libutti, SK, 201(ab), 266(ab)
Liebowitz, MR, 118(ab)
Liepe, K, 953
Lievshitz, G, 1413
Lill, M, 1496(ab)
Lim, S, 1496(ab)
Lim, SJ, 261(ab)
Lim, SM, 542(ab), 790(ab), 1309(ab), 1371(ab), 1388(ab), 1399(ab), 1410(ab), 1453(ab), 1472(ab)
Lim, ST, 1210(ab)
Limbruno, U, 720(ab)
Lin, J, 1254(ab)
Lin, J-C, 999
Lin, KJ, 888(ab), 1455(ab)
Lin, KS, 321(ab)
Lin, M, 276
Lin, Q, 457
Lin, SJ, 395(ab)
Lin, SZ, 844(ab)
Lin, TX, 439(ab), 877(ab)
Lin, W, 1459(ab)
Lin, W-J, 1775
Lin, WJ, 1387(ab), 1431(ab), 1455(ab)
Lin, WY, 1204(ab)
Lin, YK, 576(ab), 1085(ab)
Lin, YM, 1450(ab)
Lincke, T, 393(ab), 839, 849(ab)
Lincke, TJ, 855(ab)
Lincoln, C, 422
Linden, HM, 249(ab), 250(ab), 412(ab), 1310(ab), 1411(ab), 1806
Lindsley, SL, 1411(ab)
Line, BR, 280(ab), 447(ab), 774(ab), 1014(ab), 1221(ab), 1335(ab)
Ling, C, 378(ab), 1153(ab)
Ling, CC, 969(ab)
Link, B, 1495(ab)
Link, JM, 31(ab), 412(ab), 786(ab), 1303(ab)
Linke, R, 387(ab), 862, 1384(ab)
Links, JM, 366(ab), 412, 461(ab)
Liow, J, 529(ab), 781(ab)
Liow, J-S, 85
Liow, JS, 35(ab)
Lipiecki, J, 1625
Lipke, CS, 274(ab)
Lipowska, M, 1134(ab)
Lipp, RW, 305(ab), 306(ab)
Lippold, R, 1184(ab)
Lipská, L, 1784
Lipszyc, H, 327(ab), 480(ab)
Lira, A, 867(ab)
Lisbona, A, 1163(ab)
Little, DG, 1235(ab)
Liu, C, 326(ab), 1160(ab), 1331(ab)
Liu, CY, 888(ab)
Liu, G, 163(ab), 326(ab), 1070(ab), 1089(ab), 1115(ab), 1116(ab), 1124(ab), 1295(ab)
Liu, H, 770
Liu, HG, 69(ab), 536(ab), 867(ab), 1269(ab), 1353(ab), 1406(ab), 1492(ab)
Liu, HM, 69(ab)
Liu, J, 1293, 222(ab)
Liu, JC, 794(ab)
Liu, L, 1323(ab)
Liu, M, 1374(ab)
Liu, N, 1331(ab)
Liu, PT, 961(ab)
Liu, R, 1160(ab)
Liu, R-S, 999
Liu, RS, 155(ab), 172(ab), 313(ab), 370(ab), 380(ab), 399(ab), 419(ab), 544(ab), 858(ab), 911(ab), 932(ab), 999(ab), 1251(ab), 1256(ab), 1299(ab), 1327(ab), 1412(ab), 1416(ab)
Liu, S, 1087, 1131(ab)
Liu, X, 158(ab), 947, 1065(ab)
Liu, XJ, 9(ab), 13(ab), 15(ab), 180(ab), 189(ab), 350(ab), 469(ab)
Liu, Y, 958(ab), 1000(ab), 1015(ab), 1018(ab), 1019(ab), 1039(ab)
Liu, Y-H, 995(le)
Liu, Z, 525(ab), 705(ab), 1307(ab)
Livieratos, L, 358(ab), 490(ab)
Livingston, RB, 1806, 249(ab), 250(ab), 412(ab), 1310(ab), 1411(ab)
Livni, E, 217(ab)
Ljungberg, M, 491(ab), 1162(ab)
Lo, JM, 1106(ab), 1133(ab)
LoBuglio, AF, 334(ab), 434, 494(ab), 1159(ab)
Locher, J Th., 1210
Lochmann, M, 1184(ab)
Lodge, MA, 280(ab), 1014(ab), 1335(ab)
Loeffler, M, 550(ab), 1379(ab)
Loehe, F, 1347(ab)
Logan, J, 38(ab), 117(ab), 213(ab), 216(ab), 225(ab), 782(ab), 800(ab), 802(ab), 815
Lohith, TG, 916(ab)
Loiseau, P, 340(ab)
Lomena, FJ, 835(ab), 887(ab)
Loncar, R, 641
London, ED, 215(ab)
Longari, V, 406(ab)
Lonn, AH, 123(ab)
Lonneux, M, 425(ab)
López, L, 179(ab)
Lopresti, B, 50(ab), 398(ab), 837(ab)
Lorberboym, M, 904, 1898
Lordick, F, 1336(ab)
Lorenz, E, 530(ab)
Lorenz, W, 551(ab)
Loudos, G, 1032(ab)
Loudos, GK, 1028(ab)
Lourenco, CM, 714(ab)
Loutfi, I, 775(ab)
Louvrou, A, 413(ab)
Love, C, 147(ab), 311(ab), 483(ab), 488(ab), 1216(ab), 1229(ab), 1230(ab)
Love, P, 1044(ab)
Lowe, VJ, 1402
Lu, C, 860(ab)
Lu, HK, 553(ab), 1321(ab), 1462(ab)
Lu, JQ, 35(ab)
Lu, MJ, 287(ab)
Luck, Jr, JL, 1236(ab)
Luedemann, L, 394(ab)
Luescher, AU, 795(ab), 952(ab)
Lui, D, 1037
Lukas, J, 1547
Lundberg, J, 219(ab)
Luo, SZ, 1096(ab), 1107(ab)
Lupetti, A, 1368(le)
Lupi, E, 777(ab)
Luthra, SK, 80(ab)
Lütolf, UM, 24
Luu, A, 321(ab)
Luxen, A, 533
Lyass, O, 555(ab), 1496(ab)
Lyons, S, 586(ab)
Lyshchik, A, 1314(ab)

Ma, HX, 804(ab)
Ma, J, 484(le)
Ma, KH, 794(ab)
Ma, LL, 1469(ab)
Ma, S, 1429(ab)
Ma, S-Y, 1775
Ma, SY, 1387(ab), 1430(ab), 1431(ab), 1455(ab)
Ma, Y, 38(ab), 890(ab), 898(ab), 961, 1056(ab), 1522
Maas, B, 240(ab), 547(ab), 1927
Mabuchi, H, 1612
Mabuchi, M, 713(ab), 721(ab), 1037(ab)
Mac Manus, MP, 30
Macadziob, S, 904
Macapinlac, H, 362(ab), 1011(ab), 1045(ab)
Macapinlac, HA, 268(ab), 269(ab), 610(ab), 1407
Maceri, D, 1186(ab)
Mach, R, 814(ab)
Mach, RH, 715(ab), 975(ab)
Machac, J, 19(ab), 200(ab), 290(ab), 327(ab), 480(ab), 770(ab), 773(ab), 972(ab), 1350, 1387
Machac, J, 992(le)

Machida, K, 37(ab), 842(ab), 1339(ab)
Machtay, M, 1456(ab)
Machulla, H-J, 117
Machulla, HJ, 114(ab), 212(ab), 546(ab), 1304(ab)
Machulla, JH, 314(ab)
Mackie, GC, 239(ab)
MacNaught, K, 1725
Madar, I, 160(ab), 281(ab), 584(ab), 585(ab), 1312(ab)
Maddahi, J, 134, 8(ab)
Madeddu, G, 359, 1164(ab), 1219
Madison, S, 744(ab)
Madsen, K, 943(ab)
Madsen, M, 1464(ab), 1495(ab)
Madsen, MT, 1322(ab), 1419(ab)
Maeba, H, 173(ab), 757(ab), 764(ab)
Maecke, HR, 381(ab), 478(ab), 880(ab)
Maeda, H, 988(ab)
Maeda, M, 1051
Maeda, Y, 1001(ab)
Maehara, K, 1618
Maekura, R, 325
Maertens, J, 613(ab)
Magata, Y, 417, 701(ab), 738(ab), 1088(ab)
Mageras, G, 124(ab), 968(ab)
Magram, DN, 280(ab), 774(ab)
Magram, MY, 280(ab), 447(ab), 774(ab)
Magri, G, 558(ab)
Magri, GC, 1198(ab)
Mah, K, 122(ab), 244(ab)
Mahapatra, AK, 383(ab)
Mahe, B, 2000
Mahmood, A, 320(ab)
Mahmood, H, 909(ab)
Mahmood, S, 1199(ab)
Mahmut, M, 973
Mahone, T, 69(ab), 1269(ab)
Mahone, TJ, 1406(ab)
Mahoney, DW, 1138(ab)
Mahurin, RK, 816(ab)
Mahy, N, 425(ab)
Maigne, L, 1032(ab)
Maini, A, 41(ab), 42(ab), 47(ab), 215(ab), 805(ab), 810(ab)
Mainta, K, 1028(ab)
Maintas, D, 1028(ab)
Maioli, M, 746(ab)
Mair, B, 27(ab)
Maira, G, 1198(ab)
Maisch, B, 739(ab)
Majd, M, 600(ab)
Majewski, S, 251(ab), 526(ab), 1276(ab)
Majo, VJ, 1110(ab), 1111(ab), 1127(ab)
Major, O, 817(ab)
Majorel, C, 663
Mäki, M, 682
Makino, T, 1338(ab)
Makriyannis, A, 1052(ab)
Maksud, P, 973(ab)
Makuuchi, H, 68(ab)
Mala, C, 103(ab)
Malago', E, 1149(ab)
Malek, Z, 1459
Malhi, N, 1167(ab), 1385(ab)
Malhotra, A, 383(ab), 762(ab), 1209(ab), 1215(ab), 1261(ab)
Malhotra, G, 1202(ab), 1280(ab), 1285(ab)
Malison, RT, 220(ab)
Mallet, RW, 1284
Mallett, RW, 437
Mallidi, P, 1491(ab)
Malveaux, E, 151(ab), 1134(ab)
Malveaux, EJ, 153(ab), 605(ab), 1050(ab)
Malyapa, RS, 1306(ab)
Mamade, M, 750(ab)
Mamede, M, 17(ab), 49(ab), 738(ab), 745, 864(ab), 901(ab), 1356(ab), 1357(ab), 1358(ab), 1369(ab), 1873(le)
Mamede, MH, 1314(ab)
Manatunga, A, 1282(ab)
Manca, G, 134(ab), 396(ab), 562(ab), 1008(ab), 1443
Mandel, S, 1194(le)
Mandel, SJ, 301(ab)
Mandelli, E, 454(ab)
Mandl, SJ, 582(ab), 1069(ab)
Mandler, R, 577(ab)
Mancente, S, 477(ab)
Mangner, TJ, 1328(ab)
Manjeshwar, RM, 82(ab), 198(ab), 916(ab), 941(ab), 1033(ab)
Manka-Waluch, A, 568(ab)
Mankoff, DA, 249(ab), 250(ab), 412(ab), 594, 786(ab), 809(ab), 872(ab), 913(ab), 1044, 1303(ab), 1310(ab), 1411(ab), 1482, 1806
Mann, A, 231(ab)
Mann, JJ, 1110(ab), 1111(ab), 1127(ab)
Mann, K, 212(ab)
Mannelli, M, 1057
Manni, C, 1040(ab)
Manola, J, 77(ab)
Manone, T, 1492(ab)
Manor, G, 242(ab)
Manrique, A, 598(ab), 1013
Mansour, CS, 3(ab), 776(ab)
Mantil, J, 811(ab), 1051(ab)
Mar, M, 268(ab), 269(ab)
Maran, A, 477(ab)
Marchevsky, A, 440(ab), 441(ab), 1402(ab)
Mardirrosian, G, 2000
Mardon, K, 1459
Marek, K, 388(ab), 859(ab)
Marengo, M, 1422(ab)
Maresca, KP, 154(ab), 162(ab), 703(ab), 1055(ab)
Margouleff, C, 961
Mari, C, 582(ab), 783(ab), 1031(ab), 1069(ab)
Mariani, C, 397(ab)
Mariani, G, 134(ab), 396(ab), 478(ab), 501(ab), 562(ab), 846, 1008(ab), 1164(ab), 1253, 1443, 1468(ab)
Mariani, M, 720(ab)
Mariano-Goulart, D, 1761
Marongiu, P, 359, 1219
Marotta, G, 397(ab), 889(ab)
Marres, HAM, 1690
Marsee, DK, 110(ab)
Marseille, DM, 52(ab), 857(ab)
Marshall, C, 1383(ab)
Marshall, LT, 240, 412, 1419(ab)
Marshall, RC, 282(ab)
Marsland, B, 1142(ab)
Marsteller, D, 815
Marti-Climent, JM, 1172(ab)
Martin van Hagen, P, 1315
Martin-Comin, J, 1223(ab)
Martinez, D, 109(ab), 118(ab), 214(ab), 226(ab)
Martínez, M, 1561
Martinez, TD, 158(ab), 1065(ab)
Martino, M, 1232
Martins, B, 706(ab)
Martoni, A, 1422(ab)
Martos, J, 817(ab), 839(ab)
Martyn, FS, 1313(ab)
Martyn, S, 502(ab)
Martyn, SF, 1109(ab)
Maruno, H, 716(ab)
Maruoka, N, 791(ab)
Maruoka, S, 745(ab)
Maruyama, Y, 1618
Marwin**, SE, 311(ab), 488(ab), 1229(ab)
Marwin, SE, 1230(ab)
Marx, D, 85
Marzilli, LG, 1134(ab)
Marzullo, P, 720(ab)
Mas, JF, 458(ab), 729(ab)
Maschauer, S, 284(ab)
Mason, RP, 523(ab), 528(ab), 1324(ab)
Massoudi, S, 6(ab), 489(ab), 538(ab), 1217(ab)
Masud, MM, 1228(ab), 1415(ab)
Masuda, Y, 1273(ab)
Mataró, M, 1884
Matei, C, 1148, 784
Materassi, M, 1755
Mather, SJ, 708
Mathew, S, 347(ab)
Mathews, WB, 463(ab)
Mathias, CJ, 700
Mathieu, I, 425(ab)
Mathieu, J-P, 981
Mathis, CA, 50(ab), 398(ab), 837(ab), 896(ab)
Matsuda, H, 1243, 37(ab), 825(ab), 830(ab), 840(ab), 886(ab)
Matsudaira, M, 275(ab), 799(ab)
Matsui, T, 842(ab)
Matsumoto, K, 83(ab), 901(ab), 990(ab), 1020(ab)
Matsumoto, M, 505, 707(ab)
Matsumoto, T, 37(ab)
Matsumura, K, 829(ab), 1381(ab)
Matsumura, Y, 1905
Matsunaga, N, 190(ab), 593(ab), 1270(ab)
Matsunari, I, 275(ab), 329(ab), 342(ab), 799(ab)
Matsuura, H, 990(ab)
Mattar, AG, 512(ab)
Matteini, M, 548(ab)
Mattes, MJ, 632
Mattfeldt, T, 1426
Matthay, KK, 321(le)
Matthies, A, 2000
Matthies, A, 572(ab), 1072(ab), 1460(ab)
Matuda, J, 908(ab)
Maublant, J, 1625, 411(ab)
Maunoury, C, 601(ab)
Maurer, AH, 271(ab), 296(ab), 302(ab), 988
Maurer, G, 1741
Mauri, C, 889(ab)
Mausner, LF, 1101(ab)
Mawlawi, O, 214(ab), 362(ab), 981(ab), 1011(ab), 1045(ab)
Maxim, I, 920(ab)
Mayer, CL, 59(ab), 537(ab)
Mayer-Kuckuk, P, 93(ab)
Maynard, K, 22N(10), 32N(11)
Maynard, L, 38(ab)
Mazumdar, S, 896(ab)
Mazurchuk, RV, 930(ab)
Mazza, S, 484(le)
Mazzarotto, R, 1181(ab)
McAndrew, PF, 555(ab), 1496(ab)
McArthur, D, 1709
McBride, W, 1293(ab)
McBride, WJ, 575(ab), 1057(ab)
McCarthy, DJ, 607(ab)
McCaul, ME, 211(ab)
McClish, MA, 1004(ab)
McConathy, J, 151(ab), 153(ab), 543(ab), 605(ab), 1050(ab), 1156(ab)
McCready, VR, 1470(ab)
McDevitt, MR, 1301(ab), 497(ab)
McElvany, KD, 1221(ab)
McEwan, AJ, 1200(ab)
McFalls, EO, 85
McFarlane, N, 154(ab), 1100(ab)
McGahan, J, 135(ab)
McGann, CJ, 769(ab)
McGill, JB, 347(ab)
McHenry, L, 74(ab)
McIver, B, 1402
McKenna, R, 440(ab), 441(ab), 1402(ab)
McKinley, RL, 1029(ab)
McNally, K, 836(ab)
Meadows, J, 422
Mease, RC, 1058(ab)
Meave, A, 777(ab)
Megalooikonomou, V, 302(ab)
Mehl, C, 141(ab)
Mehlberg, LM, 39N(7)
Mehta, L, 964(ab)
Meignan, M, 899(ab), 1225(ab), 1271(ab), 1459
Meignan, MA, 1543(le)
Meijer, WG, 184
Meinken, GE, 1105(ab)
Meisenzahl, E, 116(ab)
Meisetschlaeger, G, 233(ab)
Melega, WP, 1064(ab)
Melfi, FM, 562(ab)
Melissinou, M, 413(ab)
Meller, B, 418(ab), 1023(ab)
Melliere, D, 474(ab)
Mellinghoff, I, 260(ab), 1325(ab)
Melotti, B, 1422(ab)
Meltzer, CC, 1855, 50(ab), 896(ab)
Meltzer, HY, 113(ab)
Mena, E, 179(ab), 1283(ab), 1372(ab)
Ménard, J-F, 1013
Menard, L, 407(ab)
Menconi, GF, 562(ab)
Menda, Y, 232(ab), 473(ab), 616(ab), 1244(ab), 1378(ab), 1419(ab), 1464(ab), 1495(ab), 1556
Mendez, J, 308(ab)
Méndez, J, 1677
Méndez, R, 322(ab), 1084(ab), 1172(ab)
Menichetti, F, 478(ab)
Mensink, HJ, 331
Menzel, C, 174(ab), 468(ab), 940(ab), 1065, 1193(ab), 1424(ab), 1460(ab), 1463(ab)
Mercier, JA, 715(ab)
Merdler, A, 355(ab)
Meredith, RF, 334(ab), 447(ab), 494(ab), 1159(ab)
Mergui, S, 454(ab)
Merla, VC, 766(ab)
Merlet, P, 711(ab), 1459
Merlet, PM, 706(ab), 708(ab)
Mertens, J, 163, 1489
Mesangeau, D, 706(ab), 708(ab)
Messa, C, 245(ab), 264(ab)
Mestas, D, 411(ab), 1625
Mester, J, 902(ab)
Metzler, S, 382(ab)
Metzler, SD, 1036(ab)
Meulemans, A, 319(le), 340(ab), 920
Meyer, C, 19, 1282(ab)
Meyer, DL, 437
Meyer, GJ, 1445(ab)
Meyer, J, 415(ab)
Meyer, MA, 930(ab)
Meyer, PT, 671, 839, 849(ab), 855(ab)
Miao, Y, 581(ab)
Miceli, RC, 422
Michalas, S, 413(ab)
Michalski, JM, 428(ab), 549
Michel, C, 980(ab)
Michel, JB, 340(ab)
Michel, R, 876(ab)
Michel, RB, 632
Micheli, LJ, 909
Michigishi, T, 187(ab), 1291(ab), 1476(ab)
Micucci, F, 815(ab)
Middlekauff, H, 931(ab)
Miederer, M, 1301(ab)
Mier, W, 1075(ab), 1113(ab), 1297(ab)
Mihout, B, 598(ab)
Mikolajczyk, K, 146
Milenson, MM, 271(ab)

Miller, JH, 1241(ab)
Miller, JW, 59(ab)
Miller, KD, 158(ab), 1065(ab)
Miller, MA, 375(ab), 376(ab), 795(ab), 952(ab)
Miller, S, 1556, 452(ab), 982(ab), 1464(ab)
Miller, SD, 1022(ab)
Miller, TR, 192, 549, 988
Mills, C, 7
Milstein, DM, 404(ab)
Min Jeong, J, 2033
Min, HS, 130(ab)
Min, JJ, 2(ab), 96(ab), 337(ab)
Minc, LD, 1094(ab)
Minematsu, K, 792(ab)
Minichilli, F, 1253
Minoshima, S, 31(ab), 59(ab), 329(ab), 834(ab), 872(ab), 1310(ab)
Minota, E, 83(ab)
Minski, I, 904
Mintun, M, 1017(ab)
Mintun, MA, 48(ab)
Minutoli, F, 1566
Mirtcheva, RM, 236(ab), 1222(ab)
Mirtcheva-Trocheva, R, 1351(ab)
Mishani, E, 161(ab)
Mishina, M, 843(ab)
Mishra, AK, 1076(ab)
Mishra, P, 1076(ab)
Missimer, J, 1210
Mitani, K, 843(ab)
Mitchell, LG, 1329(ab)
Mitchell, P, 100(ab), 435(ab), 1105
Mitra, DK, 1209(ab)
Mitsuhashi, N, 760(ab)
Mittal, R, 486(ab)
Miyabe, K, 1434(ab)
Miyagawa, M, 702(ab), 704(ab)
Miyagawa, T, 108(ab), 1308(ab), 1845
Miyake, M, 1228(ab)
Miyake, Y, 171(ab)
Miyama, M, 353
Miyamori, I, 540
Miyamoto, S, 864(ab)
Miyamoto, T, 1338(ab)
Miyaoka, RS, 520(ab)
Mizuno, S, 540, 948(ab), 959(ab)
Mizuta, T, 974(ab)
Mo, TS, 937(ab), 984(ab)
Mochizuki, T, 92, 256(ab), 534(ab), 923(ab), 1454(ab)
Modak, S, 576(ab)
Modell, K, 35(ab), 781(ab)
Modoni, S, 207
Moeller, HJ, 116(ab)
Mohammad, M, 772(ab)
Mohammed, AM, 775(ab)
Mohannadi, S, 909(ab), 1199(ab)
Moka, D, 255(ab), 1170(ab), 1189(ab)
Molfetta, L, 478(ab)
Molina, A, 1479(ab)
Moller, DH, 1239(ab), 1522
Moller, T, 1102(ab)
Momosaki, S, 796(ab)
Momose, M, 760(ab)
Momose, T, 948(ab), 959(ab)
Moncayo, R, 1375(ab), 708
Monden, T, 564(ab), 865(ab), 1343(ab), 1363(ab), 1391(ab), 1434(ab), 1490(ab)
Monden, T, 1905
Monetti, N, 1422(ab)
Monin, JL, 899(ab)
Montagne, O, 1459
Monteleone, F, 1219
Montero, A, 357(ab)
Montilla, J, 1361(ab)
Montilla, JL, 1427(ab)
Montravers, F, 1392(ab), 1397(ab), 1398(ab)
Monzani, F, 1164(ab)
Moon, BS, 1060(ab)
Moon, DH, 182(ab), 261(ab), 725, 732(ab), 1063(ab), 1103(ab), 1140(ab), 1279(ab), 1393(ab), 1448(ab)
Moon, WY, 1103(ab)
Moore, AE, 490(ab)
Moore, AEB, 891
Moore, RY, 50(ab), 398(ab), 837(ab)
Moore, SC, 24(ab), 197(ab), 210(ab), 973(ab)
Moosig, F, 141(ab)
Mor, M, 355(ab)
Moreau, P, 533
Moreau, S, 526
Morel, C, 1048(ab)
Moretti, A, 1422(ab)
Moretti, E, 806
Moretti, J-L, 1394
Mori, H, 793(ab)
Mori, K, 716(ab)
Mori, Y, 221(ab)
Moriguchi, K, 325
Morimoto, T, 1088(ab)
Morishita, E, 1001(ab)
Morita, K, 292(ab), 294(ab), 516(ab), 713(ab), 721(ab), 1037(ab), 1120(ab), 1467
Moritan, T, 1592
Morris, ED, 32(ab), 374(ab), 905(ab)
Morris, M, 424(ab)
Morris, MJ, 101(ab)
Morrish, DW, 1200(ab)
Mortelmans, L, 613(ab), 947, 1075, 1973
Morton, DL, 549(ab)
Morton, K, 455(ab)
Morton, KA, 521(ab), 715(ab), 814(ab), 975(ab), 1026(ab), 1175(ab)
Mosca, F, 134(ab)
Mosdzianowski, C, 1140(ab)
Moses, WW, 454(ab)
Mostafawi, H, 124(ab)
Motoishi, S, 1476(ab)
Motoki, N, 1120(ab)
Motomura, N, 524(ab)
Moulder, PV, 307(ab)
Mountain, A, 100(ab)
Mountz, JM, 536(ab), 867(ab), 1353(ab), 1406(ab)
Mourtzikos, KA, 128(ab), 199(ab), 273(ab), 310(ab), 422(ab), 423(ab), 471(ab), 590(ab), 1267, 1341(ab), 1403(ab)
Mozley, L, 852(ab), 853(ab), 854(ab)
Mozley, PD, 389(ab), 797(ab), 852(ab), 853(ab), 854(ab)
MSDS Study Group, 476(ab)
Muehllehner, G, 25(ab), 1340
Mueller, A, 403(ab)
Mueller, B, 602
Mueller, HW, 879(ab), 881(ab)
Mueller, J, 145(ab), 546(ab)
Mueller, JA, 1445(ab)
Mueller, M, 798(ab)
Mueller, S, 933(ab), 986(ab)
Mueller, SP, 270(ab)
Mueller-Schauenburg, W, 114(ab)
Muenz, LR, 1263
Muhle, C, 247, 557(ab)
Mukai, T, 17(ab), 49(ab), 417, 701(ab), 738(ab), 901(ab), 1088(ab), 1314(ab), 1356(ab), 1357(ab), 1369(ab)
Mukherjee, J, 229(ab), 606(ab), 608(ab), 811(ab), 1051(ab)
Mukhopadhyay, S, 916(ab)
Mukhtar, H, 650
Mulder, NH, 106(ab)
Mulders, PA, 103(ab)
Mulders, PF, 559(ab)
Mullan, BP, 1138(ab), 1402
Müller, H-W, 618
Müller, JM, 1268(ab)
Muller, R, 802(ab)
Multani, P, 1479(ab)
Munk, OL, 22(ab), 1206(ab), 1302(ab), 1359(ab), 1862
Munz, DL, 875(ab), 1041(ab), 1180(ab), 1268(ab), 1871(le)
Munzert, G, 1690
Murad, B, 85
Murakami, M, 1338(ab)
Murakami, Y, 105, 593(ab), 609(ab), 799(ab), 1119(ab), 1516,
Murali, D, 230(ab)
Murali, R, 1081(ab)
Murase, K, 505, 1454(ab)
Murata, H, 1348(ab)
Murata, O, 842(ab), 1339(ab)
Murata, T, 791(ab)
Murohara, T, 277(ab), 719(ab), 1717
Murone, C, 435(ab)
Murphy, DG, 788(ab)
Murphy, R, 100(ab)
Murray, JL, 1479(ab)
Murugesan, S, 149(ab)
Musachio, JL, 607(ab)
Musch, G, 1982
Mussa, GC, 1253(ab)
Mutch, DG, 700
Muthukrishnan, A, 69(ab), 1269(ab), 1492(ab)
Muylle, K, 286(ab), 459(ab), 1013(ab)
Muzi, M, 786(ab), 872(ab), 878(ab), 1303(ab), 1482
Muzic, RF, 374(ab)
Muzik, O, 39(ab), 373(ab), 1151(ab), 1328(ab)
Muzzio, PC, 477(ab)
Myers, DT, 1234(ab)
Myougan, H, 329(ab)

Na, K, 1087(ab)
Nabeshima, K, 68(ab)
Nacca, A, 101(ab)
Nádas, A, 817(ab), 839(ab)
Nadgir, RN, 1494(ab)
Nag, HL, 486(ab)
Nagabhushan, N, 420(ab), 1178(ab), 1400(ab)
Nagai, M, 1490(ab)
Nagai, R, 1592
Nagamachi, S, 820(ab), 827(ab), 870(ab)
Nagamatsu, H, 760(ab)
Nagamine, H, 187(ab)
Nagano-Saito, A, 822(ab)
Nagao, M, 317(le)
Nagaoka, T, 1839
Nagaraja, HN, 110(ab)
Nagata, T, 1487(ab)
Nagel, JS, 778(ab), 846
Nagengast, WB, 801(ab)
Nagle, C, 299(ab), 1475(ab)
Nagle, CE, 11N(1), 11N(4)
Nagueh, SF, 765(ab)
Naidu, S, 47(ab)
Naiki, H, 254(ab)
Naito, S, 515(ab), 1604
Najim, N, 1142(ab)
Nakada, K, 129(ab), 256(ab), 385(ab), 414(ab), 583(ab), 587(ab), 721(ab), 883(ab), 884(ab), 934(ab), 1192(ab), 1201(ab)
Nakagami, Y, 1003(ab), 1452(ab)
Nakagawa, M, 838(ab), 845(ab), 1438(ab)
Nakagawa, T, 829(ab)
Nakagawa, Y, 829(ab), 1381(ab)
Nakahara, T, 385, 1005(ab)
Nakahata, Y, 1582
Nakai, T, 1421
Nakajima, K, 187(ab), 288(ab), 342(ab), 736(ab), 1436(ab), 1612
Nakajima, T, 1476(ab)
Nakamoto, Y, 83(ab), 240, 243(ab), 312(ab), 412, 710(ab), 990(ab), 1358(ab), 1369(ab)
Nakamura, F, 1051, 1346(ab), 1435(ab)
Nakamura, K, 1005(ab), 1089(ab)
Nakamura, M, 198
Nakamura, S, 173(ab), 757(ab), 764(ab)
Nakano, S, 825(ab), 830(ab), 870(ab), 1243
Nakashima, I, 157(ab), 318(ab)
Nakata, S, 923(ab)
Nakatsuka, A, 1381(ab)
Nakopoulou, L, 413(ab)
Nam Shin, JE, 1099(ab)
Nam, SY, 1393(ab)
Namura, M, 288(ab), 736(ab), 1436(ab)
Nanasato, M, 277(ab), 719(ab), 1717
Nanba, T, 291(ab)
Nanbu, I, 277(ab)
Nandurkar, DH, 1484(ab)
Nanni, C, 1422(ab)
Nanus, DM, 1385(ab)
Narabayashi, I, 53(ab), 900(ab)
Narayanan, D, 120(ab), 455(ab)
Narayanan, MV, 987(ab), 1725
Narayanan, T, 606(ab)
Narayanan, TK, 811(ab), 1051(ab)
Narendran, R, 33(ab), 109(ab), 218(ab), 226(ab), 231(ab), 603(ab), 807(ab), 812(ab), 1049(ab), 1053(ab)
Nariai, T, 1839
Narin, Y, 1024(ab)
Narula, J, 1(ab), 338(ab), 397, 509(ab)
Narula, N, 1(ab), 338(ab)
Nashnoush, WM, 1148(ab)
Nasu, S, 1338(ab)
Natale, D, 1039(ab)
Natsume, T, 988(ab)
Navarro, V, 610
Nazneen, L, 340(ab)
Nebeling, B, 375
Negrete, G, 1097(ab), 1992
Nehmeh, SA, 124(ab), 527(ab), 968(ab), 969(ab), 1644, 1940
Nekolla, S, 54(ab)
Nekolla, SG, 21(ab), 275(ab)
Nelkin, B, 160(ab), 584(ab)
Nelson, AD, 962(ab), 964(ab)
Nelson, EN, 1179(ab)
Nelson, RP, 1264(ab)
Nemat, AT, 561(ab)
Neti, PV, 331(ab)
Neti, PVSV, 2019
Neumaier, B, 252(ab), 328(ab), 403(ab), 434(ab), 614(ab), 1426
Neumann, DR, 938(ab)
Neumann, V, 131(ab)
Newberg, A, 325(ab), 389(ab), 574(ab), 852(ab), 853(ab), 854(ab)
Newberg, AB, 301(ab), 426(ab), 611(ab), 612(ab), 1408(ab)
Newcorn, J, 216(ab)
Newell, DW, 537(ab)
Newport, DF, 519(ab)
Ng, HT, 1299(ab), 1412(ab)
Ng, K-K, 1775
Ng, KK, 1387(ab), 1428(ab), 1430(ab), 1431(ab), 1455(ab)
Ng, P, 416(ab), 1340(ab)
Ngo, FQ, 380(ab)
Ngo, K, 226(ab)
Nguyen, C, 761(ab)
Nguyen-Dang, D, 1386(ab)
Nibbering, PH, 1368(le)
Nichols, K, 967
Nicholson, S, 186(ab)
Nickel, O, 929(ab), 939(ab)
Nickles, RJ, 230(ab)
Nicolini, JO, 482(ab)
Nielsen, FS, 19
Niemelä, O, 1368(le)
Niesen, A, 400(ab), 484(ab)

Nigavekar, SS, 1094(ab)
Nijran, KS, 963(ab)
Nikita, KS, 1028(ab)
Nikolaus, S, 618
Nikolov, G, 904
Nikula, T, 579(ab), 588(ab)
Nimmon, CC, 658(le)
Nimpoonyagampong, K, 257(ab)
Nimz, C, 339(ab)
Nishihori, H, 1122(ab)
Nishii, R, 625, 820(ab), 827(ab)
Nishii, S, 870(ab)
Nishijima, K, 256(ab), 524(ab), 1120(ab), 1168
Nishikawa, M, 886(ab)
Nishikawa, T, 505
Nishimura, K, 17(ab), 745
Nishimura, S, 105, 329(ab), 609(ab), 799(ab), 1119(ab), 1516
Nishimura, T, 1421
Nishimura, Y, 759(ab)
Nishina, H, 7(ab), 743(ab)
Nishina, T, 17(ab)
Nishioka, T, 414(ab)
Nishiyama, Y, 291(ab), 564(ab), 865(ab), 1343(ab), 1363(ab), 1391(ab), 1434(ab), 1490(ab), 1905
Nishizawa, K, 1104(ab)
Nishizawa, S, 198, 417, 785(ab)
Nitecki, S, 1214(ab)
Nitzsche, EU, 145(ab), 289(ab), 546(ab)
Niu, G, 1322(ab)
Niu, GD, 180(ab)
Nock, B, 478(ab)
Noda, A, 105, 609(ab), 799(ab), 1119(ab), 1516
Noguchi, S, 129(ab), 1192(ab)
Noguti, A, 560(ab)
Nohara, R, 14(ab), 750(ab)
Nonokawa, M, 277(ab), 719(ab), 1717
Norbury, R, 788(ab)
Noriyasu, K, 292(ab), 294(ab), 516(ab), 713(ab), 721(ab)
Norol, F, 711(ab)
Nos, P, 446
Novelli, M, 80(ab)
Nowak, B, 33, 274(ab), 592(ab)
Noy, A, 1489(ab)
Nuñez, R, 566(ab)
Nusynowitz, ML, 988
Nutt, R, 452(ab)
Nuutila, P, 682

Oakes, TR, 230(ab)
Oates, ME, 1179(ab), 1494(ab)
Obata, A, 254(ab), 1305(ab)
Obrocki, J, 375
Obrzut, M, 267(ab)
Ochi, H, 353
Oda, K, 221(ab), 843(ab)
Odaka, K, 4(ab), 343(ab)
O'Connell, W, 748(ab)
O'Connor, MK, 602, 712(ab)
ODonnell, JK, 964(ab)
O'Dorisio, MS, 1244(ab)
O'Dorisio, T, 232(ab), 1464(ab), 1556
Oe, K, 1612
Oehlwein, C, 393(ab), 849(ab), 855(ab)
Oehr, P, 263(ab)
Ogasawara, K, 520
Ogasawara, T, 198
Ogawa, A, 520
Ogawa, K, 1005(ab)
Ogawa, M, 701(ab)
Ogihara, T, 325
Ogoshi, K, 68(ab)
Ogura, T, 325
Ogura, Y, 53(ab), 900(ab)
Oh, C, 319(ab), 322(ab), 1078(ab), 1084(ab)
Oh, CW, 868(ab)
Oh, HJ, 87(ab), 88(ab), 90(ab), 1197(ab), 1203(ab), 1205(ab)
Oh, HK, 487(ab)
Oh, HY, 1226(ab)
Oh, JB, 61(ab)
Oh, P, 1114(ab)
Oh, SH, 1435
Oh, SJ, 261(ab), 1063(ab), 1103(ab), 1140(ab)
Ohana, I, 996(ab)
Ohannesian, DW, 1065(ab)
Ohba, M, 14(ab), 750(ab)
Ohkawa, M, 564(ab), 865(ab), 1343(ab), 1363(ab), 1391(ab), 1434(ab), 1490(ab), 1905
Ohkura, K, 587(ab), 1120(ab), 1168
Ohmori, K, 291(ab)
Ohnishi, T, 830(ab), 840(ab), 886(ab), 1243
Ohno, K, 908(ab), 1839
Ohtake, H, 187(ab)
Ohtawa, N, 842(ab)
Ohtomo, K, 948(ab), 959(ab), 1592
Ohyama, M, 843(ab)
Oikonen, V, 682
Ojemann, GA, 59(ab)
Ojha, B, 69(ab), 1269(ab), 1492(ab)
Ojha, BC, 1406(ab)
Oka, H, 171(ab)
Oka, T, 1174(ab)
Okada, A, 1747
Okada, F, 256(ab)
Okada, H, 1051, 1435(ab)
Okada, S, 834(ab)
Okada, T, 1339(ab)
Okada, Y, 1582
Okamoto, H, 294(ab)
Okamura, T, 353
Okazaki, A, 716(ab)
Okazawa, H, 815(ab), 866(ab), 1371, 1875
O'Keefe, GJ, 100(ab)
Okizaki, A, 475, 768(ab), 1207(ab), 1250(ab)
Oku, N, 505
Oku, S, 948(ab), 959(ab)
Oku, T, 108(ab), 1845
Okuda, Y, 325
Okuguchi, T, 520
Okuyama, C, 1421
Olafsen, T, 1296(ab)
Olah, GA, 168(ab)
Old, LJ, 100(ab)
Olianti, C, 1057, 1755
Ollenberger, G, 1259(ab)
Olsen, L, 84(ab)
Olson, J, 543(ab), 1156(ab)
Olsson, RA, 1682
O'Malley, JP, 867(ab)
Omar, AM, 368(ab)
Omata, N, 791(ab)
O'Neil, JP, 282(ab), 809(ab)
O'Neill, K, 1982
Oniankitan, O, 1225(ab)
Ono, K-I, 1839
Ono, Y, 1582
Onoe, K, 1001(ab)
Onuki, N, 1618
Oosterwijk, E, 103(ab), 559(ab)
Orange, D, 466(ab)
Ordoñez, J, 179(ab)
Orth, U, 933(ab)
Ortolan, A, 538(ab)
Ortu, G, 161(ab)
Osada, H, 842(ab), 1339(ab)
Osborne, J, 89(ab)
Oshima, S, 515(ab), 1604
Osman, M, 170, 412, 1797
Osman, MM, 60(ab), 240, 312(ab)
Osoda, K, 609(ab)
Osorio, M, 573(ab), 1161(ab)
Osso, Jr, JA, 1147(ab)
O'Sullivan, F, 872(ab)
O'Sullivan, JM, 1470(ab)
Otani, H, 1618
Ott, K, 64(ab), 1336(ab)
Ottaviani, M, 596
Otto, D, 1445(ab)
Ouchi, Y, 1051, 1435(ab)
Ouguchi, M, 1376(ab), 1442(ab)
Ouzounoglou, N, 1028(ab)
Owega, A, 671
Owen, NK, 581(ab), 823, 1066(ab), 1074(ab)
Owens, J, 788(ab)
Oya, S, 325(ab)
Oyama, N, 1062(ab), 549
Oyama/Nobuyuki, N, 262(ab)
Oyen, WJ, 102(ab), 103(ab), 144(ab), 316(ab), 317(ab), 427(ab), 498(ab), 499(ab), 578(ab), 717(ab), 1118(ab)
Oyen, WJG, 400, 853(le), 1087, 1502, 1690, 1707(le)
Oz, OK, 528(ab)
Ozaki, K, 1067(ab)
Ozawa, N, 353
Ozawa, Y, 1003(ab)
Ozcan, PP, 1377(ab)

Paans, A, 1154(ab)
Paccaly, A, 810(ab)
Pace, L, 1369(le)
Pacini, F, 211
Padhy, AK, 573(ab), 1161(ab), 1242(ab), 1255(ab)
Padma, S, 18(ab), 1284(ab)
Paeng, JC, 12(ab), 16(ab), 602(ab), 737(ab), 868(ab), 1457(ab), 1641, 1735
Paganelli, G, 444(ab), 478(ab)
Pagani, MM, 815(ab)
Pagel, JM, 437
Paghera, B, 175(ab), 558(ab), 1198(ab)
Pagliani, R, 1198(ab)
Paglianiti, I, 134(ab)
Paik, CH, 1091(ab), 1112(ab)
Paik, JY, 1126(ab)
Paik, NS, 1472(ab)
Pajoro, U, 175(ab), 558(ab), 1198(ab)
Pak, KY, 705(ab)
Palestro, CJ, 147(ab), 311(ab), 483(ab), 488(ab), 566(ab), 927, 988, 1072, 1195(le), 1216(ab), 1229(ab), 1230(ab)
Pallares, C, 1372(ab)
Palm, S, 497(ab), 1148
Palmedo, H, 568(ab), 572(ab), 1815, 2033
Pan, L, 877(ab)
Pan, MZ, 1458(ab)
Pan, T, 124(ab), 449(ab), 527(ab), 968(ab), 969(ab), 1940
Panagakos, GM, 1281(ab)
Panageas, KS, 260, 1543(le)
Panareo, S, 1407(ab)
Panarotto, MB, 175(ab), 558(ab), 1198(ab)
Pandit-Taskar, N, 101(ab), 465(ab)
Panin, VY, 980(ab)
Panjrath, G, 722(ab)
Pankau, H, 188(ab)
Pannu, HK, 170, 422(ab)
Pansini, F, 1394(ab)
Pant, GS, 1242(ab)
Panteghini, M, 175(ab)
Pantelic, MV, 1234(ab)
Panzegrau, B, 127(ab)
Papanicolas, C, 1028(ab)
Papantoniou, V, 413(ab)
Papaspirou, I, 413(ab)
Papenfus, T, 100(ab)
Papi, S, 444(ab)
Pappas, N, 117(ab), 213(ab), 800(ab), 890(ab), 898(ab)
Pappas, V, 34N(6), 40N(7), 50N(8), 25N(9), 33N(10), 28N(12)
Paquette, M, 285(ab)
Paquette, V, 895(ab)
Parain, D, 598(ab)
Parellada, E, 887(ab)
Pareto, D, 835(ab), 887(ab)
Park, BK, 520(ab)
Park, CC, 992(ab)
Park, CK, 246(ab)
Park, HM, 2039(le)
Park, I, 1125(ab), 1129(ab)
Park, JH, 2033
Park, JM, 1296(ab)
Park, K, 846(ab)
Park, LS, 1091(ab), 1112(ab)
Park, MA, 24(ab)
Park, R, 152(ab), 977(ab)
Park, SH, 130(ab), 1453(ab)
Park, YH, 1182(ab)
Park, YS, 725, 1279(ab)
Parker, JA, 988
Parker, S, 1556
Parkey, RW, 528(ab)
Parkman, HP, 302(ab)
Parry-Jones, DR, 11
Parsey, RV, 1110(ab), 1111(ab), 1127(ab)
Parving, H-H, 19
Pasqualini, R, 981
Pasquier, J, 1232
Passalaqua, AM, 1258(ab)
Pastina, I, 1468(ab)
Patel, B, 1115(ab)
Patel, CD, 762(ab)
Patel, PV, 309(ab)
Patel, V, 722(ab)
Pathak, H, 1480(ab)
Pathmaraj, KU, 435(ab)
Patrick, H, 722(ab)
Patterson, LM, 416(ab)
Patterson, RE, 3(ab), 776(ab)
Patton, DD, 1362, 525(ab)
Patton, JA, 996(ab)
Patton, PW, 774
Paul, JF, 761(ab)
Paul, M, 510(ab)
Pauleit, D, 879(ab)
Pauleit, DO, 881(ab)
Paulmurugan, R, 98(ab), 1135(ab)
Paulsen, F, 438(ab), 563(ab), 1304(ab)
Pauwels, EKJ, 1368(le), 658(le)
Pauwels, S, 443(ab), 493(ab)
Pavel, DG, 961(ab)
Pavese, N, 386(ab)
Pavia, J, 887(ab)
Pávics, L, 839(ab)
Payne, RM, 715(ab), 975(ab)
Payoux, P, 663, 847(ab)
Peñuelas, I, 1172(ab)
Pearson, JR, 570(ab)
Pecorella, GR, 1566
Pedersen, H, 177
Pegram, M, 1333(ab)
Peker, C, 340(ab)
Pelizzo, MR, 1181(ab), 1183(ab), 1443
Pellegrino, D, 501(ab), 1109(ab)
Peller, M, 54(ab), 897(ab)
Pellikka, R, 1210
Pelosi, E, 409(ab), 1213(ab)
Pena, FJ, 357(ab)
Penault-Llorca, F, 411(ab)
Peng, NJ, 1256(ab)
Peng, NX, 52(ab)
Pennanen, M, 1374(ab)
Pennone, M, 1213(ab)
Pentlow, K, 424(ab)
Pentlow, KS, 1069
Perani, D, 833(ab)
Peretz, T, 202(ab)
Perez, A, 101(ab), 214(ab)
Perez, G, 835(ab), 887(ab)
Perez, S, 1413(ab)
Pereztol-Valdez, O, 731(ab)
Peric-Simov, B, 167(ab), 1132(ab)

Perkins, AE, 25(ab)
Perrier, ND, 1175(ab)
Perry, J, 1330(ab)
Peschel, C, 1401(ab)
Peschke, P, 973, 1324(ab)
Pételle, B, 1767
Peter, J, 1332(ab)
Peters, AM, 11, 1037
Peters, C, 214(ab)
Peters, N, 862
Petersen, K, 375
Petersen, V, 1401(ab)
Peterson, CD, 1545(le)
Peterson, LM, 412(ab), 1340(ab), 1482
Petiet, A, 657(le)
Petrarulo, M, 1574
Petretta, A, 1023
Petretta, M, 1023
Petric, A, 222(ab)
Petrov, A, 1(ab), 338(ab)
Pettinato, C, 1422(ab)
Peuhkurinen, K, 487
Pevsner, D, 466(ab)
Pezzoli, G, 397(ab)
Pfluger, T, 597(ab), 1246(ab)
Pham, KH, 748(ab)
Pham, P, 1044
Phan, V, 1049(ab)
Phelps, ME, 52(ab), 246(ab), 248(ab), 260(ab), 333(ab), 384(ab), 402(ab), 431(ab), 615(ab), 857(ab), 885(ab), 1016(ab), 1025(ab), 1238, 1325(ab), 1497(ab), 1709
Phillips, E, 607(ab)
Phillips, EH, 555(ab)
Phillips, M, 415(ab)
Phillips, SW, 602
Phillips, WT, 1097(ab), 1992
Phom, H, 486(ab)
Phongkitkarun, S, 268(ab), 269(ab)
Picchio, M, 245(ab), 264(ab)
Picciotto, G, 1574
Pichika, R, 803(ab)
Pichler, BJ, 530(ab)
Picus, J, 428(ab), 549
Piel, M, 109
Pieper, BC, 583
Piepsz, A, 659(le)
Pierini, A, 1253
Pieroni, C, 548(ab)
Piers, BA, 184
Piers, DA, 1187(ab)
Piert, M, 117, 314(ab)
Pieslor, P, 1479(ab)
Pigeot, J, 1271(ab)
Pihl, RO, 895(ab)
Pijpers, R, 1022(ab)
Pillai, V, 961
Pillay, M, 1007(ab)
Pilowsky, LS, 917(ab)
Pinkus, E, 192
Pinson, CW, 222
Pinto, C, 1422(ab)
Pio, BS, 246(ab), 828(ab)
Piotto, A, 1183(ab)
Pirina, P, 1219
Pisu, N, 359
Piswanger-Soelkner, JC, 305(ab), 306(ab)
Pitre, S, 407(ab)
Pittenger, MF, 710(ab)
Pitterle, K, 614(ab)
Pixberg, M, 1238(ab)
Pixberg, MK, 476(ab)
Pizzocaro, C, 558(ab)
Plössl, K, 325(ab), 377(ab), 852(ab), 853(ab), 854(ab)
Platsch, G, 824(ab), 1423(ab)
Plisson, C, 605(ab), 1050(ab)
Ploessl, K, 389(ab)
Plotkin, M, 394(ab), 876(ab)
Plukker, JT, 1187(ab)
Poca, MA, 1884
Podoloff, D, 1077(ab), 1078(ab)
Podoloff, DA, 268(ab), 269(ab), 319(ab), 322(ab), 362(ab), 465, 610(ab), 700, 789(ab), 1011(ab), 1067(ab), 1071(ab), 1082(ab), 1084(ab), 1158(ab), 1477(ab)
Poepperl, G, 36(ab), 112(ab), 387(ab), 541(ab), 862
Poethko, T, 148(ab)
Pogarell, O, 390(ab)
Pohlen, JM, 1264(ab)
Pointon, BW, 989(ab)
Pointurier, I, 155, 734(ab)
Poldermans, D, 10(ab), 11(ab), 127, 140, 877
Pollycove, M, 125(le)
Pomper, MG, 607(ab)
Ponce, J, 446
Ponde, DE, 1062(ab)
Ponde/Datta, DE, 262(ab)
Ponomarev, V, 93(ab), 150(ab), 156(ab)
Ponomarev, VB, 1326(ab)
Pons, V, 446
Ponsonnaille, J, 1625
Pont, J, 567(ab)
Ponto, J, 139(ab), 1464(ab)
Ponto, R, 33N(1)
Ponzo, F, 1247(ab)
Poon, A, 100(ab), 435(ab)
Poot, L, 1154(ab)
Porenta, G, 1741
Porjesz, B, 213(ab)
Porn, U, 597(ab)
Porter, DV, 903(ab)
Postal, ES, 132(ab), 133(ab)
Postema, EJ, 102(ab), 853(le), 1690, 1707(le)
Postmus, PE, 739
Potasz, N, 100(ab)
Potkin, S, 606(ab)
Potter, WZ, 797(ab)
Poupon, MF, 157(ab), 318(ab)
Pourabdollah, S, 39(ab)
Powers-Risius, P, 282(ab)
Powles, R, 1105
Powsner, RA, 778(ab)
Prévost, S, 565(ab), 985(ab)
Prabhakaran, J, 1110(ab), 1111(ab), 1127(ab)
Pradhan, PK, 1202(ab)
Prakash, GK, 168(ab)
Prante, O, 284(ab), 1315(ab)
Praus, A, 339(ab)
Press, MF, 1296(ab)
Press, OW, 437
Pretorius, PH, 987(ab), 1725
Priario, J, 1561
Price, JC, 896(ab)
Price, JP, 359(ab)
Prins, MH, 739
Prior, J, 71(ab), 1649
Prior, JO, 170(ab), 289(ab), 293(ab), 349(ab), 351(ab), 756(ab), 945(ab)
Pruim, J, 331, 341, 1154(ab)
Prunier, C, 663
Prvulovich, L, 420(ab)
Przetak, C, 1156
Puccini, M, 1443
Pugachev, A, 378(ab)
Pugliese, P, 566(ab)
Pugliese, PV, 311(ab), 1216(ab)
Pupi, A, 371(ab), 1057
Purohit, A, 1131(ab)
Puttaraju, M, 1329(ab)
Pyatt, B, 1052(ab)

Qi, J, 121(ab)
Qi, YJ, 997(ab)
Qian, CN, 580(ab)
Qiao, JH, 337(ab)
Qin, SW, 1194(ab)
Qiu, F, 1317(ab)
Quadri, N, 109(ab), 1053(ab)
Quaife, RA, 348(ab), 727(ab)
Quarless, SA, 259(ab)
Que, TH, 341
Quelven, I, 847(ab)
Quigley, AM, 237(ab)
Quinn, J, 1085(ab)
Quinn, TP, 581(ab)
Quinones, C, 1236(ab)
Quinones, MJ, 349(ab)
Quirce, R, 357(ab)
Quon, A, 402(ab), 1190(ab), 1238, 1355(ab)

Rabbia, C, 1574
Rabiller, G, 1223(ab)
Rachinger, W, 112(ab), 541(ab)
Radau, P, 36(ab), 372(ab), 390(ab), 918(ab), 942(ab)
Raderer, M, 234(ab)
Raemaekers, JM, 102(ab)
Rafecas, M, 530(ab)
Raffel, DM, 297(ab), 341(ab), 1121(ab)
Raffelt, K, 255(ab)
Rahul, C, 18(ab), 1284(ab)
Raichle, ME, 48(ab)
Raijmakers, PR, 1022(ab)
Rajagopalan, S, 915
Rajendram, AR, 1466(ab)
Rajendran, JG, 415(ab), 878(ab), 1340(ab), 1467(ab)
Rajendren, JG, 416(ab)
Rajon, DA, 774, 1113
Ramakers, B, 717(ab)
Ramamoorthy, N, 1123(ab)
Raman, A, 1353(ab)
Ramanna, L, 241(ab), 1186(ab)
Rambaldi, R, 140
Ramsden, RT, 44(ab)
Rao, M, 890(ab), 898(ab)
Rao, SP, 1293
Rapoport, SI, 51(ab)
Rappoport, V, 452(ab)
Rascol, O, 847(ab)
Rashkin, J, 987(ab)
Rassovsky, Y, 384(ab)
Rastogi, S, 486(ab)
Ratib, O, 950(ab), 1016(ab), 1025(ab), 1190(ab), 1355(ab), 1497(ab)
Rau, F, 148(ab)
Raubitschek, A, 1433(ab)
Raubitschek, AA, 1296(ab), 1962
Rauch, SL, 894(ab)
Rauseo, P, 463(ab), 805(ab)
Ravasi, L, 779(ab), 784(ab)
Ravert, HT, 115(ab), 160(ab), 281(ab), 463(ab), 584(ab), 585(ab), 1312(ab)
Ravi, A, 244(ab)
Ravizzini, GC, 1195(ab)
Ray, P, 96(ab)
Ray, S, 98(ab)
Raylman, RR, 526(ab)
Razzouk, M, 177(ab), 734(ab), 767(ab), 771(ab)
Rbah, L, 1495
Reardon, DA, 382(ab)
Rebenstock, A, 517(ab), 611(ab), 612(ab)
Rebenstock, AI, 57(ab), 1231(ab)
Reber, H, 493(ab), 939(ab)
Rebholz, CG, 1320(ab)
Reder, PJ, 1264(ab)
Reder, S, 702(ab), 704(ab)
Refosco, F, 806
Regan, DD, 457
Regeasse, A, 526
Regoli, M, 895(ab)
Rehm, PK, 1277(ab)
Reibke, R, 552(ab)
Reich, PE, 611(ab), 612(ab)
Reijs, AEM, 140
Reilly, RM, 1469
Reimold, M, 114(ab), 212(ab), 563(ab)
Reinartz, P, 592(ab)
Reincke, B, 733(ab)
Reinhardt, M, 568(ab), 572(ab)
Reinhold-Keller, E, 733(ab)
Reinholz, U, 1189(ab)
Reischl, G, 314(ab)
Renaud, B, 1495
Rennen, H, 498(ab)
Rennen, HJ, 499(ab), 500(ab), 1118(ab)
Rennen, HJJM, 1087, 1502
Renner, EC, 138(ab)
Rentrop, M, 897(ab)
Resau, JH, 580(ab)
Reske, SN, 252(ab), 328(ab), 403(ab), 432(ab), 433(ab), 434(ab), 614(ab), 965(ab), 966(ab), 1426
Restom, TS, 1009(ab)
Reubi, J-C, 1315
Reubi, JC, 71(ab), 1649
Reulen, HJ, 112(ab), 541(ab)
Reutelingsperger, CP, 5(ab), 338(ab), 500(ab), 509(ab)
Reutelingsperger, CPM, 391
Reutter, BW, 121(ab), 282(ab)
Rewers, M, 348(ab)
Reynolds III, CF, 896(ab)
Rhodes, DJ, 602
Ribeiro, MJ, 711(ab)
Riboldi, S, 779(ab)
Ricalde, A, 777(ab)
Ricard, M, 492(ab), 596, 1169(ab)
Ricci, S, 1468(ab)
Riccobene, TA, 422
Rice, KC, 813(ab)
Richardson, AC, 1148(ab)
Richer, E, 523(ab)
Richmond, JC, 1141(ab)
Richter, E, 73(ab), 418(ab), 733(ab), 1023(ab), 1224(ab)
Richter, M, 875(ab)
Richter, T, 1982
Rickert, CH, 873(ab)
Riedel, E, 82(ab)
Rieker, O, 1424(ab)
Riemann, B, 709(ab)
Rietveld, T, 140
Rigo, P, 1386(ab)
Rigopoulos, A, 1105
Rijo, J, 565(ab), 985(ab)
Rimoldi, O, 510(ab)
Rimpler, A, 1170(ab)
Rini, JN, 566(ab), 1072
Rinke, A, 1362(ab)
Riou, LM, 981, 1092
Rizi, RR, 920(ab)
Rizzo, G, 245(ab)
Rizzo, N, 1767
Roach, PJ, 1046(ab)
Robbins, M, 975(ab)
Robbins, R, 570(ab)
Robbins, RJ, 552(ab), 1069
Robenstock, A, 72(ab), 1456(ab)
Robert, F, 334(ab), 1159(ab)
Robert, PH, 55(ab)
Roberts, AR, 230(ab)
Roberts, DW, 1379
Roberts, EG, 297(ab)
Robeson, W, 961
Robinson, MK, 941(ab)
Robinson, PJ, 186(ab)
Roca, M, 1223(ab)
Rocca, P, 444(ab)
Roccatello, D, 1574
Rockson, S, 43
Rodari, M, 1407(ab)
Rodriguez, JA, 1281(ab)
Rodriguez, R, 871(ab)
Roelandt, JRTC, 127, 140, 877
Roelants, V, 276(ab)
Roelcke, U, 1210
Roemer, W, 1423(ab)
Roesch, F, 595(ab), 798(ab)

Roeske, JC, 252
Roessler, A, 849(ab)
Rogatko, A, 2000
Rogers, J, 1405(ab)
Roh, M, 1360(ab)
Roland, PS, 43(ab), 45(ab)
Romagnani, F, 134(ab)
Rommelfanger, SG, 457
Roney, CA, 826(ab)
Roney, CB, 832(ab)
Rongen, GA, 717(ab)
Rooney, WD, 1239(ab), 1522
Roos, JC, 1690
Ros, D, 835(ab)
Rosato, EF, 410(ab)
Rösch, F, 109
Rosch, F, 503(ab)
Rosen, N, 1290(ab)
Rosenbloom, BE, 1496(ab)
Rosenfelt, F, 1496(ab)
Rosenzweig, KE, 124(ab), 527(ab), 968(ab), 1644
Ross, RS, 283(ab)
Rossi, M, 1761
Rossini, P, 175(ab), 558(ab), 1198(ab)
Rosso, J, 899(ab)
Rothman, RB, 805(ab)
Roumenov, D, 596
Rousseau, J, 285(ab), 1334(ab)
Rousset, O, 41(ab)
Rousset, OG, 30(ab), 810(ab)
Rouze, NC, 376(ab), 1035(ab)
Rouzet, F, 181(ab), 749(ab)
Rowe, CC, 56(ab)
Royal, HD, 38N(7), 32N(11)
Rozen, Y, 161(ab)
Ruan, S, 378(ab), 1153(ab)
Ruan, YM, 287(ab)
Ruangma, A, 519(ab), 1017(ab)
Rubello, D, 477(ab), 1181(ab), 1183(ab), 1443
Rubin, B, 882(ab)
Rubin, J, 1257(ab)
Rubin, JT, 1254(ab)
Rubin, SC, 1059(ab)
Rubinstein, R, 202(ab)
Rückert, JC, 1268(ab)
Ruckgaber, J, 965(ab)
Ruddy, TD, 169(ab), 744(ab), 772(ab)
Rudi, J, 78(ab)
Rudoltz, MS, 447(ab)
Ruehm, SG, 1354(ab)
Ruf, J, 876(ab)
Ruhwedel, H, 484(ab)
Ruiz, M, 1092
Rundle, MM, 48(ab)
Runge, R, 953
Rusckowski, M, 163(ab), 326(ab), 1070(ab), 1116(ab), 1124(ab), 1295(ab), 1331(ab)
Russell, CD, 1357
Russo-Marie, F, 157(ab), 318(ab)
Rust, TC, 976(ab)
Rutar, F, 1171(ab)
Ruter, RL, 712(ab)
Rutlin, JR, 1122(ab)
Ruzicka, E, 387(ab), 848(ab)
Ryan, CM, 896(ab)
Ryan, L, 154(ab), 1100(ab)
Rychlinski, CW, 708
Rydzewski, B, 961(ab)
Ryo, Y, 752(ab)
Ryu, EK, 1099(ab)
Ryu, JS, 261(ab), 1063(ab), 1393(ab), 1432(ab), 1448(ab)
Ryu, RH, 1365(ab)
Ryu, S-Y, 347
Ryu, YH, 891(ab), 893(ab), 1370(ab), 1439(ab)
Ryuo, H, 1003(ab)

Sabba, N, 806
Sabbah, A, 485(le)
Sabina, K, 1228(ab)
Sabri, O, 188(ab), 393(ab), 671, 723(ab), 839, 849(ab), 855(ab), 1245(ab)
Sachinidis, J, 435(ab)
Sadato, A, 864(ab)
Sadato, N, 198
Sadeh, M, 1898
Safaei, A, 260(ab)
Safai Samnani, E, 111(ab)
Saffer, JR, 1890
Saffrich, R, 1332(ab)
Saga, T, 49(ab), 901(ab), 1088(ab), 1314(ab), 1356(ab), 1357(ab), 1358(ab), 1369(ab)
Saghari, M, 1176(ab)
Saginoya, T, 690, 1228(ab), 1415(ab)
Sagoh, M, 171(ab)
Sagou, K, 1348(ab)
Sahuquillo, J, 1884
Sain, JD, 58
Saito, T, 1618
Saitoh, K, 716(ab)
Sajdak, RA, 361(ab)
Saji, H, 40, 254(ab), 417, 701(ab), 1088(ab), 1092(ab), 1305(ab)
Sakahara, H, 1346(ab)
Sakai, K, 292(ab)
Sakai, Y, 886(ab)
Sakamoto, S, 83(ab), 990(ab), 1020(ab)
Sakane, H, 1104(ab)
Sakayama, K, 923(ab), 1454(ab)
Sakdinawat, AE, 1004(ab)
Sakou, M, 534(ab)
Salanci, BV, 1267(ab)
Saleh-Mghir, A, 319(le)
Salem, N, 1152(ab)
Salem, R, 1475(ab)
Salgado-Pineda, P, 1884
Salibian, R, 8(ab)
Salmon, AS, 1407
Salmon, E, 833(ab)
Salvatore, M, 1369(le)
Sambuceti, G, 720(ab)
Samei, E, 1029(ab)
Sampson, JH, 382(ab)
Sandberg, K, 463(ab)
Sander, D, 671, 839
Sanders, M, 216(ab)
Sanderson, J, 576(ab), 1085(ab)
Sandler, MP, 661, 996(ab)
Sandrock, D, 1180(ab), 1268(ab)
Sanjeevan, KV, 1284(ab)
Sanl fi, U, 1394
Sano, K, 198
Sanson, A, 157(ab), 318(ab)
Santana, CA, 279(ab), 731(ab)
Santin, G, 1032(ab), 1048(ab)
Santoro, A, 871(ab)
Santos, EB, 1292(ab)
Santos, PA, 197(ab)
Sanvito, F, 264(ab)
Sarda, L, 920
Sarda, L, 319(le)
Sarda-Mantel, L, 340(ab), 749(ab)
Sargiotto, A, 1574
Sarikaya, I, 1417(ab)
Sarikonda, KV, 69(ab), 1269(ab), 1492(ab)
Sarkar, SD, 1195(le)
Sartor, J, 1072(ab)
Sasajima, T, 108(ab), 1845
Sasaki, M, 540, 838(ab)
Sasaki, T, 221(ab), 815(ab), 843(ab)
Sasaki, Y, 1348(ab)
Saso, H, 1067(ab)
Sasoh, M, 520
Sata, M, 1747
Satake, S, 1092(ab)
Sato, J, 475, 768(ab), 1207(ab), 1250(ab)
Sato, M, 4(ab), 587(ab), 1618
Sato, N, 1091(ab), 1112(ab)
Satoh, K, 564(ab), 1343(ab), 1363(ab), 1391(ab), 1434(ab), 1490(ab), 1905
Satpati, D, 1123(ab)
Satyamurthy, N, 222(ab), 246(ab), 333(ab), 402(ab), 431(ab), 1325(ab)
Saumon, G, 340(ab), 1274(ab), 1275(ab)
Sauvaget, E, 1767
Savenkova, L, 1053(ab)
Savino, F, 1253(ab)
Sawyers, CL, 260(ab), 1325(ab)
Sayek, I, 1185(ab)
Sayeram, S, 195(ab), 1042(ab)
Sayinalp, N, 1481(ab)
Sayre, JW, 945(ab)
Saze, T, 1104(ab)
Schächinger, V, 174(ab)
Schäfer, H, 1461(ab)
Schäfers, KP, 510(ab)
Schäfers, M, 510(ab)
Schaadt, BK, 177
Schachter, P, 904
Schaefer, NG, 272(ab)
Schaefer, W, 592(ab)
Schaefer, WM, 33, 274(ab)
Schaefers, KP, 709(ab)
Schaefers, MA, 709(ab)
Schaeffer, J, 1315
Schaffland, AO, 71(ab), 1649
Scharf, B, 1239(ab), 1522
Scharnhorst, J, 416(ab), 1340(ab)
Schebler, SE, 1143(ab)
Schechter, NR, 1157(ab)
Scheffel, U, 160(ab), 584(ab), 585(ab), 1312(ab)
Scheidhauer, K, 233(ab)
Scheinberg, DA, 497(ab), 1301(ab)
Schelbert, H, 303(ab), 931(ab)
Schelbert, HR, 170(ab), 283(ab), 289(ab), 293(ab), 349(ab), 351(ab), 756(ab), 945(ab), 988
Schelper, LF, 1023(ab)
Scher, B, 70(ab), 1347(ab)
Scher, H, 424(ab)
Scher, HI, 101(ab)
Scheuermann, EH, 468(ab)
Schiavini, M, 406(ab)
Schicha, H, 255(ab), 1170(ab), 1189(ab)
Schiepers, C, 402(ab), 615(ab), 950(ab), 1025(ab), 1238, 1355(ab), 1497(ab), 1804
Schiepers, CS, 1016(ab)
Schiffer, WK, 225(ab)
Schillaci, O, 359, 1040(ab), 1219
Schindler, TH, 170(ab), 289(ab), 293(ab), 349(ab), 351(ab), 756(ab), 945(ab)
Schinkel, A, 10(ab), 11(ab)
Schinkel, AFL, 127, 877
Schipper, M, 1298(ab)
Schipper, ML, 91(ab), 238(ab), 446(ab), 448(ab), 551(ab), 739(ab), 869(ab), 1320(ab), 1362(ab), 1425(ab)
Schirbel, A, 167(ab), 504(ab), 1132(ab)
Schirp, U, 145(ab), 546(ab)
Schirrmacher, E, 595(ab)
Schirrmacher, R, 503(ab), 595(ab)
Schirrmeister, H, 252(ab), 403(ab), 614(ab), 1426
Schleiff, P, 484(le)
Schleyer, P, 100(ab)
Schlieck, A, 238(ab), 448(ab), 869(ab), 1425(ab)
Schlief, R, 447(ab)
Schlumberger, M, 492(ab)
Schlösser, NJJ, 336
Schlyer, D, 1522
Schmaling, KB, 816(ab)
Schmid, DT, 417(ab), 1382(ab)
Schmid, E, 579(ab), 588(ab)
Schmid, R, 143(ab)
Schmidt, AM, 1323(ab)
Schmidt, CM, 74(ab)
Schmidt, K, 779(ab), 784(ab), 1332(ab)
Schmidt, MA, 915
Schmidt-Wolf, I, 568(ab)
Schmied, C, 597(ab)
Schmitt, BA, 1141(ab)
Schmitt, G, 116(ab)
Schmitz, A, 503(ab)
Schmitz, V, 596(ab), 1237(ab)
Schmuecking, M, 484(ab)
Schnall, M, 953(ab)
Schnedl, WJ, 305(ab), 306(ab)
Schneebaum, S, 1413
Schneider, RF, 1153(ab)
Schneiderová, M, 1784
Schneier, FR, 118(ab)
Schnitzer, J, 1114(ab)
Schober, O, 476(ab), 510(ab), 550(ab), 709(ab), 873(ab), 997(le), 1238(ab), 1379(ab)
Schoder, H, 124(ab), 527(ab), 968(ab), 1349(ab), 1417(ab), 1420(ab), 1489(ab), 1644
Schöder, H, 1789
Schoenknecht, P, 833(ab)
Schoensiegel, F, 1316(ab)
Schoenstra, T, 752(ab)
Schoepp, DD, 797(ab)
Schottelius, M, 233(ab)
Schramm, NU, 28(ab)
Schreckenberger, M, 671, 929(ab)
Schretlen, D, 215(ab)
Schroeck, H, 588(ab)
Schroeder, JO, 141(ab)
Schubert, EK, 249(ab), 250(ab), 412(ab), 1044, 1310(ab), 1806
Schubiger, PA, 1210, 71(ab)
Schuchter, LM, 1367(ab), 1451(ab)
Schuemichen, C, 131(ab)
Schuette, J, 75(ab)
Schuhmacher, C, 579(ab)
Schuhmacher, J, 381(ab), 880(ab)
Schultz, K, 216(ab)
Schurrat, T, 28(ab)
Schuster, DM, 543(ab), 1156(ab)
Schuster, E, 1741
Schuster, S, 611(ab), 1486(ab)
Schuster, SJ, 612(ab), 1485(ab), 2000
Schuurmans, M, 437(ab)
Schwab, M, 1297(ab)
Schwaegler, M, 798(ab)
Schwaiger, M, 21(ab), 54(ab), 64(ab), 86(ab), 148(ab), 233(ab), 339(ab), 530(ab), 579(ab), 588(ab), 702(ab), 704(ab), 856(ab), 897(ab), 1336(ab), 1401(ab)
Schwartz, A, 1413
Schwartz, DL, 415(ab), 416(ab), 1340(ab)
Schwartz, JL, 2027
Schwarz, A, 824(ab)
Schwarz, J, 387(ab), 390(ab), 393(ab)
Sciagrà, R, 752, 1873(le)
Sciuk, J, 997(le)
Scopinaro, F, 359, 1219
Scott, AM, 100(ab), 435(ab), 1105, 1282
Scott, TM, 770
See, L-C, 1775
See, LC, 1387(ab), 1430(ab), 1431(ab), 1455(ab)
Seese, A, 723(ab), 839, 1245(ab)
Segars, W, 27(ab), 208(ab)
Segars, WP, 195(ab), 366(ab), 462(ab)
Segers, P, 967
Seibyl, J, 836(ab)
Seibyl, JP, 119(ab), 220(ab), 388(ab), 859(ab)
Seidel, J, 529(ab), 779(ab), 781(ab), 784(ab)
Seidenschwang, S, 588(ab)
Seidl, C, 579(ab), 588(ab)

Seki, H, 1376(ab)
Seki, K, 587(ab), 1120(ab), 1168
Seki, R, 515(ab), 1604
Sellers, D, 201(ab), 266(ab)
Seltzer, MA, 333(ab), 431(ab)
Sen, S, 1261(ab)
Senda, M, 83(ab), 901(ab), 912(ab), 990(ab), 1020(ab), 1352(ab), 1839
Senda, S, 291(ab)
Senekowitsch-Schmidtke, R, 579(ab), 588(ab)
Sener, M, 1286(ab)
Senthilnathan, MS, 1202(ab)
Seo, IS, 1443(ab), 1444(ab)
Seok, JW, 1373(ab), 1395(ab)
Seret, A, 993(ab)
Serganova, I, 89(ab), 150(ab), 156(ab)
Serganova, IS, 1326(ab)
Serra, P, 1172(ab)
Serra-Grima, R, 179(ab)
Seshadri, N, 1280(ab), 1285(ab)
Sestini, S, 746(ab), 1755
Sfakianaki, E, 466(ab), 1281(ab)
Sfakianakis, GN, 466(ab), 1281(ab)
Sgouros, G, 260, 497(ab), 784, 1113, 1148, 1543(le)
Shah, AA, 766(ab)
Shah, AP, 774
Shah, KS, 1004(ab)
Shah, NJ, 1682
Shahinian, A, 1061(ab), 1108(ab)
Shahinian, AH, 152(ab)
Shalaby-Rana, El, 600(ab)
Shaller, C, 941(ab)
Shamim-Uzzaman, Q (Afifa), 915
Shan, DE, 399(ab), 858(ab)
Shangde, C, 1153(ab)
Shankar, LK, 1374(ab)
Shankovich, A, 280(ab), 774(ab)
Shannon, M, 1495(ab)
Shao, L, 194(ab), 970(ab)
Sharkey, RM, 67, 77, 575(ab), 1057(ab), 1293(ab), 2000
Sharma, BD, 1215(ab)
Sharma, C, 1077(ab)
Sharma, RK, 1076(ab)
Sharp, TL, 367(ab)
Shaver, K, 506(ab)
Shavrin, A, 156(ab)
Shaw, J, 803(ab)
Shaw, L, 8(ab)
Shaw, LJ, 134
Shaw, SM, 832
Shazad, A, 967
Shea, C, 800(ab), 1052(ab)
Sheerin, AA, 1057(ab)
Sheikh, A, 570(ab)
Shelton, DK, 135(ab)
Shen, DH, 110(ab)
Shen, R, 189(ab), 350(ab), 365(ab), 1002(ab)
Shen, S, 334(ab), 447(ab), 494(ab), 1159(ab)
Shen, Y, 1081(ab)
Shenoy, N, 1318(ab)
Sherman, PS, 341(ab), 1121(ab)
Sherman, S, 74(ab)
Shestosowsky, J, 895(ab)
Sheybani, A, 8(ab)
Shi, B, 606(ab), 608(ab), 811(ab), 1051(ab)
Shi, HC, 104(ab)
Shi, RF, 9(ab), 13(ab), 15(ab), 180(ab), 189(ab), 287(ab), 350(ab), 469(ab)
Shi, XY, 1094(ab)
Shi, Y, 1107(ab)
Shia, J, 82(ab)
Shiba, K, 793(ab)
Shibata, Y, 1747
Shidahara, M, 512, 947(ab)
Shields, AF, 1151(ab), 1328(ab), 1432
Shiga, T, 385(ab), 721(ab), 792(ab), 884(ab), 934(ab), 1010(ab), 1037(ab)
Shiga, Y, 565
Shigeto, K, 17(ab)
Shih, W, 752(ab)
Shih, W-J, 995(le)
Shikano, N, 244, 625
Shim, AY, 790(ab)
Shim, YM, 66(ab), 67(ab), 1345(ab)
Shimada, H, 68(ab)
Shimada, J, 1839
Shimada, Y, 1839
Shimazu, T, 604(ab)
Shimizu, M, 1612
Shimoji, K, 779(ab), 784(ab)
Shimokawa, A, 820(ab)
Shin, D, 1337(ab)
Shin, JH, 87(ab), 88(ab), 90(ab), 130(ab), 1197(ab), 1203(ab), 1205(ab)
Shin, WS, 43
Shiomi, M, 701(ab)
Shirai, N, 1030
Shirakawa, S, 988(ab)
Shiran, S, 1248(ab)
Shirane, R, 565
Shirato, H, 883(ab)
Shiue, C-Y, 1890
Shiue, CY, 503(ab), 604(ab), 1059(ab)
Shiue, GG, 604(ab), 1059(ab), 1890
Shively, J, 1433(ab)
Shively, JE, 1296(ab), 1962
Shizukuishi, K, 1003(ab)
Shoghi-Jadid, K, 907(ab), 951(ab)
Shon, JH, 1370(ab)
Shoner, SC, 786(ab)
Shoup, TM, 502(ab)
Shoyeb, AH, 967
Shue, S, 1429(ab)
Shuke, N, 475, 768(ab), 1207(ab), 1250(ab)
Shulkin, B, 846
Shulkin, BL, 297(ab), 898, 1366(br)
Shwartz, SC, 996(ab)
Siderowf, A, 852(ab), 853(ab), 854(ab)
Sidi, D, 601(ab)
Siebner, H, 54(ab)
Siebner, HR, 897(ab)
Sieckman, GL, 823, 1066(ab), 1074(ab)
Sieg, P, 1224(ab)
Siegel, AH, 1379
Siegel, AM, 1379
Siegel, B, 7
Siegel, BA, 247(ab), 428(ab), 549, 700
Siegel, EL, 14N(10)
Siegel, JA, 67, 320(le), 334(ab), 1113, 1137(ab)
Siegel, ME, 1236(ab)
Siegel, S, 519(ab)
Sieger, S, 1316(ab)
Siessmeier, T, 109
Sigman, SR, 776(ab)
Sikora, J, 85
Silberman, SS, 77(ab)
Silberstein, EB, 27N(6)
Silhova, E, 1218(ab)
Silverman, DH, 51(ab), 52(ab), 246(ab), 248(ab), 303(ab), 402(ab), 615(ab), 828(ab), 857(ab), 1064(ab), 1190(ab), 1238, 1325(ab), 1333(ab), 1355(ab), 1497(ab)
Silverman, RW, 1027(ab)
Silvestro, L, 1253(ab)
Simo, M, 835(ab), 887(ab)
Simoes, MV, 339(ab), 702(ab), 704(ab)
Simon, E, 987(ab), 1725
Simon, WE, 1137(ab)
Simonetti, G, 1040(ab)
Simonian, HP, 302(ab)
Simpson, NR, 1110(ab), 1111(ab), 1127(ab), 1145(ab)
Simula, S, 487
Singh, A, 304(ab)
Singh, B, 1374(ab)
Singh, R, 69(ab), 1269(ab), 1492(ab)
Sinha, A, 465(ab), 1420(ab), 1940
Sinusas, AJ, 958(ab), 995(le)
Sipola, P, 487
Sisson, JA, 297(ab)
Sisson, JC, 898
Skehan, SJ, 11
Skerrett, DW, 206(ab)
Skinner, M, 122(ab)
Skinner, RS, 580(ab)
Skornick, Y, 1413
Slama, M, 155, 176(ab), 177(ab), 178(ab), 749(ab), 767(ab)
Slavine, NV, 528(ab)
Sledge, GW, 158(ab), 1065(ab)
Slegers, G, 63(ab), 163
Slifstein, M, 33(ab), 34(ab), 218(ab)
Slomka, PJ, 725(ab), 743(ab), 1156
Small, GW, 52(ab), 222(ab)
Smekal, U, 533(ab)
Smith, BJ, 523(ab)
Smith, C, 443(ab)
Smith, CJ, 823, 1066(ab)
Smith, GT, 405(ab), 914(ab), 928(ab), 1418(ab)
Smith, H, 814(ab)
Smith, HC, 521(ab), 715(ab), 975(ab)
Smith, MF, 526(ab)
Smith, MP, 166(ab), 703(ab), 1055(ab), 1128(ab)
Smith, N, 586(ab)
Smith, R, 602, 1378(ab)
Smith-Jones, P, 101(ab), 424(ab)
Smith-Jones, PM, 159(ab), 610, 1290(ab), 1292(ab)
Smits, P, 717(ab)
Smyth, FE, 1105
Snell-Bergeon, JK, 348(ab)
Snow, GB, 1271, 1663
Snowden, G, 1046(ab)
Snyder, SE, 803(ab)
So, MK, 87(ab), 1205(ab)
So, Y, 16(ab), 130(ab), 401(ab), 535(ab), 571(ab), 1342(ab), 1350(ab)
Sobesky, J, 533(ab)
Sobrio, F, 526
Sochor, H, 1741
Sodee, DB, 594(ab), 964(ab)
Soede, AC, 500(ab), 578(ab)
Soghomonian, S, 150(ab), 156(ab)
Sohn, HS, 821(ab), 851(ab), 1182(ab), 1278(ab)
Sohn, JH, 1122(ab)
Sohn, KR, 1437(ab)
Sohn, MH, 1210(ab)
Sojkova, J, 1379
Sokoloff, L, 779(ab), 781(ab), 784(ab)
Sokoloff, P, 231(ab)
Solanki, CK, 11
Solanki, KK, 317(le)
Solanto, M, 216(ab)
Solbach, C, 328(ab)
Solin, O, 682
Solinas, ME, 1219
Solit, D, 1290(ab)
Somanesan, S, 1161(ab)
Sommer, K, 418(ab)
Son, HK, 954(ab)
Son, M, 2033
Song, HC, 323(ab), 485(ab), 487(ab), 508(ab), 571(ab), 1087(ab), 1139(ab)
Song, LP, 469(ab)
Song, OR, 790(ab)
Song, X, 208(ab)
Sonmezoglu, K, 1368(ab)
Soong, BW, 858(ab)
Sopena, R, 446
Sörensen, J, 1176
Sørensen, M, 1302(ab)
Soret, M, 40(ab), 55(ab), 125(ab), 1184
Soriani-Lefèvre, M-H, 1013
Soroa, VE, 482(ab), 1223(ab)
Sossi, V, 989(ab)
Sotiropoulou, M, 413(ab)
Soto, PF, 345(ab)
Soto-Montenegro, ML, 779(ab), 784(ab)
Sotti, G, 1181(ab), 1443
Soucy, JP, 895(ab)
Soulen, MC, 574(ab)
Southwick, SM, 119(ab)
Souvatzoglou, M, 413(ab)
Sovago, J, 219(ab)
Sozzi, FB, 127
Spaepen, K, 613(ab)
Spana, G, 1293
Spangler, T, 77(ab)
Spanoudaki, V, 1032(ab)
Spanu, A, 359, 1164(ab), 1219
Sparks, R, 333(ab)
Sparks, RB, 67, 320(le), 336(ab), 465
Spence, AM, 786(ab), 872(ab), 878(ab)
Spencer, A, 1484(ab)
Spencer, F, 1725, 987(ab)
Spencer, TJ, 217(ab)
Sperling, MR, 57(ab)
Spermon, JR, 427(ab)
Spiegl, U, 21(ab)
Spies, S, 465
Spijkerboer, AL, 1099
Spinelli, L, 1023
Springer, IN, 557(ab)
Squeri, S, 260, 1543(le)
Squire, O, 124(ab), 527(ab), 968(ab), 1940
Squire, OD, 1644
Srinivas, JV, 486(ab)
Srinivasan, A, 1315
Srivastava, SC, 1105(ab), 1165(ab)
Srivatsa, S, 1195(ab)
Stabin, MG, 67, 320(le), 335(ab), 336(ab), 422, 465
Stachowiak, AM, 1157(ab)
Stadtmauer, EA, 2000
Staedele, C, 704(ab)
Staelens, S, 1032(ab), 1048(ab)
Stahl, A, 64(ab), 233(ab)
Ståhle, E, 1176
Stahlschmidt, A, 117, 314(ab)
Staley, JK, 220(ab)
Stayton, PS, 437
Steadham, RE, 1045(ab)
Stearns, CW, 123(ab), 362(ab), 363(ab)
Steele, P, 484(le), 993(le)
Steele, PP, 205(ab), 511(ab), 518(ab)
Stefanis, K, 1028(ab)
Stegeman, CA, 1187(ab)
Stegger, L, 510(ab)
Stein, R, 1220(ab)
Steinert, HC, 24, 1911
Steinling, M, 391(ab), 1413(ab)
Steinmetz, A, 1243(ab)
Steinmetz, AP, 1248(ab), 1272(ab)
Steinmetz, N, 500(ab), 509(ab)
Steinmetz, ND, 947
Stejskal, L, 848(ab)
Stekhova, S, 412(ab)
Stellhorn, S, 347(ab)
Stenzel, A, 191(ab)
Stepanov, P, 455(ab)
Stephan, K, 1384(ab)
Stephens, GM, 755(ab)
Stephenson, KA, 154(ab), 1100(ab)
Sterman, D, 1390(ab)
Stern, M, 852(ab), 853(ab), 854(ab)
Stern, RC, 594(ab)
Stevens, H, 336
Stevenson, G, 525(ab)
Stevenson, GD, 705(ab), 1307(ab)
Stewart, P, 99(ab)
Stigter-van Walsum, M, 1271
Stocker, S, 112(ab)
Stokkel, MPM, 739
Stolin, AV, 1277(ab)
Stolk, LM, 5(ab)
Stollfuss, J, 64(ab)

Stone, KL, 158(ab), 1065(ab)
Storch, A, 387(ab), 390(ab)
Stout, D, 260(ab), 1325(ab)
Stout, DB, 333(ab)
Straatsburg, IH, 136(ab)
Strand, SE, 491(ab), 1162(ab)
Strapp, LC, 512(ab)
Strauss, HF, 583(ab)
Strauss, HW, 43, 92, 159(ab), 185(ab), 342(ab), 397, 501(ab), 587(ab)
Strauss, LG, 78(ab), 203(ab), 257(ab), 258(ab), 381(ab), 556, 880(ab), 935(ab), 1316(ab), 1319(ab), 1933
Strauss, WH, 552(ab)
Strijckmans, K, 63(ab)
Stroobants, S, 613(ab)
Strul, D, 1032(ab), 1048(ab)
Stubbs, JB, 447(ab)
Stumpe, KD, 138(ab), 1911
Stundzia, A, 53(ab), 900(ab)
Sturz, L, 671
Styliaris, S, 1032(ab)
Su, Y, 580(ab)
Su, Z, 1081(ab)
Subbarayan, M, 650
Subbiah, K, 437, 1114(ab)
Suga, K, 190(ab), 593(ab), 1270(ab)
Suga, R, 820(ab)
Sugawara, Y, 534(ab), 923(ab), 1454(ab)
Sugimoto, K, 866(ab), 1371, 1875
Sugimura, K, 707(ab)
Sugiyama, M, 1346(ab)
Suh, TS, 821(ab)
Suh, Y-G, 2033
Suhara, T, 35(ab)
Sulaiman, A, 728(ab)
Sullivan, G, 1171(ab)
Sumiya, H, 793(ab), 1436(ab)
Sun, CM, 399(ab), 858(ab)
Sun, H, 1151(ab), 1328(ab)
Sun, HB, 158(ab)
Sun, SM, 323(ab)
Sundaram, PS, 18(ab), 1284(ab)
Sundaram, SK, 201(ab), 266(ab)
Sundaresan, G, 2(ab), 149(ab), 1296(ab), 1962
Sundram, FX, 1161(ab)
Sung, C, 422, 1330(ab)
Sung, HD, 790(ab), 1060(ab)
Sung, LY, 1094(ab)
Sung, SW, 401(ab)
Suriano, S, 396(ab)
Surti, S, 25(ab), 1340
Sutton, GP, 700
Sutton, R, 1540(le)
Suurmeijer, AJ, 240(ab), 547(ab)
Suurmeijer, AJH, 1927
Suzuki, A, 1452(ab)
Suzuki, K, 343(ab), 1348(ab)
Suzuki, M, 253(ab), 454(ab), 1311(ab)
Suzuki, T, 385, 884, 1174(ab)
Suzuki, Y, 68(ab), 1338(ab)
Svarer, C, 943(ab)
Sviri, GE, 537(ab)
Swanson, JM, 117(ab), 216(ab)
Swanson, KR, 786(ab)
Swanson, N, 610(ab)
Swanson, SM, 1300(ab)
Swensson, R, 276
Sy, MA, 463(ab)
Syed, GM, 775(ab), 1232(ab)
Syed, R, 420(ab), 1178(ab), 1400(ab)
Syed, S, 502(ab), 1109(ab)
Syed, SZ, 1313(ab)
Symonds, EL, 1099
Syrjälä, HP, 1368(le)
Syrota, A, 157(ab), 318(ab), 706(ab), 708(ab), 711(ab), 749(ab), 1459
Szabo, M, 234(ab)
Szabo, Z, 463(ab)
Szajek, LP, 813(ab)
Szuba, A, 43
T H E Staging Breast Cancer with PET Group, 247(ab)
Tabamo, R, 388(ab), 859(ab)
Tachibana, K, 1001(ab)
Tadamura, E, 14(ab), 17(ab), 738(ab), 745, 750(ab), 1873(le)
Tadayyon, S, 1407(ab)
Tadokoro, H, 4(ab), 343(ab)
Tafani, M, 663
Tagaya, M, 792(ab)
Taggart, L, 154(ab), 1100(ab)
Tai, YC, 519(ab)
Taillefer, R, 505(ab), 506(ab), 1039(ab)
Taintor, NB, 815
Tait, J, 159(ab)
Tait, JF, 92, 342(ab), 501(ab), 582(ab), 583(ab), 587(ab), 783(ab), 1058(ab)
Tajima, T, 68(ab)
Takabatake, N, 1747
Takada, Y, 719(ab)
Takagi, M, 1030
Takahashi, H, 690, 1273(ab)
Takahashi, K, 1747
Takahashi, M, 866(ab), 904(ab), 1371
Takahashi, N, 20(ab), 1003(ab), 1452(ab)
Takahashi, S, 745(ab)
Takahashi, T, 256(ab), 842(ab), 1339(ab)
Takala, T, 682
Takamatsu, H, 105, 609(ab), 799(ab), 1119(ab), 1516
Takamatsu, S, 1305(ab)
Takano, A, 35(ab)
Takano, B, 897(ab)
Takano, M, 904(ab)
Takao, M, 1381(ab)
Takasaki, M, 820(ab)
Takasawa, M, 505
Takasugi, JE, 1389(ab)
Takayama, Y, 884
Takechi, M, 68(ab)
Takeda, K, 829(ab), 988(ab), 1174(ab), 1381(ab)
Takehana, K, 173(ab), 757(ab), 764(ab)
Takei, N, 883(ab)
Takei, T, 129(ab), 414(ab), 583(ab), 587(ab), 1192(ab), 1201(ab)
Takeichi, Y, 1717
Takeishi, Y, 1747
Takekoshi, N, 275(ab)
Takekuma, M, 1051
Takeuchi, K, 1030
Takeuchi, R, 912(ab)
Takeuchi, Y, 1005(ab)
Taki, J, 288(ab), 342(ab), 369, 736(ab), 1436(ab), 1612
Taki, S, 1376(ab), 1442(ab)
Talbot, JN, 1392(ab), 1397(ab), 1398(ab)
Talbot, PS, 34(ab), 109(ab), 218(ab), 226(ab), 231(ab), 603(ab), 807(ab), 812(ab), 1049(ab), 1053(ab)
Talcott, JA, 1006(ab)
Tallet, J, 3(ab), 776(ab)
Tam, YM, 978(ab)
Tamaki, N, 17(ab), 92, 129(ab), 256(ab), 291(ab), 292(ab), 294(ab), 385(ab), 414(ab), 516(ab), 524(ab), 583(ab), 587(ab), 713(ab), 721(ab), 738(ab), 745, 792(ab), 883(ab), 884(ab), 934(ab), 1010(ab), 1037(ab), 1120(ab), 1168, 1192(ab), 1201(ab), 1467
Tamas, C, 749(ab)
Tamgac, F, 1394
Tamir, A, 183(ab), 355(ab), 1272(ab)
Tamura, K, 1348(ab)
Tamura, S, 820(ab), 827(ab), 870(ab)
Tamura, Y, 2027
Tan, GJ, 1296(ab)
Tan, PS, 1262(ab)
Tan, TZ, 1469(ab), 1471(ab)
Tanada, S, 4(ab), 343(ab), 1348(ab)
Tanaka, A, 904(ab)
Tanaka, F, 1243, 830(ab), 840(ab)
Tanaka, K, 974(ab)
Tancioni, F, 871(ab)
Taniguchi, K, 515(ab), 1604
Taniguchi, M, 1376(ab), 1442(ab)
Tann, MA, 74(ab)
Tarantola, G, 756
Tarazi, FI, 166(ab), 1055(ab)
Targino Rodrigues dos, S, 1415(ab)
Targino, SR, 1228(ab)
Tarkiainen, J, 219(ab)
Tates, AD, 658(le)
Tatsch, K, 36(ab), 112(ab), 116(ab), 372(ab), 387(ab), 390(ab), 541(ab), 862, 918(ab), 942(ab)
Tatsumi, M, 105, 243(ab), 295(ab), 423(ab), 1119(ab), 1241(ab), 1403(ab), 1404(ab), 1516
Taubman, KL, 56(ab)
Taverna, C, 272(ab)
Tavitian, B, 157(ab), 318(ab)
Tayfun, E, 763(ab)
Taylor, A, 467(ab), 1134(ab), 1282(ab), 1288(ab), 1289(ab)
Taylor, AT, Jr., 988
Taylor, C, 591(ab)
Taylor, I, 80(ab), 81(ab)
Tcherniamtchouk, O, 441(ab), 555(ab), 1496(ab)
Tcherniantchouk, O, 440(ab), 1402(ab)
te Velde, AA, 140(ab)
Teh, BT, 580(ab)
Teising, A, 1424(ab)
Teitcher, JB, 260, 1543(le)
Telang, F, 38(ab), 117(ab), 213(ab), 800(ab), 890(ab), 898(ab)
Terae, S, 1201(ab)
Terai, H, 1612
Teramoto, N, 701(ab)
Terasaki, K, 520
Terheyden, H, 557(ab)
Terhune, KP, 410(ab)
Terschueren, B, 986(ab)
Terwinghe, C, 1973
Terzi, A, 175(ab), 558(ab), 1198(ab)
Testanera, G, 1407(ab)
Tetrault, RJ, 77(ab)
Teule, GJ, 554(ab), 1022(ab)
Teunissen, JJ, 442(ab)
Thackray, S, 494
Thadani, VM, 1379
Thakur, ML, 1293
Thalamas, C, 847(ab)
Thaler, A, 1547
Thanos, PK, 815
Thede-Reynolds, K, 1144(ab)
Theobald, I, 1238(ab)
Theodore, C, 1397(ab)
Theodore, LJ, 437, 576(ab), 1284, 1292(ab)
Theodore, WH, 62(ab)
Thews, O, 595(ab)
Thie, JA, 405(ab), 914(ab), 928(ab)
Thiesen, HJ, 257(ab), 258(ab)
Thimister, PW, 1249(ab)
Thimister, PWL, 391
Thirion, JP, 899(ab)
Thomas, A, 304(ab)
Thomas, AV, 545(ab)
Thomas, C, 231(ab)
Thomas, EJ, 762(ab)
Thomas, MD, 358(ab)
Thomasius, R, 375
Thompson, JF, 570, 1871(le)
Thompson, NW, 297(ab)
Thorpe, D, 1351(ab)
Thouly, C, 1625
Thrall, JH, 1197
Thumshirn, G, 148(ab)
Tian, R, 1194(ab)
Tian, YQ, 9(ab), 15(ab), 189(ab), 350(ab), 469(ab)
Tibbals, J, 445(ab)
Tiengo, A, 477(ab)
Tientz, J, 832(ab)
Tietze, F, 393(ab), 849(ab), 855(ab)
Tiling, R, 1384(ab)
Ting, G, 794(ab), 860(ab), 888(ab)
Tirona, R, 244(ab)
Tjuvajev, JG, 1845
Tluczek, L, 1121(ab)
Tobey, EA, 43(ab), 45(ab)
Toczek, MT, 62(ab)
Toder, SP, 2000
Tognoni, G, 396(ab)
Tohgoh, A, 1338(ab)
Tomas, MB, 1072, 566(ab)
Tomemori, T, 1174(ab), 1348(ab)
Tomita, K, 369
Tomiyoshi, K, 1174(ab)
Tonami, H, 1376(ab), 1442(ab)
Tonami, N, 187(ab), 275(ab), 288(ab), 342(ab), 369, 736(ab), 793(ab), 799(ab), 1291(ab), 1436(ab), 1476(ab)
Toniato, A, 1183(ab)
Tonn, JC, 541(ab)
Tonpkins, RG, 1012(ab)
Toporov, Y, 1105(ab)
Toretsky, JA, 1058(ab)
Torigoe, S, 1003(ab), 1452(ab)
Torii, K, 353
Torizuka, T, 1051, 1346(ab), 1435(ab)
Tornai, MP, 583, 1029(ab)
Torres, G, 1283(ab)
Totani, Y, 540
Toufektsian, M-C, 1092
Tourkova, V, 150(ab), 156(ab)
Tourwé, D, 1649
Tovar-Salazar, A, 165(ab)
Townsend, DW, 360(ab), 364(ab), 983(ab), 991(ab), 1855
Toyama, H, 35(ab), 529(ab), 781(ab), 988(ab)
Toyama, T, 515(ab), 884, 1604
Toyoda, H, 17(ab), 738(ab), 745, 1875
Toyohara, J, 1080(ab), 1305(ab), 1671
Toyokuni, T, 1325(ab)
Toyozaki, T, 4(ab)
Traino, C, 1164(ab)
Tran, A, 248(ab)
Tran, C, 260(ab), 1325(ab)
Tran, VH, 1027(ab)
Travaini, LL, 871(ab), 1407(ab)
Travis, MJ, 788(ab)
Trébossen, R, 276
Treleaven, J, 1470(ab)
Treslova, L, 1218(ab)
Treves, ST, 599(ab), 909, 988
Tripathi, M, 762(ab), 1209(ab)
Tripati, M, 383(ab)
Triquenot, A, 598(ab)
Trischitta, V, 207
Tronco, GG, 147(ab), 566(ab)
Trubač, M, 1784
Truhlar, S, 1495(ab)
Tsai, C, 1429(ab)
Tsai, C-S, 1775
Tsai, CC, 1428(ab), 1430(ab)
Tsai, CS, 1387(ab), 1428(ab), 1430(ab), 1431(ab), 1455(ab)
Tsai, DE, 2000
Tsai, G, 1429(ab)
Tsai, LC, 1299(ab)
Tsay, DG, 1256(ab)
Tseng, J, 250(ab), 913(ab), 1044, 1310(ab), 1806
Tseng, JS, 249(ab)
Tseng, L, 370(ab)
Tseng, LY, 932(ab)
Tsopelas, C, 1540(le)
Tsuchida, T, 540, 785(ab)
Tsuchiya, H, 369

Tsuchiya, K, 414(ab)
Tsui, B, 27(ab)
Tsui, BM, 23(ab), 195(ab), 207(ab), 208(ab), 366(ab), 461(ab), 971(ab), 997(ab), 1042(ab)
Tsui, BMW, 462(ab)
Tsuji, S, 793(ab)
Tsujii, H, 1348(ab)
Tsukada, H, 223(ab)
Tsukamoto, E, 92, 256(ab), 414(ab), 524(ab), 583(ab), 587(ab), 721(ab), 883(ab), 1120(ab), 1168, 1192(ab), 1201(ab)
Tsukamoto, M, 385(ab), 884(ab), 934(ab)
Tsukamoto, S, 129(ab)
Tsukamoto, T, 292(ab), 294(ab), 516(ab), 713(ab), 721(ab)
Tsushima, M, 171(ab)
Tsutimoto, K, 329(ab)
Tsyganov, EN, 528(ab)
Tung, C, 1160(ab)
Turcotte, E, 26(ab), 882(ab), 1918
Turhan, AG, 157(ab), 318(ab)
Turkington, TG, 363(ab), 926(ab)
Turkmen, C, 1368(ab)
Turlakow, A, 1407, 1484(ab)
Turnquist, S, 1510
Twaddle, J, 473(ab), 1244(ab)
Twieg, DB, 536(ab)
Tyndall, A, 145(ab)
Tzen, K, 860(ab), 1429(ab)
Tzen, KY, 888(ab)

Uccelli, L, 806
Uchida, H, 1487(ab)
Uchida, Y, 834(ab)
Uchiyama, K, 1612
Ucros, G, 573(ab)
Udeshi, M, 389(ab), 852(ab), 853(ab), 854(ab)
Udupa, J, 953(ab)
Uebelhart, D, 1227(ab)
Ueda, Y, 1376(ab), 1442(ab)
Uehara, T, 4(ab), 1092(ab)
Ueno, S, 1168
Uffelman, W, 20N(3), 44N(4), 22N(5), 44N(6), 41N(7), 51(8), 32N(9), 35N(10), 38N(11), 33N(12)
Ugur, O, 1185(ab), 1481(ab)
Ulmer, H, 708
Umemura, S, 20(ab)
Umeno, MM, 1276(ab)
Umesaki, N, 353
Unadkat, JD, 1303(ab)
Underwood, MD, 1110(ab), 1111(ab), 1127(ab)
Ung, YC, 244(ab)
Unger, S, 1092
Unnithan, J, 650
Uno, K, 1174(ab)
Uno, T, 820(ab)
Uren, RF, 570, 1871(le)
Urhan, M, 1024(ab)
Uribe, J, 1000(ab), 1015(ab), 1018(ab), 1019(ab)
Ushijima, Y, 1421
Utkusavas, A, 1368(ab)
Utsunomiya, K, 53(ab), 900(ab)

Vaalburg, W, 106(ab), 223(ab), 331, 341, 801(ab), 1154(ab), 1700
Vaggelli, L, 548(ab)
Vaiano, A, 1008(ab)
Vajda, J, 817(ab)
Vakhetov, F, 1105(ab)
Valdivia, A, 137(ab)
Valentine, S, 766(ab)
Valette, H, 596
Valkema, R, 10(ab), 11(ab), 127, 140, 443(ab), 877
Vallabhajosula, S, 429(ab), 430(ab), 610, 1093(ab), 1155(ab), 1167(ab), 1173(ab), 1385(ab)
Valli, I, 889(ab)
Valliant, JF, 154(ab), 162(ab), 1100(ab)
Vallis, KA, 1469
Valotassiou, V, 413(ab)
Van de Walle, R, 919(ab), 1048(ab)
Van de Wiele, C, 967, 1219(ab), 1531
Van den Abbeele, AD, 77(ab), 197(ab)
Van den Broek, WJ, 103(ab)
van den Wijngaard, RM, 1099
van der Graaf, WT, 76(ab)
van der Hoeven, JJ, 554(ab)
van der Jagt, EJ, 184
van der Laan, BFAM, 341
van der Meer, JW, 144(ab)
van der Veer, E, 184
van der Weerdt, AP, 967(ab)
van der Wilt, G, 522(ab)
van Deventer, SJ, 140(ab)
van Domburg, R, 10(ab), 11(ab), 127
van Domburg, RT, 877
van Dongen, GAMS, 1271, 1663, 1690
van Dyck, CH, 220(ab)
van Eerd, J, 1663
van Eerd, JE, 498(ab), 1118(ab)
van Eerd, JEM, 1087
van Gulik, TM, 136(ab)
van Heeringen, C, 163
van Heertum, R, 1110(ab), 1111(ab), 1127(ab)
Van Heertum, RL, 1145(ab)
van Koetsveld, PM, 1315
van Kroonenburgh, MJ, 1249(ab)
Van Laere, K, 163, 63(ab)
van Leuven, F, 269
van Lier, JE, 1334(ab)
van Lingen, A, 1022(ab)
van Montfrans, C, 140(ab)
Van Oosterwyck, G, 1075
Van rijk, PP, 1177(ab)
Van Rijk, PP, 1188(ab)
van Rijk, PP, 336, 472(ab), 522(ab)
van Schaijk, FG, 400
van Schijndel, GM, 1105
van Waarde, A, 1700
VanBrocklin, HF, 282(ab), 809(ab)
Vande Woude, GF, 580(ab)
Vanden Bempt, V, 1973
Vandenberghe, P, 613(ab)
Vandenberghe, S, 919(ab), 967, 1048(ab)
Vanderheyden, J-L, 947
Vanderheyden, JL, 1(ab), 500(ab), 1069(ab), 1115(ab)
Vandierendonck, M, 725(ab)
Vanguru, R, 69(ab), 1269(ab), 1492(ab)
Vanhove, C, 286(ab), 459(ab), 993(ab), 1013(ab)
Vanninen, E, 487
Vanoverschelde, JL, 276(ab)
Vanzetto, G, 981
Vanzi, E, 371(ab)
Varavithya, V, 268(ab), 269(ab)
Vardareli, E, 1024(ab)
Varela, J, 566(ab)
Varetto, T, 1213(ab)
Varga, J, 902(ab)
Varrone, A, 512
Varvarigou, A, 1028(ab)
Vaska, P, 451(ab), 780(ab), 815, 1522
Vassileva-Belnikolovska, D, 1293
Vassiliadi, E, 413(ab)
Vastenhouw, B, 522(ab)
Veach, D, 1068(ab)
Vega, HR, 1172(ab)
Velazquez Espeche, MH, 482(ab), 1223(ab)
Velez, O, 573(ab)
Venderheyden, JL, 326(ab)
Vendrell, P, 1884
Venegas, JG, 1982
Venkatesh, M, 1123(ab)
Venz, S, 394(ab)
Vera, DR, 196(ab), 308(ab), 1677
Vera, P, 598(ab), 1013
Verani, M, 346(ab)
Verbeke, K, 947
Verbeke, KA, 1086(ab)
Verbruggen, AM, 269, 947, 1075, 1086(ab), 1973
Vercouillie, J, 219(ab)
Verdenet, J, 485(le)
Verdonck, P, 967
Verel, I, 1271, 1663
Veress, AI, 460(ab)
Verhoef, G, 613(ab)
Vernaleken, I, 109
Vernon, C, 315(ab), 1467(ab)
Vernon, CM, 786(ab)
Verreault, J, 1225
Versijpt, J, 63(ab)
Vervaet, AM, 724(ab)
Vervaet, M, 163
Vervloet, M, 522(ab)
Vespa, PM, 384(ab), 885(ab), 1709
Vessella, RL, 1085(ab)
Vesselle, H, 26(ab), 1389(ab), 1482, 1918
Veyhl, M, 1075, 1973
Vezina, WC, 512(ab)
Vidal Melo, MF, 1982
Vider, J, 150(ab), 156(ab)
Vija, AH, 456(ab), 747(ab)
Vilain, D, 155
Villa, E, 245(ab)
Villa, G, 1253, 478(ab)
Villalpando, J, 1238
Villemagne, V, 276, 1855
Vilstrup, H, 1206(ab)
Vines, D, 781(ab)
Virgolini, I, 1547
Virmani, R, 1(ab)
Visikis, D, 788(ab)
Visokai, V, 1784
Visscher, R, 522(ab)
Visser, FC, 967(ab)
Visser, GWM, 1271, 1663
Visvikis, D, 80(ab), 81(ab), 420(ab), 1178(ab), 1400(ab)
Viswanathan, V, 566(ab)
Vlassenko, AG, 48(ab)
Vogelaers, D, 1219(ab)
Vogt, FM, 1354(ab)
Vogt, H, 451
Volkert, WA, 823, 1066(ab), 1074(ab)
Volkmer, BG, 434(ab)
Volkow, ND, 38(ab), 117(ab), 213(ab), 216(ab), 798(ab), 800(ab), 815, 890(ab), 898(ab), 1239(ab), 1522
Voll, RJ, 855
Volpino, P, 1219
Volterrani, D, 134(ab), 396(ab), 501(ab), 562(ab), 1008(ab), 1443
vom Dahl, J, 33
Vomocil, B, 769(ab)
von Forstner, C, 247
von Hof, K, 418(ab)
von Schulthess, GK, 24, 138(ab), 146, 417(ab), 732, 1227(ab), 1382(ab), 1911
Vonderheid, EC, 273(ab)
Vosberg, H, 618
Vose, J, 616(ab)
Voss, P, 1023(ab)
Votaw, JR, 153(ab), 543(ab), 605(ab), 855, 1050(ab), 1156(ab)
Voung, B, 1152(ab)
Vourvouri, EC, 127, 877
Vranjesevic, D, 260(ab), 402(ab), 1238, 1355(ab)
Vrigneaud, JM, 340(ab)
Vuillemard, C, 318(ab)
Vuong, B, 1056(ab)

Waaijers, M, 1315
Wachsberger, P, 1293
Wackers, FJ, 958(ab), 1039(ab)
Wackers, FJT, 995(le)
Wada, Y, 791(ab), 990(ab)
Waddington, W, 788(ab)
Wagner, B, 86(ab)
Wagner, HN, Jr., 35N(1), 15N(2), 12N(3), 30N(4), 16N(5), 40N(6), 33N(7), 11N(8), 20N(9), 26N(10), 26N(11), 20N(12)
Wagner, JD, 486(le)
Wagner, R, 263(ab)
Wagner, S, 709(ab)
Wahab Benada, A, 155
Wahl, A, 252(ab), 403(ab), 432(ab), 433(ab)
Wahl, R, 105(ab), 710(ab), 1478(ab)
Wahl, RL, 99(ab), 128(ab), 170, 199(ab), 240, 243(ab), 247(ab), 259(ab), 273(ab), 295(ab), 310(ab), 312(ab), 412, 422(ab), 423(ab), 457, 471(ab), 590(ab), 927(ab), 1241(ab), 1267, 1341(ab), 1403(ab), 1404(ab), 1477(ab), 1541(le), 1797
Wakasugi, S, 560(ab)
Wakisaka, S, 870(ab)
Waldherr, C, 260(ab), 1325(ab), 1355(ab), 1497(ab)
Waldmann, TA, 577(ab)
Walkner, W, 1464(ab)
Wallace, AM, 308(ab), 1006(ab), 1677
Wallace, WE, 484(le)
Wallack, M, 7
Walter, MA, 145(ab), 546(ab)
Wan, Q, 552(ab)
Wand, GS, 211(ab)
Wang, C, 287(ab), 374(ab), 905(ab)
Wang, CH, 313(ab), 514(ab), 999(ab)
Wang, FZ, 180(ab)
Wang, GJ, 38(ab), 117(ab), 213(ab), 216(ab), 800(ab), 890(ab), 898(ab)
Wang, HE, 155(ab), 544(ab), 1327(ab)
Wang, J, 1469
Wang, JK, 380(ab), 419(ab)
Wang, JQ, 158(ab), 1065(ab)
Wang, K, 1095(ab)
Wang, KC, 535(ab)
Wang, L, 770
Wang, LL, 469(ab)
Wang, M, 1284
Wang, P, 1095(ab)
Wang, Q, 298(ab), 1075(ab), 1113(ab)
Wang, RF, 1294(ab), 1317(ab)
Wang, S, 789(ab), 1325(ab), 1459(ab)
Wang, SG, 1395(ab)
Wang, SJ, 1204(ab)
Wang, W, 570(ab)
Wang, XM, 287(ab)
Wang, Y, 23(ab), 207(ab), 1000(ab), 1015(ab), 1018(ab), 1019(ab)
Wang, ZJ, 1122(ab)
Ward, CA, 1141(ab)
Ward, HB, 85
Wareham, DW, 317(le)
Warner, D, 1239(ab)
Warner, DA, 1522
Wartberg, L, 375
Wartski, M, 761(ab)
Washimi, Y, 822(ab)
Wassef, M, 1767
Wassmann, H, 873(ab)
Watabe, H, 512, 701(ab), 906(ab), 947(ab), 992(ab)
Watanabe, E, 990(ab)
Watanabe, G, 187(ab)
Watanabe, M, 565, 1338(ab)
Watanabe, N, 475
Watanabe, W, 1339(ab)
Watanuki, S, 1228(ab)

Watarai, M, 1487(ab)
Waterhouse, RN, 807(ab), 1323(ab)
Watfah, C, 1375(ab)
Watkins, GL, 1141(ab), 1143(ab), 1144(ab)
Watkinson, AJ, 445(ab)
Watson, A, 586(ab)
Watson, CC, 360(ab), 364(ab)
Watson, DD, 1092
Watson, NE, 1175(ab)
Watson, T, 784
Waxman, AD, 440(ab), 441(ab), 555(ab), 1369(le), 1402(ab), 1496(ab)
Weber, A, 91(ab), 1320(ab)
Weber, MM, 493(ab)
Weber, S, 1682
Weber, WA, 64(ab), 86(ab), 1336(ab), 1401(ab)
Weckesser, M, 550(ab), 873(ab), 1379(ab)
Wedrich, A, 1547
Wegener, WA, 84(ab), 1220(ab), 1258(ab)
Wegman, TD, 801(ab)
Wehrmann, M, 438(ab)
Wei, HX, 189(ab), 350(ab), 365(ab), 1002(ab)
Wei, HY, 13(ab)
Wei, L, 162(ab), 164(ab)
Wei, YQ, 287(ab)
Weiland, F, 742(ab)
Weinberg, BD, 1276(ab)
Weinberg, IN, 455(ab), 1026(ab), 1058(ab)
Weinberger, DR, 224(ab)
Weiner, MF, 826(ab)
Weininger, J, 1260(ab)
Weintraub, S, 307(ab)
Weise, SW, 1313(ab)
Weisenbach, S, 831(ab)
Weisenberger, AG, 251(ab)
Weiss, JA, 460(ab)
Welch, M, 424(ab)
Welch, MJ, 254(ab), 428(ab), 549, 1017(ab), 1062(ab), 1122(ab), 1284, 1305(ab), 1306(ab)
Welch/Michael, MJ, 262(ab)
Welier, R, 965(ab)
Welling, MM, 1368(le)
Wellner, U, 1189(ab)
Wen, B, 378(ab)
Wen, CY, 395(ab), 514(ab)
Wen, GH, 1469(ab)
Wen, J, 979(ab), 995(ab)
Wen, WT, 395(ab), 514(ab)
Wendt III, RE, 453(ab), 1034(ab)
Wendt, R, 700
Wendt, RE, 925(ab), 1157(ab)
Weng, Y, 860(ab)
Wereley, JP, 943
Wermke, M, 54(ab)
Werner, C, 966(ab)
Wessels, BW, 1113
Wester, HJ, 148(ab), 233(ab)
Weterings, R, 1007(ab)
Wey, S, 860(ab)
Wey, SP, 794(ab), 844(ab), 888(ab)
Whatley, M, 201(ab), 266(ab)
White, CA, 465, 1479(ab)
White, JF, 11
Whittington, R, 72(ab)
Whone, AL, 386(ab)
Wichter, T, 510(ab)
Wied, MU, 238(ab), 1362(ab)
Wiedenmann, B, 493(ab)
Wieder, H, 64(ab)
Wieder, HA, 1336(ab)
Wiekowski, J, 709(ab)
Wieland, DW, 297(ab)
Wienhard, K, 29(ab), 107(ab)
Wiens, L, 26(ab), 1918
Wierzbinski, B, 995(le)
Wiggins, J, 505(ab)
Wikström, G, 1176
Wilbert, S, 576(ab)
Wilbur, DS, 437, 1085(ab), 1540(le)
Wilczynski, S, 1433(ab)
Wildberger, JE, 592(ab)
Wilhelm, A, 468(ab)
Wilke, F, 375
Wilkowsky, R, 70(ab)
Willemart, B, 425(ab)
Willemse, PHB, 184
Willemsen, ATM, 341
Williams, CM, 440(ab), 441(ab), 555(ab), 1369 (le), 1402(ab), 1496(ab)
Williams, JJ, 362(ab), 363(ab)
Williams, L, 151(ab)
Williams, LA, 153(ab), 605(ab), 1050(ab)
Williams, LE, 991(br), 1433(ab), 1962
Williams, MB, 1277(ab)
Williams, RC, 455(ab), 1026(ab)
Williams, SP, 998(ab)
Williamson, PD, 1379
Willmore, LJ, 60(ab)
Wilson, AA, 1047(ab)
Wilson, DW, 525(ab), 705(ab), 1307(ab)
Wilson, M, 1098(ab)
Wiltfang, J, 824(ab)
Winarko, B, 1402(ab), 1496(ab)
Winkeler, A, 107(ab)
Winkle, WL, 797(ab)
Winkler, J, 188(ab)
Winkler, T, 1982
Wintering, N, 389(ab), 852(ab), 853(ab), 854(ab)
Wischmann, HA, 192(ab)
Wiseman, G, 616(ab)
Wiseman, GA, 465, 569(ab), 1479(ab)
Wissmeyer, M, 956(ab)
Witjes, JA, 427(ab)
Witzig, T, 465
Witzig, TE, 1479(ab)
Woerdehoff, N, 1460(ab), 1463(ab)
Wojtkiewicz, GR, 1276(ab)
Wolf, BA, 503(ab)
Wollenweber, F, 432(ab)
Wollner, M, 436(ab)
Won, K, 1337(ab)
Wong, C, 117(ab), 213(ab), 216(ab), 890(ab)
Wong, CY, 299(ab), 1475(ab)
Wong, D, 82(ab)
Wong, DF, 30(ab), 41(ab), 42(ab), 47(ab), 109, 115(ab), 215(ab), 805(ab), 810(ab), 922(ab)
Wong, FC, 789(ab)
Wong, JY, 1433(ab)
Wong, KJ, 1091(ab), 1112(ab)
Wong, KT, 1475(ab)
Wong, S, 978(ab)
Wong, W, 1018(ab)
Wong, WH, 1000(ab), 1015(ab), 1019(ab)
Woo, KS, 790(ab), 1060(ab)
Woo, SK, 992(ab)
Wood, AJ, 109(ab)
Wood, M, 109(ab)
Woodward, M, 56(ab)
Woolfenden, JM, 705(ab), 1307(ab)
Wördehoff, N, 940(ab), 1193(ab)
Worlein, JM, 31(ab)
Worsley, DF, 1259(ab)
Wright, GA, 494
Wszolek, ZK, 1440
Wu, A, 1433(ab)
Wu, AM, 1296(ab), 1962
Wu, CY, 1256(ab)
Wu, G, 1429(ab)
Wu, H-M, 1709
Wu, HM, 384(ab), 885(ab), 907(ab)
Wu, J, 1174(ab)
Wu, JC, 2(ab), 104(ab), 337(ab)
Wu, L, 94(ab), 97(ab), 98(ab)
Wu, LC, 370(ab), 380(ab), 419(ab), 911(ab), 1251(ab)
Wu, PY, 1106(ab)
Wu, QY, 15(ab)
Wu, SY, 155(ab), 544(ab)
Wu, ZX, 365(ab), 1002(ab)
Wunderbaldinger, P, 234(ab)
Wurm, R, 875(ab), 876(ab)
Wurm, T, 191(ab)
Wurziger, I, 1426
Wymer, DC, 251(ab)
Wyss, CA, 146
Wyss, MT, 1911

Xiao, W, 770
Xie, H, 104(ab)
Xie, S, 1000(ab), 1015(ab), 1018(ab), 1019(ab)
Xing, T, 1000(ab), 1015(ab), 1018(ab), 1019(ab)
Xu, LW, 804(ab)
Xu, S, 784, 1148
Xu, Y, 800(ab), 1052(ab)
Xu, ZS, 1331(ab)
Xue, B, 229(ab), 606(ab), 608(ab)

Yaes, RJ, 332(ab)
Yaghoubi, SS, 95(ab)
Yajima, K, 105, 329(ab), 799(ab)
Yalcin, H, 763(ab)
Yamada, M, 1348(ab)
Yamada, R, 353
Yamada, S, 745(ab)
Yamada, T, 822(ab)
Yamagishi, H, 1030
Yamaguchi, K, 253(ab), 690, 1228(ab), 1311(ab), 1415(ab)
Yamaguchi, M, 1612
Yamakado, K, 1381(ab)
Yamakawa, Y, 20(ab)
Yamaki, N, 988(ab)
Yamamoto, F, 414(ab), 883(ab)
Yamamoto, I, 1376(ab), 1442(ab)
Yamamoto, M, 829(ab)
Yamamoto, S, 901(ab), 1020(ab), 1352(ab)
Yamamoto, W, 1250(ab)
Yamamoto, Y, 564(ab), 865(ab), 1343(ab), 1363(ab), 1391(ab), 1434(ab), 1490(ab), 1905
Yamamuro, M, 17(ab), 738(ab), 745, 1873(le)
Yamane, T, 1487(ab)
Yamashina, H, 904(ab)
Yamashina, S, 904(ab)
Yamashita, F, 825(ab)
Yamashita, H, 129(ab), 1192(ab)
Yamashita, N, 830(ab)
Yamauchi, A, 1391(ab)
Yamauchi, DM, 1433(ab)
Yamauchi, H, 866(ab), 1371, 1875
Yamaura, G, 690
Yamazaki, J, 904(ab)
Yamazaki, T, 690
Yang, BH, 313(ab)
Yang, D, 92(ab), 1077(ab), 1078(ab), 1084(ab)
Yang, DJ, 319(ab), 322(ab), 508(ab), 1067(ab), 1071(ab), 1082(ab), 1157(ab), 1158(ab)
Yang, DM, 1327(ab)
Yang, G, 1300(ab)
Yang, HK, 1205(ab)
Yang, JC, 201(ab), 266(ab)
Yang, L, 972(ab)
Yang, MF, 9(ab), 13(ab), 469(ab)
Yang, SD, 1060(ab)
Yang, W, 110(ab)
Yang, WK, 1327(ab)
Yang, X, 1303(ab)
Yang, YJ, 732(ab), 1279(ab), 1393(ab), 1432(ab), 1448(ab)
Yaniv, I, 1243(ab), 1248(ab)
Yanoo, S, 1001(ab)
Yao, IW, 857(ab)
Yao, Z, 1330(ab)
Yaoita, H, 1618
Yap, CS, 402(ab), 615(ab)
Yap, JT, 364(ab), 991(ab)
Yarnall, S, 455(ab)
Yasuda, A, 886(ab)
Yasuda, M, 1381(ab)
Yasuda, S, 68(ab), 865(ab), 1338(ab)
Yasui, I, 1338(ab)
Yasumura, Y, 759(ab)
Yau, YY, 978(ab)
Yazaki, P, 1433(ab)
Yazaki, PJ, 1962
Yefremov, N, 242(ab), 1200
Yeh, E, 1709
Yeh, SH, 172(ab), 313(ab), 380(ab), 419(ab), 1412(ab)
Yeldell, D, 67
Yen, SH, 380(ab), 419(ab)
Yen, T, 860(ab), 1429(ab)
Yen, T-C, 1775
Yen, TC, 888(ab), 1387(ab), 1428(ab), 1430(ab), 1431(ab), 1455(ab)
Yenari, M, 783(ab)
Yeo, JS, 261(ab), 1063(ab), 1393(ab), 1432(ab), 1448(ab)
Yester, MV, 1406(ab)
Yetkin, I, 475(ab)
Yeung, DWC, 213
Yeung, H, 1940
Yeung, HW, 465(ab), 527(ab), 968(ab), 969(ab), 1349(ab), 1407, 1417(ab), 1420(ab), 1489(ab)
Yeung, HWD, 1789
Yoda, S, 7(ab), 743(ab)
Yoder, KK, 905(ab)
Yokogami, S, 870(ab)
Yokota, C, 792(ab)
Yokota, M, 277(ab), 719(ab), 1717
Yokoyama, I, 1592
Yokoyama, K, 475, 1291(ab), 1476(ab)
Yonekura, K, 948(ab), 959(ab)
Yonekura, Y, 198, 254(ab), 540, 785(ab), 791(ab), 815(ab), 912(ab), 1080(ab), 1305(ab), 1671, 1875
Yoneyama, T, 275(ab)
Yoo, IR, 1182(ab)
Yoo, SK, 954(ab)
Yook, JH, 1432(ab)
Yoon, CH, 725, 808(ab), 841(ab)
Yoon, CJ, 2033
Yoon, J, 66(ab), 1493(ab)
Yoon, JK, 1226(ab)
Yoon, SN, 1493(ab)
Yoon, YH, 808(ab), 1054(ab)
Yoriyaz, H, 335(ab)
Yorke, E, 124(ab)
Yorke, ED, 968(ab)
Yoshida, K, 4(ab), 343(ab)
Yoshida, M, 198
Yoshida, T, 4(ab), 1421
Yoshikawa, E, 1051, 1435(ab)
Yoshikawa, J, 1030
Yoshikawa, K, 1348(ab)
Yoshikawa, T, 505
Yoshimoto, M, 254(ab), 815(ab)
Yoshimura, H, 924(ab), 1001(ab)
Yoshimura, K, 325
Yoshinaga, K, 292(ab)
Yoshioka, T, 690
Yoshiya, K, 1487(ab)
Yoshiyama, M, 1030
Yosilevsky, G, 470(ab)
You, DL, 1450(ab)
Young, KS, 1489(ab)
Young, S, 466(ab)
Young, SA, 1098(ab)
Young, SN, 895(ab)

Younsi, N, 1392(ab), 1398(ab)
Yu, C, 931(ab)
Yu, CL, 885(ab)
Yu, D, 319(ab), 322(ab), 1067(ab), 1071(ab), 1077(ab), 1078(ab), 1082(ab), 1084(ab), 1158(ab)
Yu, JQ, 142(ab), 235(ab), 464(ab), 479(ab), 517(ab), 589(ab), 1191(ab), 1211(ab), 1409(ab), 1421(ab)
Yu, LZ, 1294(ab)
Yu, M-D, 832
Yu, S, 1112(ab)
Yu, SCH, 213
Yu, TC, 172(ab)
Yu, W, 151(ab)
Yu, X, 949(ab)
Yu, Z, 770
Yuan, CC, 1299(ab), 1412(ab)
Yuen, HY, 940(ab)
Yukawa, H, 520
Yukihiro, M, 319(ab), 322(ab), 1071(ab), 1077(ab), 1078(ab), 1082(ab), 1084(ab), 1158(ab)
Yun, M, 480(ab), 532(ab), 891(ab), 893(ab), 954(ab), 1365(ab), 1370(ab), 1410(ab), 1439(ab), 1440(ab)
Yun, MK, 261(ab), 1063(ab), 1099(ab), 1140(ab)

Zaidi, H, 291
Zaikin, R, 454(ab)
Zalutsky, MR, 792, 1827
Zander, A, 875(ab), 1041(ab)
Zanotti-Fregonara, P, 474(ab)
Zanzonico, P, 85(ab), 159(ab), 424(ab), 573(ab), 1292(ab)
Zanzonico, PB, 378(ab), 1148, 1153(ab), 1161(ab)
Zapico, E, 179(ab)
Zaplatnikov, K, 468(ab), 940(ab), 1193(ab)
Zaplatnikow, K, 1184(ab)
Zapletalova, P, 375
Zaretsky, V, 327(ab)
Zasadny, KR, 457, 1478(ab)
Zavarzin, V, 455(ab)
Zavattini, G, 806
Zawarzin, V, 1026(ab)
Zbijewski, W, 522(ab)
Zehr, P, 1556
Zeiher, AM, 6(ab), 174(ab)
Zekri, H, 1761
Zelenetz, A, 105(ab)
Zelenetz, AD, 260, 1543(le)
Zellars, R, 1404(ab)
Zeng, GL, 204(ab)
Zeng, JH, 1255(ab)
Zent, GW, 903(ab)
Zerva, C, 413(ab)
Zettinig, G, 234(ab), 806(ab)
Zhang, CL, 1294(ab), 1317(ab)
Zhang, J, 94(ab), 507(ab), 1318(ab)
Zhang, JY, 365(ab), 1002(ab)
Zhang, L, 224(ab)
Zhang, S, 180(ab)
Zhang, T, 404(ab)
Zhang, XL, 9(ab), 13(ab), 15(ab), 469(ab)
Zhang, XY, 1471(ab)
Zhang, Y, 1089(ab)
Zhang, YM, 1070(ab), 1116(ab), 1295(ab), 1331(ab)
Zhang, Z, 327(ab), 480(ab)
Zhao, C, 475, 768(ab), 1207(ab), 1250(ab)
Zhao, J, 439(ab), 877(ab)
Zhao, RF, 1255(ab)
Zhao, S, 256(ab), 524(ab), 583(ab), 587(ab), 92
Zhao, SH, 287(ab)
Zhao, XD, 195(ab), 1042(ab)
Zhao, Z, 970(ab)
Zheng, L, 1064(ab)
Zheng, QH, 158(ab), 1065(ab)
Zhi, LD, 180(ab)
Zhou, LY, 937(ab), 984(ab)
Zhou, Y, 30(ab), 42(ab), 109, 215(ab), 810(ab)
Zhu, HJ, 458(ab), 1031(ab)
Zhu, JH, 783(ab)
Zhu, RS, 553(ab), 1321(ab), 1462(ab)
Zhu, W, 800(ab), 890(ab), 898(ab)
Zhu, Z, 118(ab), 603(ab), 812(ab), 1049(ab)
Zhuang, H, 532(ab), 1231(ab), 1367(ab), 1451(ab), 1486(ab)
Zhuang, HM, 142(ab), 184(ab), 235(ab), 426(ab), 464(ab), 479(ab), 517(ab), 589(ab), 611(ab), 612(ab), 1059(ab), 1191(ab), 1196(ab), 1211(ab), 1364(ab), 1366(ab), 1408(ab), 1409(ab), 1421(ab), 1485(ab), 1488(ab)
Ziada, GA, 368(ab)
Ziady, AG, 1276(ab)
Ziegler, S, 702(ab)
Ziegler, SI, 530(ab)
Ziessman, HA, 1263
Ziffer, JA, 457(ab)
Zilles, K, 1682
Zimmer, L, 1495
Zimmerman, BE, 1137(ab)
Zimmerman, I, 1168(ab)
Zimmerman, RE, 973(ab)
Zinchenko, A, 528(ab)
Zingrillo, M, 207
Zinnes, A, 280(ab)
Zito, F, 397(ab), 756, 889(ab)
Zittel, TT, 117, 314(ab)
Zitzmann, S, 973, 1297(ab)
Zober, TG, 463(ab)
Zoghbi, SS, 119(ab)
Zolle, I, 167(ab), 504(ab), 1132(ab)
Zubieta, J, 154(ab), 1100(ab)
Zubieta, JA, 162(ab), 164(ab), 703(ab), 1055(ab), 1090(ab)
Zuckier, LS, 1707(le)
Zuendorf, G, 51(ab), 831(ab), 833(ab)
Zuhayra, M, 6(ab), 247
Zukin, S, 215(ab)
Zukin, SR, 805(ab)
Zuo, TC, 439(ab), 877(ab)
Zuo, YT, 576(ab)
Zurakowski, D, 599(ab)
Zwahlen, D, 1911
Zweit, J, 586(ab), 1142(ab)

A

Accreditation Council for Graduate Medical Education (ACGME), work week for residents, 46N(4)
Acetazolamide
cerebral blood flow and volume, in cerebrovascular disease, 1371
cerebrovascular reactivity to, ^{123}I IMP SPECT, 520
Acetazolamide challenge, balloon test occlusion, bilateral vertebral arteries, 864(ab)
Acetazolamide test, vasodilation and cerebral blood flow changes, in cerebrovascular disease, 1875
Acetylcholine receptors, radiolabeled 7 nicotinic ligands, synthesis and biodistribution, 607(ab)
Acetylcholinesterase
activity
cognitive-behavioral correlates of, in Parkinson's disease, 398(ab)
dementia patients, 837(ab)
mild cognitive impairment, 831(ab)
^{11}C PMP radioligand, Alzheimer's disease, 50(ab)
Acquisition, GSO small animal 3D PET scanner, imaging performance of, 25(ab)
Activation study, cerebral
Alzheimer patients, virtual reality environment, 54(ab)
during hallucinations, in schizophrenia, 887(ab)
novel modes of cochlear implantation, 44(ab)
orbitofrontal activation, during food presentation, 890(ab)
Adenocarcinoma, distal esophagus and cardia, PET in, 41N(10)
Adenoma, parathyroid, diagnosis with preoperative ^{99m}Tc MIBI SPECT, 904
Adenosine
fluorinated analogues, studies in tumor-bearing mice, 1108(ab)
tracer, myocardial flow marker, 641
Adenosine A1 receptors, brain, PET imaging of, 52N(11)
Adenosine receptors, ^{11}C MPDX PET imaging
brain, 221(ab)
cerebral ischemia, 1839
Adenosine stress, bicycle vs, PET assessment of coronary reserve, 146
Adipocytes, spatial distributions, bone marrow, skeletal dosimetry models, 774
Adnexal masses, ^{99m}Tc-labeled SM3 in assessment of, 45N(7)
Adrenal gland
abnormal FDG uptake, predictive accuracy, 1420(ab)
improved characterization of normal appearance, FDG PET/CT, 296(ab)
lesions, cancer patients, FDG PET evaluation, 404(ab)
metastasis in, FDG PET for diagnosis of, 1389(ab)
new labeled derivatives of etomidate for imaging of, 504(ab)
precursor synthesis, ^{131}I MTO, 1132(ab)
β-Adrenergic receptors
^{11}C as a radioligand for, 1120(ab)
desensitization, cardiac neuroimaging in cardiomyopathies, 1459, 1467
pulmonary, quantification with ^{18}F FEFE, 890(ab)
Adrenergic receptors, myocardial density, diabetic minipigs, PET with ^{11}C CGP-12177, 706(ab)
Aging
brain benzodiazepine receptors and, ^{11}C FMZ PET study, 49(ab)
brain perfusion SPECT, correction for partial volume effect, healthy men, 1243
cardiac sympathetic function and, ^{18}F fluorodopamine PET, 1599
dobutamine and the heart, 42N(10)
myocardial fatty acid uptake, during dobutamine, exercise training effects in the elderly, 345(ab)
variations in sternal uptake, bone scintigraphy, 1232(ab)
Alcohol, *see also* Ethanol
dependence, effect of naltrexone treatment in, 211(ab)
intoxication, metabolic spectral signature analysis of FDG with, 38(ab)
methylphenidate challenge in alcoholics, metabolic changes, 898(ab)
Alcohol ablation, radioiodine and, treatment of toxic thyroid nodules, 207, 211
Alcoholism
elevated mu-opioid receptors, ventral striatum and amygdalae, PET imaging, 212(ab)
genetic risk for, orbitofrontal cortex activity and dopamine D2 receptors in, 213(ab)
Alpha-particle emitters
comparison with β-emitter ^{89}Sr, targeting of osseous sites, 252
depleted uranium, lungs of Gulf War Veterans, 1168(ab)
monoclonal antibodies, 1301(ab)
targeted radiotherapeutics, microdosimetric analysis, 792
Alzheimer's disease
blood flow reduction role, posterior cingulate cortex, 826(ab)
brain perfusion SPECT
correction for partial volume effects in, 830(ab)
diagnostic performance of, 37(ab)
^{11}C MP4A PET, acetylcholinesterase activity, 831(ab)
cerebral activation differences, virtual reality environment, 54(ab)
cerebral blood flow, in minimal cognitive impairment, 824(ab)
3D perfusion isosurfaces, cerebral perfusion changes, global assessment, 53(ab)
delusion in, cerebral blood flow effects, 825(ab)
diagnosis with FDG PET data, against autopsies of human brain, 51(ab)
donepezil treatment, acetylcholinesterase PET imaging and, 50(ab)
early detection, PET in, 39N(1)
evaluation, SPECT and Mini-Mental State Examination, 56N(6)
medial temporal lobe serotonin 1A receptor density in, 222(ab)
memory loss, molecular basis for, 46N(11)
neuroimaging initiative, NIA requests proposals, 41N(12)
PET and, Wall Street Journal, 41N(12)
real-time imaging of binding in, 51N(11)
rise in numbers predicted, 38N(10)
American Board of Nuclear Medicine (ABNM)
news, 12N(9)
Position Statement, physician competence, 988
Resident-in-Training examination, 40N(11)
American Medical Association (AMA), on Medicare participation options, 38N(1)
American Society of Clinical Oncologists (ASCO), new policy on cancer trial review, 48N(6)
American Society of Nuclear Cardiology (ASNC), Hendel, Robert C. installed as president, 41N(12)
Amino acid transporters, L-type, ^{131}I IMT membrane transport, 244
Amino acids
^{18}F-labeled, dynamic acquisition, brain tumors, 873(ab)
imaging early treatment response, gene therapy in brain tumors, 108(ab)
intravenous administration, with ^{90}Y DOTA-PHE-1-TYR3-octreotide, 1464(ab)
iodinated, comparative biodistribution, 1489
potential SPECT tumor imaging agent, 151(ab)
transport, via kidney, 625
Amphetamines
dopamine release induced by, head movement correction effects, 41(ab)
MDMA abusers, ^{11}C methyltryptophan cerebral uptake, 895(ab)
physiological effects, parametric imaging vs statistical moment analysis, 42(ab)
Amyloidosis, ^{99m}Tc aprotinin scintigraphy, 177
Anatomical standardization, SPM99, brain, 912(ab)
Angiography
coronary
changes of luminal area of epicardial artery to cold pressor test, 289(ab)
findings in patients with myocardial stunning, 758(ab)
myocardial perfusion defects with, 54N(6)
radionuclide
atrioventricular sequential biventricular pacing in congestive heart failure, 180(ab)
cardiomyopathy in left bundle branch block ventricular premature contraction patients, 181(ab)
^{99m}Tc MAA lung scan, pediatric peripheral pulmonary artery stenosis, 1251(ab)
total body, bronchogenic lung cancer, 1444(ab)
Angioplasty
abnormal SPECT after, 49N(4)
cardioprotective effect of nicorandil, SPECT assessment of, 173(ab)
with or without stenting, ^{99m}Tc MIBI exercise myocardial SPECT, 13(ab)
Angiotensin II (AT1) receptor antagonists, chronic therapy, captopril renography in, 1574
Angiotensin receptor blocker, with ACE inhibitor, effects on congestive heart failure, 884
Angiotensin-converting enzyme inhibitor, acute cyclosporine nephrotoxicity, acute tubular necrosis and, rats, 1278(ab)
Angular compression, for 3D whole-body FDG PET, reduction of data volume and reconstruction time, 990(ab)
Annexin
apoptotic tumor response after, experimental tumor model, 583(ab)
assessment of efficacy of chemotherapy, 582(ab)
detection of cell death, area at risk in acute myocardial infarction, 391, 397
detection of myocyte death, rat myocardium, 340(ab)
^{124}I-labeled, imaging of cell death, 586(ab)
noninvasive detection of ischemia memory, in myocardial ischemia, 338(ab)
radiolabeled with ^{99m}Tc HYNIC and Mag3, comparison, 1115(ab)
^{18}F-labeled, imaging of cell death, 1058(ab)
^{68}Ga labeling, biodistribution, 159(ab)
^{99m}Tc HYNIC-labeled
ischemic preconditioning model, 717(ab)
rat ischemia model, 500(ab)
safety, biodistribution and dosimetry of, 947
^{99m}Tc-labeled
accumulation in tumor, previous treatment effects, 587(ab)
biodistribution patterns, mice, 501(ab)
Anorexia nervosa, decreased serotonin receptor binding in, 163
Antibodies
pharmacokinetics, internalization, enhanced therapy of tumors, 577(ab)
vascular targeted imaging with, lungs, 1114(ab)
Antibody fragments
bone infection, LeukoScan, 477(ab)
^{124}I, imaging agent for PET, 941(ab)
tumor targeting, biodistribution, microPET, 1296(ab)
Antibody targeting
anti-PMSA antibody
hormone refractory advanced prostate cancer, 429(ab), 430(ab)
imaging of tumor vascular endothelium, 1385(ab)
^{131}I HEPAMA-1, in hepatocellular cancer, 104(ab)
^{111}In, genetically engineering constructs, 1079(ab)
lymphoid system, autoimmune uveitis, 1122(ab)
^{99m}Tc, macrocycle chelate, 1076(ab)
Antibody therapy, radiolabeled, ^{90}Y DOTA-J591, 1093(ab)
Anticancer therapy, enzyme-mediated, solid tumors, 1095(ab)

Anti-CEA antibodies
pharmacokinetics of, after resection of primary colorectal cancer, 84(ab)
tumor imaging with, colorectal cancer, 1433(ab)
Antidementia drug, FK960, measurement of brain concentration, 105
Antigranulocyte antibodies
detection of infected vascular prostheses, 1217(ab)
sulesomab binding, older patients with suspected infections, 1220(ab)
Antimicrobial peptides, radiolabeled, in infection, 56N(6)
Antineoplastic agents, tyrosine kinase inhibitors, in gastrointestinal stromal tumors, 77(ab)
Antisense probe
oligonucleotides, identification of lymphoma cell, 1317(ab)
targeting of P-glycoprotein MDR expression, tissue culture, 1089(ab)
^{99m}Tc labeled, cellular accumulation of, mRNA steady-state levels and, 1116(ab)
Anxiety, m-chlorophenyl-piperazine, PET study with, conscious monkeys, 1516
Aphasia, primary progressive, bilateral temporal lobe involvement in, SPECT, 1013
Apoptosis
after photodynamic therapy, ^{99m}Tc annexin V for evaluation, 650
androgen-depletion-induced, in prostate, 585(ab)
cardiomyopathy in heart failure, ^{18}F FBnTP PET, 281(ab)
detection in tumors, ^{18}F tracer for, 157(ab)
low-dose radiation, 40N(1)
monitoring of mitochondrial membrane potential, ^{18}F p-FBNTP, 160(ab)
PET and detection of, 41N(12)
PET imaging, ^{18}F-labeled annexin V for, 1119(ab)
prevention of, plaque stabilization in atherosclerosis, 1(ab)
quantitative tumor SPECT with, 51N(11)
SPECT tracer, detection in melanoma, 318(ab)
taxotere-induced, tumor response to, 584(ab)
^{99m}Tc HYNIC annexin V, human application, 947
^{99m}Tc tricarbonyl labeled HYNIC-annexin as imaging agent for, 1133(ab)
time course of ^{99m}Tc annexin V, after ischemia/reperfusion, 342(ab)
tumor response, ^{99m}Tc annexin V chemotherapy, 92
Appendicitis, sulesomab, anti-granulocyte imaging, 1258(ab)
Arcitumomab, pharmacokinetics of multiple injections, after resection of primary colorectal cancer, 84(ab)
Arthroplasty
aseptic loosening of, radionuclide bone imaging, 1230(ab)
asymptomatic, FDG imaging of, 1229(ab)
FDG PET, painful hip replacements, 311(ab)
infected him and knee prosthesis, FDG PET diagnosis, 1219(ab)
prosthetic knee infection, leukocyte/marrow and leukocyte/bone imaging comparison, 488(ab)
Artifacts
FDG PET, adipose tissue, neck, chest and abdomen, 1349(ab)
^{123}I MIBG SPECT and CT, renal pelvis, 1248(ab)
metal, combined PET/CT imaging systems, 1017(ab)
motion, myocardial SPECT, 484(le)
oral contrast, correction in PET/CT, 1940
PET/CT
mislocalization of lesions, 240
oral contrast use in, 412
respiratory motion, lung cancer PET imaging, 1645
Asialoglycoprotein receptor imaging, 1707(le)
hepatic blood flow and, changes after portal vein embolization, 1207(ab)
liver, ^{99m}Tc GSA SPECT, 475
Asthma, stress-testing procedures, comparison of two procedures, 512(ab)
Atherosclerosis
coronary inflammation, FDG PET, 938(ab)
C21-AcLD detection of, 770
FDG uptake, endothelial cells, 284(ab)
imaging, abdominal aorta in old and hyperlipidemic rabbit, 343(ab)
lesions, dual-time point FDG PET, 184(ab)
plaque stabilization, preventing apoptosis, 1(ab)
vulnerable plaque, FDG accumulation to, 701(ab)
Atherosclerotic lesions, oxidation-specific antibody imaging of, 27N(2)
Atoms for Peace anniversary, 36N(12)
Attention deficit hyperactivity disorder
dopamine transporter density in basal ganglia, children, 891(ab)
dopamine transporters in, ^{11}C atropane PET measurement, 217(ab)
methylphenidate effects, increases in dopamine, 117(ab)
PET, decreased brain dopamine function, 216(ab)
regional cerebral perfusion, parametric mapping analysis, 892(ab)
Attenuation correction
artifacts, interindividual variability in myocardial perfusion SPECT, 723(ab)
contrast media artifacts, PET/CT, 1940
corrective image reconstruction, oncological SPECT, 195(ab)
CT contrast agents-induced error, PET emission studies, 732
CT-based
discrimination of contrast media, PET, 983(ab)
SUV of contrast agents in multimodality imaging, 933(ab)
determination of map, in emission tomography, 291
different CT-based schemes, PET with respiratory motion, 121(ab)
effects on brain SPECT, normally distributed activities, 512
effects on tumor detection, whole-body PET oncology imaging, 1855
hybrid SPECT/CT system, validation of, 1039(ab)
impact on PET, using microPET, 975(ab)
IV contrast in PET/CT and, 978(ab)
myocardial, diagnostic accuracy, 357(ab)
myocardial SPECT
artifactual apical defect in, 457(ab)
computer simulation method for, 988(ab)
heavy patients, CAD assessment, 356(ab)
normal SPECT perfusion databases, 3D beam modeling effects, 747(ab)
PET/CT
extension of the CT attenuation map in, 123(ab)
segmentation-dependent scaling of CT values, 991(ab)
porous phantom for evaluation, 359(ab)
vs prone imaging, tissue attenuation effects on myocardial perfusion imaging, 748(ab)
ROC evaluation, ^{99m}Tc myocardial perfusion imaging, 1725
rotating slant hole collimators, breast SPECT, 207(ab)
SPECT, X-ray CT and transmission scan with external source, 1001(ab)
^{99m}Tc GSA dynamic SPECT and, liver function after hepatectomy, 924(ab)
transmission, comparison with combined PET/CT, 1348(ab)
whole-body PET, segmentation algorithm, 980(ab)
X-ray CT and SPECT, phantom validation, 958(ab)
Attenuation map, in emission tomography, 291
Auger electrons, antitumor effects, human breast cancer xenografts, 1469, 1479
Autoradiography
assessment of treatment response, herpes simplex virus, 1845
distribution of FDG, experimental tumors, 256(ab)
quantitative receptor, small animal PET, 1682
Avascular necrosis, femoral head, renal transplant patients, 1226(ab)
Avidin, pretargeted radioimmunotherapy, cancer, 400

B

B cell tumors, radiolabeled B lymphocyte stimulator, mice, 422, 434
B lymphocyte stimulator, radiolabeled, B cell tumors, mice, 422, 434
Background correction
LSO natural radiation, microPET quantitation, 451(ab)
in ^{99m}Tc MAG3 renography, renal transplantation, 1288(ab)
Basal ganglia
asymmetric, in seizure foci localization, ictal SPECT studies, 1379
disorders, functional vs structural changes in, Lewy bodies and Alzheimer's disease, 55(ab)
dopamine transporter density, children with Tourette's syndrome, 893(ab)
BECON 2003 symposium, 46N(4)
Benzodiazepine receptors
aging effects, ^{11}C FMZ PET study, 49(ab)
central type, ^{123}I iomazenil, childhood trauma, 119(ab)
estimation of, ^{11}C FMZ PET, 417
one-step reaction for, ^{18}F FEFMZ synthesized by, 1054(ab)
PET and, in HIV, 50N(4)
Beta imaging, detector for, malignant tissue, 1009(ab)
Bexxar, approved and commercially available, 36N(9)
Biliary dyskinesia, gallbladder contraction in, dietary corn oil as stimulant for diagnosis, 1208(ab)
Binding potential, validity, dopamine receptor occupancy, 905(ab)
Biodistribution studies
Albuleukin, IL-2 HSA fusion protein, 1330(ab)
annexin V, human application, 947
artificial amino acid, kidney, 625
^{14}C D-luciferin, optical imaging, 1135(ab)
comparative, iodinated amino acids, 1489
^{18}F FAU, imaging tumors, 1328(ab)
FDG, in brown adipose tissue, pharmacologic reduction of, 295(ab)
^{68}Ga labeling of annexin V, 159(ab)
gene transfer therapy, functional and anatomic imaging after, 92(ab)
gold-dendrimer nanocomposite devices, tumor microvasculature, 1094(ab)
hand-held, high-resolution gamma camera, 1030(ab)
^{131}I and ^{99m}Tc pertechnetate, neuroendocrine tumors, 1320(ab)
^{111}I herceptin, breast tumors, 1300(ab)
^{123}I hyp, tumor-to-normal tissue ratio, 1086(ab)
^{125}I MIB, in antibody pretargeting, 1091(ab)
labeled tyrosine kinase inhibitor, imaging EGFR density, 1325(ab)
PEG-PEI-GAL, non-viral gene delivery vector, 1129(ab)
radiation dosimetry and, ^{18}F fluoro-A-85380, 596
radiolabeled B lymphocyte stimulator, B cell tumors, mice, 422, 434
^{99m}Tc annexin A5, enoporide effects, ischemia/reperfusion model, 5(ab)
^{99m}Tc APD, for bone uptake, 1235(ab)
^{99m}Tc-labeled annexin, native and mutant mice, 501(ab)
Biological markers, ^{99m}Tc WBC and, in inflammatory bowel disease, 1586
Biotin
pretargeted radioimmunotherapy, cancer, 400
pretargeted radioimmunotherapy, CD20-expressing lymphoma xenografts, 437
radiolabeled, suspected orthopedic infections, 478(ab)
Biventricular dynamic physical phantom, gated blood-pool SPECT, cardiac measurements, 967
Bladder cancer, anti-human bladder tumor chimeric antibody, radioimmunoimaging and, 1294(ab)
Blood flow, primary breast tumor, response to chemotherapy and, 249(ab)
Blood vessels, uptake of FDG in, comparison to vascular calcification, 185(ab)
Blood-brain barrier, ^{99m}Tc DTPA SPECT of, neurologic outcome after acute stroke, 1898
Blood-pool imaging
ECG-gated, assessment of diastolic function, 736(ab)
gated
left ventricular function measurement, animal study, 459(ab)
RNA SPECT, left ventricular function, 767(ab)
gated SPECT, biventricular dynamic physical phantom, 967
planar gated, comparison with gated blood-pool SPECT, 494

tomographic equilibrium gated, 3D Fourier analysis of, 1002(ab)
Blumgart and Yens, birth of nuclear medicine instrumentation, 1362
Body shield, for PET, Tungsten curtains, 1020(ab)
Bombesin
^{99m}Tc carbonyl-bombesin analogs, design and development, 1066(ab)
^{99m}Tc labeling of, receptor imaging, 321(ab)
Bone grafts, metabolism, PET studies, 315(ab)
Bone marrow
absorbed dose of ^{131}I after thyrotropin, differentiated thyroid cancer, 472(ab)
absorbed radiation dose, hematologic toxicity predicted by, 1167(ab)
adipocyte spatial distributions, skeletal dosimetry models, 774
cells, surgical implantation, coronary intervention, 720(ab)
granulocyte colony stimulating factor, FDG investigation, 610(ab)
involvement in Gaucher's disease, ^{99m}Tc sestamibi scintigraphy, 1253
red, dose estimates, 320(le)
scintigraphy
incidental abnormal marrow signal on MRI, 1233(ab)
for staging of multiple myeloma, 1483(ab)
in vivo reporter gene, 93(ab)
Bone metabolism
^{18}F fluoride ion PET, after total gastrectomy, 117
^{18}F fluoride ion PET, porcine, 314(ab)
markers of, carcinoid tumors, 184
Bone metastases
breast cancer, solitary rib lesions, 1377(ab)
carcinoid tumors, imaging of, 184
characterization, FDG PET/CT, 243(ab)
FDG PET and ^{99m}Tc MDP comparison, bone scans, 1342(ab)
femoral, ^{99m}Tc MIBI and ^{99m}Tc HMDP accumulations in, 560(ab)
lymphoma, PET/CT detection of occult extra nodal disease, 271(ab)
PET restaging studies, lymphoma, 1491(ab)
from prostate cancer
PSA measurements in, 1470(ab)
repeated bone targeted therapy, 568(ab)
prostate cancer, dosimetry of ^{186}Re HEDP, 953
whole-body FDG PET, compared with ^{99m}Tc HDP, 1343(ab)
Bone mineral density, ^{18}F fluoride ion PET, after total gastrectomy, 117
Bone pain, palliation
hyaluronan treatment, ^{99m}Tc HMDP bone scintigraphy, 1225(ab)
^{153}Sm EDTMP for, 1469(ab)
^{89}Sr for bone tumor treatment, 1471(ab)
Bone scanning, pinhole imaging and, Legg-Calvé-Perthes disease, 1761
Bone scintigraphy
after incidental abnormal marrow signal on MRI, 1233(ab)
collagen crosslink excretion and, oral cancer, 557(ab)
compression fracture, thoraco-lumbar, 485(ab)
detection of child abuse, 45N(7)
late onset avascular necrosis, renal transplant patients, 1226(ab)
low-back pain, lumbosacral transitional vertebra and, young patients, 909
open-mouth, condylar hyperplasia and temporomandibular arthritis, 487(ab)
positive, histological features of breast cancer and, 1449(ab)
radionuclide, aseptic loosening of arthroplasty, 1230(ab)
resolution coded aperture, growth plates in children, 1240(ab)
skeletal kinetics for ^{99m}Tc MDP, quantitative SPECT, 490(ab)
solitary rib lesions, breast cancer patients, 1377(ab)
sternal uptake, age-related variations, 1232(ab)
^{99m}Tc APD, biodistribution for bone uptake, 1235(ab)
^{99m}Tc HMDP, knee osteoarthritis treated with hyaluronan, 1225(ab)
^{99m}Tc MDP
detecting osteomyelitis in violated peripheral bones, 909(ab)
outcome of fracture shaft femur, 486(ab)
three-phase
additional routine whole-body delayed imaging with, 1234(ab)
outcome of distraction osteogenesis and, 369
Bone targeting, osseous sites, α-particle emitter comparison with β-emitter ^{89}Sr, 252
Bone tumors
huge, ^{153}Sm EDTMP for, 1469(ab)
primary, scintigraphic evaluation, 600(ab)
^{186}Re HEDTMP therapy, biodistribution, 1096(ab)
residual disease, FDG PET in evaluation, 241(ab)
thallium activity, tumor type effects, 239(ab)
Book reviews
Nuclear Oncology: Diagnosis and Therapy, 1366
Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine, 991
Boron neutron capture therapy, hepatoma, 1106(ab)
Brain
atlas data online, 36N(10)
atrophy, aging effects, cerebral glucose metabolism, PET and MRI, 822(ab)
^{11}C raclopride binding, microPET, rat, 815
competing systems, facial memory, 823(ab)
fully-automated ROI delineation, 912(ab)
neoplasm, glioma, stereotactic biopsy and radiation therapy, PET, 379(ab)
traumatic injury, loss of neuronal integrity, 884(ab)
traumatic injury, oxygen metabolism in pericontusional low-density areas, 885(ab)
Web-based fusion modeling of, epilepsy seizure foci, 954(ab)
Brain death
procedure guidelines for scintigraphy, 846
^{99m}Tc HMPAO SPECT and, 33N(5)
Brain imaging
^{11}C raclopride PET, amphetamine-induced dopamine release, 214(ab)
definition of ROI, 943(ab)
dopamine transporter, Parkinson's patients, 388(ab)
dopamine transporter binding, SPECT, 118(ab)
^{18}F fallypride in, 32N(2)
^{18}F FPT as imaging agent, 1060(ab)
FDG PET, age-associated changes, pediatric patients, 46(ab)
FDG PET diagnosis, Alzheimer's disease, against autopsies of human brain, 51(ab)
interictal FDG PET, presurgical evaluation of epileptic foci, 840(ab)
Parkinson's disease
brain PET, FDOPA or FDG ET, 857(ab)
essential tremor and, using statistical parametric mapping, 850(ab)
perfusion, permanent magnetic stimulation, 821(ab)
PET
adenosine A1 receptors, 52N(11)
long-term use of ecstasy effects, 375
PET camera, anger-logic gadolinium oxyorthosilicate detectors, 1340
rCBF auditory stimuli, SPECT, 45(ab)
serotonin transporters, ^{11}C DASB as a ligand for, 218(ab)
unilateral electroconvulsive therapy, prefrontal deactivation after, 897(ab)
Brain PET
camera, anger-logic gadolinium oxyorthosilicate detectors, 1340
quantitation, rat brain phantom for, 522(ab)
3D, neuro-insert in, 1021(ab)
Brain SPECT
acetazolamide, prediction of postoperative outcome, 535(ab)
acetylcholine receptors, Rett disorder, 47(ab)
balloon test occlusion, bilateral vertebral arteries, 864(ab)
cerebral blood flow
comparison with "patient normal" and normal volunteers, 908(ab)
delusion and, Alzheimer patients, 825(ab)
as predictive factor in Parkinson's disease, 391(ab)
cerebral perfusion, in strategic infarction, 846(ab)
cerebral protein transudation, cluster headache patients, 538(ab)
competing systems, facial memory, 823(ab)
dementia, radiotracer effects, 834(ab)
diagnostic performance, Alzheimer's disease, 37(ab)
early detection of SLE, without cognitive dysfunction, 861(ab)
^{123}I FP-CIT and IBZM, differentiation of vascular Parkinsonism, 855(ab)
migraine with prolonged aura, children, 598(ab)
quantitative, striatal uptake measurements, neurodegenerative diseases, 40(ab)
short focal-length cone-beam collimation, 24(ab)
speech vs nonspeech activation, normal controls, 43(ab)
statistical parametric map, statistical probabilistic anatomical map and, 868(ab)
stroke recovery and, 36N(5)
subthalamic nuclei stimulation, in Parkinson's disease, 397(ab)
^{99m}Tc ECD
in mild traumatic injury, 383(ab)
psychose hallucinatoire chronique, 889(ab)
^{99m}Tc sestamibi use in, recurrent glioma in adults, 1413(ab)
^{99m}Tc/^{123}I, perfusion and dopamine transporter density, 973(ab)
uniformly attenuated, with fan-beam geometry, 995(ab)
Brain tumors
amino acid metabolism, malignant glioma, 203(ab)
brachytherapy, combined PET of proliferations nd glycolysis, 546(ab)
delayed FDG PET imaging, detection of metastasis and, 877(ab)
dynamic acquisition, ^{18}F FET as tracer in, 873(ab)
extracellular space in, measurement with ^{76}Br bromide PET, 1210
^{18}F FET uptake, blood-brain barrier disruption and, gliomas, 881(ab)
^{18}F FPT as imaging agent, 1060(ab)
FDG PET, compared to ^{18}F FET PET, 542(ab)
histologic grades of, ^{18}F FET uptake and, 1309(ab)
imaging amino acid transporter upregulation, blood-tumor barrier, 1308(ab)
malignant, ^{111}In D-Glu1-minigastrin diagnosis, 1425(ab)
neoplastic and nonneoplastic, ^{99m}Tc MIBI SPECT in, 1566
non glial, ^{123}I IMT SPECT for planning of radiotherapy, 876(ab)
recurrent, after radiation therapy, ^{11}C methionine PET for, 883(ab)
recurrent astrocytoma, ^{18}F FET for diagnosis, 541(ab)
recurrent metastatic, radiation necrosis, MET PET in, 45N(7)
TP-38 immunotoxin, convection enhanced delivery, 382(ab)
whole-body FDG PET, evaluation and staging, 1353(ab)
Breast
density, FDG PET uptake and, 1238
scintimammography, cadmium zinc telluride detector for, 602
visualization of internal mammary sentinel nodes, during lymphoscintigraphy, 1387
Breast cancer
application specific emission transmission tomography, 1029(ab)
biopsy, full-field positron emission mammography device, 455(ab)
BRCA mutation carriers, role of FDG PET and ductal lavage in, 1374(ab)
chemotherapy response, blood flow changes, 250(ab)
combined imaging, FDG PET in, 45N(7)
dedicated PET mammography, 1026(ab)
early, PET and axillary metastases, 44N(9)
FDG and blood flow tumor biology, 1310(ab)
FDG PET, SUV variation in, 913(ab)
FDG PET/CT evaluation of, 1403(ab)
FDG SUV in, variation with time after injection, 1044
highly suspected, ^{99m}Tc MIBI and contrast-enhanced MRI comparison, 1373(ab)
histological features, positive bone scan and, 1449(ab)

human xenografts, antitumor effects of ^{111}In-labeled EGFR, 1469, 1479
hyperemic lesion, ^{99m}Tc MDP total body flow, 1443(ab)
inhibition of multidrug resistance, sestamibi and tetrofosmin tumor imaging, 1307(ab)
inner quadrant primary tumors, FDG PET in staging, 248(ab)
locally advanced
blood flow and metabolism change in, 1806, 1815
post-therapy imaging patterns and survival prediction, 249(ab)
lymphoscintigraphy, nonvisualization of axillary sentinel node during, 1232
mammotomography
with dedicated detectors, 526(ab)
with pinhole incomplete circular orbit, 583, 594
modulation of estrogen receptors, small animal PET imaging, 1334(ab)
multifocal or multicentric, sentinel node localization in, 7
non-invasive prognostic tool, ^{18}F PAC PET, 1333(ab)
PET and MRI, registration of, 954(ab)
PET compact rotating scanner, design and initial performance of, 1027(ab)
prediction of chemotherapy response, PET tumor tracers, 1064(ab)
presurgical chemotherapy response in, ^{99m}Tc MIBI scintimammography or FDG PET, 1391(ab)
recurrent
FDG in management of, 1398(ab)
^{18}F FES prediction of response to hormonal therapy, 412(ab)
recurrent and metastatic, FDG PET evaluation, 556(ab), 1411(ab)
response to therapy, FDG PET evaluation, 224
restaging, morphological and functional imaging with FDG PET/CT for, 252(ab)
rotating slant hole collimators, attenuation and attenuation correction effects in, 207(ab)
scintigraphic patterns in preinvasive lesions, 413(ab)
sentinel lymph node mapping, for clinical staging, 410(ab)
sentinel node detection
periareolar injection technique for, 409(ab)
peritumoral vs periareolar injection, 411(ab)
staging, axillary nodal, FDG PET, 247(ab)
suspected, uptake of ^{99m}Tc MIBI in, 1384(ab)
^{99m}Tc depreotide for detection, 1427(ab)
^{99m}Tc sestamibi as imaging adjunct, 42N(9)
tumor targeting, ^{111}In-labeled E. coli STh analog, 1074(ab)
tumor to background ratio in, after chemotherapy, 1382(ab)
Breast scintigraphy, with enhanced gamma camera, breast cancer diagnosis, 251(ab)
Bronchial cancer. *see* Lung Cancer
Brown adipose tissue
^{123}I MIBG accumulation, nape of neck, children, 1421
interscapular, visualization with ^{99m}Tc tetrofosmin, children, 1582
temperature effects, FDG PET/CT evaluation, 1267
Brugada syndrome, myocardial muscarinic receptors in, 749(ab)

C

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), FDG findings in, 863
Cadmium zinc telluride detector, for scintimammography, 602
Calcium, measuring absorption, 28N(3)
Camera systems, performance evaluations, SPECT, prostate cancer, 1042(ab)
Cancer imaging. *see also* specific type and site
biodistribution and microPET studies, sigma receptors, breast cancer, 1323(ab)
^{11}C EGFR-TK inhibitors for, 161(ab)
^{18}F FDG PET, tumor recurrence in gastrointestinal cancer, 1435(ab)
FASTSPECT II, high-resolution small animal, 525(ab)
fusion reporter vector, multimodality imaging, 96(ab)
gynecologic malignancies, hybrid PET/CT with FDG in, 421(ab)
hybrid PET/CT, patient management and, 1200
^{125}I-labeled monoclonal antibody, MET-expressing tumors, 580(ab)
PET and MRI, registration of, breast, 954(ab)
positron tracer, differentiation of tumor from inflammation, 1311(ab)
reporter genes, charged couple device, PET, 98(ab)
screening, new data, 22N(2)
staging, differentiation of tumor from inflammation, ^{18}F FBnTP compared with FDG, 1312(ab)
unknown primary syndrome, FDG PET, 1301
Cancer research
drug development, NCI/FDA program, 52N(8)
international research portfolio, 53N(8)
new data issued by HHS, 38N(1)
Carbon monoxide, poisoning, SPECT and cardiac assessment, 42N(12)
Carbon-11
dopamine D2 receptor agonists labeled with, comparison, 1053(ab)
FK506 labeled with, rapid synthesis and distribution image, 609(ab)
HPLC quality control of, retention time shifts during, 1145(ab)
Carbon-11 acetate
assessment of myocardial oxygen consumption, in failing heart, 516(ab)
dosimetry, whole-body PET, 333(ab)
FDG PET combined with, recurrent prostate cancer, 431(ab)
PET
hepatocellular carcinoma and other liver masses, 213, 222
metastases of prostate cancer, 434(ab)
mobilized stem cells in myocardial infarction, baboons, 711(ab)
prostate cancer, 549, 557
vs ^{123}I MIBG, chronic heart failure, 14(ab)
1-Carbon-11 acetate, forward cardiac output, pig model, 1176
Carbon-11 altropane, PET, dopamine transporters in ADHD, 217(ab)
Carbon-11 CGP, PET, Brugada syndrome, 510(ab)
Carbon-11 choline
lymph node staging, prostate cancer, 331
PET, FDG comparison, gynecologic tumors, 1051
PET, metastases of prostate cancer, 434(ab)
Carbon-11 DADAM, PET, serotonin transporters with a fast equilibrium, 219(ab)
Carbon-11 DHA, radiation dosimetry estimates for, alcoholism and affective disorders, 1152(ab)
Carbon-11 epinephrine, PET
imaging of pheochromocytoma, 297(ab)
radiotracer for sympathetic nervous system, 1121(ab)
Carbon-11 fallypride, PET, dopamine D2/D3 receptors, 1051(ab)
Carbon-11 FMZ, PET, central benzodiazepine receptor estimation, 417
Carbon-11 hydroxyephedrine, retention, norepinephrine transporter density, 341(ab)
Carbon-11 (+)-McN5652, PET, brain, long-term use of ecstasy effects, 375
Carbon-11 methionine
compared with FDG PET, human glioma, 540(ab)
discrepant pattern with FDG, brain tumor, 874(ab)
PET
advanced head and neck cancer, 414(ab)
differentiating recurrent brain tumor after radiation therapy, 883(ab)
Carbon-11 methyl-D-glucoside, synthesis and evaluation, tracer of sodium-dependent glucose transporters, 1075, 1082
Carbon-11 MET, PET, chemotherapy monitoring in hypopharyngeal cancer, 526
Carbon-11 MOV, PET probe, for COX-2 expression, 1110(ab)
Carbon-11 MPDX, PET, imaging of adenosine receptors, brain, 221(ab)
1-Carbon-11 octanoate, brain distribution of, focal cerebral ischemia, 1168
Carbon-11 pipzA-4, evaluation, high-affinity choline uptake system, 269
Carbon-11 raclopride
binding, rat brain, microPET R4, 815
PET, subcortical dopamine activity, 228(ab)
Carbon-11 tyrosine, radiation dosimetry in, 1154(ab)
L-1-Carbon-11 tyrosine, in laryngeal cancer, 341
Carbon-11 verapamil, transport changes, after cyclosporin A, 1303(ab)
Carbon-11 ZIENT, microPET imaging, serotonin transporters, 605(ab)
Carbon-13 acetate breath test, ^{99m}Tc gastric emptying scintigraphy and, children with impaired gastric motility, 1246(ab)
Carbon-14 ACPC, autoradiography with, herpes simplex virus, 1845
Carbon-14 urea breath test, comparison of quantitative values, *H. pylori* infection, 1210(ab)
Carcinoembryonic antigen, engineered antibody fragments, small animal PET, 1962, 1970
Carcinoid tumors
bone metastases in, imaging of, 184
primary and recurrent, FDG PET, comparison with ^{111}In pentetreotide, 232(ab)
Cardiac events, preoperative risk in noncardiac surgery, stress SPECT with ECG, 385
Cardiac function
dynamic beating phantom, small heart, 716(ab)
effects of volatile halogenated anesthetics, pinhole gated SPECT use in, 286(ab)
normal limits, gender differences in, gated SPECT, 755(ab)
3D left ventricular deformation, hyperelastic warping of PET and cine-MRI, 460(ab)
Cardiac imaging. *see also* Myocardial perfusion imaging; Myocardial SPECT
gated perfusion SPECT, quantitative reproducibility, 730(ab)
gene expression, bicistronic PET reporter gene, 2(ab)
^{123}I BMIPP, clinical efficacy of, 703(ab)
^{124}I FIAU, after transfer of HSV1-tk, 704(ab)
myocardial perfusion SPECT and resting ECG, elderly asymptomatic CAD, 346(ab)
practice guidelines, 36N(10)
respiratory, myocardial SPECT images, 1038(ab)
ROC comparison of detection accuracy, 987(ab)
SPECT, aortic sclerosis, 765(ab)
statistical filter, end-diastolic image processing with, 458(ab)
^{99m}Tc annexin A5, intracardiac masses, 509(ab)
2D-3D interchanged acquisition, dynamic scans in, 967(ab)
Cardiac output, forward, ^{11}C acetate PET, pig model, 1176
Cardiac PET, FDG, left ventricular geometry and contractile function, 1741
Cardiac SPECT, circular acquisition in, 995(le)
Cardiac stress testing, combined with V/Q scan, emergency department patients, 1265(ab)
Cardiac sympathetic innervation, Brugada syndrome, PET, 510(ab)
Cardiac sympathetic nerve function, ^{123}I MIBG, in Kawasaki disease, 1250(ab)
Cardiac volume, post-stress changes, false-positive rotational SPECT, 518(ab)
Cardiomyocytes, programmed cell death, area at risk in acute myocardial infarction, 391, 397
Cardiomyopathy
arrhythmogenic right ventricular, left bundle branch ventricular premature contraction patients, 181(ab)
^{11}C acetate vs ^{123}I MIBG, 14(ab)
cardiac neuroimaging in, 1459, 1467
carvedilol treatment, assessed by ^{123}I MIBG scintigraphy, 601(ab)
diabetic
cardiac autonomic neuropathy and myocardial perfusion defects, 718(ab)
dobutamine effects on substrate metabolism, 347(ab)
dilated, metoprolol and carvedilol comparison, 1604
hypertrophic
cardiac adrenergic activity in, 487
cardiac sympathetic nerve innervation changes, 1612

ischemia and left ventricular distensibility in, 1717
myocardial fatty acid metabolism in, compartmental model, 768(ab)
idiopathic dilated, impaired myocardial glucose accumulation in, 719(ab)
myocardial flow reserve, evaluation by ^{15}O water PET, 750(ab)
myocardial perfusion and regional function, electrocardiographic gated SPECT assessment of, 757(ab)
Cardiovascular Young Investigator Competition, Chen, Y., 46N(8)
Carvedilol, comparison with metoprolol, dilated cardiomyopathy, 1604
Caudate nucleus, quantification of dopamine receptors with ^{18}F DMFP, 109
CD20
lymphoma xenografts, pretargeting of, 437
single cell kill, radiolabeled antibodies, 632
Cell death. *see also* Apoptosis
programmed, area at risk in acute myocardial infarction, 391, 397
Centers for Medicare & Medicaid Services (CMS)
definition of "Good Faith" in HIPAA compliance, 38N(9)
HIPAA contingency plan, 40N(11)
Medical Technology Council, 25N(5)
Medicare cuts published on eve of new year, 10N(2)
outlier payments, 24N(2)
PET coverage by, 19N(6)
Cerebral artery, middle, occlusion, ^{11}C MPDX PET imaging, 1839
Cerebral blood flow
activity distribution, rat brain phantom for, 522(ab)
after subarachnoid hemorrhage, brain SPECT and TCD correlations in, 537(ab)
branched-chain amino acid solution effects, liver cirrhosis patients, ECD SPECT, 829(ab)
changes, acetazolamide-induced, cerebrovascular disease, 1371
distribution of ^{11}C octanoate, focal cerebral ischemia, 1168
global, changes via 3D perfusion isosurfaces, in Alzheimer's disease, 53(ab)
hypothyroidism, response to therapy, 475(ab)
lactate injection effects, physiologically activated brain, 48(ab)
normal volunteers, comparison with "patient normal," 908(ab)
PET quantitation, during anesthesia, 863(ab)
quantitation, reactivity to acetazolamide, 520
regional
chronic pain patients, 820(ab)
differential diagnosis of dementias, 396(ab)
ECD-SPECT measurement, in minimal cognitive impairment, 824(ab)
ictal/postictal SPECT, 839(ab)
infants with premature synostoses of cranial sutures, 1245(ab)
normal databases for imaging, 539(ab)
SPECT and functional MRI, 536(ab)
SPECT
acetazolamide stress test comparison, 865(ab)
in evaluating delirium, 836(ab)
vascular dementia with small vessel disease, statistical image analysis of, 505, 1874(le)
vasodilation and, in cerebrovascular disease, acetazolamide test, 1875
Cerebral infarction, reorganization after, prefrontal perfusion changes, 867(ab)
Cerebral ischemia
distribution of ^{11}C octanoate, rat brain model, 1168
imaging adenosine A_1 receptors, PET, 1839
Cerebral oxygen metabolism, quantification and, dynamic PET, 934(ab)
Cerebral perfusion reserve, percutaneous transluminal angioplasty and stenting, SPECT, 534(ab)
Cerebral SPECT
comparisons, dementia evaluation and normal databases, 52(ab)
^{123}I IMP, cerebrovascular reactivity to acetazolamide, 520
ictal cerebral blood flow patterns, unilateral temporal lobe epilepsy, 60(ab)
perfusion, in transient global amnesia, 819(ab)
Cerebral vascular reserve, acetazolamide study, vasodilatation and blood flow increase induced by, 866(ab)
Cerebrovascular disease
acetazolamide study, vasodilatation and blood flow increase induced by, 866(ab)
blood flow changes, acetazolamide-induced, 1371
stents, percutaneous transluminal angioplasty and, SPECT, 534(ab)
vasodilation and cerebral blood flow changes, acetazolamide test, 1875
Cerebrovascular reactivity, acetazolamide, ^{123}I IMP SPECT, 520
Cervical cancer
dual-phase FDG PET use in, 1387(ab)
early recurrence, FDG PET in detection of, 347
FDG PET and MRI/CT, discrepancies between, 1429(ab)
FDG PET usefulness for, 1430(ab)
lymph node metastasis in, FDG PET for detection of, 1431(ab)
paraortic lymph node metastases in, FDG PET, 1775
PET, CT and, 54N(6)
recurrent or persistent, FDG PET for restaging of, 1455(ab)
therapeutic response, PET and, 35N(5)
tumor characteristics in, FDG PET, 192
uterine, FDG PET/CT, 1404(ab)
Chemotherapy
annexin V, apoptotic tumor response after, experimental model, 583(ab)
blood flow changes as response, breast cancer, 250(ab)
cognitive dysfunction associated with, brain activity relations, 828(ab)
expression of mRNA, glucose transporter-1 and hexokinase type-II, 259(ab)
HSV thymidine kinase and sodium/iodide symporter, gene expression after, 1319(ab)
intraarterial, radiotherapy, for head and neck cancer, imaging comparison, 198
metabolism and blood flow response, advanced breast cancer, 1310(ab)
monitoring, ^{11}C MET PET, hypopharyngeal cancer, 526
neoadjuvant, blood flow and metabolism changes, breast cancer, 1806, 1815
prediction of, ^{18}F fluorocyclophosphamide, breast cancer, 1064(ab)
presurgical response in breast cancer, ^{99m}Tc MIBI scintimammography or FDG PET, 1391(ab)
receptor-based, 48N(7)
response
breast cancer, tumor to background ratio prediction of, 1382(ab)
cancer cell lines, FLT comparison with FDG, 261(ab)
^{18}F FLT for prediction of, breast cancer, 246(ab)
osteosarcoma, ^{201}Tl scan, 1337(ab)
^{89}Sr chloride therapy, marrow suppression and palliative pain control, breast cancer, 1472(ab)
^{99m}Tc annexin V, apoptotic tumor response, 92
Chest pain
acute evaluation protocol, with ^{99m}Tc tetrofosmin SPECT, 354(ab)
low-risk patients, SPECT myocardial perfusion imaging use in ER, 353(ab)
M-Chlorophenyl-piperazine, anxiety-provoking agent, PET study with, conscious monkeys, 1516
Cholecystitis, chronic, comparison of regular CCK-8 and pharmacy-compounded CCK-8, 499
Cholecystokinin (CCK)
cholescintigraphy, use of lactose-free fatty-meal food supplement, 1263
dynamic cholescintigraphy with, 446
pharmacy-compounded octapeptide of, regular CCK-8 comparison, gallbladder function, 499
Cholecystokinin receptor ligands, ^{99m}Tc-labeled, synthesis and characterization, 317(ab)
Cholescintigraphy
bile leak variations, after cholecystectomy, 137(ab)
cholecystokinin, use of lactose-free fatty-meal food supplement, 1263
dietary corn oil as stimulant for diagnosis, biliary dyskinesia, 1208(ab)
dynamic, random dose for CCK-33, 446
oral corn oil emulsion as a cholecystagogue, 139(ab)
Cholesteryl 1,3-diiopanoate glyceryl ether, detection of atherosclerosis, rabbits, 770
Chromosomal damage, industrial radiography and, 40N(1)
Chronic obstructive pulmonary disease (COPD), endothelial injury in, ^{123}I MIBG scintigraphic assessment, lung, 1747
Cigarette smoking, FDG uptake in PET/CT, effects on intercostal respiratory muscles, 309(ab)
Ciprofloxacin, radiolabeled, septic and sterile osteoarticular diseases, 920
Clinical trials
guidance on race and ethnicity data in, 26N(3)
purpose of, 26N(2)
Cloud chamber, Blumgart and Yens, 1925, 1362
Cobalt-57, cyclotron target for dual isotope production, 1101(ab)
Cocaine
addiction, amphetamine-induced dopamine release, PET imaging of, 214(ab)
cue-induced craving, dopamine release and, 215(ab)
Cochlear implant
mapping speech response, good and poor users, 45(ab)
novel modes, neuroactivation study, 44(ab)
PET evidence of neuroplasticity, adult hearing disorders, 1435, 1440
Cognitive dysfunction
chemotherapy-associated, brain activity relations, 828(ab)
left medial temporal lobe epilepsy, ^{15}O water PET study, 61(ab)
Coincidence imaging
axially-focused slat collimators, 976(ab)
dedicated PET comparison, lesion detectability, 1024(ab)
FDG and, staging of non-small cell lung cancer, 336
mediastinal staging, non-small cell lung cancer, 1022(ab)
3D dual head, model-based scatter correction for, 989(ab)
Cold pressor test, endothelial dysfunction, myocardial PET in diabetes, 19
Colitis, eosinophilic, pediatric, ^{99m}Tc white blood cells for assessment, 1247(ab)
Collimation, collimators
cone-beam and fan-beam, myocardial SPECT, 204(ab)
effect of characteristics on gated myocardial SPECT, with QGS software, 1043(ab)
response in reconstruction, MicroSPECT images, 998(ab)
short focal-length cone-beam collimation, brain SPECT with, 24(ab)
variable focal length fan-slat, hybrid PET cardiac imaging, 976(ab)
Colon cancer
iodine uptake, human sodium/iodide symporter gene enhancement of, 1321(ab)
liver metastases from, radioimmunotherapy use in, mice, 1291(ab)
liver metastasis from, ^{186}Re vs ^{131}I radioimmunotherapy, 1476(ab)
LSO scanner, PET, 1407(ab)
Colonic transit, ^{67}Ga-labeled activated charcoal used in, 1204(ab)
Colorectal cancer
cellular proliferation in, FDG and ^{18}TF FLT PET tumor tracers, 80(ab)
early FDG PET, response of cancer treated with preoperative therapy, 82(ab)
FDG PET/CT, management of, outcome study, 81(ab)
^{131}I HUA33, phase I radioimmunotherapy, 100(ab)
liver metastases, whole-body FDG PET, 1366(ab)
metastatic, FDG PET, therapy outcome and, 78(ab)
PET and cellular proliferation in, 44N(12)
preoperative staging, FDG PET, 1784
response to therapy, FDG PET evaluation, 224

sentinel node detection, ^{99m}Tc DTPA-mannosyl-dextran, pigs, 1677
short-term prognosis, FDG PET use in, 1358(ab)
small peritoneal metastases from, radioimmunotherapy use in, 578(ab)
Coma, cerebral glucose metabolism, after traumatic brain injury, PET, 1709
Compartmental models
Bayesian, ^{99m}Tc MAG3 renal clearance, 1357
determination of regional flow, pig livers, 1862
factorial analysis, FDOPA PET brain imaging, 29(ab)
regression coefficient maps, rapid index of suitability, 32(ab)
Computer-assisted imaging
biokinetic analysis and dosimetry, OLINDA, 336(ab)
3D patient dosimetry analyses, radionuclide therapy, 335(ab)
Concussion, cerebral glucose metabolism, after traumatic brain injury, PET, 1709
Congestive heart failure
atrioventricular sequential biventricular pacing in, 180(ab)
cardiomyopathy in, ^{18}F FBnTP PET, 281(ab)
central sleep apnea and, home oxygen therapy effects, 515(ab)
compromised cerebral perfusion in, ^{99m}Tc ECD radionuclide angiography, 182(ab)
Contrast media
artifacts, CT attenuation-corrected images with PET/CT, 1940
^{18}F FDHR as a deposited myocardial flow tracer, comparison to ^{201}Tl, 282(ab)
negative oral, value in multimodality PET/CT, 1344(ab)
oral, PET/CT, initial experience, 412
Copper-64
lipophilic complexes, radiotherapy, molecular and cellular response, 1295(ab)
pretargeted, tumor imaging and therapy, 1284
Coronary artery bypass graft (CABG)
cognitive dysfunction after, SPECT, 41N(1)
intermediate term restenosis, myocardial SPECT for, 737(ab)
myocardial flow reserve, stress myocardial perfusion SPECT, 732(ab)
prediction of outcomes, myocardial gated SPECT for, 12(ab)
Coronary artery disease (CAD)
angiographic, myocardial SPECT in, 9(ab)
aortic sclerosis, abnormal myocardial perfusion SPECT in, 765(ab)
asymptomatic elderly, myocardial perfusion SPECT and resting ECG, 346(ab)
attenuation correction effects, myocardial sestamibi SPECT, 739(ab)
brachytherapy with ^{188}Re, radiation exposure of medical personnel during, 1170(ab)
diagnosis, myocardial perfusion SPECT, 7(ab)
fuzzy logic-based automatic quantitative analysis, myocardial perfusion imaging, 1625
left ventricular aneurysm and, ^{99m}Tc MIBI SPECT and FDG PET for viability, 15(ab)
multidetector CT, radionuclide perfusion imaging comparison, 352(ab)
perfusion defect, myocardial flow changes to CPT and adenosine, 756(ab)
plaque imaging, using radiolabeled MMP inhibitor, 709(ab)
response to therapies, serial imaging of, 169(ab)
simulation of motion defects, 462(ab)
^{99m}Tc tetrofosmin SPECT, prognostic value of, 8(ab)
^{201}Tl gated SPECT, individual coronary arteries, 762(ab)
Coronary artery stenosis, myocardial flow changes to CPT and adenosine, 756(ab)
Coronary endothelium, tracer adenosine as flow marker, 641
Coronary flow reserve
measured by ^{99m}Tc MIBI retention increase, during vasodilation, 288(ab)
quantification, myocardial perfusion imaging, 290(ab)
stress perfusion SPECT, CAD patients, 292(ab)
Correction methods, impact of, planar scintigraphic quantitative imaging, 1163(ab)
Crohn's disease, biological markers, ^{99m}Tc WBC scintigraphy, 1257(ab)
Cross-talk correction
^{123}I and ^{99m}Tc tetrofosmin SPECT, cardiac imaging, 745(ab)
model-based, ^{99m}Tc and ^{123}I simultaneous dual-isotope imaging, 971(ab)
CT
gastrointestinal stromal tumors, tumor response to Imatinib, 75(ab)
multi-detector, Graves' disease after radioiodine therapy, 1201(ab)
16-slice systems, 24N(2)
^{99m}Tc tetrofosmin SPECT comparison, mediastinal lymph nodes in non-small cell lung cancer, 1219
translation and co-registration, automatic rigid dual study co-registration system, 946(ab)
3D tumor volumes, 35N(5)
Cushing's syndrome, adrenal incidentaloma, SPECT semiquantitative analysis, 1057
Cyclooxygenase-2, expression, PET tracer for, 1700
Cyclopentadienyl technetium, metabolism, liver, 1126(ab)
Cystic fibrosis
CFTR gene transfer in, 1276(ab)
children, prediction of ventilation heterogeneity with lung perfusion scan, 1271(ab)
lung scintigraphy, sulesomab for, 594(ab)
Cystography, radionuclide
repeat bladder filling effects, 1252(ab)
vesicoureteric reflux in children with pyelonephritis, 1256(ab)

D

Data analysis
automation of, neuroreceptor PET studies, 30(ab)
FDG PET and CT combination, optimal diagnosis of solitary pulmonary nodule, 928(ab)
image and lesion noise comparison, PET, 1016(ab)
methods in geometrical parameter estimation, SPECT, 23(ab)
parametric imaging vs statistical moment analysis, 42(ab)
PET/CT fusion, immobilization device for patient positioning, 964(ab)
Prostascint image volumes, manual fusion reproducibility, 962(ab)
Deafness, *see* Hearing disorders
Deep brain stimulation, PET and, 33N(5)
Dementia
differentiation of subtypes, FDG PET, 833(ab)
FDG PET, normal databases compared with, 52(ab)
frontotemporal variants, SPECT, 832(ab)
glucose metabolic dysfunction in, 44N(12)
with Lewey bodies, distinguished from Alzheimer's, ^{123}I CIT SPECT, 56(ab)
progressive supranuclear palsy, 843(ab)
SPECT diagnosis of, radiotracer effects, 834(ab)
strategic infarction, brain perfusion SPECT and MRI findings, 846(ab)
vascular
CBF in, statistical image analysis of, 505, 1874(le)
SPECT and, 49N(4)
Dendritic cells, mature and immature, radiation resistance, 496(ab)
Department of Energy (DOE)
contract to produce medical isotopes, 34N(12)
funding of imaging center in Russian Nuclear City, 42N(11)
grants for nuclear medicine research, 36N(10)
isotope program changes, 31N(1)
nuclear medicine research grants, 34N(1)
recovery of radioactive sources, 43N(7)
request for increase in science funding, 46N(4)
task force on the future of science programs, 24N(2)
Depression, anger attacks in, ^{15}O inhalation PET in, 894(ab)
Detectability index, modular gamma camera, performance evaluation of, 58
Diabetes
beta-cell imaging, ^{18}F-labeled glyburide analogs, 503(ab)
depression, measurement of serotonin receptors in brain, 896(ab)
effects on FDG SPECT with acipimox, assessment of myocardial viability, 877
endothelial dysfunction in, myocardial PET, 19
FDG myocardial SPECT, after oral acipmox, 350(ab)
hypertension and, worse left ventricular function, 728(ab)
insulin-resistance, coronary circulatory dysfunction in, 349(ab)
malignancies, insulin effects on FDG PET imaging quality, 79(ab)
myocardial beta-adrenergic receptor density in, ^{11}C CGP-12177 PET, 706(ab)
myocardial muscarinic receptor density in, ^{11}C MQNB PET, 708(ab)
osteomyelitis in, leukocytes labeled with monoclonal antibody in detection of, 1218(ab)
rapid gastric emptying, early dumping syndrome and, 304(ab)
^{99m}Tc sestamibi SPECT, myocardial perfusion reserve, 348(ab)
type I
gastric emptying disorders, time sequence of, 306(ab)
sildenafil effects on gastropathy, 305(ab)
Diabetic neuropathy, PET assessment of pain, 27N(2)
DICOM image display, interactive 3D view, SPECT and PET in clinical conferences, 929(ab)
Dipyridamole, cold pressor test and endothelial dysfunction, myocardial perfusion, 19
Dirty bomb, *see* Radiological dispersal devices
Distraction osteogenesis, outcome, prediction by 3-phase bone scintigraphy, 369
Dobutamine
effects on substrate metabolism, diabetic cardiomyopathy, 347(ab)
myocardial perfusion imaging, in uncomplicated acute myocardial infarction, 1023
simplification of protocol, stress-testing procedures in asthma, 512(ab)
Dopamine
continuous measurements, PET modeling techniques, 374(ab)
decreased function, never-medicated adults with ADHD, PET, 216(ab)
mood and, PET study, 28N(2)
presynaptic ligand and nigrostriatal pathways, dementia and parkinsonism, 396(ab)
receptor occupancy, binding potential, 905(ab)
release, nicotine-induced, rodent nucleus accumbens, 229(ab)
role in metabolic changes, alcoholics, 898(ab)
3D brain PET multiframe images, using factorial analysis, 29(ab)
Dopamine D1 receptors, striatal aromatic L-amino acid decarboxylase activity and, monkey, 230(ab)
Dopamine D2 receptors
amphetamine-induced release, head movement correction effects, 41(ab)
binding fluctuation assessments, PET, 226(ab)
density evaluation, ^{123}I IBZM SPECT, 848(ab)
in extrastriatal and striatal regions, in schizophrenia, 113(ab)
methylphenidate enhancement of dopamine, in ADHD, 117(ab)
multiple systems disease, Parkinson's disease and, differentiation, 845(ab)
occupancy
under antipsychotic treatment, PET, 115(ab)
PET measurement of, 114(ab)
orbitofrontal cortex activity and, genetic risk for alcoholism, 213(ab)
quantification of, reference tissue modeling of ^{123}I epidepride, 917(ab)
radiotracer binding, MicroPET, 225(ab)
SPECT, diagnosis of parkinsonian syndrome, 394(ab)
SPECT studies
automated evaluation of, 942(ab)
filtered backprojection or iterative reconstruction, 372(ab)

striatal dopamine transporter, schizophrenic patients, 116(ab)
two ^{11}C labeled agonists, comparison, 1053(ab)
Dopamine D3 receptors
^{11}C nafadotride, potential imaging agent, 231(ab)
mathematical modeling, PET, 922(ab)
Dopamine neurons, degeneration, different patterns in Parkinson's disease, 393(ab)
Dopamine receptors
agonist radiotracer, ^{18}F -OH-FHXPAT, 608(ab)
memory and, 44N(9)
quantification with ^{18}FDMFP, human brain, 109
^{11}C raclopride binding, microPET, rat brain, 815
Dopamine transporters
4-arylpiperidines as ligands, comparison to tropane ligands, 1056(ab)
automated evaluation, optimized software solution for, 918(ab)
automated registration for, SPECT, 36(ab)
basal ganglia, ADHD in children, 891(ab)
binding, in social phobia, SPECT, 118(ab)
DaTSCAN, in movement disorders, 392(ab)
density after antipsychotic treatment, ^{99m}Tc TRODAT-1 SPECT, 888(ab)
differential diagnosis, Lewy bodies and Alzheimer's disease, 55(ab)
differentiating hemi-Parkinson's from Parkinson's, ^{99m}Tc TRODAT SPECT, 854(ab)
dosimetry of radioligand, human subjects, 961
D2-receptor SPECT, parkinsonian syndrome, 394(ab)
^{18}F FECNT PET, 855
^{123}I FP CIT SPECT, in management of Parkinson's disease, 849(ab)
^{123}I FP-CIT SPECT, 839
isoflurane anesthesia and, 51N(4)
Parkinson's
dihydroergocryptine monotherapy or levodopa monotherapy, 387(ab)
treated with subthalamic nuclei stimulation, 389(ab)
quantification of, ^{123}I PE21 SPECT and Logan graphical method, Parkinson's disease, 663
SPECT to assess disease progression, 390(ab)
striatal, schizophrenic patients, 116(ab)
^{99m}Tc TRODAT-1, staging of Parkinson's disease, 395(ab)
uptake
in multiple system atrophy, 853(ab)
in progressive supranuclear palsy, 852(ab)
Dopaminergic system, ^{123}I SPECT neurotransmission imaging, 1184
Dosimetry
AC-225-antibody targeting, disseminated cancer, 497(ab)
biokinetic analysis and, OLINDA, 336(ab)
^{11}C acetate, whole-body PET, 333(ab)
cellular, low energy electron, 1160(ab)
estimated, acute myelogenous leukemia, 51N(4)
^{18}F FPCIT dopamine transporter, human subjects, 961
FDG, tritium contamination in water, 1104(ab)
^{131}I radiolabeled magic gel, 1044(ab)
^{131}I treatment guided by, metastatic differentiated thyroid cancer, 451, 2039(le)
imaging and acute toxicity, ^{99m}Tc EC-DG, tumor-bearing animals, 1158(ab)
inhomogeneous radioactivity uptake and, renal cortex, 330(ab)
multicellular, experimental, ^{131}I distribution, 2019
murine S factors, liver, spleen and kidney, 784
neutron, during positron emission radionuclide production, 1172(ab)
nonuniform distribution of ^{131}I, 331(ab)
organ, ^{111}In/^{90}Y CC49 trial, 1159(ab)
patient-specific 3D, non-Hodgkin's lymphoma patients, 260, 1541(le)
Pgp modulation studies, ^{18}F paclitaxel, nonhuman primates, 1330
pretherapeutic, ^{86}Y DOTAC vs ^{111}In DTPA octreotide, neuroendocrine tumors, 493(ab)
radiation
Bexxar radioimmunotherapy, whole-body exposure, 1171(ab)
^{11}C tyrosine, 1154(ab)
^{18}F FLT PET imaging studies, 1482
^{18}F fluoro-A-85380, central nicotinic receptor imaging, 596
^{18}F FMAU and FAU, 1151(ab)
impact of nodal regression, lymphoma patients, 495(ab)
new hypoxia PET tracer, ^{124}I IAZGP, 1153(ab)
nodal regression effects, lymphoma patients, 1322
pretarget radioimmunotherapy for GI cancer, 494(ab)
^{186}Re bivatuzamab, head and neck cancer, 1690
^{188}Re HEDP, prostate cancer skeletal metastases, 953
^{188}Re lipiodol therapy, liver cancer, 1161(ab)
toxicity prediction, 334(ab)
^{90}Y ibritumomab tiuxetan, non-Hodgkin's lymphoma, 465, 1707(le)
radioiodine, body retention, in thyroid cancers, 898
radionuclide therapy, IDL and MCNP-based software, 335(ab)
red marrow dose adjustment, FLT3-L cytokine levels, 67
renal, MIRD schema, 1113
renal antibody distribution and, 28N(3)
RIT, tumor mass and, 44N(11)
skeletal models, adipocyte spatial distributions, 774
small animal, mice and rats, 491(ab)
^{99m}Tc EC-Erbitux, squamous cell cancer, head and neck, 1157(ab)
total-body and red marrow estimates, 320(le)
tumor, conjugate-view SPECT, ^{131}I tositumomab, 457
^{90}Y ibritumomab tiuxetan, single-dose calibrator setting, 1137(ab)
Dual-isotope imaging
brain SPECT, perfusion and dopamine transporter density, 973(ab)
^{64}Cu ATSM compared with FDG, intratumor distribution, 254(ab)
pinhole SPECT, small animal, 524(ab)
simultaneous, pre- and post-synaptic dopamine sites, Parkinson's disease, 377(ab)
SPECT, fast Monte Carlo simulation of the cross-talk in, 208(ab)
^{99m}Tc and ^{123}I simultaneous, model-based crosstalk compensation in, 971(ab)
Dyskinesis, true nature of, 763(ab)

E

Echocardiography (ECG)
gated SPECT with, aortic and mitral insufficiency, 751(ab)
scintigraphy and, in hibernating myocardium, 52N(4)
Education, nuclear medicine's future, 26N(1)
Electrocardiography
exercise-induced changes, chronic respiratory disease patients, 325
gated acquisition, left ventricular geometry and contractile function, 1741
Encephalitis, pediatric, ^{99m}Tc HMPAO SPECT in monitoring of, 827(ab)
Endothelial cell injury, microvascular, in COPD, ^{123}I MIBG scintigraphic assessment, 1747
Endothelial dysfunction, dipyridamole, cold pressor test and, myocardial perfusion, 19
Endothelial progenitor cells, radiolabeling of, in myocardium, 52N(6)
Enzyme inhibitors
new labeled derivatives of etomidate, imaging of adrenal pathology, 504(ab)
synthesis, stereoselective approach and structure-activity studies, 167(ab)
Epidermal growth factor receptor (EGFR)
expression, imaging with kinase-specific irreversible radioligands, 1073(ab)
^{111}In-labeled, antitumor effects of, human breast cancer xenografts, 1469, 1479
molecular imaging, ^{11}C EGFR-TK inhibitors, 161(ab)
Epilepsy
cortex, electrophysiological and functional data in children, 39(ab)
epileptogenic area, SPECT evaluation, 839(ab)
^{18}F FCWAY PET, with partial volume correction, 62(ab)
FDG PET, predicting outcome after temporal lobectomy, 59(ab)
ictal SPECT studies, basal ganglia or thalamic activation effects, 1379
left medial temporal lobe, memory network changes in, 61(ab)
neocortical, FDG uptake on PET, 841(ab)
pediatric, ictal SPECT and, 30N(2)
pediatric, PET evaluation of GABA-A receptor complex, 373(ab)
PET, SPECT, and magnetic field in, 41N(10)
presurgical evaluation, interictal FDG PET, 840(ab)
temporal lobe
diagnosis, pediatric, 602(ab)
epileptogenic area of, ^{123}I IMZ SPECT identification, 838(ab)
gyral FDG uptake corrected by partial volume effect, 58(ab)
metabolic abnormalities, FDG PET with SPM, 1006
Esophageal cancer
chemoradiotherapy, FDG PET for assessment, 1438(ab)
FDG PET, ultrasonography and, comparison, 1335(ab)
FDG PET positive nodes, prognosis and, 1345(ab)
Hilar node uptake, FDG PET, 67(ab)
histopathological subtypes, FDG PET, 1424(ab)
induction of therapy, FDG PET and, 50N(4)
locally advanced adenocarcinoma, esophagogastric junction, FDG PET for, 64(ab)
PET/CT with FDG value in, 65(ab)
radiotherapy, combined with chemotherapy, 69(ab)
staging with FDG PET, 66(ab)
therapy control, FDG PET/CT, 1336(ab)
Estrogen receptors, modulation of, small animal PET imaging, 1334(ab)
Estrogen therapy, metastatic breast cancer, PET, 412(ab)
Ethnicity, guidance in clinical trials, 26N(3)
Ethylenedicysteine
^{99m}Tc
imaging, dosimetry and acute toxicity with, 1158(ab)
radiosynthesis, biodistribution and planar scintigraphy, 319(ab)
squamous cell cancer, head and neck, 1157(ab)
Etomidate analogs, synthesis, stereoselective approach and structure-activity studies, 167(ab)
European Association of Nuclear Medicine (EANM) 2003, report, 22N(10)
Eustachian tube, dysfunction, intracavitary radionuclide therapy, 559
Euthyroid, potential interference on radioiodide thyroid uptake, rat, 832
Ewing sarcoma, metastatic, high-dose ^{166}Ho DOTMP treatment for, 1467(ab)
Exercise
continuous radionuclide LV function monitoring, chronic heart failure, 179(ab)
dynamic, ^{123}I MIBG uptake and, chronic heart failure, 1618
Experimental tumors, FDG, distribution by autoradiography, 256(ab)
Extracellular matrix, ^{111}In anti-tenascin-C antibody and ^{99m}Tc sestamibi, myocarditis in rats, 4(ab)
Extracellular space, brain tumors, measurement with ^{76}Br bromide PET, 1210

F

Factor analysis, with system constraints, nonparametric input-function reconstruction using, 907(ab)
Fallopian tube cancer, recurrent, PET/CT in, 30N(2)
Fatty acids
^{18}F-labeled modified PET, detection of heart disease, 502(ab)
metabolism
liver, 1126(ab)
myocardial BMIPP uptake, 707(ab)
^{99m}Tc EC-TML targeting, 1077(ab)
Federal eGOV Health Information Exchange Standards announced, 28N(5)
Filtering
myocardial gated SPECT, Shine noise reduction procedure, 729(ab)
statistical, end-diastolic image processing with, 458(ab)
FK960, brain concentration, development of novel antidementia drug, 105
Flow reserve, lower extremity, ^{15}O water PET in, 915

Flumazenil, *see* Carbon-11 FMZ
Fluorine-18
dual-head coincidence gamma cameras, comparison, 1023(ab)
gene therapy, potential PET imaging agents, 1061(ab)
glucose analogs labeled with, assay to screen substrate specificity, 1099(ab)
labeling strategy, RGD-peptide uptake, 148(ab)
modified fatty acids labeled with, detection of heart disease, 502(ab)
4-Fluorine-18 ADAM, improved radioligand, PET, serotonin transporters, 1890
Fluorine-18 annexin V, PET, apoptosis imaging, 1119(ab)
Fluorine-18 celecoxib, synthesis and evaluation, PET marker for COX-2 expression, 1127(ab)
Fluorine-18 choline, PET, glioma, stereotactic biopsy and radiation therapy, 379(ab)
Fluorine-18 CPFPX, adenosine A_1 receptor ligand, small animal PET, 1682
Fluorine-18 cyclic RGD peptide, PET, imaging of tumor angiogenesis, 152(ab)
Fluorine-18 desbromo-DuP-697, evaluation, PET tracer for cyclooxygenase-2 expression, 1700
Fluorine-18 DMFP, quantification of dopamine receptors, human brain, 109
Fluorine-18 DOPA, PET, small-cell lung cancer, 1392(ab)
Fluorine-18 FAA, ^{18}F FXA and, studies in tumor-bearing mice, 1108(ab)
Fluorine-18 FACBC
compared with FDG, diagnosis of brain tumor, 543(ab)
estimated radiation dosimetry, animal data, 1156(ab)
Fluorine-18 fallypride, in brain imaging, 32N(2)
Fluorine-18 FA-4, evaluation, high-affinity choline uptake system, 269
Fluorine-18 FBnTP, taxotere-induced apoptosis, tumor response to, 584(ab)
Fluorine-18 FCH, intratumoral distribution, autoradiographic comparison, 265(ab)
Fluorine-18 FDG, *see* Fluorodeoxyglucose (FDG)
Fluorine-18 FDOPA
dopaminergic nerve function, spinocerebellar ataxia type 2 and Parkinsonism, 858(ab)
dopaminergic neuron function, progressive supranuclear palsy comparison to Parkinsonism, 399(ab)
PET, ^{99m}Tc TRODAT-1 SPECT crossover study, Parkinson's disease, 999
visualization, neuroendocrine tumors, 234(ab)
Fluorine-18 FECh, optimized reaction parameter for radiosynthesis of, 328(ab)
Fluorine-18 FECNT, PET, dopamine transporter ligand, 855
Fluorine-18 FEFE, quantification of pulmonary beta-adrenergic receptors with, small animal model, 890(ab)
Fluorine-18 FEFMZ, one-step reaction, benzodiazepine receptor, 1054(ab)
Fluorine-18 FET
comparative study with IMT, brain tumors, 879(ab)
FDG comparison study, brain tumor, 544(ab)
novel synthesis of, animal tumor models, 155(ab)
PET
brain tumor and radiation necrosis, 1410(ab)
compared to FDG PET, brain tumors, 542(ab)
differential diagnosis of malignant melanoma, 203(ab)
recurrent astrocytomas, 541(ab)
uptake
blood-brain barrier disruption and, gliomas, 881(ab)
correlation of histologic grades of brain tumors, 1309(ab)
Fluorine-18 FHPG, HSV-tk-1 imaging, gene therapy, 107(ab)
Fluorine-18 FLT
automated production of, 1140(ab)
comparison with FDG, chemotherapy response in human cancer cell lines, 261(ab)
detection and differentiation, low and high grade sarcoma, 240(ab)
vs FDG, image proliferation in lung tumors, 1426, 1432
FDG PET comparison, solitary pulmonary nodules and lung cancer, 402(ab)
immunomodulation of, concanavalin A and steroid use, 1314(ab)
microPET I, treatment with CDK2 inhibitor, nude mouse tumor model, 1313(ab)
PET
diagnosis of thoracic tumors, 438(ab)
DNA and amino acid metabolism identification, 545(ab)
staging of metastatic melanoma, 547(ab)
prediction of chemotherapy response, breast cancer, 246(ab)
as proliferation marker, prostate cancer tumor model, 262(ab)
radiation dosimetry, in human PET imaging, 1482
Fluorine-18 fluoride
bone metabolism, porcine, 314(ab)
capillary electrophoresis, analysis of trace metal isotope impurities, 1142(ab)
heterotopic ossification after spinal cord injury, 484(ab)
osteosarcoma, 930
Patlak values, bone graft patients, 315(ab)
Fluorine-18 fluoroacetate, for tumor imaging, 1062(ab)
Fluorine-18 fluoroalkyl-β-D-glucosides, synthesis, sodium-dependent glucose transporters, 1973
Fluorine-18 fluoro-A-85380, PET, central nicotinic receptor imaging, 596
Fluorine-18 fluorodopamine, PET, aging changes in cardiac sympathetic function, 1599
3′-Fluorine-18 fluoro-3′-deoxy-L-thymidine, staging of metastatic melanoma, 1927
Fluorine-18 FMB, small animal PET, D2 re618ceptor density and affinity for
Fluorine-18 FMISO
head and neck tumors, treatment response to radiotherapy, 416(ab)
hypoxia, brain tumor metabolism and, 380(ab)
information relationship to FDG, glioma assessment, 878(ab)
PET, tumor hypoxia in non-small cell lung cancer, 435(ab)
radiation and concurrent chemotherapy, nasopharyngeal cancer, 419(ab)
tumor hypoxia imaging, head and neck cancer, 1340(ab)
uptake, mice tumor models, PET and autoradiography, 1302(ab)
Fluorine-18 FPCIT, dosimetry, human subjects, 961
Fluorine-18 FU, synthesis, tumor proliferation imaging agent, 1063(ab)
Fluorine-18 Gluc-TOCA, step labeling, somatostatin receptor imaging, 233(ab)
Fluorine-18 MPPF, binding, extracellular serotonin level and, rat hippocampus, 1495
Fluorine-18 nifrolidine, PET, imaging for nicotinic receptors, 606(ab)
Fluorine-18 paclitaxel, Pgp modulation studies of, nonhuman primates, 1330
Fluorine-18 p-FBnTP, detection of apoptosis, prostate, 585(ab)
Fluorine-18 SFB, annexin V labeled with, imaging of cell death, 1058(ab)
Fluorine-18 TFMKs, synthesis, PET imaging, 168(ab)
Fluorine-18 TYR, PET, whole-body tumor imaging, 533
Fluorodeoxyglucose (FDG)
autoradiography with, herpes simplex virus, 1845
coincidence camera and, staging of non-small cell lung cancer, 336
comparison with ^{18}F TYR, whole-body tumor imaging, 533
dual-time PET, thoracic lesions, 540
findings in CADASIL, 863
hybrid PET/CT, cancer imaging, 1200
ischemic myocardium, glucose uptake, 85
PET
accumulation to vulnerable plaque, atherosclerosis, 701(ab)
accuracy in different infectious processes, 142(ab)
acquisition and processing methods, patient size, randoms variance reduction, and acquisition geometry, 197(ab)
acquisition protocol optimization, 198(ab)
activity in fat tissue, 310(ab)
adipose tissue, fast positives, 1349(ab)
adrenal lesions in cancer patients, 404(ab)
advanced, metastatic or recurrent gastric cancer, 690
advanced pancreatic cancer, 1357(ab)
after chemotherapy for lymphoma, 1492(ab)
aggressive lymphoma treated with chemotherapy and stem cell transplant, 613(ab)
anorexia nervosa, cerebral metabolic abnormalities in, 886(ab)
appearance of schwannoma, 882(ab)
application to infection of vascular graft, 1211(ab)
arterial input function, glucose metabolism, 201(ab)
assessment of malignant recurrent lymphoma, 1490(ab)
atherosclerotic plaque in old and hyperlipidemic rat, 343(ab)
attenuation correction, in small pancreatic cancers, 1356(ab)
with bladder irrigation, uterine and ovarian tumors, 353
blood flow and metabolism changes, breast cancer, 1806, 1815
bone marrow infiltration in malignant lymphomas, 1493(ab)
bone scintigraphy comparison, osteomyelitis of the mandible, 1224(ab)
brain tumor metabolism and hypoxia, 380(ab)
breast cancer, management of suspected recurrence, 1398(ab)
breast density and, 1238
bronchial cancer, 561(ab)
cell membrane metabolism and, differentiated thyroid cancer, 255(ab)
cervical cancer after treatment, 1430(ab)
chemotherapy response monitoring, testicular cancer, 427(ab)
CoDe with dual head SPECT, differentiated thyroid cancer, 553(ab)
combined imaging for breast cancer, 45N(7)
compared with ^{99m}Tc HDP, detection of bone metastases, 1343(ab)
comparison of ^{67}Ga, lymphoma patients, 1489(ab)
Concord P4 microPET I, small parts imaging, 1012(ab)
contrast-induced artifacts, 1344(ab)
vs CT
metastatic or recurrent melanoma, 1367(ab)
staging of lymphoma, 1072
CT and, squamous cell head and neck cancer, 1378(ab)
2D and 3D acquisition comparison, 1014(ab)
decreased accuracy with increased myocardial activity, 405(ab)
dedicated PET mammography, breast cancer, 1026(ab)
delayed, assessment of k4 dephosphorylation, glioma, 872(ab)
delayed additional imaging, abdominal tumor patients, 1363(ab)
delayed regional PET, lymph node staging in non-small cell lung cancer, 401(ab)
detection of hidden metastases, primary liver cancer, 1448(ab)
detection of thyroid incidentaloma, 1416(ab)
diagnosis and follow-up, Takayasu arteritis, 146(ab)
diagnosis of infected hip and knee prosthesis, 1219(ab)
diagnosis of pleural mesothelioma, 1390(ab)
diagnosis of recurrent ovarian cancer, 425(ab)
diagnosis of thoracic tumors, 438(ab)
diagnostic accuracy, head and neck cancer, 1393(ab)
differentiating lung cancer from tuberculosis, 439(ab)
differentiation of lung masses, 1445(ab)
differentiation of subtypes of dementia, 833(ab)
discrepant findings between MRI/CT, cervical cancer, 1429(ab)
distribution by autoradiography, experimental tumors, 256(ab)
dosage required with LSO-PET camera, 1013(ab)
dose-dispensing system for in-house production, 1141(ab)
dual-phase, value in cervical cancer, 1387(ab)

dual-time point, atherosclerotic lesions on, 184(ab)
dual-time point imaging, pulmonary nodules, 566(ab), 589(ab)
ductal lavage and, role in breast cancer diagnosis, BRCA mutation carriers, 1374(ab)
early recurrence of cervical cancer, 347
ECG-gated PET, myocardial viability and function, 20(ab)
echinococcus multilocularis liver lesions, 138(ab)
endometrial cancer, 1412(ab)
epilepsy, predicting outcome after temporal lobectomy, 59(ab)
esophageal cancer after, 69(ab)
evaluation of chemoradiotherapy in esophageal cancer, 1438(ab)
evaluation of chemotherapy, non-Hodgkin's lymphoma, 1487(ab)
evaluation of response to therapy, 224
extrahepatic metastases from hepatocellular cancer, 1346(ab)
false staging of mediastinal nodes
lung cancer, 1371(ab)
non-small cell lung cancer, 313(ab)
FET comparison study, brain tumor, 544(ab)
in fever of unknown origin patients, 143(ab)
focal thyroid incidentaloma, 52N(11)
gastrointestinal stroma cell tumors, Glivec treatment, 76(ab)
gliomas, 43N(12)
glucose metabolism in alcohol dependence, T1190(ab)
granulocyte colony stimulating factor, increased uptake and optimal length of time, 610(ab)
gynecologic cancer patients, 1428(ab)
head and neck cancer, 1482(ab)
hepatic residual or recurrent tumors, 1452(ab)
hilar lymphadenopathy, 1350(ab)
hilar node uptake, esophageal cancer, 67(ab)
Hürthle cell carcinoma, 1402
hybrid PET, cardiac imaging, 769(ab)
hypothyroidism effects on thyroid uptake, 1191(ab)
identification of cardiac sarcoidosis, 1030
imaging, MR technologies, 930(ab)
imaging of asymptomatic joint prostheses, 1229(ab)
imaging of breast cancer, 555(ab)
incidental FDG uptake of thyroid gland, 1174(ab)
infected hip arthroplasties, 311(ab)
infection, 1216(ab)
initial staging and therapy, squamous cell cancer in oral cavity, 1382(ab)
insulin effects, in malignancies, 79(ab)
insulin effects on glucose uptake, liver, 682
intrahepatic cholangiocarcinoma, 1365(ab)
intraoperative probe system, preoperative cancer patients, 901(ab)
kinetics
association with cyclin-A and VEGF, 258(ab)
coexpression with other genes and, 257(ab)
shortened acquisition protocols for, 935(ab)
Ki-67 expression and glycolytic activity, lymphoma tissue, 615(ab)
labeling of leukocytes with, efficiency and cell viability, 147(ab)
left ventricular geometry and contractile function, 1741
liver malignancy from colorectal cancer, 1366(ab)
locally advanced adenocarcinoma of distal esophagus, 64(ab)
long-term outcome after traumatic brain injury, 384(ab)
lung tumors, Patlak images, 202(ab)
lymph node metastasis in cervical cancer, 1431(ab)
lymphomatous involvement of gastrointestinal tract, 269(ab)
malignant pleural mesothelioma, 1422(ab)
management in oral cancer, 32N(3)
management of malignant melanoma, 1451(ab)
management of metastatic melanoma, 549(ab)
management of testicular cancer, 567(ab)
measurement of tumor motion, radiation therapy planning, 122(ab)
medullary thyroid cancer, 1417(ab)
meta-analysis of infection imaging, 479(ab)
metabolic activity measurements, lung cancer, 565(ab)
metabolic regression grade and survival, lung cancer, 400(ab)
metabolic tumor volume imaging
lung cancer, 1456(ab)
pancreatic cancer, 72(ab)
midbrain hypometabolism, progressive supranuclear palsy, 843(ab)
monitoring of progenitor cell therapy PET, after acute MI, 174(ab)
MRI, CT and scintigraphy comparison, head and neck cancer, 198
MRI and, in nasopharyngeal cancer, 41N(9)
multidrug resistance protein and, lung cancer, 1376(ab)
musculoskeletal lesions and, 36N(5)
myocardial glucose metabolism, idiopathic dilated cardiomyopathy, 719(ab)
myocardial SPECT, after oral acipmox, diabetes, 350(ab)
myocardial uptake, patients with malignant disorder, 517(ab)
needle biopsy and, detection of lymphoma, 1486(ab)
neocortical epilepsy, 841(ab)
neuroendocrine tumors, 235(ab)
non-Hodgkin's lymphoma, 612(ab), 616(ab)
subtypes, 1485(ab)
non-small cell lung cancer, 1401(ab)
economics of, 1426(ab)
normal SUV of tonsils with, 940(ab)
occult metastases, 51N(11)
osteosarcoma, 930
paraortic lymph node metastases, cervical cancer, 1775
Parkinson's disease dementia, glucose metabolism in, 856(ab)
pediatric lymphoma, 596(ab), 1237(ab)
peritoneal carcinomatosis, 1407
positive nodes in esophageal cancer, 1345(ab)
postoperative patients with endometrial cancer, 1369(ab)
posttreatment evaluation of Hodgkin's disease, 1225
prediction of histopathologic differentiation, renal cell carcinoma, 1453(ab)
predictive accuracy of abnormal FDG uptake, 1420(ab)
preoperative M-staging, lung cancer, 1368(ab)
preoperative staging of colorectal cancer, 1784
primary and recurrent carcinoid tumor, 232(ab)
primary tumor detection, 1301
production in a commercial cyclotron, 1136(ab)
prognosis in lung cancer, 1402(ab)
prognostic significance in head and neck cancer, 1388(ab)
radiation and chemotherapy effects, 263(ab)
rectal cancer recurrence, 45N(9)
recurrence detection in stomach cancer, 1399(ab)
recurrent and metastatic breast cancer, 1409(ab)
recurrent or metastatic breast cancer, 1411(ab)
recurrent or persistent cervical cancer, 1455(ab)
in recurrent ovarian cancer, 426(ab)
recurrent pancreatic cancer, 1408(ab)
role in fever of unknown origin patients, 144(ab)
seizure focus localization, 57(ab)
skeletal muscle glucose utilization, 1592
small cell lung cancer, 1392(ab), 1911
soft-tissue sarcoma, 717
solitary pulmonary nodule, 1418(ab)
with SPM, temporal lobe epilepsy, 1006
staging accuracy, non-small cell lung cancer, 1918
staging in breast cancer, 247(ab)
staging of esophageal cancer, 66(ab)
staging of gastric cancer, 1432(ab)
staging of head and neck tumors, 52N(11)
surrogate marker of therapeutic response, 77(ab)
suspected vertebral osteomyelitis, 483(ab)
SUV variation in breast cancer, 913(ab)
^{99m}Tc DEP comparison, in lung cancer, 441(ab)
therapy for esophageal cancer and, 50N(4)
vs thoracic PET, lung cancer, 1396(ab)
thyroid cancer, 552(ab)
transmyocardial laser revascularization, 172(ab)
treatment response in NSCLC, 52N(6)
tumor characteristics in cervical cancer, 192
tumor recurrence in gastrointestinal cancer, 1435(ab)
unexpected foci, 22N(2)
use in Down syndrome, 835(ab)
use in malignant melanoma, 550(ab)
uterine sarcoma, 1338(ab)
variation in lower extremities, 1231(ab)
vascular inflammation in polymyalgia rheumatica patients, 141(ab)
who should read and interpret?, 1197(ed)
whole-body, urinary tract abnormalities incidentally detected on, 464(ab)
without blood sampling, 60- and 120-min protocols, 911(ab)
3D, brachytherapy planning, 41N(1)
PET/CT
brown fat evaluation, 1267
comparison, colorectal cancer, 1797, 1804
comparison with whole-body MRI, 1354(ab)
cutaneous T-cell lymphomas, 273(ab)
cystic pancreatic tumors, 74(ab)
endometrial cancer, 423(ab)
evaluation of breast cancer, 1403(ab)
gynecological tumors, 1400(ab)
head and neck cancer, 420(ab)
impact of fusion on oncological interpretation, 1351(ab)
oncological, inclusion of lower limbs in, 1341(ab)
oral contrast in, 412
ovarian cancer, 422(ab)
pediatric nuclear imaging, 1241(ab)
pituitary adenomas and metastases, 471(ab)
solitary pulmonary nodule, granuloma and, 1269(ab)
therapy control in esophageal cancer, 1336(ab)
uptake of supraclavicular area fat, 170
uterine cervical cancer, comparison with PET alone, 1404(ab)
vascular uptake, arterial wall calcifications, 183(ab)
whole-body, restaging of lymphoma, 270(ab)
postchemotherapy residual mass evaluation, testicular cancer, 1397(ab)
prediction of therapy outcome, metastatic colorectal cancer, 78(ab)
production, off-site supply of ^{18}F fluoride, 1149(ab)
pulmonary uptake, low birth weight effects, 43N(12)
quantification of, shortened PET data acquisition protocol for, 1933
regional changes of GLUT-1 and GLUT-4 expression, ischemically injured pig myocardium, 339(ab)
SPECT
acipimox with, assessment of myocardial viability, diabetes effects, 877
contractile reserve in ischemic cardiomyopathy, 127
stand-alone whole-body PET, three-dimensional registration, 1156
sternal uptake, post-sternotomy, 312(ab)
SUV, filtered backprojection and iterative reconstruction, 200(ab)
^{99m}Tc tetrofosmin and, metabolism perfusion mismatch, 33, 40
tetrofosmin and, dual-isotope SPECT after acipimox administration, 140
transport of IMT, non-stimulated human monocyte macrophages, 1315(ab)
tritium contamination in water, 1104(ab)
tumor autoradiography, uptake of FCH, 265(ab)
tumor viability, lung tumors treated with radiofrequency ablation, 1381(ab)
tumoricidal effects, Eisntein Group report, 10N(10)
ultrasound-guided fine needle biopsy and, metastatic thyroid cancer, 1192(ab)
uptake
adipose tissue and muscle, false-positives for PET, 1789
brown adipose tissue, pharmacologic reduction of, 295(ab)
endothelial cells, 284(ab)
smoking effects, 309(ab)
vessels, comparison to vascular calcification, 185(ab)
urinary excretion rate, different physiological conditions, 1415(ab)

whole-body PET
evaluation and staging of brain malignancy, 1353(ab)
staging and management for radiotherapy, 24, 30
suspicious renal masses, 1414(ab)
vs ^{18}F FLT, image proliferation in lung tumors, 1426, 1432
Fluoro-m-tyrosine, striatal aromatic L-amino acid decarboxylase activity, D1 receptor inhibition effects, 230(ab)
Fluorotyrosin. *see* Fluorine-18(ab) FTP
Folate receptors, ^{111}In DTPA, diagnosis of ovarian cancer, 700
Food and Drug Administration (FDA)
device approval time to be reduced, 38N(10)
new draft guidances for industry, 43N(7)
new office established for combined products, 28N(3)
Prussian Blue to treat radiation exposure, 45N(4)
Fractal analysis
CBF, in vascular dementia, 505, 1874(le)
nuclear medicine images, 316(le)

G

GABA-A receptor complex, noninvasive PET, children with epilepsy, 373(ab)
GABA, dopamine modulation, measured by ^{11}C raclopride PET, 228(ab)
Gadolinium oxyorthosilicate, detectors, brain PET camera based on, 1340
Gallbladder
dysfunction, dynamic cholescintigraphy with CCK-33, 446
ejection fractions
comparison of regular CCK-8 and pharmacy-compounded CCK-8, 499
measurement, 1544(le)
use of lactose-free fatty-meal food supplement, 1263
function, comparison of regular CCK-8 and pharmacy-compounded CCK-8, 499
Gallium-67
activated charcoal labeled with, colon transit study, 1204(ab)
cellular uptake of, *HFE* gene modulation, 943
chemical purification of, for peptide labeling, 1147(ab)
SPECT, suspected vertebral osteomyelitis, 483(ab)
SPECT with, recurrent lesions in hepatocellular cancer, 1450(ab)
whole-body SPECT, planar imaging and, lymphoma patients, 1494(ab)
Gallium-67 citrate, scintigraphy, idiopathic pulmonary fibrosis and ARDS, 1273(ab)
Gallium-67 DTPA, autoradiography with, herpes simplex virus, 1845
Gallium-68 DOTA-F(ab')$_2$ Herceptin, rapid microPET imaging, 17AAG induced HER2 protein, 1290(ab)
Gallium-68, PET, bispecific antibody pretargeting in, 1057(ab)
Gamma camera
avalanche photodiode for use in, 1004(ab)
CsI(Tl), Monte Carlo simulation, small animal imaging, 1032(ab)
eZ-scope hand-held, multicenter experience, 1007(ab)
hand-held, high-resolution, biodistribution studies, 1030(ab)
high sensitivity, sentinel node imaging, staging of cancer, 1006(ab)
^{111}In, planar and SPECT imaging with, 1034(ab)
intraoperative imaging, sentinel lymph node in breast cancer, 407(ab)
modular, using a detectability index, 58
multi-head, intrinsic uniformity testing, 1046(ab)
semiconductor based, performance evaluation, 1003(ab)
small field of view, lymph node scintigraphy, 454(ab)
small FOV, high resolution for breast cancer diagnosis, 251(ab)
uniformity correction arrays, SPECT nuclides, 1041(ab)
Gamma probe
handheld, intraoperative semiconductor, 1008(ab)
parathyroid adenoma, minimally invasive radio-guided surgery of, 1183(ab)
during parathyroidectomy, for secondary hyperparathyroidism, 1187(ab)
parathyroidectomy guided by, optimization of, 1185(ab)
sentinel node localization, multifocal or multicentric breast cancer, 7
surgery guided by, parathyroid, 1443
^{99m}Tc sulfur colloid, intestinal perforation study, 307(ab)
Gastrectomy, bone disease after, ^{18}F fluoride ion PET detection of, 117
Gastric cancer
advanced, metastatic or recurrent, FDG PET evaluation of, 690
recurrence, detection with FDG PET, 1399(ab)
sodium/iodide symporter, glucose transporter-1 gene expression and, 1205(ab)
staging, FDG whole-body PET, 1432(ab)
Gastric emptying
accommodation and, simultaneous assessment, 302(ab)
early dumping syndrome and, diabetic patients, 304(ab)
examination of rate, 303(ab)
scintigraphy, dedicated animal pinhole scintigraphy, 1099
scintigraphy and bioelectric impedance, evaluation in infants, 1253(ab)
sildenafil effects, in type I diabetes, 305(ab)
time sequence of disorders, in type I diabetes, 306(ab)
^{99m}Tc scintigraphy, children with impaired gastrointestinal motility, 1246(ab)
Gastrin receptor scintigraphy, ^{111}In D-Glu1-minigastrin, medullary thyroid cancer, 551(ab)
Gastrin-releasing peptide, expressed on prostate cancer cells, ^{111}In-labeled bombesin analogs, 823
Gastroenteropancreatic cancer
liver metastases from, somatostatin receptor scintigraphy use in, 359
radionuclide gene therapy, using sodium-iodide symporter, 1203(ab)
Gastroesophageal cancer
FDG PET, prediction of early therapy response, 70(ab)
sentinel lymph node, detection with ^{99m}Tc tin colloids, 68(ab)
Gastroesophageal reflux
with chronic respiratory diseases, children, 1255(ab)
esophagitis or, FDG PET imaging, 1364(ab)
Gastrointestinal tract
ectopic gastric mucosa, ^{99m}Tc pertechnetate, 1209(ab)
evaluation of upper GI dysmotility, new scintigraphic test, 302(ab)
laparoscopic radioguided sentinel node mapping, with Lymphoseek, 308(ab)
lymphomatous involvement, FDG PET evaluation, 269(ab)
stroma cell tumors, Glivec treatment, FDG PET evaluation, 76(ab)
whole gut transit time, children with recurrent abdominal pain, 1249(ab)
Gates Foundation, global challenge grants announced, 24N(3)
Gaucher's disease, bone marrow involvement in, ^{99m}Tc sestamibi scintigraphy, 1253
Gene expression
bicistronic PET reporter gene, microPET imaging, rat, 2(ab)
bi-directional promotor GAL4-VP16 strategy for, 98(ab)
cyclin-A and VEGF, FDG kinetics, 258(ab)
endogenous p53, using sodium iodide symporter, 88(ab)
FDG kinetics and, glucose transporters and hexokinase, 257(ab)
glucose transporter-1 and hexokinase type-II, chemotherapy agent effects, 259(ab)
herpes simplex virus thymidine kinase, FIAU preparation for, 1327(ab)
HNIS-IRES-GFP dual reporter imaging, 89(ab)
HSV thymidine kinase and sodium/iodide symporter, after chemo- gene therapy, 1319(ab)
patterns, in papillary thyroid cancer, 130(ab)
prostate-specific antigen, development and imaging, 94(ab)
reporter gene, ^{99m}Tc adenovirus and, living subjects, 149(ab)
serotonin transporter availability, measured with ^{123}I CIT SPECT, 220(ab)
SMART technique, 1329(ab)
sodium/iodide symporter and glucose transporter-1, gastric cancer, 1205(ab)
^{99m}Tc-labeled guanine analog, tumor imaging, 1067(ab)
two-step transcriptional amplification, prostate cancer, 97(ab)
Gene therapy
biodistribution of ^{131}I and ^{99m}Tc pertechnetate, neuroendocrine tumors, 1320(ab)
CFTR gene transfer, in cystic fibrosis patients, 1276(ab)
Drosophila melanogaster multisubstrate deoxyribonucleoside kinase gene, 1324(ab)
imaging therapeutic transgene expression, 95(ab)
intracerebral sodium/iodide symporter, transduced gliomas, 110(ab)
MIBG uptake after, rat hepatoma, 973
reporter gene for, norepinephrine transporter as, 86(ab)
SMART technique, 1329(ab)
sodium/oxide symporter expression, radionuclide therapy for hepatoma, 1316(ab)
Gene transfer
functional and anatomic imaging after, 92(ab)
perfusion studies, angiostatin and troponin, hepatomas, 1332(ab)
sodium iodide symporter, radioiodine therapy of neuroendocrine tumors after, 91(ab)
sodium/iodide symporter, cancer cells expressing, 90(ab)
transplanted bone marrow progenitor cells, non-invasive imaging, 93(ab)
Genetics, cardiac adrenergic activity, in hypertrophic cardiomyopathy, 487
Glioblastoma, ^{111}In D-Glu1-minigastrin diagnosis, 1425(ab)
Glioma
assessment with ^{18}F fmiso and FDG, 878(ab)
^{11}C methionine PET, FDG PET compared with, 540(ab)
delayed FDG imaging, k4 difference, 872(ab)
FDG PET in outcomes prediction, 43N(12)
high-grade, ^{125}I mAB 425 in, 26N(2)
malignant, inflammatory demyelinating disease mimicking, 565
PET, DNA and amino acid metabolism identification, 545(ab)
postop radiotherapy planning, SPECT in, 41N(1)
recurrent
^{125}I catheter in, 45N(10)
^{99m}Tc sestamibi SPECT use in, 1413(ab)
^{201}Tl SPECT, 44N(10)
survival analysis, brain SPECT with ^{99m}Tc MIBI, 870(ab)
tumor cells, expressing sodium iodide symporter, ^{211}At astatide and ^{131}I iodide, 1827
Glomerular filtration rate
indexing to body surface, children, 1037
role in hyperfiltration after donor nephrectomy, 1286(ab)
ultrafiltration method, use in measuring ^{99m}Tc MDP, 891
Glucose metabolic rates
exercise induced changes, FDG PET, 1228(ab)
ventricular myocardium, severe pulmonary hypertension, 188(ab)
Glucose metabolism
assay to screen substrate specificity, ^{18}F glucose analogs, 1099(ab)
cerebral
after traumatic brain injury, 1709
aging effects, PET and MRI study, 822(ab)
Down syndrome and progressive dementia, 835(ab)
FDG findings in CADASIL, 863
characterization of, FDG PET, 201(ab)
FDG uptake, GLUT4-null mice, 702(ab)
myocardial, ^{11}C glucose PET, 367(ab)
orbitofrontal activation, during food presentation, 890(ab)
renal, blood flow relations, in renal cell cancer, 266(ab)
Glucose transporters
FDG uptake, GLUT4-null mice, 702(ab)
sodium-dependent, ^{11}C as tracer for, 1075, 1082
sodium-dependent, ^{18}F, 1973

Glucose, utilization, skeletal muscle, static FDG PET, 1592
Graves' disease
carbonate lithium and hydrochlorothiazide trial, ^{131}I absorbed dose and, 300(ab)
dietary supplement with ginkgo biloba extract, radioiodine therapy and, 1164(ab)
ophthalmopathy, ^{131}I therapy for hyperthyroidism and, 1199(ab)
radioiodine therapy
effects of addition of ^{127}I to, 1189(ab)
individual dose concept, 131(ab)
multi-detector CT, 1201(ab)
predictive variables, 1184(ab)
radionuclide therapy, pretreatment with antithyroid drugs and, 1202(ab)
^{99m}Tc P829 somatostatin receptor tracing, 1547
Gynecologic cancer
combined PET/CT use in, 1400(ab)
FDG comparison with ^{11}C choline PET, 1051
sentinel node navigation surgery in, 1446(ab)

H

Head and neck cancer
advanced, ^{11}C methionine PET for prediction, 414(ab)
cervical LN metastasis, detection with ^{99m}Tc MIBI SPECT, 1395(ab)
cervical lymph node metastasis, FDG PET, 1393(ab)
combined PET/CT, 420(ab)
distance metastases, FDG PET use in, 1482(ab)
dosimetric analysis of radioimmunotherapy, ^{186}Re-labeled bivatuzumab, 1690
FDG PET, prognostic significance in, 1388(ab)
FDG PET/CT, confidence of anatomic assignment, 417(ab)
laryngeal, 1-^{11}C-tyrosine use in, 341
lymph node metastases in, high-energy probe with FDG, 418(ab)
lymphoscintigraphy for, hybrid SPECT/CT system, 1413
PET, 42N(1)
PET comparison, conventional imaging modalities, 198
quantitative FDG uptake, 1419(ab)
squamous cell
FDG PET and CT, 1378(ab)
PET effects on initial staging and therapy, 1382(ab)
staging, FDG PET vs conventional examination, 52N(11)
Head trauma
cerebral glucose metabolism after, 1709
persistent symptoms, PET in, 50N(4)
Health care initiatives, "paperless", HHS, 52N(8)
Health Insurance Portability and Accountability Act (HIPAA)
federal and private organizations, 39N(1)
final security and transaction standards, 47N(4)
Hearing disorders, neuroplasticity, PET evidence of, 1435, 1440
Heart failure
chronic, exercise and ^{123}I MIBG uptake, 1618
dobutamine-induced contractile reserve, with ischemic cardiomyopathy, 127
LV function monitoring, N-terminal pro-brain natriuretic peptide and, 179(ab)
planar gated blood-pool imaging, comparison with gated SPECT, 494
valsartan with ACE inhibitor, ^{123}I MIBG SPECT in, 884
Heart, norepinephrine system, phosphodiesterase type IV inhibitors, 714(ab)
Helicobacter pylori, ongoing infection, carbon-14 urea breath test for, 1210(ab)
Hemochromatosis, expression, cellular uptake of ^{67}Ga and, 943
Hepatobiliary scan
bile leak variations, after cholecystectomy, 137(ab)
preoperative assessment, total and regional liver function, 136(ab)
Hepatocellular cancer
^{11}C acetate PET in, 213, 222
detection of, FDG PET, 1359(ab)
extrahepatic metastases from, FDG PET for detection of, 1346(ab)
PET quantitation, identifiability analysis of the PV contribution to liver, 910(ab)
recurrent lesions in, ^{67}Ga scan and SPECT, 1450(ab)
Hepatocytes, nuclear nanoimaging, ^{99m}Tc GMC for, 1125(ab)
Hepatoma
boron neutron capture therapy for, 1106(ab)
Drosophila melanogaster multisubstrate deoxyribonucleoside kinase gene, 1324(ab)
MIBG uptake, after transfer of norepinephrine transporter gene, 973
primary, detection of hidden metastases with FDG, 1448(ab)
^{90}Y microsphere radioembolization of, 574(ab)
Herman Blumgart Award, 2003, Hendel, Robert C., 46N(8)
Herpes simplex virus
thymidine kinase
cardiac adenoviral gene transfer of, 704(ab)
^{18}F labeled radioligands for, 106(ab)
gene expression, FIAU preparation for, 1327(ab)
PET reporter gene, 95(ab)
thymidine kinase/ganciclovir, brain tumor therapy, 108(ab)
thymidine kinase/ganciclovir brain tumor model, autoradiography, 1845
HER2
breast cancer, MCF-7, nude xenografts, 1296(ab)
internalization, enhanced therapy of tumors, 577(ab)
protein, rapid microPET imaging, 1290(ab)
radiolabeled peptides, tumor targeting, 1081(ab)
Heterotopic ossification, after spinal cord injury, ^{18}F fluoride ion PET, 484(ab)
Hippocampus, ^{18}F MPPF binding, extracellular serotonin level and, 1495
Hodgkin's disease
FDG PET, posttreatment evaluation, 1225
FDG PET/CT, vs contrast-enhanced CT, 272(ab)
relapse, PET and, 28N(2)
Holmium-166 DOTMP
gamma camera imaging, physical simulation of, 453(ab)
high-dose, use in treatment for Ewing sarcoma in children, 1467(ab)
5-HT receptors, *see* Serotonin receptors
Human IgG antimouse antibody, in B-cell malignancy, 42N(11)
Human research, HHS conflict-of-interest guidance for, 28N(5)
Hürthle cell carcinoma, FDG PET in, 1402
Hydrazinonicotinamide (HYNIC)
Annexin V and, potential apoptosis imaging agent, 1133(ab)
bifunctional chelating agent, ^{99m}Tc labeling of, 1131(ab)
Hydrocephalus, idiopathic normal pressure, postsurgical perfusion changes, SPECT, 1884
Hydronephrosis
differential renal function, determination by ^{99m}Tc DMSA, 1283(ab)
incidentally detected, whole-body FDG PET for cancer, 464(ab)
low differential function, on diuretic renogram, 1254(ab)
neonatal, ^{99m}Tc MAG3 renography, 725
Hypercholesterolemia, response to lipid-lowering therapy, myocardial flow reserve, 171(ab)
Hyperglycemia, myocardial FDG uptake, patients with malignant disorder, 517(ab)
Hyperparathyroidism
abnormal glands in, MRI and ^{99m}Tc sestamibi use in, 298(ab)
minimally invasive parathyroidectomy, localization, 1175(ab)
preoperative localization and radioguided surgery, 1443
preoperative localization of adenoma, SPECT/CT in, 470(ab)
Hypertension
pulmonary, glucose uptake of ventricular myocardium and, 188(ab)
^{99m}Tc tetrofosmin myocardial imaging, hypertension, 10(ab)
Hypopharyngeal cancer, early response to chemotherapy in, ^{11}C MET PET, 526
Hypoxia
^{60}Cu ATSM PET, histological comparison, 1306(ab)
detection with intracoronary infusion of ^{99m}Tc EC, myocardial uptake, chronic CAD, 508(ab)
^{18}F FMISO imaging, head and neck cancer, 1340(ab)
^{18}F misonidazole and PET, non-small cell lung cancer and head and neck cancer, 1304(ab)
nasopharyngeal cancer, radiation and chemotherapy, 419(ab)
noninvasive assessment, ^{99m}Tc and ^{188}Re EC MN, 322(ab)
treatment response, ^{18}F FMISO PET for head and neck tumors, 416(ab)
tumor heterogeneity in imaging, PET and autoradiography, 1302(ab)

I

Ideal observer models
acquisition protocol optimization, FDG PET, 198(ab)
^{124}I and ^{18}F PET, lesion detectability, 916(ab)
Image analysis
channelized hoteling observer, 461(ab)
data acquisition geometries and strategies, multi-head SPECT system, 997(ab)
defect detection, myocardial perfusion imaging, 366(ab)
definition of ROI, brain, 943(ab)
digital scintillator-photodiode camera, with converging collimator, 1010(ab)
Hamming distance classification, tumor temporal signatures, prostate cancer, 944(ab)
^{111}In ProstaScint, tumor segmentation, prostate cancer, 955(ab)
multimodality imaging, framework for education, 956(ab)
quantitative
automatic image registration, 743(ab)
automatic polar plot analysis for myocardial SPECT, 904(ab)
dose-toxicity correlation in radioimmunotherapy and, 334(ab)
reference-tissue based modeling applied to, 34(ab)
striatal monoamine transporter density, 31(ab)
^{99m}Tc MIBI and FDG, perfusion-metabolism mismatch, 365(ab)
tomographic equilibrium gated blood-pool, 1002(ab)
X-ray CT and transmission scan with external source, attenuation correction comparison, 1001(ab)
^{99m}Tc ECD SPECT, psychose hallucinatoire chronique, 889(ab)
Image coregistration
^{123}I MIBG SPECT and CT, renal pelvis, 1248(ab)
PET/CT
cancer imaging, 1200
value of a negative oral contrast agent, 1344(ab)
^{201}Tl SPECT and CT fusion, thoracic malignancy, 1339(ab)
Image enhancement, filtered backprojection, vs wide beam reconstruction, 996(ab)
Image fusion
automatic, PET/CT, 42N(10)
CT/PET, hypoxia-directed radiotherapy, head and neck cancer, 415(ab)
CT/SPECT, ventilation-perfusion scan using energy minimization, 900(ab)
FDG PET and X-Ray CT, management of metastases of thyroid cancer, 1423(ab)
FDG PET/CT
confidence of anatomic assignment, head and neck lesions, 417(ab)
lung cancer, 436(ab)
LSO-PET/CT, feasibility, 1344(ab)
microSPECT/CT, lung imaging, small animals, 1031(ab)
MRI/CT and FDG PET, gynecologic cancer patients, 1428(ab)
PET/CT
evaluation of aggressive lymphoma, 1497(ab)

extension of the CT attenuation map in, 123(ab)
FDG, restaging of breast cancer, 252(ab)
with FDG, value in esophageal cancer, 65(ab)
FDG coincidence detector, 1351(ab)
FDG in, suspected infected vascular graft, 1214(ab)
immobilization device for patient positioning, 964(ab)
market outlook, 28N(7)
mislocalization of lesions, 240
progress, rewards, and challenges, 10N(7)
staging of lung cancer, 403(ab)
PET/CT with FDG, gynecologic malignancies, 421(ab)
PET/MRI, recurrent disease, malignant brain tumors, 875(ab)
SPECT/CT
added clinical value, 1040(ab)
differentiated thyroid cancer, 1905
^{111}In octreotide, somatostatin receptor positive tumors, 236(ab)
^{111}In WBC scintigraphy, 1222(ab)
localization of mediastinal parathyroid gland, 42N(12)
localization of parathyroid adenoma, 470(ab)
lung perfusion scintigraphy, 1260(ab)
radiation therapy of neuroblastoma, children, 1243(ab)
sentinel node mapping, 1413
X-ray attenuation correction, SPECT/CT and, malignant lung lesions, 242(ab)

Image management
lossy JPEG 2000 compression, static nuclear medicine image, 937(ab)
PET/CT, integrating into traditional PACS environment, 927(ab)
SPECT and PET in clinical conferences, 929(ab)

Image processing
elastic PET/CT images, stochastic optimization and robustness by preprocessing, 192(ab)
helicoidal CT/PET FDG, 193(ab)
mathematical model, artificial lesions, 984(ab)
Monte Carlo simulation, BGO, GSO, and LSO crystals, 1019(ab)

Image proliferation, FDG vs ^{18}F FLT, lung tumors, 1426, 1432

Image quality, whole-body PET, oncology imaging, 915(ab)

Image quantitation, Patlak, whole-body PET, 196(ab)

Image reconstruction
3D motion estimation and, myocardial gated SPECT, 27(ab)
analytical SPECT non-parallel geometries, 979(ab)
corrective, oncological SPECT, 195(ab)
correlated MR images, 999(ab)
count rate dependent axial normalization, panel detector, 982(ab)
CT transmission truncation, beam hardening artifacts and, on quantitative PET, 981(ab)
3D techniques for, cardiac SPECT, 456(ab)
data-driven motion correction, real SPECT, 206(ab)
different CT-based attenuation correction, PET with respiratory motion, 121(ab)
filtered backprojection, vs wide beam reconstruction, 996(ab)
filtered backprojection vs iterative reconstruction, ^{82}Ru PET, 972(ab)
high resolution OSEM, small animal PET scanner, 529(ab)
iterative
incorporation of collimator response, 998(ab)
SPECT algorithm, tumor activity estimation, 210(ab)
LOR-based, histograms, 531(ab)
maximization algorithm, small animal PET imager, 528(ab)
mechanical and electronic shift effects, pinhole SPECT, 1036(ab)
normal SPECT perfusion databases, 3D beam modeling effects, 747(ab)
3D-OSEM, 3DRP, and rebinning algorithms, brain lesion detectability, 1000(ab)
parallel data acquisition and, PET cameras, 1015(ab)
PET, attenuation correction effects on tumor detection, 1855
PET/CT, segmented contrast correction, 969(ab)
rebinning methods for, large aperture PET scanner, 974(ab)
ROC analysis, lesion detectability in PET, 966(ab)
ROC comparison of detection accuracy, 987(ab)
sorted PET listmode data, 919(ab)
tumor detection, 3D whole-body PET oncology imaging, 276
whole-body PET, 3D RAMLA vs 2D RAMLA, 532(ab)

Image registration
automated 3-dimensional, FDG whole-body PET, 1156
canine PET and MR, registration of, 952(ab)
combined PET/CT, limited breath-hold technique in, 986(ab)
EEG and PET data, epileptic children, 39(ab)
multi-resolution elastic, PT/CT images, 192(ab)
PET and microCT method, 376(ab)
PET/CT, observer variability, 244(ab)
SPECT and MRI, convection enhanced delivery of TP-38 immunotoxin, 382(ab)
whole-body
FDG CT/PET, 193(ab)
post-hoc software realignment, 961(ab)

Image resolution, improvement
attenuated brain SPECT with fan-beam geometry, 995(ab)
energy and spatial resolution relationships for, 1018(ab)
gamma camera based PET devices, 1023(ab)

Immunoconjugates, radioimmunotargetting with pancarcinoma anti-tissue polypeptide, 1480(ab)

Immunohistochemistry, detection of myocyte death, rat myocardium, 340(ab)

Immunomodulation, effects on ^{18}F FLT uptake, concanavalin A and steroid use effects, 1314(ab)

Immunoscintigraphy
anti-granulocyte, detection of infected vascular prostheses, 1217(ab)
conventional and pretargeted radioimmunotherapy, CD20-expressing lymphoma xenografts, 437
Hamming distance classification, tumor temporal signatures, prostate cancer, 944(ab)
^{111}In Zevalin, non-Hodgkin's lymphoma, 611(ab)

Immunotherapy
conference scheduled, 24N(2)
in depth, 36N(5)

In Memoriam
Cooper, Malcolm, 20N(5)
Feldsted, Eggert T., 11N(2)
Wetzel, Richard A., 33N(1)

Incidentaloma
adrenal, SPECT semiquantitative analysis, 1057
focal thyroid, FDG PET screening for, 52N(11)

Indium-111
albumin fusion, biodistribution of IL-2, 1330(ab)
EGFR labeled with, antitumor effects of, human breast cancer xenografts, 1469, 1479
planar and SPECT imaging with, small animal gamma camera, 1034(ab)
pretargeting, improved imaging in pancreatic cancer, 575(ab)
scintillation camera imaging, Monte Carlo simulation, 1162(ab)

Indium-111 bombesin analogs, targeting of gastrin-releasing peptide receptors, expressed on prostate cancer cells, 823

Indium-111 DTPA octreotide, somatostatin receptors, cervical cancer, 1299(ab)

Indium-111 DTPA-cG250, advanced renal cell carcinoma, quantitative image analysis, 559(ab)

Indium-111 DTPA-DGLU(1)-minigastrins, metabolites of, different organs, 1298(ab)

Indium-111 DTPA-D-PHE-octreotide, efficacy and toxicity, advanced neuroendocrine tumors, 446(ab)

Indium-111 DTPA-folate, receptor-targeted diagnostic agent, ovarian cancer, 700

Indium-111 DTPA-octreotide, ^{99m}Tc EDDA/HYNIC-TOC comparison, somatostatin receptor-expressing tumors, 708

Indium-111 DTPA, uptake, somatostatin receptor subtype 2, 1315

Indium-111 DTPA^0 octreotide, peptide receptor radionuclide therapy, 98

Indium-111 leukocytes
imaging of infection with, 1216(ab)
scintigraphy, automated labeling, 329(ab)

Indium-111 octreotide
neuroendocrine tumors, FDG PET to identify candidates for, 235(ab)
progressive thyroid cancer, 44N(7)
somatostatin receptor scintigraphy, meningiomas, 869(ab)
somatostatin scanning, neuroendocrine tumors, 1362(ab)

Indium-111 oxide, progenitor cells labeled with, rat model of myocardial infarction, 6(ab)

Indium-111 oxine, *Cryptococcus neoformans* cells labeled with, high-resolution, hand-held gamma camera, 481(ab)

Indium-111 pentetreotide
carcinoid tumors, imaging somatostatin receptors and amine uptake, 237(ab)
high-activity therapy, disseminated neuroendocrine tumors, 1
somatostatin-receptor scintigraphy, octreoscan, 1421(ab)
staging/restaging, somatostatin-receptor positive pediatric tumors, 1244(ab)

Indium-111 WBC, high RBC contamination of, images in infants, 480(ab)

Infection/inflammation imaging
accuracy of FDG PET in, 142(ab)
bivalent leukotriene B_4 antagonist for, 1087
COX-2 expression, PET probe for, 1110(ab)
differentiation of tumor from inflammation, potential positron tracer for, 1311(ab)
eosinophilic colitis, pediatric, ^{99m}Tc white blood cells for assessment, 1247(ab)
experimental, ^{99m}Tc labeled IL-8, 1502
experimental colitis, radiolabeled leukotriene B4 antagonist, 498(ab)
^{18}F desbromo-DuP-697, for cyclooxygenase expression, 1700
^{18}F FBnTP compared with FDG, differentiation of tumor from inflammation, 1312(ab)
FDG accumulation, chronic inflammatory foci, steroid effects, 253(ab)
FDG and ^{111}In leukocytes, comparison, 1216(ab)
FDG PET
meta-analysis, 479(ab)
vascular graft, 1211(ab)
FDG PET/CT, suspected infected vascular graft, 1214(ab)
fever of unknown origin, FDG PET role in, 143(ab), 144(ab)
^{111}In leukocyte scintigraphy, automated labeling, 329(ab)
^{111}In WBC scintigraphy, hybrid SPECT/CT, 1222(ab)
inflammatory bowel disease, biological markers and ^{99m}Tc WBC, 1586
iodinated amino acids, comparative biodistribution, 1489
large vessels, PET in giant cell arteritis, 145(ab)
leukocyte/marrow and leukocyte/bone comparison, prosthetic knee infection, 488(ab)
LeukoScan, bone infection, 477(ab)
murine monoclonal antibodies for, safety of, 1221(ab)
novel radiopharmaceuticals, flexible and automated solid-phase synthesis for, 1100(ab)
orthopedic, one-step radiolabeled biotin scintigraphy, 478(ab)
painful prosthetic joint, nuclear medicine role in, 927
PET and, HIV-1, 41N(12)
positron targeting of fungal infections, Eismein Group report, 10N(10)
pulmonary infection, ^{99m}Tc labeled IL-8 for detection, 1118(ab)
radiolabeled antimicrobial peptides in, 56N(6)
radiolabeled ciprofloxacin, septic and sterile osteoarticular diseases, 920
spread of *Cryptococcus neoformans*, ^{111}In, high-resolution hand-held gamma camera, 481(ab)
sulesomab binding, older patients with suspected infections, 1220(ab)

suspected prosthetic infection, after total knee arthroplasty, ^{99m}Tc ciprofloxacin use in, 1212(ab)
Takayasu arteritis, FDG PET for diagnosis and follow-up, 146(ab)
^{99m}Tc ceftizoxime, 1223(ab)
^{99m}Tc ciprofloxacin, prosthetic joint model, 317(le)
^{99m}Tc HMPAO-labeled leukocytes, hip prosthesis infection, 1213(ab)
^{99m}Tc IL-8 kinetics in, 499(ab)
^{99m}Tc leukotriene B4 receptor antagonist in, 482(ab)
^{99m}Tc phage, for specific imaging, 1124(ab)
^{99m}Tc Sulesomab, mechanism of accumulation, 11
white blood cell, localization properties of, focal infection, 1109(ab)

Inflammatory bowel disease
biological markers, ^{99m}Tc WBC and, 1586
^{111}In labeled lymphocyte gut homing, pinhole SPECT, 140(ab)

Inflammatory demyelinating diseases, mimicking malignant glioma, 565

Input function
optimization, parameter estimation, 951(ab)
reconstruction, factor analysis with system constraints, 907(ab)

Institute of Electrical and Electronics Engineers (IEEE), NIBIB and, symposium on biomedical imaging, 40N(9)

Instrumentation
GE Discovery ST PET/CT scanner
clinical image standard, 1011(ab)
NEMA standard, 362(ab)
micro crystal element scanner, small animal PET, 520(ab)
microSPECT/CT, lung imaging, small animals, 1031(ab)
Monte Carlo simulation, BGO, GSO, and LSO crystals, 1019(ab)
multi-pinhole/CCD-coupled CsI(Tl) crystal gamma camera, small animal imaging, 523(ab)
nuclear medicine, Blumgart and Yens, 1925, 1362
PET scanner performance, 360(ab)
PET ultra-high resolution detectors, novel prototype for, 450(ab)
PET whole-body imaging, 756
PET/CT, treatment planning in radiation therapy, 1045(ab)
second generation small animal PET system, MicroPET I, 519(ab)
small animal PET, design of system with 1 microliter volume resolution, 1035(ab)
whole-body PET/CT scanner, 1033(ab)

Insulin, glucose uptake and, liver, FDG PET study, 682

Interleukin-8, ^{99m}Tc labeled, experimental infection and inflammation, 1502

Intrathecal cancer
auger electrons, therapeutic potential, 111(ab)
brain, locoregional therapy of, 871(ab)

Intrathoracic lesions, ^{99m}Tc SPECT and, 48N(4)

Iodide biokinetics model, proposed revisions of, 46N(11)

Iodine-123
combinatorial solid phase approach for preparation, 166(ab)
controversy, 8N(9)
estrogen upregulates sigma receptor activity, hippocampus, rat, 224(ab)
improved preparation, human studies, 325(ab)
solid phase synthesis, polymer-supported prosthetic group, 1128(ab)
SPECT, dopaminergic neurotransmission imaging, 1184
whole-body scintigraphy, thyroid tumor, 852(le)

Iodine-123 alpha-methyl tyrosine, uptake in macrophages, transport studies of, 1315(ab)

Iodine-123 β-CIT, SPECT
vs clinical examination, Parkinson's syndrome, 859(ab)
Lewy body dementia diagnosis, 56
Parkinson's and depression, 48N(4)
serotonin transporters in Parkinson's patients, 870

Iodine-123 BMIPP
clinical efficacy of, effects of R isomer of BMIPP, 703(ab)
myocardial uptake, salt-sensitive hypertensive rats, 707(ab)

Iodine-123 epidepride, reference tissue modeling for, lipophilic metabolite effects, 917(ab)

Iodine-123 FEZIENT, imaging agent, serotonin transporters, 1050(ab)

Iodine-123 FP-CIT, SPECT
dopaminergic neurotransmission, 839
Parkinson's disease, 22N(2)

Iodine-123 hippuran, renal scintigraphy, prediction of renal scarring after urinary tract infection, 1755

Iodine-123 hyp, biodistribution and protein binding, 1086(ab)

Iodine-123 IMP, SPECT
cerebrovascular reactivity to acetazolamide, 520
image-based scatter correction, 947(ab)

Iodine-123 IMT
comparative study with FET, brain tumors, 879(ab)
isoform selectivity of transport, L-type amino acid transporters, 244
planning of radiotherapy, non glial brain tumor, 876(ab)

Iodine-123 IMZ, SPECT, epileptogenic area of temporal lobe epilepsy, 838(ab)

Iodine-123 MIBG
carcinoid tumors, imaging somatostatin receptors and amine uptake, 237(ab)
cardiac sympathetic nerve innervation, changes in hypertrophic cardiomyopathy, 1612
carvedilol and metoprolol therapy, dilated cardiomyopathy, 1604
carvedilol treatment, cardiac neuronal adrenergic function after, 601(ab)
clearance, estimation of sympathetic activity, 759(ab)
lung scintigraphy, endothelial injury in COPD, 1747
MRI and, diagnosis of pediatric neuroblastoma, 597(ab)
PET, cardiac neuroimaging in cardiomyopathy, 1459, 1467
uptake
exercise and, chronic heart failure patients, 1618
nape of neck, children, 1421
valsartan with ACE inhibitor, in congestive heart failure, 884

Iodine-123 2β-CIT, brain SPECT, scatter correction effects, 512

Iodine-124, PET, engineered antibody fragments, 1962, 1970

Iodine-125
B lymphocyte stimulator labeled with, B cell tumors, mice, 422, 434
catheter, in recurrent glioma, 45N(10)

Iodine-125 ITdU
pharmacokinetics, tissue fractionation studies and, 1080(ab)
pharmacokinetics and metabolism, rodents, 1671

Iodine-125 IUdR, intrathecal cancer therapy, therapeutic potential, 111(ab)

Iodine-125 mAB 425, in high-grade gliomas, 26N(2)

Iodine-125 MIB, synthesis and evaluation, antibody pretargeting, 1091(ab)

Iodine-131
body retention of, thyroid cancers and, 898
diagnostic dose, thyroid stunning, 1182(ab)
elevated thyroglobulin levels and, 50N(6)
^{123}I and, for whole-body scanning, 1194(le)
lead collar reduces exposure, 46N(11)
magic gel, MRI dosimetry study, 1044(ab)
nonuniform distribution, multicellular dosimetry, 2019
nonuniform distribution of, when is it considered uniform, 331(ab)
pre-treatment scan, after total thyroidectomy in cancer patients, 299(ab)
serial scans, differentiated thyroid cancer after ^{131}I therapy, 1462(ab)
SPECT and CT fusion, differentiated thyroid cancer, 1905
therapy
ablation of remnant after differentiated thyroid cancer, 476(ab)
dietary supplement with ginkgo biloba extract, 1164(ab)
differentiated thyroid cancer, 570(ab), 1194(ab), 1458(ab)
effects on gonadal function, thyroid cancer patients, 1176(ab)
functioning pulmonary metastases of thyroid cancer, 474(ab)
hyperthyroidism, Graves' ophthalmopathy and, 1199(ab)
maximal safe administered dose, thyroid cancer, 571(ab)
metastatic differentiated thyroid cancer, 451, 2039(le)
outpatient safety, 127(ab)
pulmonary metastases, thyroid cancer, pediatric, 1242(ab)
thyrotropin pretreatment in, nodular goiter, 40N(9)
toxic nodular goiter, 1198(ab)
treatment in pediatric patients, 50N(6)
uptake, thyroid, interference of agents on, euthyroid rat, 832
whole-body scan
differentiated thyroid cancer, 1379(ab)
isotretinoin for treatment of thyroid cancer, 572(ab)

Iodine-131 anti-B1 antibody, non-Hodgkin's lymphoma, patient-specific 3D dosimetry, 260, 1541(le)

Iodine-131 anti-CD20, relapsed follicular lymphoma, 47N(7)

Iodine-131 anti-CD33 antibodies, before bone marrow transplant, 46N(11)

Iodine-131 MIBG
uptake, after transfer of norepinephrine transporter, rat hepatoma, 973
use for melanoma, thyroid protection in, 40N(9)

Iodine-131 NP-59, uptake, adrenal incidentaloma, 1057

Iodine-131 sodium iodide, dual reporter gene imaging, 89(ab)

Iodine-131 tositumomab, conjugate-view SPECT, tumor dosimetry, 457

Iodium-131 sodium, therapy, thyroid microcarcinoma, 1181(ab)

4-Iodo-L-*meta*-tyrosine, biodistribution and excretion, via kidney, 625

Iridium, as a weapon, 42N(11)

Ischemia
muscle blood flow, ^{201}Tl evaluation for angiogenesis, 187(ab)
preconditioning model, ^{99m}Tc HYNIC-labeled annexin V, 717(ab)
^{99m}Tc HYNIC-annexin V, rat model, 500(ab)

Ischemic heart disease
BMIPP uptake and perfusion, occlusion-reperfusion rat model, 713(ab)
eniporide effects, ischemia/reperfusion model, 5(ab)
glucose transporter expression, pig myocardium, 339(ab)
myocardial fatty acid metabolism in, compartmental model, 768(ab)
time course of ^{99m}Tc annexin V, after ischemia/reperfusion, 342(ab)

Isotope programs, DOE, 31N(1)

Isotopes
American-Russian Agreement announced, 34N(12)
explosion at Isotec plant, 40N(11)
gold-dendrimer nanocomposite devices, activation analysis for imaging and therapy, 1094(ab)
medical, DOE contract to produce, 34N(12)

Iterative reconstruction
cardiac gated SPECT, pinhole collimator, living rat, 993(ab)
filtered backprojection and, gated SPECT, 178(ab)
filtered backprojection or, dopamine D2 receptor SPECT studies, 372(ab)
OSEM and depth-dependent resolution recovery, myocardial gated SPECT, 155
small animal PET, Monte Carlo-based system, statistical noise in, 530(ab)
SPECT, ordered subset–expectation maximization, 734(ab)

J

Journal of Nuclear Medicine
editorial, 661, 1197
new Editor-in-Chief, 13N(12)
Newsline review 2003, 11N(1)
online submission and peer review, 53N(8)
outstanding articles of 2002, 44N(8)
Sandler on JNM Editorship, 16N(12)

standing and influence grow, 30N(1)
Journal of Nuclear Medicine Technology, outstanding articles of 2002, 44N(8)

K

Kawasaki disease, myocardial perfusion, ^{201}Tl SPECT for, 1250(ab)
Kidney
dosimetry, MIRD schema, 1113
phosphorodiamidate morpholino accumulation, pretargeting, 1070(ab)
transplant (*see* Transplantation)
Kidney function
blood flow, parametric imaging approach for, 931(ab)
donor's remaining kidney, ^{99m}Tc MAG3 assessment of, 468(ab)
effects on output efficiency, 658(le)
glomerular filtration rate before chemotherapy, children with cancer, 599(ab)
low differential, diuretic renography, 1254(ab)
renal volume, diuretic renography, 1280(ab)
^{99m}Tc carbonyl complex as potential imaging agent, 1134(ab)
^{99m}Tc DMSA absolute renal uptake and, 1285(ab)
^{99m}Tc MAG3 clearance, Bayesian 3-compartment model for, 1357
three-headed SPECT system, kinetic parameter estimation from, 371(ab)
Kinevac, availability, 33N(1)

L

Lactate, injection, blood flow and, physiologically activated brain, 48(ab)
Laryngeal cancer
L-1-C^{11} tyrosine use in, 341
TYR PET in follow-up, 42N(10)
Left bundle branch block, severe left ventricular defect and, myocardial perfusion imaging, 726(ab)
Left ventricular distensibility, myocardial ischemia relations, nonobstructive hypertrophic cardiomyopathy, 1717
Left ventricular dysfunction
deformation, hyperelastic warping of PET and cine-MRI, 460(ab)
ischemic
bypass surgery, prognosis after, 1735
myocardial perfusion SPECT, 7(ab)
temporal sampling effects on gated SPECT, 276(ab)
myocardial perfusion and regional function, electrocardiographic gated SPECT assessment of, 757(ab)
Left ventricular ejection fraction
calculation in gated SPECT, 657(le)
ECG-gated FDG PET, myocardial viability and function, 20(ab)
FDG gated myocardial SPECT, perfusion-metabolism mismatch, 189(ab)
pinhole SPECT, vs planar blood-pool, 511(ab)
quantitative gated SPECT, small animal, 1655, 1662
reduced, referral bias in, 43N(12)
regional myocardial contractility, SPECT, 921(ab)
^{201}Tl/^{99m}Tc teboroxime dual isotope protocol, post-stress ^{99m}Tc sestamibi comparison, 279(ab)
volumes and, gated blood-pool SPECT, 494
Left ventricular function
ECG-gated ^{13}N ammonia PET, after myocardial infarction, 275(ab)
electrocardiography-gated acquisition PET, 1741
estimation by gated FDG PET, MRI validation of, 274(ab)
gated SPECT, coexistent diabetes and hypertension effects, 728(ab)
measurements, gated blood-pool tomography, animal study, 459(ab)
myocardial perfusion and, in uncomplicated acute myocardial infarction, 1023
OSEM, depth-dependent resolution recovery and, SPECT, 155
post-stress myocardial dysfunction, dual-isotope SPECT, 355(ab)
quantitative gated PET, small animals, 1655, 1662
quantitative gated SPECT, comparison, 724(ab)
RNA SPECT, depth-dependent resolution recovery, 767(ab)
small hearts, gated myocardial SPECT, 368(ab)
^{201}Tl/^{99m}Tc teboroxime dual isotope protocol, post-stress ^{99m}Tc sestamibi comparison, 279(ab)
Legg-Calvé-Perthes disease, bone scanning and pinhole imaging of hip, prognostic value, 1761
Leukemia
acute myelogenous, estimating radiographic doses in, 51N(4)
chronic myeloid, Gleevec approved for first-line treatment, 24N(3)
lymphoblastic, radiolabeled Anti-CD19 monoclonal antibodies, 1105
radioimmunotherapy, preselection using FDG PET, 1473(ab)
Leukocytes
^{18}F and ^{111}In-labeled, rat model of focal infection study, 1109(ab)
^{18}F FDG-labeled, efficiency and cell viability, 147(ab)
high RBC contamination of, images in infants, 480(ab)
labeled with monoclonal antibody, detection of osteomyelitis in diabetic foot syndrome, 1218(ab)
RBC lysis and color dilution processes, biodistribution of ^{99m}Tc exametazime, 1138(ab)
^{99m}Tc HMPAO-labeled, hip prosthesis infection, 1213(ab)
Leukotriene B_4 antagonist, bivalent, for imaging of infectious foci, 1087
Lewy body disease, dementia with, acetylcholinesterase cerebral activity in, 837(ab)
Lhermitte's sign, chronic radiation-induced, PET in, 44N(12)
Lipid-soluble complexes, in targeted radionuclide tumor therapy, 1293
Lipids, effects on intrinsic washout of ^{99m}Tc N-NOET, myocardial perfusion imaging, 1092
Lipiodol, solution of ^{186}Re-HDD, transhepatic arterial embolization, liver cancer model, 2033
Lipoprotein, acetylated low-density, detection of atherosclerosis, 770
Liposomes
delivery of ^{99m}Tc bovine serum albumin, Peyer's patch, 1139(ab)
labeled with ^{86}Re, for radionuclide therapy, 1097(ab)
labeling with ^{186}Re, stability, imaging, and biodistribution, rats, 1992
^{99m}Tc HMPAO-labeled, PEG effects on biodistribution of, 323(ab)
Liver
echinococcus multiocularis lesions, FDG PET, 138(ab)
galactose receptor, imaging with ^{99m}Tc LSA, 1117(ab)
glucose uptake, insulin effects, FDG PET study, 682
metastases, from gastroenteropancreatic tumors, somatostatin receptor scintigraphy use in, 359
^{13}N ammonia PET, intact pig, 1206(ab)
regional flow, intravascular PET tracers, 1862
Liver cancer
^{188}Re lipiodol treatment, 573(ab)
recurrence, PET and, 42N(1)
residual or recurrent, FDG PET evaluation, 1452(ab)
^{99m}Tc sulfur colloid uptake, focal nodular hyperplasia on CT/MR, 135(ab)
transhepatic arterial embolization, rabbit model, 2033
^{90}Y microspheres in, 34N(5)
^{90}Y oxine-ethiodol in, 48N(7)
Liver cirrhosis, cerebral blood flow in, branched-chain amino acid solution effects, 829(ab)
Liver function
regional, asialoglycoprotein receptor imaging, 475
^{99m}Tc GSA dynamic SPECT, attenuation correction and, hepatectomy, 924(ab)
^{99m}Tc mebrofenin, preoperative assessment, 136(ab)
Liver metastases, radioimmunotargetting with pancarcinoma anti-tissue polypeptide, 1480(ab)
Loevinger-Berman Award, 2003, Poston, John W., Sr., Ph.D., 40N(8)
Logan plot, ^{123}I PE21 SPECT and, dopamine transporters in Parkinson's disease, 663
Low-back pain, lumbosacral transitional vertebra and, skeletal scintigraphy, young patients, 909
Lung
alpha dose of depleted uranium, Gulf War Veterans, 1168(ab)
^{67}Ga citrate scintigraphy, idiopathic pulmonary fibrosis and ARDS, 1273(ab)
microvascular permeability changes, during high-volume ventilation, rats, 1274(ab)
nodules, FDG PET dual-time point imaging, 566(ab), 589(ab)
pulmonary embolism
V/Q scintigraphy and helical CT comparison, 592(ab)
who diagnoses in the 21st Century, 1263(ab)
quantification of ventilation/perfusion ratios with PET, 1982
scan interpretation, observer variability and different criteria effects, 739
vascular targeted imaging with antibodies, 1114(ab)
Lung cancer
bone lesions in, detection with ^{99m}Tc depreotide scintigraphy, 1372(ab)
bronchogenic, flip-flop on total body angiogram, 1444(ab)
correlation histology and FDG PET, after neoadjuvant chemotherapy, 400(ab)
CT motion quantitation, impact on measured SUVs, 527(ab)
delayed additional FDG PET imaging, lymph node metastasis, 564(ab)
differentiating from tuberculosis, dual time point FDG PET for, 439(ab)
differentiation from tuberculosis, ^{99m}Tc MIBI and ^{201}Tl SPECT, 437(ab)
FDG PET target to background ratios, ROCs of, 963(ab)
FDG PET use in management of, 406(ab)
FDG PET/CT use in, 436(ab)
FDG vs ^{18}F FLT, in image proliferation, 1426, 1432
gated PET and CT data, combined PET/CT unit, 968(ab)
imaging, 33N(3)
lesion characterization, positron volume imaging, 590(ab)
non-small cell
coincidence camera and FDG for staging of, 336
false staging of mediastinal nodes by FDG PET, 1371(ab)
FDG and ^{11}C choline uptake in, 264(ab)
FDG PET, neural network for improvement, 1918
FDG PET after neoadjuvant radiochemotherapy, 563(ab)
FDG PET for diagnosis of adrenal metastasis, 1389(ab)
FDG PET in, 1401(ab)
FDG PET predicts treatment response, 52N(6)
hilar and mediastinal lymph nodes, ^{99m}Tc DEP, 440(ab)
lymph node staging, delayed regional FDG PET in, 401(ab)
mediastinal lymph node involvement, SPECT and CT, 1219
mediastinal staging, coincidence imaging, 1022(ab)
mediastinal staging by FDG PET, 313(ab)
PET metabolic activity measurements, 565(ab)
preoperative endoscopic ^{99m}Tc in, 44N(7)
preoperative M-staging, FDG PET in, 1368(ab)
radioguided biopsy of sentinel node, 562(ab)
respiratory correlated acquisition on PET/CT, 124(ab)
staging of mediastinum in, neural network use in, 26(ab)
staging with FDG PET, 561(ab)
tumor hypoxia in, ^{18}F FMISO PET, 435(ab)
whole-body FDG PET in, 1426(ab)
percutaneous radiofrequency ablation treatment, FDG PET for viability, 1381(ab)
PET for prebiopsy guidance, in percutaneous biopsy, 591(ab)
PET imaging, respiratory motion artifacts in, 1645
proven, FDG PET and ^{99m}Tc DEP comparison, 441(ab)
radiopeptide therapy using P2045, 447(ab)

response to therapy, FDG PET evaluation, 224
screening, spiral CT and PET in, 52N(11)
small cell, whole-body FDG PET in management of, 1911
solitary pulmonary nodule
FDG PET, 914(ab)
FDG PET/CT in, 1269(ab)
FLT and FDG PET comparison, 402(ab)
specificity of ^{99m}Tc depreotide, sequential SPECT, 1361(ab)
staging
FDG PET accuracy, 1405(ab)
image fusion with PET/CT, 403(ab)
PET and PET/CT, 1406(ab)
whole-body vs PET for, 1396(ab)
suspected recurrent and metastatic, coincidence imaging with FDG in, T0493(ab)
^{99m}Tc depreotide labeled somatostatin receptor tracer, 1268(ab)
thoracic lesions, FDG accumulation with PET, 540
^{201}Tl SPECT and CT fusion, image coregistration, 1339(ab)
X-ray attenuation correction and SPECT/CT, image fusion, 242(ab)
Lung clearance, after transthoracic injection, gamma and digital radiographic imaging, 1277(ab)
Lung disease
obstructive, dynamic ^{133}Xe SPECT-based 3D volume-rendering pulmonary function maps, 1270(ab)
pulmonary perfusion in, ^{99m}Tc MAA gated SPECT for, 593(ab)
Lung injury, ventilation-induced, pulmonary capillary permeability changes, rat, 1275(ab)
Lung masses, single solid, FDG PET diagnostic accuracy, 405(ab)
Lung perfusion scan, SPECT/CT, change in interpretation and confidence, 1260(ab)
Lung reduction surgery, short and long-term outcome, lung scintigraphy role in, 1272(ab)
Lung scintigraphy
acute pulmonary thromboembolism and, 1266(ab)
volume reduction surgery, short and long-term outcome, 1272(ab)
Luteinizing hormone releasing hormone, receptors for, peptide targeting of, breast cancer, 1072(ab)
Lymph nodes
gynecologic malignancies, sentinel node navigation surgery, 1446(ab)
mediastinal, involvement in lung cancer, SPECT and CT, 1219
melanoma metastases in, PET detection, 486(le)
metastases
lung cancer, delayed additional FDG PET imaging, 564(ab)
melanoma, ^{99m}Tc MIBI scintigraphy, 1561
papillary thyroid cancer
diagnosed at post-ablative scintigraphy, 1177(ab)
treatment, 1188(ab)
paraortic metastases, cervical cancer, FDG PET in, 1775
pelvic, ^{11}C choline PET staging of prostate cancer, 331
small field of view gamma camera for, 454(ab)
uptake of supraclavicular area fat, FDG PET/CT, 170
Lymphadenopathy, hilar, observed in FDG PET, 1350(ab)
Lymphatic drainage, skin, melanoma patients, 570, 1871(le)
Lymphatic system, radionuclide lymphoscintigraphy, 43
Lymphedema
lymphoscintigraphy in evaluation, 43
radionuclide lymphogaphy, correlation with MRI, 186(ab)
Lymphocytes, cycotoxic, monitoring with PET non-invasive in vivo imaging, 85(ab)
Lymphoma
aggressive, treated with chemotherapy and stem cell transplant, FDG PET for assessment, 613(ab)
bone marrow involvement in, FDG PET imaging and needle biopsy for detection, 1486(ab)
CD20-expressing xenografts, pretargeted radioimmunotherapy, 437
chemotherapy, organ distribution of FDG, 1488(ab)
cutaneous T-cell, FDG PET/CT, 273(ab)
FDG PET
after chemotherapy, 1492(ab)
comparison of ^{67}Ga, 1489(ab)
posttreatment evaluation, 1225
identification, antisense oligonucleotides, 1317(ab)
liver, FDG PET vs CT lesion detection, 268(ab)
low-grade, ^{99m}Tc depreotide staging, 1496(ab)
malignant recurrent, FDG PET for assessment, 1490(ab)
need for planar imaging, ^{67}G whole-body SPECT and, 1494(ab)
non-Hodgkin's (*see* Non-Hodgkin's lymphoma)
pediatric, whole-body FDG PET, 596(ab), 1237(ab)
relapsed follicular, ^{131}I anti-CD20 in, 47N(7)
response to therapy, FDG PET evaluation, 224
restaging, whole-body FDG PET/CT, 270(ab)
staging, FDG PET, 1491(ab)
staging, FDG PET vs CT, 1072
tumor dosimetry, ^{131}I tositumomab therapy, 457
Lymphoscintigraphy
breast, ultrafiltered sulfur colloid use in, 408(ab)
breast cancer, nonvisualization of axillary sentinel node during, 1232
correlation with MRI, chronic limb edema, 186(ab)
high specific activity of ^{99m}Tc sulfur colloid, 327(ab)
methods to outline the patient, 992(le)
sentinel node biopsy in melanoma, prognosis value, 548(ab)
sentinel node biopsy and, gastric cancer, 1360(ab)
sentinel node detection, periareolar injection technique, 409(ab)
sentinel node mapping, hybrid SPECT/CT system, 1413
visualization rates during, internal mammary sentinel nodes, 1387

M

Major histocompatibility complex class II, single cell kill, radiolabeled antibodies, 632
Malignant tissue, radiolabeled, detectors for beta imaging, 1009(ab)
Mammotomography
with dedicated detectors, 526(ab)
pinhole incomplete circular orbit, 583, 594
Maternal-fetal exchange, combined PET and MRI study, 1522
Mathematical modeling
artificial lesions, generation from acquired images, 984(ab)
D3 receptor occupancy, PET, 922(ab)
myocardial glucose metabolism, ^{11}C glucose PET, 367(ab)
Medical ethics, nuclear medicine and radiology practice, 1818
Medical imaging, market remains strong, 46N(4)
Medical lawsuits, caps on damages, 38N(9)
Medicare
congressional action on, 24N(3)
cuts published on eve of new year, 10N(2)
Melanoma
^{131}I MIBG use, thyroid protection in, 40N(9)
lymphatic drainage from skin in, 570, 1871(le)
malignant
FDG PET in, 550(ab)
FDG role in management of, 1451(ab)
metastatic
diagnostic probe for, 320(ab)
FDG PET vs CT, 1367(ab)
lymph nodes, PET detection, 486(le)
role of FDG PET in management, 549(ab)
staging with ^{18}F FLT PET, 547(ab), 1927
regional lymph node staging in, ^{99m}Tc MIBI scintigraphy, 1561
sentinel node biopsy in, prognosis value, 548(ab)
sentinel node lymphoscintigraphy in, prognostic implications, 558(ab)
thin primary, lymphatic mapping and SLN in, 56N(6)
xenografted SCID mouse model, ^{188}Re (Arg^{11})CCMSH efficacy in, 581(ab)
Membrane transport, ^{131}I IMT, L-type amino acid transporters, 244
Meningioma
^{68}Ga DOTATOC PET, kinetic analysis, 880(ab)
therapy planning and follow-up, 869(ab)
Mesothelioma
malignant pleural
evaluation with FDG PET, 1422(ab)
PET staging of, 44N(9)
pleural, FDG PET imaging in diagnosis, 1390(ab)
Metabolism-perfusion mismatch, myocardial showing, 33, 40
Metaiodobenzylguanidine (MIBG), cardiac sympathetic activity, in CAD, 760(ab)
Metastatic cancers
FDG PET in evaluation of, 1369(ab)
primary tumor with extracervical metastases, FDG PET search for, 554(ab)
3,4-Methylenedioxymethamphetamine (MDMA), *see* Ecstasy
Metoprolol, comparison with carvedilol, dilated cardiomyopathy, 1604
Microdosimetry, using histologic images, α-particle emitting targeted radiotherapeutics, 792
Micrometastases, single cell kill, radiolabeled antibodies, 632
MicroPET
^{11}C raclopride binding, rat brain, 815
prostate cancer and, 56N(6)
quantitation, natural LSO radioactivity, 451(ab)
radiotracer binding, dopaminergic system, rodent, 225(ab)
small animal, left ventricular function, 1655, 1662
tumor imaging, FDG and FMISO, animal-specific positioning molds, 378(ab)
^{86}Y trastuzumab, ovarian cancer model, 1148
MicroPET I
3D image reconstruction, expectation maximization algorithm for, 528(ab)
autoimmune uveitis, secondary lymphoid system, 1122(ab)
^{18}F FLT and ^{18}F FDG, for targeted tumor therapy, 260(ab)
new hypoxia PET tracer, ^{124}I IAZGP, radiation dosimetry of, 1153(ab)
second generation small animal system, 519(ab)
small parts imaging, humans, 1012(ab)
treatment with CDK2 inhibitor, nude mouse tumor model, 1313(ab)
Micro-SPECT, 3D image, multi-pinhole/CCD-coupled CsI(Tl) crystal gamma camera, 523(ab)
Microspheres, ^{90}Y radioembolization of, hepatoma, 574(ab)
Microvascular model, intravascular tracers analyzed by, PET, 22(ab)
MIRD schema, renal dosimetry, 1113
Mitochondria, membrane potential difference, radiopharmaceuticals for cancer diagnosis, 1088(ab)
Molecular nuclear medicine
gene therapy, universal HSV-1 amplicon vectors for, 107(ab)
ligand binding with new DNA, new radiopharmaceutical design, 1083(ab)
optical image of tumor burden, 582(ab)
optical imaging, ^{14}C D-luciferin for, 1135(ab)
personalized, 45N(4)
PET, imaging of signal transduction pathways, 1326(ab)
plaque imaging, using radiolabeled MMP inhibitor, in CAD, 709(ab)
sodium iodide symporter, endogenous p53 gene expression using, 88(ab)
sodium iodide symporter, gene transfer and expression, 1322(ab)
survival of cardiac cell transplant, living rats, 337(ab)
targeting, radionuclide therapy, 1945
^{99m}Tc annexin A5, intracardiac masses, 509(ab)
Monoamine oxidase B, imaging in peripheral organs, smokers, 12N(10)
Monoclonal antibodies
anti-PMSA antibody, imaging of tumor vascular endothelium, 1385(ab)
conference in Cyprus, 28N(3)
murine, infection imaging, 1221(ab)

radiolabeled, specific to prostate-specific membrane antigen, 610
radiolabeled Anti-CD19, leukemia-engrafted SCID mice, 1105
therapy, ^{131}I HUA33, advanced colorectal cancer, 100(ab)
^{90}Y-labeled, PET, xenograft-bearing nude mice, 1663
Monte Carlo simulation
CsI(Tl) gamma camera for small animal imaging, 1032(ab)
emission and attenuation maps, realistic patient data, 1048(ab)
follicular level in thyroid cancer, 492(ab)
^{111}In/^{88}Y scintillation camera imaging, 1162(ab)
MIRD S values, 1160(ab)
Motion correction, event-based, PET study, 992(ab)
Movement disorders
dopamine D2 receptors, evaluation with ^{123}I IBZM SPECT, 848(ab)
dopamine transporter imaging, Parkinson's patients, 388(ab)
dopamine transporters in, DaTSCAN, 392(ab)
^{123}I CIT SPECT, vs clinical examination, Parkinson's syndrome, 859(ab)
multiple system atrophy, dopamine transporter uptake in, 853(ab)
Parkinson's and vascular Parkinsonism, ^{123}I IBZM/^{99m}Tc TRODAT-1 simultaneous dual-isotope SPECT, 860(ab)
progressive supranuclear palsy, dopamine transporter uptake in, 852(ab)
Moyamoya disease, pediatric, after bypass surgery, brain SPECT, 535(ab)
MRI
cardiac adrenergic activity, in hypertrophic cardiomyopathy, 487
contrast-enhanced, comparison with PET/CT in tumor staging, 1354(ab)
correction of spill-over and partial volume effect, PET, 370(ab)
gamma probe compatible with intraoperative use, 1352(ab)
gated SPECT perfusion comparison, left ventricular mass and ejection fraction, 727(ab)
hyperpolarized helium-3 imaging, regional ventilation/perfusion, 920(ab)
^{123}I MIBG and, diagnosis of pediatric neuroblastoma, 597(ab)
MAG3 scan, determination of renal size, 1282(ab)
partial volume correction based on, PET, 932(ab)
perfusion, vs SPECT, acute lymphoblastic leukemia, 33N(3)
PET combined study, maternal-fetal exchange, 1522
primary progressive aphasia, bilateral temporal lobe involvement in, 1013
^{99m}Tc MIBI scintimammography or, tumor localization, 1394(ab)
techniques for FDG imaging, 930(ab)
tumor blood flow, musculoskeletal tumors, 1454(ab)
validation, gated FDG SPECT estimation of cardiac function, 274(ab)
Multidrug resistance
doxorubicin, ^{99m}Tc EC as marker of, 1084(ab)
FDG PET correlation, lung cancer, 1376(ab)
p-glycoprotein expression, ^{99m}Tc MIBI as predictor of therapy response and, osteosarcoma, 1394
p-glycoprotein inhibitor PSC833, high-resolution image recognition of, 1307(ab)
Pgp modulation, ^{18}F paclitaxel studies, 1330
protein pump associated with, lung cancer, ^{99m}Tc MIBI SPECT use in, 1442(ab)
Multilinear regression analysis, receptor occupancy, with PET, 902(ab)
Multimodality imaging
automated 3-dimensional registration, FDG whole-body PET with CT, 1156
CT/PET
CT truncation compensation in, 970(ab)
CT-based attenuation correction in, 933(ab)
limited breath-hold technique in, 986(ab)
misregistration effects on tumor detection, 194(ab)
uptake of supraclavicular area fat, 170
framework for education, 956(ab)
gamma and digital radiographic, lung after transthoracic injection, 1277(ab)
hybrid PET/CT
market outlook, 28N(7)
progress, rewards, and challenges, 10N(7)
hybrid SPECT/CT
added clinical value, 1040(ab)
attenuation correction validation of, 1039(ab)
hybrid SPECT/XCT, computed mammotomography, 1029(ab)
LSO-PET/CT, feasibility, 1344(ab)
multitracer PET, DW/PW MRI and, diagnosis of stroke, 533(ab)
PET/CT
attenuation correction in, 991(ab)
cancer imaging, 1200
comparison with PET, endometrial cancer, 423(ab)
comparison with whole-body MRI, tumor staging, 1354(ab)
correction for oral contrast artifacts, 1940
FDG
brown fat evaluation, 1267
management of colorectal cancer, 81(ab)
pituitary adenomas and metastases, 471(ab)
vascular uptake, arterial wall calcifications, 183(ab)
visualization of thyroid during, 1178(ab)
FDG PET comparison and, colorectal cancer, 1797, 1804
integrating into traditional PACS environment, 927(ab)
lesion volume measurement, 1025(ab)
lymphoma, detection of occult extra nodal disease, 271(ab)
metal artifacts on, 1017(ab)
mislocalization of lesions, 240
oral contrast in, 412
partial volume compensation for, 126(ab)
recurrent fallopian tube cancer, 30N(2)
regionally-dependent count rate performance, 364(ab)
respiratory correlated acquisition on, lung cancer, 124(ab)
small lesion volumes, activity concentration in, 950(ab)
SUV error by oral CT contrast agent, 732
whole-body scanner, 1033(ab)
reporter gene expression, triple fusion vector, 96(ab)
SPECT/CT, attenuation correction, phantom validation, 958(ab)
SPECT/PET/CT, quality control, 358(ab)
Multiple myeloma
nuclear medicine role in, 1369(le)
radioiosotope therapy, 569(ab)
staging, imaging comparison, 1483(ab)
Multiple sclerosis
microglial activation with PET, atrophy with MRI, 63(ab)
PET in, 46N(7)
Mu-opioid receptors, ventral striatum and amygdalae, alcoholic brain, PET imaging, 212(ab)
Muscarinic receptors
myocardial, Brugada syndrome, 749(ab)
myocardial density, diabetic minipigs, ^{11}C MQNB PET, 708(ab)
Muscle, FDG uptake, false positives for PET and, 1789
Musculoskeletal lesions, FDG PET, 36N(5)
Musculoskeletal sarcoma, residual disease, FDG PET in evaluation, 241(ab)
Myeloma, active, ^{99m}Tc sestamibi for demonstration of, 1484(ab)
Myelotoxicity, ^{90}Y DOTA-J591, phase I dose escalation trial with, 1167(ab)
Myocardial blood flow
adenosine triphosphate and dobutamine, caffeine intake effects, 738(ab)
bicycle exercise stress in PET, adenosine stress vs, 146
cold pressor/adenosine effect, ^{15}O water PET, 957(ab)
coronary stenosis severity, risk factors and, in CAD, 294(ab)
metabolism perfusion mismatch, ^{99m}Tc tetrofosmin and FDG, 33, 40
^{13}N ammonia measurements, small animal PET scanner, anesthesia effects, 285(ab)
^{13}N ammonia PET, data analysis, 945(ab)
nitroglycerin effects, rest-redistribution thallium SPECT, 745, 752, 1872(le)
perfusion gradient, response to cold pressor test and adenosine, 293(ab)
PET measured responses, quantitative angiography, 289(ab)
PET measurement of, severe coronary artery calcification, 351(ab)
tracer adenosine as marker, 641
Myocardial contractile reserve, dobutamine-induced, with ischemic cardiomyopathy, 127
Myocardial flow reserve
attenuated response to atorvastatin, familial hypercholesterolemia patients, 171(ab)
evaluated by ^{15}O water PET, 291(ab)
^{13}N ammonia measurements, small animal PET scanner, anesthesia effects, 285(ab)
Myocardial infarction
acute
cardioprotective effect of nicorandil, SPECT assessment of, 173(ab)
dobutamine and rest gated SPECT in, 1023
factors of LV functional recovery after, 753(ab)
factors of LV remodeling after, 740(ab)
left ventricular mass, 175(ab)
mobilized stem cell therapy, baboons, 711(ab)
progenitor cell therapy, 174(ab)
vasodilator stress during, heart rate response to, 513(ab)
experimental, mice microPET polar maps, 283(ab)
FDG PET, infarct size and location, rat heart, 715(ab)
^{111}In-oxine-labeled progenitor cells, rat model, 6(ab)
mesenchymal stem cell imaging in, 710(ab)
myocardial perfusion after, quantitative SPECT, 899(ab)
nitroglycerin effects on blood flow, ^{201}Tl SPECT, 745, 752, 1872(le)
non-transmural and transmural, utility of myocardial perfusion SPECT, 18(ab)
perfusion and regional function, gated SPECT, 764(ab)
reperfused acute, rest gates SPECT in, 761(ab)
SPECT and Echo compared after, 30N(2)
^{99m}Tc sestamibi gated SPECT, perfusional and functional changes, 746(ab)
Myocardial ischemia
acute, abnormal SPECT after, 49N(4)
dobutamine stress SPECT and, 49N(4)
ischemic memory, ^{99m}Tc annexin detection of, 338(ab)
left ventricular distensibility relations, nonobstructive hypertrophic cardiomyopathy, 1717
long-term ACAT inhibitor, beneficial effect on myocardial flow reserve, 170(ab)
reperfusion injury, ischemic preconditioning in hearts, 705(ab)
repetitive supply-demand, glucose uptake, 85
Myocardial oxygen consumption, in failing heart, PET with ^{11}c acetate, 516(ab)
Myocardial perfusion imaging, *see also* Myocardial SPECT
assessment of renal transplant candidates, 32N(3)
attenuation correction in diagnostic accuracy of, 357(ab)
combined prone and supine acquisitions, prognostic implications, 1633, 1641
comparison with coronary calcium and angiography, multidetector CT, 352(ab)
2D and 3D PET comparison, 1350
defects, 54N(6)
dual-isotope gated, post-stress myocardial dysfunction evaluation, 355(ab)
in emergent cardiac care, 27N(2)
endothelial dysfunction, diabetes, 19
expert system for localizing single vessel, CAD, 731(ab)
^{18}F FDHR as a deposited flow tracer, comparison to ^{201}Tl, 282(ab)
fuzzy logic-based automatic quantitative analysis in, 1625
gated SPECT
blinded interpretation of Myoview, 754(ab)
collimator characteristics and, 1043(ab)
quantitative reproducibility, 730(ab)

in left bundle branch block, 44N(10)
left ventricular function, in uncomplicated acute myocardial infarction, 1023
nitroglycerin-augmented thallium reinjection, blood flow after, 17(ab)
^{82}Rb, prediction of death, 3(ab)
resting ECG and, use asymptomatic elderly CAD, 346(ab)
rest-stress, ischemia from, 743(ab)
^{82}Ru, filtered backprojection vs iterative reconstruction, 972(ab)
^{82}Ru PET, coronary flow reserve quantification, 290(ab)
sarcoidosis, cardiac involvement in, 722(ab)
septal defect, left bundle branch block, left ventricular dysfunction and, 726(ab)
stress, prediction of cardiac death and, 43N(12)
stress SPECT, with ECG gating, preoperative risk stratification, 385
^{99m}Tc, attenuation, scatter, and resolution compensation, 1725
^{99m}Tc nitride complexes, 806
^{99m}Tc N-NOET, determinants of intrinsic washout, 1092
^{99m}Tc N-NOET uptake, verapamil effects, canine myocardium, 981
^{99m}Tc tetrofosmin
hypertension, 10(ab)
myocardial revascularization by, 11(ab)
^{99m}Tc tetrofosmin, prognostic value, 134
^{99m}Tc tetrofosmin and FDG, metabolism perfusion mismatch, 33, 40
^{99m}Tc tetrofosmin SPECT, ECG changes in chronic respiratory disease patients, 325
^{99m}Tc tracers, transient ischemic dilatation, 744(ab)
^{99m}Tc-carbonyl-TBI, 1123(ab)
tissue attenuation effects, attenuation correction vs prone imaging, 748(ab)
^{201}Tl gated, CAD in individual coronary arteries, 762(ab)
uptake
calcium antagonist effects, 505(ab)
increased smoking effects, 506(ab)
Myocardial perfusion reserve, SPECT, diabetes patients, 348(ab)
Myocardial PET, ECG-gated ^{13}N ammonia, left ventricular function after myocardial infarction, 275(ab)
Myocardial SPECT, *see also* Myocardial perfusion imaging
180 and 360 acquisition for, channelized hoteling observer, 461(ab)
3D techniques for, defect extent quantification, 456(ab)
apparent count distribution, angular rotation and type of orbit, 712(ab)
attenuation correction
artifactual apical defect in, 457(ab)
computer simulation method for, 988(ab)
automatic polar plot analysis for, normal patients, 904(ab)
combined prone and supine acquisitions, prognostic implications, 1633, 1641
compensation methods, defect detection, 366(ab)
data acquisition, cone-beam and fan-beam collimators, 204(ab)
dynamic teboroxime, two-compartment model, 369(ab)
ECG-gated
ejection fraction validation of pinhole SPECT, 511(ab)
factors of LV remodeling after acute MI, 740(ab)
myocardial perfusion and wall-thickening, 721(ab)
value of automatic sine mode, ischemic heart disease, 277(ab)
exercise ^{99m}Tc MIBI, angiographic CAD, 9(ab)
false-positive rotational, post-stress changes in cardiac volume, 518(ab)
FDG, contractile reserve in ischemic cardiomyopathy, 127
FDG gated, left ventricular ejection fraction, 189(ab)
findings in patients with myocardial stunning, 758(ab)
fuzzy logic-based automatic quantitative analysis in, 1625
gated
acute infarction patients, 746(ab)
blinded interpretation of Myoview perfusion imaging, 754(ab)
cardiac functional parameters, gender differences, 755(ab)
comparison with radionuclide ventriculography, 742(ab)
dynamic beating phantom, 716(ab)
dyskinesia, 763(ab)
ECG with, aortic and mitral insufficiency, 751(ab)
effect on perfusion interpretation, 735(ab)
effects of temporal sampling, 276(ab)
left ventricular dysfunction, 741(ab)
left ventricular ejection fraction and volumes, 280(ab)
left ventricular ejection fraction evaluation, 176(ab)
left ventricular ejection fraction measurements, 344(ab)
left ventricular functional parameters, in small hearts, 368(ab)
left ventricular mass, during and after acute MI, 175(ab)
left ventricular mass and ejection fraction, 727(ab)
left ventricular volume measurement, 921(ab)
low-risk chest pain patients in ER, 353(ab)
measurement of cardiac effects of anesthetics, rats, 286(ab)
non-transmural and transmural myocardial infarction, 18(ab)
normal limits of thickening wall thickening, 278(ab)
OSEM and depth-dependent resolution recovery in, 155
oxygen-enriched breathing effects, 514(ab)
perfusion and regional function, myocardial salvage, 764(ab)
prediction of outcomes after CABG, 12(ab)
respiratory motion correction of, 1038(ab)
right ventricular function, coronary artery disease, 177(ab)
Shine noise reduction procedure, 729(ab)
simultaneous reconstruction and 3D motion estimation, 27(ab)
surgical implantation of bone marrow cells, 720(ab)
viability assessment with, 16(ab)
without mechanical rotation, 205(ab)
gated rest ^{201}Tl/adenosine stress ^{99m}Tc teboroxime, quantitation of, 507(ab)
^{123}I and ^{99m}Tc tetrofosmin, scatter and cross-talk correction for, 745(ab)
interindividual variability in, attenuation artifacts, 723(ab)
intermediate term restenosis, after coronary artery bypass graft, 737(ab)
motion artifacts in, 484(le)
multi-head system, data acquisition geometries and strategies, 997(ab)
perfusion and wall-thickening, serial imaging of, 169(ab)
perfusion-metabolism mismatch, ^{99m}Tc MIBI and FDG, 365(ab)
predictive value, after bypass surgery, ischemic left ventricular dysfunction patients, 1735
quantitative
after myocardial infarction, 899(ab)
expert system for localizing single vessel CAD, 731(ab)
quantitative attenuation correction, heavy patients, CAD assessment, 356(ab)
sestamibi, attenuation correction effects, CAD patients, 739(ab)
suspected coronary artery disease, diabetic patients, 718(ab)
^{99m}Tc, attenuation, scatter, and resolution compensation, 1725
^{99m}Tc MIBI exercise, angioplasty with or without stenting, 13(ab)
vasodilator stress, during myocardial infarction, 513(ab)
Myocardial stunning, glucose uptake, dobutamine effects, 85
Myocardial viability
after acipimox, FDG and ^{99m}Tc tetrofosmin SPECT, 140
in CAD, cardiac sympathetic activity and, 760(ab)
in chronic myocardial hibernation, myocardial SPECT, 287(ab)
dobutamine-induced contractile reserve, with ischemic cardiomyopathy, 127
ECG-gated SPECT assessment, myocardial perfusion and wall-thickening in, 721(ab)
FDG SPECT with acipimox, diabetes effects on, 877
quantitative gated SPECT, optimization of, 16(ab)
rest and stress ^{82}Ru washout for determination of, 19(ab)
rule-based assessment, quantitative imaging, 21(ab)
^{99m}Tc MIBI SPECT and FDG PET, CAD and left ventricular aneurysm patients, 15(ab)
Myocardial wall
normal limits of thickening, gated perfusion studies, 278(ab)
thickening, ventricular pacing and, 766(ab)
Myocarditis, dual isotope SPECT to assess disease activity, rats, 4(ab)
Myocardium
fatty acid metabolism
BMIPP uptake in occlusion-reperfusion rat model, 713(ab)
during dobutamine, exercise training effects in the elderly, 345(ab)
hibernating, echocardiography and scintigraphy in, 52N(4)
response to dobutamine, age-related changes, 42N(10)

N

Nanotechnology, research facility at Oak Ridge, 36N(9)
Nasopharyngeal cancer
FDG PET
and MRI in, 41N(9)
treatment response and follow up, 1439(ab)
National Cancer Institute (NCI), medical x-rays as carcinogens, 9N(2)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
advisory council, 42N(11)
future research, 28N(5)
IEEE and, symposium on biomedical imaging, 40N(9)
K-level research training, 48N(6)
Maynard named to Advisory Council, 18N(2)
McNeil named to Advisory Council, 20N(6)
new structure announced, 43N(7)
research requests, 34N(1)
a year of organization, 31N(1)
National Institute on Aging (NIA), request for proposals on AD initiative, 41N(12)
National Institute on Drug Abuse (NIDA), Nora Volkow named new director, 11N(3)
National Institutes of Health (NIH)
Clinical Center, 50th anniversary, 52N(8)
Decision-Making Committee, 36N(9)
NIHSeniorHealth.gov, 36N(12)
roadmap to future of research, 34N(12)
Neonates, ureteropelvic junction obstruction, ^{99m}Tc MAG3 renography, 725
Nephrectomy, choice of side in living donors, renal scans in, 45N(10)
Nephrolithiasis, diuretic renography, 466(ab)
Neural networks
nodal staging accuracy, FDG PET, non-small cell lung cancer, 1918
staging of mediastinum, non-small cell lung cancer, 26(ab)
Neuroblastoma, radiation therapy of, children, 1243(ab)
Neuroendocrine tumors
disseminated, high-activity ^{111}In pentetreotide therapy in, 1
^{18}F DOPA for visualization, 234(ab)
functional volume assessment of, SPECT, 1474(ab)
^{123}I MIBG accumulation, nape of neck, children, 1421
image modality effects on therapy, 1362(ab)
^{111}In D-Glu1-minigastrin in diagnosis, comparison to ^{111}In pentetreotide, 238(ab)
^{177}Lu octreotate targeted therapy, 442(ab)
metastatic, ^{90}Y lanreotide treatment of all sites, 1465(ab)
octreoscan, detecting somatostatin receptor-rich malignancy, 1421(ab)

paragangliomas of head and neck, somatostatin receptor imaging, 1767
phase-1 study, ^{90}Y octreotide therapy, 443(ab)
radioligand therapy of, ^{111}In DTPA-D-Phe-octreotide, 446(ab)
targeted radiotherapy, ^{90}Y SMT487, 1556
^{86}Y DOTAC vs ^{111}In DTPA octreotide, pretherapeutic dosimetry, 493(ab)
^{90}Y lanreotide treatment, intrahepatic artery infusions, 445(ab)

Neuroimaging
anorexia nervosa, cerebral metabolic abnormalities in, 886(ab)
^{11}C FMZ PET, traumatic brain injury patients, 385(ab)
canine PET and MR, registration of, 952(ab)
FDG PET
long-term outcome after traumatic brain injury, 384(ab)
seizure focus localization, 57(ab)
ictal cerebral blood flow patterns, unilateral temporal lobe epilepsy, 60(ab)
multiple sclerosis, interrelationship and clinical correlates, 63(ab)
naltrexone treatment, alcohol dependence, 211(ab)
neuro-insert in 3D PET, 1021(ab)
speech and language mapping, 43(ab)
traumatic brain injury, loss of neuronal integrity, 884(ab)
visual attention in unilateral spatial neglect, after stroke, 862(ab)

Neuroleptic treatment, dopamine D2 receptor occupancy, PET measurement, 114(ab)

Neuronal imaging, in cardiomyopathies, β-adrenergic receptors desensitization, 1459, 1467

Neuropediatrics, Rett disorder, acetylcholine receptors in brain SPECT, 47(ab)

Neuroplasticity, PET evidence of, adult hearing disorders, 1435, 1440

Neuropsychological examination, SPECT use in, primary progressive aphasia, 1013

Neurotensin, scintigraphy, ductal pancreatic adenocarcinoma patients, 1649

Neurotransmitters, cannabinoid receptors, PET studies, 1052(ab)

Newsline History Corner, Hal Anger: Nuclear medicine's quiet genius, 26N(11)

Newsline letters to the editor, 27N(12), 37N(5), 46N(6)

Newsline Public Affairs Update, 20N(3), 22N(5), 32N(9), 33N(12), 35N(10), 38N(11), 41N(7), 44N(4), 44N(6), 51N(8)

Newsline review, state of nuclear medicine, 2003, 11N(1)

Nicotinic receptors
dopamine release and, rodent nucleus accumbens, 229(ab)
PET and, 28N(2)

Nitrogen-13 ammonia
myocardial blood flow measurements, small animal PET scanner, anesthesia effects, 285(ab)
PET, liver in intact pig, 1206(ab)

Nitroglycerin
effects on myocardial blood flow, ^{201}Tl SPECT, 745, 752, 1872(le)
thallium rejection augmented by, redistribution of blood flow after, 17(ab)

Non-Hodgkin's lymphoma
Bexxar therapy for
with mild thrombocytopenia, 105(ab)
obese patients, 1478(ab)
responses of 5 years, 99(ab)
bone marrow infiltration, FDG PET, 1493(ab)
CD20+ B-cell, dosing methodology, 1479(ab)
evaluation with PET/CT, before stem cell transplant, 1497(ab)
FDG PET
evaluation of response to chemotherapy, 1487(ab)
Ki-67 expression and glycolytic activity, 615(ab)
FDG PET/CT, vs contrast-enhanced CT, 272(ab)
idiotypic cascade after RIT, 44N(11)
imaging and therapy, *bcl-2*-antisense peptide PNA conjugates, 1318(ab)
metabolism-based response criteria for, FDG PET, 616(ab)
nodal regression after radioimmunotherapy, impact on radiation dose, 495(ab)
nodal regression effects, radiation dose, 1322
proliferative activity in, ^{18}F FLT PET for imaging, 614(ab)
radioimmunotherapy, ^{90}Y DOTA humanized anti-CD22 IgG, 2000
radiolabeled monoclonal antibody treatment for, FDG PET for, 612(ab)
radionuclide therapy, FDG PET imaging prior to, 611(ab)
^{186}Re epratuzumab radioimmunotherapy, dosimetry of, 102(ab)
Rituximab-refractory patients with, radioimmunotherapy for, 1477(ab)
subtypes, FDG PET, varying sensitivity of, 1485(ab)
^{99m}Tc depreotide uptake, tumor uptake, 1495(ab)
^{90}Y DOTA-hLL2 radioimmunotherapy for, 77
^{90}Y ibritumomab tiuxetan radioimmunotherapy, dosimetry for, 465, 1707(le)
^{90}Y-labeled anti-CD20 monoclonal antibodies, administration guidelines, 853(le)

Norepinephrine
cardiac adrenergic activity, in hypertrophic cardiomyopathy, 487
cardiomyopathy, implications for cardiac neuroimaging, 1459, 1467
^{123}I MIBG uptake and, chronic heart failure, 1618

Norepinephrine transporter
density, ^{11}C meta-hydroxyephedrine retention, 341(ab)
MIGB uptake after transfer, rat hepatoma, 973
PET non-invasive in vivo imaging, cytotoxic T-lymphocyte monitoring, 85(ab)
as reporter gene, for gene therapy, 86(ab)

Nuclear medicine
analytical SPECT non-parallel geometries, 979(ab)
components of professional competence for physicians, ABNM Position Statement, 988
computers in, 20N(10)(br)
DOE research grants, 34N(1)
educational future of, 26N(1)
ethics in, 1818
European, History of, 24N(10)(br)
fractal analysis of images, 316(le)
instrumentation, Blumgart and Yens, 1925, 1362
interconnectivity, 14N(10)
international collaborative research initiative, 26N(3)
long-term exposure in physicians, 47N(4)
Physician Outreach Program, 25N(4)
physics in, 2002, 22N(1)
physicist support in UK, 28N(3)
radiation injury, heart and lung, 1531
radiation safety, structural shielding, 925(ab)
research, DOE grants, 36N(10)
role in multiple myeloma, 1369(le)
role in orthopedic infections, 927
role in parathyroid adenoma imaging, 1186(ab)
specialists among most influential in radiology, 37N(1)
Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine, 991(br)
UK report, 26N(5)
World Federation of Nuclear Medicine and Biology (WFNMB), 13N(5)

Nuclear Medicine Ambulatory Payment Classification (NMAPC) Task Force, HOPPS system, 10N(2)

Nuclear Medicine, SARS in Toronto, 13N(6)

Nuclear oncology, diagnosis and therapy, 1366(br)

Nuclear pharmacy
FDG, dose-dispensing system for in-house production, 1141(ab)
reduced internal binding of ^{99m}Tc tetrofosmin, two-part syringe, 1148(ab)

Nuclear reactor, research, construction in Australia, 38N(1)

Nuclear Regulatory Commission (NRC)
Advisory Committee on the Medical Uses of Isotopes, 25N(5)
annual fees rule amendment, 25N(5)
Diaz appointed as Chair, 25N(5)
recovery of radioactive sources, 43N(7)
regulation for low-radioactivity materials, 26N(5)
Wisconsin joins agreement states, 36N(9)

Nuclear telecardiology, for remote communities, 51N(11)

O

Obesity, standardization of image counts, stress perfusion tomography, 725(ab)

Obstipation, whole gut transit time, children with recurrent abdominal pain, 1249(ab)

Octreotide
derivatives with C-terminal substituent, synthesis and evaluation, 1075(ab)
evaluation as potential tracer, pancreas-specific, 1113(ab)

Otitis media, chronic, intracavitary radionuclide therapy, 559

Oncology imaging, 3D whole-body PET, for tumor detection, 276

Oral cancer, staging, collagen crosslink excretion and bone scintigraphy, 557(ab)

Oral squamous cell cancer, whole-body PET in, 44N(9)

Orbitopathy, thyroid associated, ^{99m}Tc P829 somatostatin receptor tracing, 1547

Organ preservation, head and neck cancer, imaging comparison, 198

Osteoarthritis, digital joints, efficacy of radiosynoviorthesis, 489(ab)

Osteoarticular disease, septic and sterile, radiolabeled ciprofloxacin in, 920

Osteomyelitis
mandible, bone scintigraphy and FDG PET comparison, 1224(ab)
in violated peripheral bones, detection with ^{99m}Tc MDP bone scan, 909(ab)

Osteosarcoma
FDG PET imaging, 930
prediction of response to chemotherapy, ^{99m}Tc tetrofosmin, 1437(ab)
primary, prognosis, 996(le)
^{153}Sm EDTMP, effects on cartilage, rabbit, 1510
^{99m}Tc MIBI as predictor of therapy response, 1394
^{201}Tl scan, chemotherapeutic response, 1337(ab)

Outcomes assessment, ^{82}Rb PET, prediction of death, 3(ab)

Ovarian cancer
epithelial, tissue polypeptide specific antigen and CA-125 in diagnosis, 1447(ab)
FDG PET with bladder irrigation in evaluation of, 353
^{111}In DTPA-folate as receptor-targeted diagnostic agent in, 700
overexpressing VEGF-164, PET tumor tracers in, 1059(ab)
recurrent
FDG PET and PET/CT, 422(ab)
FDG PET imaging in, 426(ab)
FDG PET in diagnosis, 425(ab)
^{99m}Tc mAb and, 40N(9)
^{86}Y trastuzumab, pharmacokinetics and biodistribution, 1148

Oxidative metabolism
cerebral, factor analysis, 906(ab)
pericontusional low-density areas, after traumatic brain injury, 885(ab)
^{188}Re carbonyl, radiolabeling morpholinos with, 326(ab)

Oxygen therapy, home, central sleep apnea and congestive heart failure patients, 515(ab)

Oxygen-15 inhalation, PET
anger attacks in depressed patients, 894(ab)
cerebral blood flow and, 934(ab)
traumatic brain injury patients, 385(ab)

Oxygen-15 water
myocardial blood flow reserve, in suspected CAD, 294(ab)
perfusion studies, angiostatin and troponin, hepatomas, 1332(ab)
PET
blood flow and metabolism changes, breast cancer, 1806, 1815
myocardial flow reserve, 750(ab)
quantifiable index of lower extremity flow, 915
stress perfusion SPECT and, CAD patients, 292(ab)
transcranial Doppler sonography and, schizophrenia, 671

Oxygen-18 water, recovered, purification of, for production of ^{18}F fluoride, 1103(ab)

P

Pancreas
octreotate as potential tracer, 1113(ab)
transplants (*see* Transplantation)
Pancreatic adenocarcinoma, ductal, neurotensin scintigraphy, 1649
Pancreatic cancer
advanced, therapeutic effect using FDG PET, 1357(ab)
cystic, FDG PET/CT, 74(ab)
ductal adenocarcinoma, peptide receptor imaging, 71(ab)
endosonography, coincidence gamma camera PET and, 73(ab)
low-dose RIT and gemcitabine in, 44N(11)
pretargeting with bispecific antibody, 575(ab)
recurrent, FDG PET, 1408(ab)
staging, usefulness of FDG PET, 1356(ab)
Paragangliomas, head and neck, somatostatin receptor imaging, 1767
Parameter coupling, multiple brain time-activity curves, modeling, 34(ab)
Parameter estimation, kinetic modeling of, 951(ab)
Parametric imaging
normal databases, cerebral perfusion imaging, 539(ab)
^{15}O water, renal blood flow studies, 931(ab)
Patlak images, interpretation of FDG PET lung tumor scans, 202(ab)
regional cerebral perfusion, in attention deficit hyperactivity disorder, 892(ab)
Parametric mapping, statistical
FDG PET, temporal lobe epilepsy, 1006
partial volume effects, brain SPECT, 1243
SPECT study of hydrocephalus, 1884
Paranasal sinusitis, intracavitary radionuclide therapy, 559
Parathyroid adenoma
nuclear medicine role in, 1186(ab)
preoperative procedures, minimally invasive radio-guided surgery of, 1183(ab)
Parathyroid gland
adenoma, preoperative ^{99m}Tc MIBI SPECT in, 904
adenomas, preoperative localization and radioguided surgery, 1443
mediastinal, SPECT/CT in localization of, 42N(12)
MRI and ^{99m}Tc sestamibi, in primary hyperparathyroidism, 298(ab)
overactive, identification and localization of, 1179(ab)
primary hyperparathyroidism, dual-phase ^{99m}Tc MIBI accuracy in, 473(ab)
wash-out kinetics, ^{99m}Tc MIBI, 1180(ab)
Parathyroidectomy
gamma probe use during, for secondary hyperparathyroidism, 1187(ab)
gamma probe-guided, optimization of, 1185(ab)
gamma probes in, 42N(9)
minimally invasive, revised scintigraphic protocol for, 1175(ab)
Parkinson's disease
brain PET, FDOPA or FDG ET, long-term clinical outcomes, 857(ab)
brain SPECT, during subthalamic nuclei stimulation, 397(ab)
dementia in, FDG PET study, 856(ab)
depression and, ^{123}I β-CIT SPECT in, 48N(4)
different patterns, dopaminergic nerve cell degeneration, 393(ab)
differentiating hemi-Parkinson's from, ^{99m}Tc TRODAT SPECT, 854(ab)
dihydroergocryptine monotherapy or levodopa monotherapy in, 387(ab)
dopamine transporter evaluation, optimized software solution for, 918(ab)
dopamine transporters
automated registration for, SPECT, 36(ab)
SPECT to assess disease progression, 390(ab)
treated with subthalamic nuclei stimulation, 389(ab)
D2 receptor SPECT studies, automated evaluation of, 942(ab)
evaluation of treatment response, 386(ab)
experimental pain in, levodopa effects, PET activation study, 847(ab)
^{18}F FECNT PET, dopamine transporter imaging, 855
hemospheric cholinergic denervation in, cognitive-behavioral correlates of, 398(ab)
^{123}I FP CIT SPECT in management of, 849(ab)
^{123}I FP-CIT SPECT in, 22N(2)
^{123}I PE21 SPECT and Logan graphical method, quantification of dopamine transporters, 663
multiple system atrophy and, dual-isotope brain SPECT, 851(ab)
onset, PET and, 34N(3)
PET, evaluation of movement speed, 32N(3)
pre- and post-synaptic dopamine sites, simultaneous dual-isotope SPECT, 377(ab)
predictive factors, perfusion SPECT and, 391(ab)
progressive supranuclear palsy comparison, ^{18}F FDOPA, 399(ab)
serotonin transporters in midbrain, ^{123}I β-CIT SPECT, 870
spinocerebellar ataxia type 2, ^{18}F FDOPA, 858(ab)
staging, ^{99m}Tc TRODAT-1, 395(ab)
^{99m}Tc TRODAT-1 SPECT and ^{18}F FDOPA PET crossover study, 999
^{99m}Tc TRODAT-1 SPECT in, 844(ab)
transplantation in, PET and, 42N(10)
vascular, SPECT for differential diagnosis, 855(ab)
Partial volume effect
correction for
brain perfusion SPECT, healthy men, 1243
brain perfusion SPECT for Alzheimer's disease, 830(ab)
estimate of tumor uptake in PET, 125(ab)
^{123}I SPECT neurotransmission imaging, dopaminergic system, 1184
lesions seen on whole-body PET after, 267(ab)
SUV and, small malignant lung nodules, 926(ab)
CT-based PET compensation, 126(ab)
gyral FDG uptake corrected by, MRI, temporal lobe epilepsy, 58(ab)
PET/CT, small lesion volumes, activity concentration in, 950(ab)
striatal uptake measurements, neurodegenerative diseases, 40(ab)
SUV measurements and, dedicated PET scanners, 985(ab)
Pediatric patients
acute urinary tract infections, prediction of renal scarring after, 1755
anti-granulocyte imaging, suspected acute nonclassical appendicitis, 1258(ab)
cardiac surgery, PET, 32N(3)
cardiomyopathy, assessed by ^{123}I MIBG scintigraphy, 601(ab)
child abuse, bone scintigraphy in detection, 45N(7)
chronic respiratory diseases, gastroesophageal reflux with, 1255(ab)
cystic fibrosis, prediction of ventilation heterogeneity with lung perfusion scan, 1271(ab)
encephalitis, ^{99m}Tc HMPAO monitoring of, 827(ab)
eosinophilic colitis, ^{99m}Tc white blood cells for assessment, 1247(ab)
epilepsy, ictal SPECT and, 30N(2)
epileptic
electrophysiological and functional data in cortex, 39(ab)
PET evaluation of GABA-A receptor complex, 373(ab)
FDG PET brain study, age-associated changes, 46(ab)
FDG PET staging of, modification, CT comparison, 1238(ab)
growth plates, 1.7mm resolution coded aperture bone scintigraphy, 1240(ab)
^{123}I MIBG uptake, nape of neck, 1421
^{131}I treatment, 50N(6)
impaired gastrointestinal motility, ^{99m}Tc gastric emptying scintigraphy, 1246(ab)
indexing glomerular filtration rate for, 1037
infants, evaluation of gastric emptying, 1253(ab)
infants with premature synostoses of cranial sutures, brain perfusion in, 1245(ab)
interscapular brown adipose tissue, visualization with ^{99m}Tc tetrofosmin, 1582
kidney dosimetry, MIRD schema, 1113
lymphoma, whole-body FDG PET, 596(ab), 1237(ab)
metastatic Ewing sarcoma, high-dose ^{166}Ho DOTMP treatment for, 1467(ab)
migraine with prolonged aura, brain SPECT, 598(ab)
neuroblastoma
^{123}I MIBG and MRI, 597(ab)
radiation therapy, SPECT/CT for, 1243(ab)
nuclear imaging in, FDG PET/CT initial experience, 1241(ab)
peripheral pulmonary artery stenosis, ^{99m}Tc MAA lung scan, 1251(ab)
PET in cardiology of, 34N(5)
pyelonephritis, vesicoureteric reflux in, cystography for, 1256(ab)
recurrent abdominal pain, whole gut transit time in, 1249(ab)
renal cancer, glomerular filtration rate before chemotherapy, 599(ab)
silent pulmonary thromboembolism, ^{99m}Tc MAA and DTPA for screening, 1261(ab)
staging-restaging of tumors, somatostatin receptor imaging, 1244(ab)
temporal lobe epilepsy, diagnosis with FDG PET, 602(ab)
Pediatric Research Equity Act, 38N(10)
Peptide nucleic acid, ^{18}F labeling, solid-phase synthesis, 165(ab)
Peptide P160, as targeting agent, for tumor imaging and radiotherapy, 1297(ab)
Peptide receptor imaging
peptidomimetics, tumor targeting, 316(ab)
^{99m}Tc NT-XI, ductal pancreatic adenocarcinoma patients, 71(ab)
Peptides
imaging bombesin receptors, 321(ab)
labeling with ^{67}Ga, chemical purification, 1147(ab)
novel radiopharmaceuticals, flexible and automated solid-phase synthesis for, 1100(ab)
nucleic acid, lymphoma cell uptake and retention, 1318(ab)
pegylated RGD-, improved tumor uptake, 148(ab)
radiolabeled
determination of average loading values, 1098(ab)
pretargeting for cancer radioimmunotherapy, 1293(ab)
radiolabeled gastrins, diagnosis and therapy, 1298(ab)
Peptidic chelator, solid-phase synthesis of, 154(ab)
Peripheral artery disease, ^{15}O water PET for quantifiable index, 915
Peritoneal carcinomatosis, FDG PET role in, 1407
Peritoneal scintigraphy, evaluation of leakage, continuous ambulatory peritoneal dialysis, 1287(ab)
Peritoneography, continuous ambulatory peritoneal dialysis, leakage complications of, 1287(ab)
PET
academic, Pennsylvania, 15N(7)
acetazolamide test, in cerebrovascular disease, 1875
acquisition, respiratory gating, 120(ab)
adenosine A_1 receptors, severe cerebral ischemic insult, 1839
after anxiety-provoking agent, conscious monkeys, 1516
after cardiac resuscitation, 46N(7)
Alzheimer's disease and, Wall Street Journal, 41N(12)
angiotensin receptor regulation, renovascular hypertension, 463(ab)
antitumor cell response and, 47N(4)
apoptosis detection and, 41N(12)
assessment of androgen receptors, in prostate cancer, 428(ab)
attenuation coefficient, CT contrast agents-induced error, 732
attenuation map in, 291
axillary metastases and, early breast cancer, 44N(9)
benzodiazepine receptors, in HIV, 50N(4)
bicycle exercise stress in, adenosine stress vs, coronary reserve, 146
body shield for, Tungsten curtains, 1020(ab)
^{76}Br bromide, measurement of extracellular space in brain tumors, 1210
^{11}C, as tracer for sodium-dependent glucose transporters, 1075, 1082

^{11}C acetate
forward cardiac output, pig model, 1176
hepatocellular carcinoma and other liver masses, 213, 222
recurrent disease at PSA relapse, prostate cancer, 549, 557
^{11}C carfentanil, P-glycoprotein inhibition, 109(ab)
^{11}C choline, detection of primary prostate cancer, 433(ab)
^{11}C choline, lymph node staging, prostate cancer, 331
^{11}C choline, staging of prostate cancer, 432(ab)
^{11}C FMZ, estimation of benzodiazepine receptors, 417
^{11}C MET, hypopharyngeal cancer, early response to chemotherapy in, 526
^{11}C methionine, discrepant uptake, brain tumor, 874(ab)
^{11}C nafadotride, potential imaging agent for dopamine D3 receptors, 231(ab)
^{11}C NPA, vulnerability to endogenous dopamine, 226(ab)
^{11}C R121920, potential ligand for imaging of CRHR$_1$ receptors, 1111(ab)
caffeine effects, myocardial hyperemic flow, 738(ab)
cameras, parallel data acquisition and image reconstruction system for, 1015(ab)
cellular proliferation and, colorectal cancer, 44N(12)
cerebral glucose metabolism, after traumatic brain injury, 1709
in chronic radiation-induced Lhermitte's sign, 44N(12)
chronic renal failure and, 40N(1)
CMS coverage, 19N(6)
coincidence gamma camera with FDG, endosonography and, diagnosis of pancreatic cancer, 73(ab)
combined CT system, FDG, characterization of bone metastases, 243(ab)
combined imaging of proliferation and glycolysis, brachytherapy in brain tumors, 546(ab)
combined MRI study, maternal-fetal imaging, 1239(ab)
compact rotating scanner, breast imaging, 1027(ab)
coronary circulatory dysfunction, severe coronary artery calcification, 351(ab)
correction of spill-over and partial volume effect, 370(ab)
costs, 45N(9)
count rate dependent axial normalization, panel detector, 982(ab)
CT-based attenuation correction, discrimination of contrast media, 983(ab)
^{64}Cu, tumor imaging and therapy, 1284
cue-induced cocaine craving, dopamine release and, 215(ab)
4D respiratory gating system for, tumor motion measurement, 449(ab)
3D tumor volumes, 35N(5)
3D whole-body, image reconstruction methods for tumor detection, 276
data acquisition protocol, quantification of FDG, 1933
dedicated, coincidence camera comparison, lesion detectability, 1024(ab)
deep brain stimulation and, 33N(5)
delivery services to customers, California, 20N(7)
diagnosis and monitoring, giant cell arteritis, 145(ab)
display, notes from SNM annual meeting, 24N(7)
distal esophagus and cardia adenocarcinomas, 41N(10)
3D-OSEM, 3DRP, and rebinning algorithms, brain lesion detectability, 1000(ab)
drug development and, 34N(5), 40N(1)
drug discovery and knockout mice, 52N(6)
dynamic
gaseous tracers, small animals, 375(ab)
quantification of striatal monoamine transporter density, 31(ab)
in early detection of Alzheimer's disease, 39N(1)
energy and spatial resolution relationships for, 1018(ab)
evaluation of anxiety associated with public speaking, 30N(2)
evaluation of treatment response, Parkinson's disease, 386(ab)
event-based motion correction, list-mode acquisition, 992(ab)
evidence of neuroplasticity, adult hearing disorders, 1435, 1440
experimental myocardial infarction, mice, 283(ab)
^{18}F AFE, for serotonin transporters, 1049(ab)
^{18}F desbromo-DuP-697, for cyclooxygenase expression, 1700
^{18}F FAU biodistribution, in tumors, 1328(ab)
^{18}F FA-4 and ^{11}C pipzA-4, high-affinity choline uptake system, 269
^{18}F FCWAY, with partial volume correction, 62(ab)
^{18}F FET, brain tumor and radiation necrosis, 1410(ab)
^{18}F FLT
radiation dosimetry, 1482
staging of metastatic melanoma, 1927
^{18}F FLT PET, non-Hodgkin's lymphoma and proliferative activity, 614(ab)
^{18}F fluoride ion, after total gastrectomy, 117
^{18}F fluorinated sigma receptor ligands, conscious monkey brain, 223(ab)
^{18}F fluoro-A-85380, central nicotinic receptor imaging, 596
^{18}F FMAU and FAU, radiation dosimetry, 1151(ab)
^{18}F FPCIT dopamine transporter, human subjects, 961
^{18}F gene therapy as potential agents, 1061(ab)
^{18}F misonidazole and, hypoxia imaging with, non-small cell lung cancer and head and neck cancer, 1304(ab)
^{18}F nifrolidine, imaging for nicotinic receptors, 606(ab)
^{18}F PAC biodistribution and uptake, breast cancer, 1333(ab)
^{18}F TFMK synthesis, 168(ab)
^{18}F TYR, FDG comparison, whole-body tumor imaging, 533
FDG
3D whole-body, angular compression for, 990(ab)
accuracy in staging of small cell lung cancer, 1405(ab)
advanced, metastatic or recurrent gastric cancer, 690
after neoadjuvant radiochemotherapy, non-small cell lung cancer, 563(ab)
assessing and optimizing data quality, 360(ab)
with bladder irrigation, uterine and ovarian tumors, 353
bone scintigraphy comparison, rheumatoid arthritis, 1227(ab)
brown fat evaluation, 1267
^{11}C choline comparison, gynecologic tumors, 1051
carcinoma of unknown primary origin, 1369(ab)
choline and, different types of non-small cell lung cancer, 264(ab)
conformal radiotherapy in lung cancer patients, 245(ab)
vs CT
lymphoma, lesion detection in liver, 268(ab)
staging of lymphoma, 1072
CT and, cervical cancer, 54N(6)
delayed, detection of brain metastases and, 877(ab)
detectability of coronary inflammation, 938(ab)
diagnosis of pediatric temporal lobe epilepsy, 602(ab)
dosage required with LSO-PET camera, 1013(ab)
early recurrence of cervical cancer, 347
esophageal cancer
comparison with ultrasonography, 1335(ab)
prediction of early therapy response, 70(ab)
evaluation of recurrent and metastatic breast cancer, 556(ab)
evaluation of response to therapy, 224
evaluation of skin cancer, 1440(ab)
false-positives, adipose tissue and muscle uptake, 1789
findings in CADASIL, 863
hTg levels and, thyroid cancer imaging, 1193(ab)
Hürthle cell carcinoma, 1402
identification of cardiac sarcoidosis, 1030
impact of image fusion, recurrent disease, malignant brain tumors, 875(ab)
infarct size and location, rat heart, 715(ab)
insulin effects on glucose uptake, liver, 682
intrahepatic cholangiocarcinoma, 1365(ab)
management of lung cancer patients, 406(ab)
metabolic spectral signature analysis of FDG with, 38(ab)
MRI, CT and scintigraphy comparison, head and neck cancer, 198
nasopharyngeal cancer, 1439(ab)
occult metastases, 51N(11)
oncological, inclusion of lower limbs in, 1341(ab)
osteosarcoma, 930
paraortic lymph node metastases, cervical cancer, 1775
peritoneal carcinomatosis, 1407
PET/CT comparison, colorectal cancer, 1797, 1804
positive findings in high CEA levels, 83(ab)
posttreatment evaluation of Hodgkin's disease, 1225
preoperative staging of colorectal cancer, 1784
preselection of antiCD66 myeloablative therapy for leukemia, 1473(ab)
primary tumor with extracervical metastases, 554(ab)
production in a commercial cyclotron, 1136(ab)
quantitation, normal adrenal gland appearance, 296(ab)
quantitation by autoradiographic method, 1228(ab)
quantitation in lung lesions, 199(ab)
radiofrequency ablation, hepatic metastases, 1347(ab)
screening for focal thyroid incidentaloma, 52N(11)
short-term prognosis in colorectal cancer, 1358(ab)
skeletal muscle glucose utilization, 1592
small cell lung cancer, 1911
soft-tissue sarcoma, 717
with SPM, temporal lobe epilepsy, 1006
staging of esophageal cancer, 1424(ab)
staging of inner quadrant primary tumors, breast cancer, 248(ab)
staging of lymphoma, modification in childhood, 1238(ab)
SUV varies with time after injection, breast cancer, 1044
^{99m}Tc MDP comparison, equivocal bone scan, 1342(ab)
testicular uptake, 465(ab)
thoracic, three-dimensional registration, 1156
thoracic lesions, 540
thyroid incidentalomas, 128(ab)
thyroidal uptake, effect of TSH levels, 1190(ab)
tumor characteristics in cervical cancer, 192
unknown primary syndrome, 1301
unresectable metastatic colorectal cancer to liver, 1475(ab)
utility in renal cell carcinoma, 1441(ab)
variation in lower extremities, 1231(ab)
who should read and interpret?, 1197(ed)
whole-body, therapy for esophageal cancer and, 50N(4)
without blood sampling, 60- and 120-min protocols, 911(ab)
FDG and ^{11}C raclopride, multiple systems disease and Parkinson's, 845(ab)
FDG and ^{18}TF FLT tumor tracers, colorectal cancer, 80(ab)
FDG uptake, pleural diseases, 1386(ab)
FDG whole-body
activity in thyroid, 1196(ab)
esophagitis and gastroesophageal reflux, 1364(ab)
full-breast PEM camera, 455(ab)
fully-3D reconstruction, histograms, 531(ab)
gamma camera, giant-cell vasculitis, 733(ab)
GE Discovery ST PET/CT scanner
clinical image quality, 1011(ab)
NEMA standard, 362(ab)
GSO small animal 3D scanner, imaging performance of, 25(ab)
head and neck cancer, 42N(1)
high-resolution scanner, quantitative capability, primate imaging, 521(ab)
Hodgkin's disease relapse and, 28N(2)
hybrid FDG, cardiac imaging, 769(ab)
^{124}I and ^{18}F, lesion detectability, 916(ab)
^{124}I as imaging agent, small animal imaging, 941(ab)
identification of viable tissue after stroke, 44N(12)
^{124}I-labeled annexin V for, imaging of cell death, 586(ab)
image quality, transmission attenuation-correction and combined PET/CT, 1348(ab)
imaging of signal transduction pathways, 1326(ab)
improved radioligand, for serotonin transporters, 1890
infection imaging and, HIV-1, 41N(12)
intravascular tracers
analyzed by microvascular models, 22(ab)
determination of regional flow, pig livers, 1862

for large B-cell lymphoma, 33N(5)
liver tumor recurrence, 42N(1)
LSO scanner, colorectal cancer, 1407(ab)
map reconstruction in, correlated MR images, 999(ab)
MBF responses to cold pressor test, coronary circulation and, 293(ab)
measurement of brain concentration, development of FK960, 105
measurement of resolution, preparation method comparison, 1047(ab)
micro crystal element scanner, small animal, 520(ab)
microCT and, registration method, 376(ab)
mild head trauma, persistent symptoms, 50N(4)
modeling techniques, replacement of microdialysis, small animals, 374(ab)
movement speed, Parkinson's disease, 32N(3)
MRI combined study, maternal-fetal exchange, 1522
multiple dynamic neuroreceptor, automation of, 30(ab)
multiple sclerosis, 46N(7)
^{13}N ammonia
myocardial blood flow, pre-diabetic subjects, 349(ab)
myocardial blood flow, 945(ab)
myocardial perfusion and, 170(ab)
neural correlates of behavior, 34N(3)
nicotinic receptors and, 28N(2)
^{15}O water
cold pressor/adenosine effect, myocardial blood flow, 957(ab)
elective percutaneous coronary intervention evaluated by, 291(ab)
quantifiable index of lower extremity flow, 915
transcranial Doppler sonography and, schizophrenia, 671
oncology
malignant and benign lesions, 949(ab)
region of interest for optimal quantification in, 948(ab)
onset of Parkinson's disease and, 34N(3)
and optical CCD imaging, survival of cardiac cell transplant, 337(ab)
painful diabetic neuropathy, 27N(2)
Parkinson's disease, experimental pain in, levodopa effects, 847(ab)
partial volume correction for, MRI-based, 932(ab)
pediatric cardiac surgery, 32N(3)
in pediatric cardiology, 34N(5)
PET/CT, lung cancer staging, 1406(ab)
post-hoc software realignment, to CT/MRI, 961(ab)
prebiopsy guidance, in percutaneous biopsy for lung cancer, 591(ab)
prefrontal deactivation, after ECT, 897(ab)
pulmonary fibrosis, 483(lc)
pulmonary gene expression, 47N(7)
quantification of dopamine receptors with ^{18}F DMFP, human brain, 109
quantification of ventilation/perfusion ratios with, 1982
quantitation
Allegro GSO 3D PET scanner for ^{18}F and ^{82}Ru, 361(ab)
amphetamine challenge, 33(ab)
attenuation correction using microPET, 975(ab)
background subtraction, ^{86}Y use in, 939(ab)
cerebral blood flow, during anesthesia, 863(ab)
combined PET/CT unit, 968(ab)
high resolution OSEM, 529(ab)
identifiability analysis of the PV contribution to liver, 910(ab)
IV contrast effects in PET-CT, attenuation correction error and, 978(ab)
motion, impact on measured SUVs, 527(ab)
segmented contrast correction, 969(ab)
quantitative accuracy, body imaging, 977(ab)
radiation dosimetry estimates for, alcoholism and affective disorders, 1152(ab)
radiation treatment planning and, 46N(12)
radioligand synthesis, cannabinoid receptors, 1052(ab)
radiotracers, serotonin transporter ligands, 603(ab)
^{82}Rb generator, inorganic ion exchangers for use in, 1102(ab)
^{82}Rb myocardial perfusion, 2D and 3D comparison, 1350
respiratory gated, reduction of respiratory motion artifacts, 1645
restaging prostate cancer, 36N(5)
rule-based viability assessment, myocardium, MRI validation of, 21(ab)
scanner performance, using a whole-body phantom, 363(ab)
sentinel node imaging and, oral cancer, 54N(6)
shielding, 46N(7)
small animal
adenosine A_1 receptor ligand, 1682
design of system with 1 microliter volume resolution, 1035(ab)
engineered antibody fragments, 1962, 1970
imaging D2 receptors with
left ventricular function, 1655, 1662
Monte Carlo-based system, statistical noise in, 530(ab)
SNM learning center, 30N(7)
sorted listmode data, compression of, 919(ab)
SPECT and, assessment of depression, 47N(7)
SPECT and magnetic field, in epilepsy, 41N(10)
staging of malignant pleural mesothelioma, 44N(9)
stand-alone or combined CT systems, lesion volume measurement, 1025(ab)
study of dopamine and mood, 28N(2)
therapeutic response in cervical cancer and, 35N(5)
transplantation and, in Parkinson's disease, 42N(10)
tumor tracers
animal tumor models, 155(ab)
bispecific antibody pretargeting in, 1057(ab)
development of, 158(ab), 1065(ab)
diagnosis of brain tumor, 543(ab)
estimated radiation dosimetry, animal data, 1156(ab)
^{18}F tracer for detection of tumors, 157(ab)
gastrointestinal stromal tumor response, 75(ab)
hepatocellular cancer, 1359(ab)
ovarian cancer, mouse model, 1059(ab)
sigma receptors, breast cancer, 1323(ab)
ultra-high resolution detectors, novel prototype for, 450(ab)
usage and number of facilities growing, 48N(6)
whole-body
attenuation correction effects on tumor detection, 1855
automatic rigid dual study co-registration system, 946(ab)
image and lesion noise comparison, 1016(ab)
instrumentation and reconstruction, 756
large aperture scanner, rebinning methods, 974(ab)
lesions seen on, after partial volume effect correction, 267(ab)
Patlak imaging, 196(ab)
regionally-dependent count rate performance, 364(ab)
in squamous cell oral cancer, 44N(9)
3D RAMLA vs 2D RAMLA, 532(ab)
whole-body FDG, chemotherapy effects on organ distribution, 1488(ab)
2D, ^{86}Y, uniformity and quantitative accuracy, 965(ab)
^{89}Zr immuno
production of monoclonal antibodies, 1271, 1282
^{90}Y-labeled monoclonal antibodies, xenograft-bearing nude mice, 1663
PET/CT. *see* Multimodality imaging
PET-Mail, list server for PET community, 32N(7)
P-glycoprotein
expression
target for antisense imaging in MDR+ cancers, 1089(ab)
^{99m}Tc MIBI as predictor of therapy response and, osteosarcoma, 1394
inhibition, effect of brain loperamide delivery, 109(ab)
transport, quantitative estimate by ^{11}C verapamil, 1303(ab)
Phantom simulations, abnormal motion of the heart, 462(ab)
Pharmacokinetics
antibody
Actinium-225 nanogenerators, 1301(ab)
after resection of primary colorectal cancer, 84(ab)
combined PET-MRI study, maternal-fetal imaging, 1239(ab)
development of FK960, PET measurement of brain concentration, 105
^{18}F FDHT vs FDG, in progressive metastatic prostate cancer, 424(ab)
FDG, shortened acquisition protocols for, 935(ab)
^{125}I ITdU, rodents, 1671
tissue fractionation and, ^{125}I ITdU, 1080(ab)
TN-Map and TN-Fab, locoregional application in C6 glioma, rat, 112(ab)
Pheochromocytoma, ^{11}C epinephrine PET imaging of, 297(ab)
Phosphodiesterase type IV inhibitors, rolipram, rat heart, 714(ab)
Photodynamic therapy, apoptosis after, ^{99m}Tc annexin V for evaluation, 650
Physicians
new MDs choose time over dime, 45N(4)
nuclear medicine, effects of long-term exposure, 47N(4)
Physics, in nuclear medicine, 2002, 22N(1)
Physis, cartilage, ^{53}Sm EDTMP effects, rabbit, 1510
Pleural diseases, evaluation with ^{18}F FDG imaging, 1386(ab)
Posttraumatic stress disorder, central type benzodiazepine receptors, Gulf War veterans, 119(ab)
Practice guidelines, PET oncology, 960(ab)
Preoperative risk, stratification of, stress SPECT with ECG gating, 385
Pretargeting, radioimmunotherapy of cancer, 400
Probe system
detection of PET tracers, head and neck cancer, 418(ab)
MR-compatible gamma probe, intraoperative use, 1352(ab)
positron intraoperative, preoperative cancer patients, 901(ab)
Procedure guidelines, brain death scintigraphy, 846
Prone imaging, combined prone and supine acquisitions, myocardial SPECT, 1633, 1641
Prostate cancer
androgen receptors in, PET assessment, 428(ab)
^{11}C acetate and FDG PET, combined metabolic imaging, 431(ab)
^{18}F FLT as proliferation marker for, 262(ab)
gastrin-releasing peptide receptors, targeting by ^{111}In-labeled bombesin analogs, 823
hormone refractory advanced, anti-PMSA antibody for targeting of, 429(ab), 430(ab)
^{111}In Prostascint SPECT, camera systems for, 1042(ab)
lymph node staging in, ^{11}C choline PET, 331
metastases, ^{188}Re HEDP in, 46N(10)
metastases of, ^{11}C acetate and ^{11}C choline PET comparison, 434(ab)
metastatic, radiolabeled mAb targeting in, 46N(12)
metastatic hormone-refractory, bone palliation therapy in, 1468(ab)
microPET and, 56N(6)
pelvic sentinel lymph node mapping, image fusion and, 191(ab)
primary, ^{11}C choline in detection of, 433(ab)
progressive metastatic, PET tumor tracers in, 424(ab)
Prostascint image volumes, manual fusion reproducibility, 962(ab)
radioimmunotherapy with huJ591, 101(ab)
recurrent disease at PSA relapse, ^{11}C acetate PET, 549, 557
restaging, PET, 36N(5)
skeletal metastases, dosimetry of ^{186}Re HEDP, 953
skeletal metastases from, PSA measurements in, 1470(ab)
staging, ^{11}C choline PET/CT, 432(ab)
tumor localization, radiolabeled monoclonal antibodies, nude mice, 610
tumor segmentation, ^{111}In ProstaScint imaging, 955(ab)
Prostate-specific antigen, reporter gene, development and imaging, 94(ab)
Prostate-specific membrane antigen, extracellular domain of, radiolabeled monoclonal antibodies specific to, 610
Prosthetic joints, painful, nuclear medicine role in, 927
Protein synthesis rate, SUV and, L-1-C^{11} tyrosine in laryngeal cancer, 341

Psychosis, dopamine transporter density, after acute antipsychotic treatment, in schizophrenia, 888(ab)
Pulmonary embolism
acute, present diagnostic strategies, 1266(ab)
clinical models, patient location effects, 1259(ab)
observer variability and different criteria, in lung scan interpretation, 739
silent, ^{99m}Tc MAA and DTPA for screening, children, 1261(ab)
ventilation-perfusion scintigraphy, high-resolution CT concordance, 1267(ab)
V/Q lung scintigraphy and technegas use in, 1262(ab)
V/Q scintigraphy, helical CT comparison, 592(ab)
who diagnoses in the 21st Century, 1263(ab)
Pulmonary fibrosis, PET, 483(le)
Putamen, quantification of dopamine receptors with ^{18}F DMFP, 109
Pyelonephritis, acute, renal scarring after, pediatric, 993(ab)

Q

Quality control
back-up radiochromatographic TLC method, 1143(ab)
bioburden recovery method, in PET radiopharmaceutical production, 1144(ab)
emission tomography, dual-modality approach, 358(ab)
HPLC control of PET radioligands, retention time shifts during, 1145(ab)
intrinsic uniformity testing, multi-head gamma camera, 1046(ab)
NEMA NU-2 protocol, Allegro GSO 3D PET scanner for ^{18}F and ^{82}Ru, 361(ab)
planar uniformity measurement, application in SPECT, 994(ab)
uniformity correction arrays, SPECT nuclides, 1041(ab)
Quantitation, ^{99m}Tc DMSA absolute renal uptake, renal function and, 1285(ab)

R

Racial differences, guidance in clinical trials, 26N(3)
Radiation damage, lung and heart, nuclear medicine role in, 1531
Radiation exposure
Prussian Blue for treatment, 45N(4)
treatment, FDA seeks new drugs for, 40N(11)
Radiation monitoring, nuclear medicine patients and, 48N(6)
Radiation necrosis, recurrent metastatic brain tumor, MET PET in, 45N(7)
Radiation safety
cell damage possible at low levels, 44N(7)
occupational exposure examined, 27N(2)
structural shielding, design of, 925(ab)
Zevalin and, 41N(9)
Radiation therapy
chemotherapy and
effects on cell proliferation and FDG PET, 263(ab)
for head and neck cancer, imaging comparison, 198
conformal, lung cancer, FDG PET in planning of, 245(ab)
FDG
metabolic tumor volume imaging, lung cancer, 1456(ab)
PET tumor volume imaging, pancreatic cancer, 72(ab)
hypoxia-directed, CT/PET image fusion and, head and neck cancer, 415(ab)
low-dose ionizing, biologic responses to, 125(le)
peptide-receptor
long-lived contaminant lutetium-177 M, 1146(ab)
neuroendocrine tumors, 442(ab)
phase 1 trial of P2045 radiopeptide therapy, lung cancer, 447(ab)
planning, PET for measurement of tumor motion, 122(ab)
planning, PET in, 46N(12)
targeted
α-particle-emitting, microdosimetric analysis, 792
^{90}Y SMT487, in neuroendocrine tumors, 1556
thoracic, nuclear medicine role in, 1531
treatment planning, PET/CT scanner for, 1045(ab)
treatment volumes, PET to reduce observer variability in, 244(ab)
using ^{111}In D-Glu1-minigastrin diagnosis, medullary thyroid cancer, 448(ab)
^{18}F FDG PET staging for, 24, 30
Radioactive materials, security for, VA facilities, 45N(9)
Radioactive sources, preparation methods for, measurement of PET resolution, 1047(ab)
Radiobiological effectiveness, radiopharmaceutical tolerance dose, 331(ab)
Radiochemistry, at Hopkins, a personal look back, 37N(7)
Radiofrequency ablation, hepatic metastases, FDG PET effects, 1347(ab)
Radiography, medical x-rays as carcinogens, 9N(2)
Radioimmunoassay
radiolabeled antibodies, immunoreactivity determination of, 1173(ab)
tissue polypeptide specific antigen and CA-125, diagnosis of ovarian cancer, 1447(ab)
Radioimmunoconjugates, production of, ^{89}Zr immuno PET, 1271, 1282
Radioimmunodiagnosis, engineered antibody fragments, small animal PET, 1962, 1970
Radioimmunoscintigraphy
anti-human bladder tumor chimeric antibody, bladder tumor, 1294(ab)
lung, sulesomab for assessment of pulmonary inflammation, 594(ab)
^{125}I-labeled monoclonal antibody, MET-expressing tumors, 580(ab)
Radioimmunotherapy
alpha-emitting radionuclides, selective killing of cancer cells, 588(ab)
alpha-particle, targeting disseminated cancer, 497(ab)
antibodies, single-cell kill with, 632
anti-CD20 and anti-CD45 antibody comparison, 35N(5)
anti-CD22 antibody, ^{90}Y DOTA and, 33N(3)
antivascular agents and, 30N(2)
apoptosis and, 40N(1)
Bexxar
non-Hodgkin's lymphoma, Rituximab-refractory patients with, 1477(ab)
non-Hodgkin's lymphoma with mild thrombocytopenia, 105(ab)
non-Hodgkin's lymphoma, responses of 5 years, 99(ab)
obese patients with non-Hodgkin's lymphoma, 1478(ab)
Bi-213, intraperitoneal cell dissemination, 579(ab)
bone marrow dose, hematologic toxicity correlation, 67
^{64}Cu, tumor imaging and therapy, 1284
3D dosimetry, non-Hodgkin's lymphoma patients, 260, 1541(le)
dose escalation, 42N(1)
dosimetric analysis, head and neck cancer patients, 1690
dosimetry for clinical studies, 1163(ab)
dosing methodology, patients with CD20+ B-cell non-Hodgkin' s lymphoma, 1479(ab)
huJ591, biodistribution parameters, 101(ab)
^{131}I cG250, advanced renal cell cancer, 103(ab)
idiotypic cascade after, in NHL, 44N(11)
^{111}In-labeled antibodies and peptides, 1155(ab)
interperitoneal and systemic, 41N(9)
intraperitoneal, β dose rates for, 46N(10)
leukemia, preselection using FDG PET, 1473(ab)
liver metastases, colon cancer, mice, 1291(ab)
locoregional, C6 glioma, rat, 112(ab)
low-dose, gemcitabine and, in pancreatic cancer, 44N(11)
lymphoma, nodal regression effects on radiation dose, 1322
multi-step targeting, pancreatic tumors, 1292(ab)
non-Hodgkin's lymphoma, ^{90}Y DOTA humanized anti-CD22 IgG, 2000
α-particle-emitting targeted, microdosimetric analysis, 792
pretargeted, cancer, 400
pretargeting and, 51N(4)
radiation-absorbed dose correlation, 1541(le)
^{186}Re, liver metastasis model, 1476(ab)
^{186}Re epratuzumab, dosimetry of, 102(ab)
residualizing form of ^{131}I, purification method for, 324(ab)
small peritoneal metastases, colorectal origin, 578(ab)
therapeutic index of, 44N(11)
timing, testicular tumors and, 41N(1)
^{90}Y DOTA-hLL2, non-Hodgkin's lymphoma, 77
^{90}Y ibritumomab tiuxetan, dosimetry, non-Hodgkin's lymphoma, 465, 1707(le)
^{90}Y-labeled anti-CD20 monoclonal antibodies, non-Hodgkin's lymphoma, 853(le)
^{89}Zr and ^{124}I PET for scouting candidates, 46N(11)
Radioiodides, thyroid uptake, potential interference, euthyroid rat, 832
Radioiodinated antibody, residualizing form of, 324(ab)
Radioiodinated benzamides, combinatorial solid phase approach for preparation, 166(ab)
Radioiodine therapy
body retention of, thyroid cancers and, 898
effects of addition of ^{127}I to, Graves' disease, 1189(ab)
ethanol injection plus, treatment of toxic thyroid nodules, 207, 211
fractionated ^{131}I therapy, thyroid stunning in, 1459(ab)
Graves' disease, pretreatment with antithyroid drugs and, 1202(ab)
high dose of ^{131}I after thyrotropin, differentiated thyroid cancer, 472(ab)
^{123}I Na whole-body imaging in surveillance, thyroid cancer, 301(ab)
individual dose concept, Graves' disease, 131(ab)
MTO labeled with, adrenal gland precursor synthesis, 1132(ab)
neuroendocrine tumors, after sodium iodide symporter gene transfer, 91(ab)
predictive variables, Graves' disease, 1184(ab)
retinoic acid, papillary thyroid cancer, 1457(ab)
rhTSH stimulation before, effects in thyroid cancer, 1065, 1069
solid phase synthesis, polymer-supported prosthetic group, 1128(ab)
therapeutic outcome of, in differentiated thyroid cancer, 1461(ab)
thyroid cancer
expressing sodium/iodide symporter gene, 1197(ab)
salivary gland damages after, 129(ab)
uptake
double reporter gene system, simultaneous nuclear imaging, 156(ab)
triple modality reporter gene for, 150(ab)
Radioisotopes, shipments of, detecting stowaway sources, 47N(4)
Radiolabeled antibody therapy
CD49, pancreatic tumors, 1292(ab)
exposure of healthcare workers, 1171(ab)
^{131}I vs ^{111}In, metastatic renal cell carcinoma, 559(ab)
immunoreactivity determination of, 1173(ab)
^{111}In/^{90}Y CC49 trial, 1159(ab)
Radiological dispersal devices
dirty bomb meeting, 39N(1)
responding to the media in emergencies, 11N(4)
Radiology, ethics in, 1818
Radiometals, generated from production of ^{18}F fluoride, capillary electrophoresis in, 1142(ab)
Radionuclide imaging
cancer, VEGFR2 receptors, 1069(ab)
normal exercise and adenosine, prognostic value, 134
Radionuclide therapy
cancer cells, expressing sodium/iodide symporter, 90(ab)
dosimetric model for mice and rats, 491(ab)
efficacy, osteoarthritis of digital joints, 489(ab)
hepatoma, sodium/oxide symporter expression, 1316(ab)
^{131}I HEPAMA-1, in hepatocellular cancer, 104(ab)
intracavitary, chronic otitis media and paranasal mucositis, 559
peptide receptor, ^{111}In-DTPA^{0} octreotide, 98
pretargeted, cancer, 400
^{186}Re liposome labeling, stability, imaging, and biodistribution, rats, 1992
^{188}Re perrhenate, glioma, 110(ab)
^{186}Re-liposome labeling for, 1097(ab)

^{89}Sr for bone tumor treatment, 1471(ab)
targeted, lipid-soluble complexes in, 1293
using sodium-iodide symporter, gastroenteropancreatic tumors, 1203(ab)
^{90}Y DOTATOC, advanced medullary thyroid cancer, 444(ab)
Radionuclides
alpha-emitting
intraperitoneal cell dissemination, 579(ab)
selective killing of cancer cells, 588(ab)
comprehensive listing for 2003, 27N(6)
molecular targeting with, 1945
positron production, neutron dosimetry during, 1172(ab)
^{57}Co and ^{109}Cd, production of large quantities, 1101(ab)
Radiopharmaceuticals
back-up radiochromatographic TLC method, 1143(ab)
biologically equivalent doses, 331(ab)
^{11}C R121920, potential ligand for imaging of $CRHR_1$ receptors, 1111(ab)
chemistry
high specific activity, 1120(ab)
luteinizing hormone releasing hormone positive tumors, targeting of, 1072(ab)
optimized reaction parameter for ^{18}F FECh, 328(ab)
radioiodination reagents for antibody fragments, 1092(ab)
rhenium tricarbonyl core complexes, 164(ab)
solid-phase synthesis of, 154(ab)
^{11}C-labeled FK506, 609(ab)
^{18}F FLT, automated production of, 1140(ab)
comprehensive listing for 2003, 27N(6)
development
bioburden recovery method in, 1144(ab)
biphenylsulfonamide MMP inhibitor tracer, 158(ab)
breast cancer, 1074(ab)
for cancer diagnosis, 1088(ab)
detection of apoptosis in melanoma, 318(ab)
for dopamine D2/D3 receptors, 1051(ab)
electrospray ionization mass spectrometry, 1098(ab)
ligand binding with new DNA, 1083(ab)
long-lived contaminant lutetium-177 M, 1146(ab)
radiolabeled antibody for therapy, 1093(ab)
radiolabeled ^{6}O BG derivatives, 1065(ab)
radiolabeled 7 nicotinic acetylcholine receptors, 607(ab)
^{186}Re HEDTMP therapy, for bone tumors, 1096(ab)
tumor proliferation imaging agent, 1063(ab)
diarylsulfide PET imaging agent, 153(ab)
evaluation, high-affinity choline uptake system, 269
^{18}F-labeled, voltage indicator phosphonium cations, 160(ab)
^{18}F-labeled radioligand, serotonin transporter imaging agent, 604(ab)
investigation of properties, 1107(ab)
PET marker for COX-2 expression, ^{18}F celecoxib, 1127(ab)
preparation of ^{90}Y, 1150(ab)
purification of recovered ^{18}O water, for production of ^{18}F fluoride, 1103(ab)
radiotracer comparison, herpes simplex virus thymidine kinase gene expression, 106(ab)
receptor-binding
imaging of experimental colitis, 498(ab)
octreotide derivatives with C-terminal substituent, 1075(ab)
single-dose calibrator setting, ^{90}Y ibritumomab tiuxetan, 1137(ab)
Radioprotection
anti- ^{90}Y, measurements or Monte Carlo calculations, 1169(ab)
FDG production, off-site supply of ^{18}F fluoride, 1149(ab)
^{131}I therapy, 127(ab)
^{90}Y lanreotide therapy, urinary excretion of, 1466(ab)
Radiosensitivity, dendritic cells, 496(ab)
Radiosynovectomy, leakage of P-32 chromic phosphate, joint, 1236(ab)
Radiosynoviorthesis
efficacy, osteoarthritis of digital joints, 489(ab)
hemophilia patients, corticosteroid injections with, 1481(ab)
Radiotherapy, *see* Radiation therapy
Radiotracer chemistry in 2002, 19N(1)
Radiotracers
agonist, PET, ^{18}F -OH-FHXPAT, 608(ab)
lymphoscintigraphy in evaluation of lymphedema, 43
Radio-tympano-sinu-orthesis, with ^{186}Re colloid, 559
Receptor imaging
effect of target density, 227(ab)
^{18}F-labeled glyburide analogs, diabetes, 503(ab)
hepatocytes, ^{99m}Tc GMC for, 1125(ab)
multilinear regression analysis, with PET, 902(ab)
Reconstruction algorithms, whole-body PET, 756
Rectal cancer
FDG PET, SUV in prognosis of, 959(ab)
preoperative modality therapy, value of early FDG PET in, 82(ab)
recurrence, FDG PET in, 45N(9)
Region of interest (ROI)
optimum quantification, oncology PET, 948(ab)
time dependency and, SUV of oncological PET, rectal cancer, 959(ab)
Renal artery stenosis, captopril renography, drug interactions with, 1574
Renal brush border enzymes, radiolabeled antibody metabolism, 1092(ab)
Renal cell carcinoma
advanced, ^{131}I cG250 radioimmunotherapy, 103(ab)
blood flow, FDG metabolism relations, 266(ab)
FDG PET utility in, 1441(ab)
prediction of histopathologic differentiation, FDG whole-body PET, 1453(ab)
Renal mass, suspicious, inaccuracy of FDG PET for, 1414(ab)
Renal scintigraphy
diuretic renography and, evaluation in patients with extrarenal pelvis, 1281(ab)
parenchymal, acute pyelonephritis, 993(ab)
Renography
acute cyclosporine nephrotoxicity, acute tubular necrosis and, rats, 1278(ab)
captopril, drug interactions with, 1574
determination of renal size, 1282(ab)
diuretic
evaluation in patients with extrarenal pelvis, 1281(ab)
hydronephrotic kidney, 1280(ab)
post pyeloplasty patients, 1284(ab)
renal colic patients, 466(ab)
suspected renal obstruction, 1289(ab)
potential renal donors referred for, abnormal scans in, 467(ab)
^{99m}Tc EC, captopril and losartan comparison, 469(ab)
^{99m}Tc MAG3, ureteropelvic junction obstruction, newborns, 725
Renovascular hypertension
angiotensin receptor regulation, PET, 463(ab)
captopril and losartan comparison, ^{99m}Tc EC, 469(ab)
captopril renography, drug interactions, 1574
Resolution improvement, SPECT, space-variant convolution and deconvolution, 209(ab)
Respiratory disease, chronic, exercise-induced ECG changes, ^{99m}Tc tetrofosmin SPECT, 325
Respiratory rehabilitation, exercise-induced ECG changes, chronic respiratory disease patients, 325
Revascularization, myocardial, ^{99m}Tc tetrofosmin perfusion imaging, 11(ab)
Rhenium-186, liposome labeling, stability, imaging, and biodistribution, rats, 1992
Rhenium-186 bivatuzamab, dosimetric analysis of radioimmunotherapy, head and neck cancer, 1690
Rhenium-186 HEDP, high-dose treatment, bone uptake of ^{99}Tc HDP before and after, 247
Rhenium-186 sulfide, radio-tympano-sinu-orthesis, chronic otitis media and paranasal mucositis, 559
Rhenium-188
dosimetry
prostate cancer skeletal metastases, 953
during vascular brachytherapy, 1170(ab)
efficacy in xenografted SCID mouse model of melanoma, 581(ab)
patient-specific dosimetry, liver cancer, 1161(ab)
rhenium tricarbonyl, radiopharmaceutical models, 1090(ab)
tricarbonyl core, labeling of biomolecules with, 162(ab)
Rhenium-188 carbonyl, phosphorodiamidate morpholino, oxidative metabolism and, 326(ab)
Rhenium-188 EC-MN, noninvasive assessment, tumor hypoxia, 322(ab)
Rhenium-188 HDD, lipiodol solution of, transhepatic arterial embolization, liver cancer model, 2033
Rhenium-188 HEDP
in prostate cancer metastases, 46N(10)
repeated bone targeted therapy, bone metastases from prostate cancer, 568(ab)
Rhenium-188 lipiodol, treatment, liver cancer, 573(ab)
Rheumatoid arthritis, FDG PET and bone scintigraphy, monitoring disease activity, 1227(ab)
Right ventricular function, RNA SPECT, coronary artery disease, 177(ab)
ROC curve
FDG PET/CT, lung lesions, 199(ab)
image quality in PET, 966(ab)
two-marker-cutoff, PET SUV and CT lesion size, optimal diagnosis of solitary pulmonary nodule, 928(ab)
varying thresholds, FDG PET in suspected lung cancer, 963(ab)
Rubidium-82
generator for, PET, 1102(ab)
myocardial perfusion imaging, 2D and 3D PET comparison, 1350
rest and stress washout, determination of myocardial viability, 19(ab)

S

S factors, liver, spleen and kidney, 784
Salivary glands, damage after radiotherapy, thyroid cancer, 129(ab)
Samarium-153 EDTMP
bone palliation with, metastatic hormone-refractory prostate cancer, 1468(ab)
effects on cartilage, rabbit, 1510
high-dose, multiple myeloma, 569(ab)
high-dose treatment, bone uptake of ^{99}Tc HDP before and after, 247
Samarium-153 HEDTMP, treatment, bone metastases, 1107(ab)
Sarcoidosis
cardiac, identification with FDG PET, 1030
cardiac involvement, myocardial perfusion imaging, 722(ab)
Sarcoma
soft-tissue, FDG PET for diagnosis and grading of, 717
uterine, PET tumor tracers for, 1338(ab)
Sarcomatoid carcinoma, low and high grade, detection and differentiation with ^{18}F FLT, 240(ab)
Scatter correction
2D-3D interchanged acquisition, cardiac imaging, 967(ab)
effects on brain SPECT, normally distributed activities, 512
image-based, ^{123}I IMP SPECT, 947(ab)
model-based, 3D dual head coincidence imaging, 989(ab)
ROC evaluation, ^{99m}Tc myocardial perfusion imaging, 1725
Schizophrenia
auditory hallucinations in, FDG PET study, 887(ab)
cognitive activation in, PET and transcranial Doppler sonography in, 671
dopamine D2 receptors, in extrastriatal and striatal regions, 113(ab)
D2 receptor occupancy, under antipsychotic treatment, PET, 115(ab)
Schwannoma, FDG PET appearance of, preoperative planning, 882(ab)
Scientific publications, self-censorship and terrorism, 24N(3)
Scintigraphy
brain death, procedure guidelines for, 846
dedicated animal pinhole, gastric emptying in mice, 1099

rate of gastric emptying, 303(ab)
^{99m}Tc aprotinin, in amyloidosis, 177
Scintillation camera
with converging collimator, for high-resolution imaging, 1010(ab)
regional left ventricular function, dynamic myocardial phantom, 1037(ab)
Scintimammography
breast phantoms, small field of view camera, 1028(ab)
cadmium zinc telluride detector for, 602
pinhole incomplete circular orbit, 583, 594
^{99m}Tc DMSA, lead shielding, benign and malignant breast disease, 1380(ab)
tumor localization, ^{99m}Tc MIBI, vs MRI, 1394(ab)
Seizures, 3D positioning of focus, fusion image using VRML, 954(ab)
Semiconductor detectors
handheld intraoperative imaging probe, 1008(ab)
portable gamma camera with, sentinel node imaging, 1005(ab)
using CdZnTe, performance evaluation, 1003(ab)
Semiquantitative analysis, accuracy and reproducibility of SUV, image acquisition, reconstruction and ROI effects, 936(ab)
Sentinel node imaging
biopsy by subareolar injection, lymphoscintigraphy comparison, breast cancer, T0409(ab)
breast, ultrafiltered sulfur colloid use in, 408(ab)
breast cancer, 1232
mapping for clinical staging, 410(ab)
periareolar injection technique for, 409(ab)
peritumoral vs periareolar injection, 411(ab)
dyes and serum protein reactions, 1540(le)
eZ-scope hand-held gamma camera, multicenter experience, 1007(ab)
gamma camera, semiconductor detector with, 1005(ab)
gastric and colonic, ^{99m}Tc DTPA-mannosyl-dextran, pigs, 1677
high sensitivity gamma camera for, staging of cancer, 1006(ab)
internal mammary, visualization rates during lymphoscintigraphy, 1387
intraoperative, breast cancer, 407(ab)
laparoscopic radioguided, with Lymphoseek, stomach and colon, 308(ab)
lymphoscintigraphy and, gastric cancer, 1360(ab)
lymphoscintigraphy for, hybrid SPECT/CT system, 1413
lymphoseek in, 42N(9)
melanoma
prognosis value, 548(ab)
prognostic implications, 558(ab)
multifocal or multicentric breast cancer, 7
navigation surgery, gynecologic malignancies, 1446(ab)
pelvic, prostate cancer, 191(ab)
PET and, oral cancer, 54N(6)
radioguided biopsy, non-small cell lung cancer, 562(ab)
^{99m}Tc MSA as receptor binding agent for, 1130(ab)
^{99m}Tc tin colloids, esophagogastric cancer, 68(ab)
Serotonin receptors
decreased binding, anorexia nervosa patients, 163
estrogen-induced changes, PET and, 41N(10)
measurement, diabetes and depression, 896(ab)
medial temporal lobe, density, in Alzheimer's disease, 222(ab)
^{18}F MPPF binding, rat hippocampus, 1495
Serotonin transporters
availability measured with ^{123}I CIT SPECT, 220(ab)
brain, ^{18}F-labeled radioligand, 604(ab)
^{11}C DASB as a ligand for, brain, 218(ab)
diarylsulfide PET imaging agent, 153(ab)
^{123}I FEZIENT as imaging agent, 1050(ab)
imaging agents, PET, 603(ab)
improved preparation of ^{123}I ADAM, 325(ab)
improved radioligand for, PET, 1890
long-term use of ecstasy effects, brain PET, 375
microPET imaging, ^{11}C ZIENT, 605(ab)
midbrain, Parkinson's disease, ^{123}I β-CIT SPECT study, 870
new PET radiotracer for, 1049(ab)
PET tracer ^{11}C DADAM, human brain, 219(ab)
quantification, ^{11}C DASB PET parametric imaging, 35(ab)
Serotonin, modifications, MDNA abusers, 895(ab)
Severe adult respiratory syndrome (SARS), nuclear medicine in Toronto, 13N(6)
Sigma receptors
brain, ^{18}Fas ligand for, conscious monkey, 223(ab)
estrogen regulation of, hippocampus, rat, 224(ab)
Signal detection, modular gamma camera, 58
Sincalide
availability, 33N(1)
comparison with pharmacy-compounded CCK-8, gallbladder function, 499
oral corn oil emulsion as an alternative, cholescintigraphy, 139(ab)
Skeletal muscle, glucose utilization, static FDG PET, 1592
Skin cancer, FDG PET evaluation of, 1440(ab)
Skin, melanoma, lymphatic drainage in, 570, 1871(le)
Smallpox web site, 24N(2)
Society of Nuclear Medicine–Technologists Section (SNM-TS)
greetings from SNM-TS President, 13N(1), 39N(7)
nuclear cardiac imaging book, 19N(9)
president's report, 38N(6)
rapid change in, 1N(11)
Society of Nuclear Medicine (SNM)
Annual Meeting, 30N(9)
PET on display, 24N(7)
Committee on Education, 25N(1)
Computer and Instrumentation Council (CalC), 19N(10)
highlights as history: 1977, 35N(1)
highlights as history: 1978, 15N(2)
highlights as history: 1979, 12N(3)
highlights as history: 1980, 30N(4)
highlights as history: 1981, 16N(5)
highlights as history: 1982, 40N(6)
highlights as history: 1983, 33N(7)
highlights as history: 1984, 20N(9)
highlights as history: 1986, 20N(12)
Highlights Lecture, 2003, 11N(8)
honoring Hutchens, Tyra T., founder, 47N(8)
leadership update, 25N(9), 28N(12), 32N(10), 34N(6), 36N(11), 40M(7), 50N(8)
message from the Executive Director, 16N(1)
message from the President, 38N(7)
Mid-winter educational symposium, 2004, 19N(11)
Mobile Coach, 32N(11)
past president Maynard named to NIBIB Advisory Council, 18N(2)
PET learning center, 30N(7)
Physician Outreach Program, 25N(4)
president's report, 36N(6)
Radioimmunotherapy Project for chapters, 16N(9)
50th Annual Meeting: A preview, 34N(4)
Sodium iodide symporter
contributions on, 1707(le)
glioma tumor cells expressing, ^{211}At astatide and ^{131}I iodide, 1827
tracking gene transfer and expression, non-invasive strategy, 1322(ab)
Soft-tissue tumor, cartilaginous, ^{201}Tl chloride for histological gradings, 1436(ab)
Somatostatin receptor imaging
clinical impact of, paragangliomas of head and neck, 1767
depreotide
evaluation of breast cancer, 555(ab)
low-grade lymphoma, 1496(ab)
detection of liver metastases, from gastroenteropancreatic neuroendocrine tumors, 359
^{68}Ga DOTATOC PET
follow-up of irradiated meningioma, 381(ab)
kinetic analysis, 880(ab)
hilar and mediastinal lymph nodes, ^{99m}Tc DEP, lung cancer, 440(ab)
^{111}In D-Glu1-minigastrin, comparison to ^{111}In pentetreotide, 238(ab)
^{111}In DTPA octreotide, cervical cancer, 1299(ab)
^{111}In DTPA uptake, 1315
^{111}In octreotide SPECT/CT, 236(ab)
prognosis determination, lung cancer, 1402(ab)
staging-restaging, pediatric tumors, 1244(ab)
suitable PET tracer for, 233(ab)
^{99m}Tc depreotide
detection of bone lesions in lung cancer, 1372(ab)
pulmonary nodule, 1268(ab)
^{99m}Tc depreotide uptake, non-Hodgkin's lymphoma, 1495(ab)
^{99m}Tc EDDA/HYNIC-TOC, non-medullary thyroid cancer, 1375(ab)
^{90}Y SMT487, neuroendocrine tumors, 1556
^{99m}Tc EDDA/HYNIC-TOC vs ^{111}In DTPA-octreotide, 708
^{99m}Tc P829, Graves' disease patients, 1547
SPECT
acceleration in flight and, 36N(5)
acquisition, use in V/Q scans, 1265(ab)
acquisition orbit effects, 993(le)
asialoglycoprotein receptor imaging, ^{99m}Tc GSA, liver, 475
assessment of cardiac mass and geometry, 42N(12)
assessment of cognitive dysfunction, after CABG, 41N(1)
attenuation map in, 291
blood-pool, assessment of diastolic function, 736(ab)
brain perfusion, correction for partial volume effect, healthy men, 1243
breast phantoms, small field of view camera, 1028(ab)
cardiac status in SLE, 34N(5)
cerebral blood flow, in vascular dementia with small vessel disease, 505, 1874(le)
cognitive-linguistic predictions, frontotemporal dementia variants, 832(ab)
data-driven motion correction, 206(ab)
decreased serotonin receptor binding, anorexia nervosa, 163
dobutamine stress, myocardial ischemia and, 49N(4)
dual isotope, fast Monte Carlo simulation of the cross-talk in, 208(ab)
dual-isotope, feasibility after acipimox administration, 140
ECG-gated
cardiac functional recovery, 753(ab)
left ventricular function, 724(ab)
FDG with acipimox, assessment of myocardial viability, diabetes effects, 877
gamma camera, avalanche photodiode for use in, 1004(ab)
gated
attenuation correction in diagnostic accuracy of, 357(ab)
calculated of ejection fraction, 657(le)
digital scintillation camera, regional left ventricular function, 1037(ab)
filtered backprojection and iterative reconstruction, 178(ab)
left ventricular apical functional abnormalities, 766(ab)
pinhole collimator, living rat, 993(ab)
gated blood-pool
biventricular dynamic physical phantom, 967
left ventricular ejection fraction and volumes from, 494
high-resolution multi-pinhole, animal imaging system, 28(ab)
high-resolution small animal, FASTSPECT II, 525(ab)
^{123}I β-CIT, serotonin transporters in midbrain, Parkinson's disease, 870
^{123}I FP-CIT, dopaminergic neurotransmission, 839
^{123}I PE21, dopamine transporters in Parkinson's disease, 663
^{131}I tositumomab tumor dosimetry, previously untreated lymphoma, 457
ictal, pediatric epilepsy and, 30N(2)
ictal studies, basal ganglia or thalamic activation effects, 1379
^{111}In oxime labeled cells, imaging of myocardial infarction, 710(ab)
low-energy, LSO panel detectors, 452(ab)
lung, tomographic evaluation, 1543(le)
lung perfusion, coregistration image of ^{99m}Tc MAA, 190(ab)
Mini-Mental State Examination and, evaluation of Alzheimer's disease, 56N(6)
multi-pinhole collimation, cardiac imaging, 205(ab)

PET and, assessment of depression, 47N(7)
PET and magnetic field, in epilepsy, 41N(10)
pinhole
mechanical and electronic shift effects, 1036(ab)
^{111}In labeled lymphocyte gut homing, IBS, 140(ab)
pinhole collimators, estimation of geometrical parameters in, 23(ab)
pinhole incomplete circular orbit, mammotomography, 583, 594
planar uniformity measurement application in, 994(ab)
posterior cingulate cortex, blood flow reduction, Alzheimer's disease, 826(ab)
postop radiotherapy planning, in gliomas, 41N(1)
prefrontal perfusion changes, after cerebral infarction, 867(ab)
primary progressive aphasia, bilateral temporal lobe involvement in, 1013
quantitative
iterative reconstruction methods, 734(ab)
multiple-energy iterative reconstruction algorithm, 210(ab)
skeletal kinetics for ^{99m}Tc MDP, bone scan, 490(ab)
quantitative gated, with ECG gating, preoperative risk stratification, 385
quantitative tumor apoptosis imaging with, 51N(11)
resolution recovery in, space-variant convolution and deconvolution, 209(ab)
scatter and attenuation compensation effects, images of nonuniformly distributed brain activities, 512
simulation of acquisition in, emission and attenuation maps, 1048(ab)
small animal, pinhole collimator for, dual-isotope study, 524(ab)
statistical parametric mapping study, hydrocephalus, 1884
^{201}T chloride, cartilage invasion by laryngohypopharyngeal cancer, 1434(ab)
^{99m}Tc DTPA, blood-brain barrier, after stroke, 1898
^{99m}Tc MAA, pulmonary perfusion in various lung diseases, 593(ab)
^{99m}Tc MIBI, neoplastic and nonneoplastic brain tumors, 1566
^{99m}Tc MIBI, washout kinetics in parathyroid imaging, 1180(ab)
^{99m}Tc MIBI and ^{201}Tl, differentiation of lung cancer and tuberculosis, 437(ab)
^{99m}Tc tetrofosmin
mediastinal lymph nodes in non-small cell lung cancer, 1219
normal exercise and adenosine imaging, 134
three-headed system, dynamic renal measurements, 371(ab)
^{201}Tl, nitroglycerin effects on myocardial blood flow, 745, 752, 1872(le)
vascular dementia and, 49N(4)
vs perfusion MRI, acute lymphoblastic leukemia, 33N(3)
^{133}Xe, pulmonary function maps, obstructive lung diseases, 1270(ab)
Spectral analysis, ^{166}Ho DOTMP gamma camera imaging, 453(ab)
Spine, skeletal scintigraphy, young patients, 909
Standardized uptake value (SUV)
accuracy and reproducibility of, image acquisition, reconstruction and ROI effects, 936(ab)
comparison of different methods, positron volume imaging, 590(ab)
contrast agent, PET/CT, CT-based attenuation correction, 933(ab)
CT contrast agents-induced, PET emission studies, 732
FDG
breast density and, 1238
filtered backprojection and iterative reconstruction, 200(ab)
head and neck cancer, 1419(ab)
testicular uptake, 465(ab)
FDG PET, solitary pulmonary nodule, 1418(ab)
FDG PET imaging, tonsils, 940(ab)
FDG urine excretion, different physiological conditions, 1415(ab)
partial volume correction impact, small malignant lung nodules, 926(ab)
partial volume effect corrections, tumor uptake in PET, 125(ab)
partial volume effects, dedicated PET scanners, 985(ab)
protein synthesis rate comparison, L-1-C^{11} tyrosine in laryngeal cancer, 341
solitary pulmonary nodules, FDG PET, 914(ab)
variation, with time after injection, FDG in breast cancer, 1044
Stem cell transplant, PET and CT in, 41N(10)
Streptavidin
kidney localization of, pretargeting protocols, 1085(ab)
pretargeted radioimmunotherapy, cancer, 400
retargeted radioimmunotherapy, CD20-expressing lymphoma xenografts, 437
Stroke
acute diagnosis, multitracer PET and DW/PW MRI, 533(ab)
neurologic outcome after, ^{99m}Tc DTPA SPECT of blood-brain barrier, 1898
PET identification of viable tissue, 44N(12)
recovery, brain SPECT and, 36N(5)
recovery of function, Xe-SPECT and fMRI reveal dynamics, 536(ab)
unilateral spatial neglect after, neural mechanism of visual attention in, 862(ab)
Strontium-89 chloride, therapy, marrow suppression and palliative pain control, breast cancer, 1472(ab)
Strontium-89, β-emitter, osseous sites with α-emitting ^{223}Ra, 252
Subarachnoid hemorrhage, vertebrobasilar vasospasm after, brain SPECT and TCD correlations in, 537(ab)
Sulfonamide, formation of bonds, dyes and serum protein reactions, 1540(le)
Swedish Medical Societies, David M. Goldenberg honored by, 9N(2)
Sympathetic activity, cardiac, changes in hypertrophic cardiomyopathy, 1612
Sympathetic function, cardiac, aging changes, ^{18}F fluorodopamine PET, 1599
Sympathetic nervous activity, estimation of, ^{123}I MIBG clearance and, 759(ab)
Sympathetic nervous system, ^{11}C MPEG as a radiotracer for, PET, 1121(ab)
Systemic lupus erythematosus (SLE)
brain perfusion SPECT, early detection, 861(ab)
complications, ^{201}Tl prediction of, 44N(10)
PET evaluation of cardiac status, 34N(5)

T

T cells, antitumor response, PET and, 47N(4)
Technetium-99m
adenovirus, reporter gene expression and, 149(ab)
antibody labeling, macrocycle chelate, 1076(ab)
antisense DNA labeled with, cellular accumulation of, mRNA steady-state levels and, 1116(ab)
4-arylpiperidines, cerebral monoamine transporters, 1056(ab)
biotin, radiopharmaceutical models, 1090(ab)
double-stranded small interfering RNAs, cell culture studies with, 1331(ab)
labeling of small biomolecules, bifunctional HYNIC chelators for, 1131(ab)
monoclonal antibodies labeled with, recurrent ovarian cancer and, 40N(9)
phenylpiperidine, radiopharmaceuticals based on, 164(ab)
polymer with galactose residue labeled with, non-viral gene delivery vector, 1129(ab)
preoperative endoscopic, before SLN in non-small cell lung cancer, 44N(7)
SPECT, intrathoracic lesions and, 48N(4)
tertiary amine complex, diagnostic probe for melanoma metastases, 320(ab)
tricarbonyl core, labeling of biomolecules with, 162(ab)
Technetium-99m annexin V
imaging of apoptosis, after photodynamic therapy, 650
single-dose chemotherapy, apoptotic tumor response after, 92
Technetium-99m aprotinin, scintigraphy, in amyloidosis, 177
Technetium-99m carbonyl
bombesin analogs, design and development, 1066(ab)
potential renal imaging agent, 1134(ab)
Technetium-99m CFT, preliminary infection images, 1223(ab)
Technetium-99m ciprofloxacil, prosthetic joint infection, 317(le)
Technetium-99m ciprofloxacin
scintigraphy, septic and sterile osteoarticular diseases, 920
specificity of imaging, 1368(le)
in suspected prosthetic infection, after total knee arthroplasty, 1212(ab)
Technetium-99m depreotide, detection of breast cancer, 1427(ab)
Technetium-99m DMSA
assessment of benign and malignant breast disease, lead shielding in, 1380(ab)
determination of differential renal function, hydronephrosis patients, 1283(ab)
preinvasive breast lesions, comparative studies with MIBI, 413(ab)
renal scintigraphy, prognostic value, 33N(3)
scanning, prediction of renal scarring after urinary tract infection, 1755
Technetium-99m DTPA
diuretic renography, post pyeloplasty patients, 1284(ab)
human serum albumin, hepatic blood flow and asialoglycoprotein receptor, 1207(ab)
renal scintigraphy, after donor nephrectomy, 1286(ab)
SPECT, blood-brain barrier, after stroke, 1898
synthesis and in vivo evaluation, 1112(ab)
Technetium-99m DTPA-mannosyl-dextran, endoscopic administration, gastric and colonic sentinel nodes, pigs, 1677
Technetium-99m EC-ADN, tumor cell proliferation, tumor-bearing rodents, 1078(ab)
Technetium-99m ECD
angiostatin for, angiogenesis imaging, 1082(ab)
brain perfusion SPECT, Alzheimer's disease, 37(ab)
brain SPECT, in mild traumatic injury, 383(ab)
permanent magnetic stimulation, brain, 821(ab)
radionuclide angiography, compromised cerebral perfusion in congestive heart failure, 182(ab)
SPECT
acetazolamide stress test comparison, 865(ab)
statistical parametric mapping, Parkinson's disease, 850(ab)
Technetium-99m EC-DG, assessment of tumor growth, 1071(ab)
Technetium-99m EC-DOX, marker of MDR to doxorubicin, 1084(ab)
Technetium-99m EC-Guan, tumor imaging using, 1067(ab)
Technetium-99m EC-metronidazole, intracoronary infusion, myocardial uptake, chronic CAD, 508(ab)
Technetium-99m EC-TML, targeting of fatty acid metabolism, 1077(ab)
Technetium-99m EDDA/HYNIC-TOC, comparison with ^{111}In DTPA-octreotide, somatostatin receptor-expressing tumors, 708
Technetium-99m exametazime, leukocytes labeled with, lysis and dilution effects, 1138(ab)
Technetium-99m glucarate, SPECT, ischemic preconditioning in rat hearts, 705(ab)
Technetium-99m GSA, SPECT, liver asialoglycoprotein receptor, 475
Technetium-99m HDP, bone uptake, before and after ^{153}Sm EDTMP or ^{186}Re-HEDP, 247
Technetium-99m HMDP, accumulation, femoral bone metastases, 560(ab)
Technetium-99m HMPAO
brain perfusion SPECT, vascular reserve, 868(ab)
cerebral blood flow, chronic pain patients after transcutaneous electrical nerve stimulation, 820(ab)
^{123}I IPT and, dual isotope brain SPECT, Parkinson's disease, 851(ab)
liposomes and microparticles for delivery of, Peyer's patch, 1139(ab)
liposomes labeled with, PEG effects on biodistribution of, 323(ab)

SPECT
brain death and, 33N(5)
cerebral perfusion in delirious patients, 836(ab)
monitoring of pediatric encephalitis, 827(ab)
white blood cell labeling with, 657(lc)
Technetium-99m HSA, SPECT, cerebral protein transudation, cluster headache patients, 538(ab)
Technetium-99m HYNIC, Mag3 and, radiolabeling of annexin V, comparison, 1115(ab)
Technetium-99m IL-8
kinetics
experimental inflammation and infection, 1502
infection/inflammation imaging, 499(ab)
Technetium-99m LSA, imaging galactose receptor, liver, 1117(ab)
Technetium-99m MAA, perfusion SPECT, coregistration image of, 190(ab)
Technetium-99m MAG3
abnormal renal scans, potential renal donors, 467(ab)
clearance, Bayesian 3-compartment model for, 1357
diuretic renography, suspected renal obstruction, 1289(ab)
MORFS, amplification targeting, 1295(ab)
supranormal function and renogram patterns, ureteropelvic junction obstruction, newborns, 725
Technetium-99m MDP
bone scintigraphy
comparison with ^{201}Tl scanning, 600(ab)
thoraco-lumbar compression fractures, 485(ab)
fracture healing, outcome of fracture shaft femur, 486(ab)
measurement, validation of ultrafiltration, 891
open-mouth bone scintigraphy, condylar hyperplasia and temporomandibular arthritis, 487(ab)
total body flow, hyperemic breast lesion, 1443(ab)
3-phase bone scintigraphy, prediction of outcome of distraction osteogenesis, 369
Technetium-99m MIBI
accumulation, femoral bone metastases, 560(ab)
accuracy, primary hyperparathyroidism, 473(ab)
brain SPECT, survival analysis in glioma, 870(ab)
coronary flow reserve index measured by, during vasodilation, 288(ab)
gated SPECT, left ventricular ejection fraction measurements, 344(ab)
multidrug resistance-associated protein pump, in lung cancer, 1442(ab)
myocardial SPECT, viability in chronic myocardial hibernation, 287(ab)
predictor of therapy response, osteosarcoma, 1394
scintigraphy, regional lymph nodes in melanoma patients, 1561
scintimammography, contrast-enhanced MRI comparison, suspected breast cancer, 1373(ab)
SPECT
detection of cervical LN metastasis in head and neck cancer, 1395(ab)
diagnosis of parathyroid adenoma, 904
intracerebral hematoma, neoplastic and nonneoplastic, 1566
uptake, patients with suspected breast cancer, 1384(ab)
Technetium-99m MORFs, cytosine-free, in pretargeting, 1070(ab)
Technetium-99m MSA, receptor binding agent for sentinel node imaging, 1130(ab)
Technetium-99m nitride complexes, novel heart imaging agents, 806
Technetium-99m N-NOET
intrinsic washout, myocardial perfusion imaging, 1092
verapamil effects, normal or ischemic canine myocardium, 981
Technetium-99m NOET
calcium antagonists effects, myocardial uptake, 505(ab)
gated SPECT, left ventricular ejection fraction and volumes, 280(ab)
lung uptake of, increased smoking effects, 506(ab)
Technetium-99m NT-XI, radiolabeled neurotensin analog, ductal pancreatic adenocarcinoma, 1649
Technetium-99m peptide conjugates, detection of pulmonary infection, 1118(ab)
Technetium-99m pertechnetate
diagnosis of ectopic gastric mucosa, 1209(ab)
whole-body scan, differentiated thyroid cancer, 1195(ab)
Technetium-99m phage, specific imaging of infection, 1124(ab)
Technetium-99m P829, sequential SPECT, specificity of, 1361(ab)
Technetium-99m RGD, constrained peptide, clot imaging, 163(ab)
Technetium-99m sestamibi
in breast cancer, 42N(9)
demonstrating active myeloma, 1484(ab)
dynamic scintigraphy, assessment of pancreas transplant, 134(ab)
myocardial SPECT, combined prone and supine acquisitions, 1633, 1641
protocols for stress injection, myocardial count statistics, 725(ab)
scintigraphy
bone marrow involvement in Gaucher's disease, 1253
parathyroid surgery, 1443
SPECT, left ventricular ejection fraction after reperfused acute MI, 761(ab)
Technetium-99m SM3, in adnexal masses, 45N(7)
Technetium-99m Sulesomab, mechanism of accumulation, inflammation, 11
Technetium-99m sulfur colloid
high specific activity of, for lymphoscintigraphy, 327(ab)
intestinal perforation study, gamma probe use in, 307(ab)
sentinel node localization, breast cancer, 7
uptake, focal nodular hyperplasia on CT/MR, 135(ab)
Technetium-99m Tc-carbonyl-TBI, myocardial perfusion imaging, 1123(ab)
Technetium-99m teboroxime, ^{201}Tl adenosine stress myocardial SPECT and, quantitation of, 507(ab)
Technetium-99m technegas, V/Q lung scintigraphy, diagnosis of pulmonary embolic disease, 1262(ab)
Technetium-99m tetrofosmin
comparison with RNA, left ventricular dysfunction, 741(ab)
FDG and, dual-isotope SPECT after acipimox administration, 140
gated SPECT
comparison with radionuclide ventriculography, 742(ab)
left ventricular aneurysms, 752(ab)
gated SPECT with, perfusion interpretation and, 735(ab)
metabolism-perfusion mismatch, myocardium, 33, 40
myocardial perfusion imaging, revascularization by, 11(ab)
perfusion imaging, transient ischemic dilatation, 744(ab)
prediction of response to chemotherapy, osteosarcoma patients, 1437(ab)
prognostic value, in coronary artery disease, 8(ab)
pulmonary tuberculosis, 1215(ab)
reduced syringe binding of, radiopharmaceutical injection, 1148(ab)
SPECT
acute chest pain evaluation protocol with, 354(ab)
ECG changes in chronic respiratory disease patients, 325
mediastinal lymph nodes in non-small cell lung cancer, 1219
overactive parathyroid gland, 1179(ab)
visualization of interscapular brown adipose tissue, pediatric patients, 1582
Technetium-99m TRODAT-1
dopamine transporter, Parkinson's disease, 844(ab)
SPECT, ^{18}F FDOPA PET crossover study, Parkinson's disease, 999
^{123}I IBZM simultaneous dual-isotope SPECT, Parkinson's and vascular Parkinsonism, 860(ab)
Technetium-99m WBC, biological markers and, in inflammatory bowel disease, 1586
Temporal lobe, blood flow in, in transient global amnesia, 819(ab)
Testicular cancer
chemotherapy response monitoring, FDG PET, 427(ab)
FDG, postchemotherapy residual mass evaluation, 1397(ab)
seminoma, FDG for management of, 567(ab)
timing of radioimmunotherapy and, 41N(1)
Thalamus
activation, in seizure foci localization, ictal SPECT studies, 1379
quantification of dopamine receptors with ^{18}F DMFP, 109
Thallium-201
bone and soft tissue activity, tumor type effects, 239(ab)
cardiac SPECT, left ventricular function, 176(ab)
dynamic MRI comparison, tumor blood flow, musculoskeletal tumors, 1454(ab)
dynamic scan, bone and soft-tissue tumors, 923(ab)
gated SPECT, global left ventricular function, 155
scintigraphy, nonobstructive hypertrophic cardiomyopathy, 1717
SLE complications, 44N(10)
SPECT
inflammatory demyelinating disease, 565
left ventricular aneurysms, 752(ab)
myocardial flow reserve, coronary artery bypass graft, 732(ab)
oxygen-enriched breathing effects, 514(ab)
recurrent glioma, 44N(10)
stress-redistribution, in ischemic heart disease, 277(ab)
thoracic lesions, 540
SPECT cartilage invasion by laryngohypopharyngeal cancer, 1434(ab)
vs ^{131}I whole body scans, follow-up after thyroidectomy, 1200(ab)
Thallium-201 chloride, histological gradings, cartilaginous tumor, 1436(ab)
Three-dimensional volume imaging, LSO based clinical PET scanner, 1014(ab)
Thrombocytopenia, red marrow absorbed dose, radioimmunotherapy patients, 67
Thrombosis
guided therapy, copolymers for, T1132(ab)
^{99m}Tc RGD constrained peptide for imaging, 163(ab)
Thymidine, proliferation tracer uptake patterns, 2027
Thyroglobulin
highly sensitive assay, for thyroid cancer, 1166(ab)
increase after rhTSH administration in, in thyroid cancer, 1463(ab)
levels, success of thyroid remnant ablation and, 133(ab)
Thyroid cancer
after thyroidectomy, pre-treatment scan with ^{131}I, 299(ab)
differentiated
cell membrane metabolism, FDG uptake and, 255(ab)
children and adolescents, 1242(ab)
FDG CoDe with dual head SPECT, 553(ab)
follow-up after thyroidectomy, 1200(ab)
^{131}I therapy for, 570(ab)
^{131}I therapy to ablate the remnant in, 476(ab)
^{131}I whole-body scan, 1379(ab)
maximal safe administered dose of ^{131}I therapy, 571(ab)
prognosis after redifferentiation therapy with isotretinoin, 1460(ab)
radioactive iodine treatment, effects on gonadal function, 1176(ab)
radioiodine therapy, therapeutic outcome, 1461(ab)
radioiodine negative metastases of, management, 1423(ab)
serial scans after ^{131}I therapy, 1462(ab)
SPECT and CT fusion, 1905
^{99m}Tc pertechnetate whole-body scan for, 1195(ab)
Tg-positive and ^{131}I WBS negative, 1458(ab)
thyroglobulin-positive whole-body scan negative, 1194(ab)
FDG PET, 552(ab)
follicular level, Monte Carlo dose calculation for, 492(ab)
functioning pulmonary metastases of, radioiodine effects on prognosis, 474(ab)
highly sensitive thyroglobulin assay for, 1166(ab)
hTg levels, functional imaging results and, 1193(ab)

Hürthle cell, FDG PET in, 1402
^{123}I Na whole-body imaging in surveillance, 301(ab)
incidentaloma, FDG PET detection, 1416(ab)
iodine deficiency in, Russia, 45N(10)
iodine-negative, isotretinoin for treatment of, 572(ab)
medullary
FDG PET for detection, 1417(ab)
^{111}In DTPA-D-Glu1, FDG PET and CT comparison for, 551(ab)
metastasized, ^{111}In D-Glu1-minigastrin diagnosis, 448(ab)
^{90}Y DOTATOC targeted therapy, 444(ab)
metastatic differentiated, radioactive iodine treatment, 451, 2039(le)
microcarcinoma, 1181(ab)
monitoring after ablation, incidence of whole-body scan positive, 132(ab)
non-medullary, ^{99m}Tc EDDA/HYNIC-TOC somatostatin receptor imaging, 1375(ab)
papillary
gene expression patterns in, 130(ab)
lymph node metastases, 1177(ab)
lymph node metastases and, treatment, 1188(ab)
redifferentiation therapy, 1457(ab)
progressive, ^{111}In octreotide in, 44N(7)
radioiodine ablation therapy, fractionated doses, 1459(ab)
radioiodine concentrating activity, expressing sodium/iodide symporter gene, 1197(ab)
radioiodine therapy, rhTSH stimulation before, 1065, 1069
rhTSH administration in, thyroglobulin increase after, 1463(ab)
successful thyroid remnant ablation, defined by thyroglobulin levels, 133(ab)
well-differentiated, body retention of ^{131}I and, 898
whole-body imaging, ^{123}I scintigraphy, 852(le)
Thyroid disease, cerebral blood flow in, response to therapy, 475(ab)
Thyroid gland
FDG activity in, whole-body PET imaging, 1196(ab)
incidental uptake of FDG, whole-body PET, 1174(ab)
incidentalomas, evaluation with PET/CT, 128(ab)
radioiodide uptake, potential interference, euthyroid rat, 832
stunning, 1194(le)
toxic nodules, ethanol injection plus radioiodine in treatment, 207, 211
visualization, during FDG PET/CT imaging, 1178(ab)
Thyroid remnant, ^{131}I absorbed dose, carbonate lithium and hydrochlorothiazide trial, 300(ab)
Thyroid stimulating hormone
effect on FDG uptake, thyroidal, 1190(ab)
elevated iodine excretion, differentiated thyroid cancer, 1379(ab)
FDG uptake, hypothyroidism effects, 1191(ab)
Thyroid stunning, diagnostic dose of ^{131}I effects, 1182(ab)
Thyroid-stimulating hormone, recombinant human, stimulation, before radioiodine therapy, thyroid cancer, 1065, 1069
Thyrotoxicosis, ^{111}In therapy, combined thyreostatic-thyreomimetic medication, 1198(ab)
Thyrotropin, pretreatment, in ^{131}I therapy for nodular goiter, 40N(9)
Tin-117m(4+)DTPA
bone palliation therapy, 1105(ab)
toxicology studies, mice, 1165(ab)
Tourette's syndrome, ^{123}I IPT SPECT, dopamine transporter density of basal ganglia, 893(ab)
Toxicity, ^{111}In pentetreotide therapy, disseminated neuroendocrine tumors, 1
Tracer kinetic modeling, ^{11}C DASB PET, parametric imaging, 35(ab)
Transmission tomography
segmentation algorithm, 980(ab)
truncation, beam hardening artifacts and, on quantitative PET, 981(ab)
truncation compensation for, combined CT/PET, 970(ab)
tumor motion measurement in 4D, 449(ab)
Transmyocardial laser revascularization, FDG PET, 172(ab)
Transplantation
pancreas, ^{99m}Tc sestamibi for assessment of, 134(ab)
renal
background subtraction in ^{99m}Tc MAG3 renography, 1288(ab)
remaining kidney function of donors, ^{99m}Tc MAG3 assessment of, 468(ab)
vascular endothelial progenitor cells, severely ischemic limbs, 187(ab)
Tuberculosis, radiotracer uptake, active disease or tubercular sequelae, 1215(ab)
Tumor cell proliferation, monitoring, thymidine and thymidine analogs, 2027
Tumor hypoxia
^{64}Cu ATSM compared with FDG, intratumor distribution studies, 254(ab)
^{64}Cu radiotherapy, molecular and cellular response, 1295(ab)
Tumor imaging
abdominal, delayed additional FDG imaging, 1363(ab)
amino acid transporter upregulation, blood-tumor barrier, 1308(ab)
angiogenesis, endostatin and angiostatin for, 1082(ab)
Bcr-Abl kinase activity, novel kinase-specific irreversible ligand for, 1068(ab)
biodegradable nano-sized pullulan derivatives, delivery of radioisotopes, 1087(ab)
bone and soft-tissue, dynamic scan of ^{201}Tl scintigraphy, 923(ab)
cellular uptake of ^{67}Ga, hemochromatosis gene modulation, 943
comparative microPET, FDG and FMISO, animal-specific positioning molds, 378(ab)
CT/PET, misregistration effects on tumor detection, 194(ab)
double reporter gene system, simultaneous nuclear imaging, 156(ab)
endometrial cancer, FDG PET in postoperative follow up, 1369(ab)
^{18}F fluoroacetate for, 1062(ab)
FDG accumulation, chronic inflammatory foci, steroid effects, 253(ab)
FDG and ^{11}C acetate PET, endometrial cancer, 1412(ab)
^{123}I IVACBC, synthesis and evaluation, 151(ab)
iodinated amino acids, comparative biodistribution, 1489
kinase-specific irreversible radioligands, EGFR expression, 1073(ab)
oncology PET, identification of malignant and benign lesions, 949(ab)
ovarian cancer, ^{111}In DTPA-folate as receptor-targeted diagnostic agent in, 700
PET, standardized communication for, 960(ab)
PET/CT, uterine cervical cancer, comparison with PET alone, 1404(ab)
sestamibi and tetrofosmin, identification of MDR in breast tumor, 1307(ab)
^{99m}Tc EC-DG
imaging, dosimetry and acute toxicity with, 1158(ab)
radiosynthesis, biodistribution and planar scintigraphy, 319(ab)
^{99m}Tc EC-DG for assessment of growth, 1071(ab)
unknown primary syndrome, FDG PET, 1301
whole-body, ^{18}F TYR comparison with FDG, 533
whole-body fluorescent, triple modality reporter gene for, 150(ab)
whole-body PET, evaluating quality, 915(ab)
^{89}Zr immuno PET, production of monoclonal antibodies, 1271, 1282
Tumor markers
^{60}Cu ATSM vs pimonidazole, histological comparison, 1306(ab)
FDG PET, positive findings in high CEA levels, 83(ab)
Tumor pretargeting
bispecific antibody
cancer radioimmunotherapy, 1293(ab)
^{99m}Tc labeling, T0887
double-stranded small interfering RNAs, labeled with ^{99m}Tc, 1331(ab)
radioimmunotherapy, GI cancer, 494(ab)
radiolabeled recombinant streptavidin use in, 1085(ab)
scFv-streptavidin for, 576(ab)
Tumor quantitation, differentiation of lung masses, FDG PET, 1445(ab)
Tumor response
annexin therapy, previous treatment effects, 587(ab)
functional volume assessment, SPECT, 1474(ab)
targeted therapy, ^{18}F FLT and ^{18}F FDG MicroPET I, 260(ab)
Tumor staging, ^{18}F FDG PET, radiation therapy, 24, 30
Tumor targeting
adenosine analog, tumor cell proliferation and, 1078(ab)
amplification of, radiolabeled MORFS-proof of concept, 1295(ab)
anti-CEA antibodies, colorectal cancer, 1433(ab)
biodegradable nano-sized pullulan derivatives, delivery of radioisotopes, 1087(ab)
evaluation of peptide P160, 1297(ab)
human sodium/iodide symporter gene enhancement, colon cancer cells, 1321(ab)
^{111}In, genetically engineering constructs, 1079(ab)
peptidomimetics, peptide receptor imaging, 316(ab)
radioiodinated quinazolinone derivative, solid tumors, 1095(ab)
radiolabeled peptides, ErbB relevant tumors, 1081(ab)
Tumor tracers
^{18}F cyclic RGD peptide, PET, 152(ab)
gaseous, impact on dynamic PET and kinetic modeling, small animals, 375(ab)
uptake, mice tumor models, PET and autoradiography, 1302(ab)
Tumor-seeking agents
^{111}I herceptin, *HER2/neu* receptor expression, breast cancer, 1300(ab)
labeled tyrosine kinase inhibitor, imaging EGFR density, 1325(ab)
Tumor-to-normal tissue ratio, substantial improvements, single-chain scFv-streptavidin, 576(ab)

U

Ulcerative colitis, biological markers, ^{99m}Tc WBC scintigraphy, 1257(ab)
Ultrafiltration, use in measuring ^{99m}Tc MDP, 891
Ultrasonography
fine needle biopsy guided by, metastatic thyroid cancer, 1192(ab)
transcranial Doppler, cognitive activation in schizophrenia, 671
Ureteropelvic junction, obstruction, newborns, ^{99m}Tc MAG3 renography, 725
Urinary catheterization codes, CPT clarification of, 20N(3)
Urinary tract infection, renal scarring after, ^{123}I hippuran renal scintigraphy, 1755
Uterine cancer, FDG PET with bladder irrigation in evaluation of, 353

V

Valsartan, with ACE inhibitor, effects on congestive heart failure, 884
Vascular endothelial growth factor receptors, radionuclide imaging, 1069(ab)
Vascular endothelial growth factor (VEGF), in tumor targeting and penetration, 40N(1)
Vasculitis
giant-cell, PET with a coincidence gamma camera, 733(ab)
in polyalgia rheumatica, FDG PET for follow up study, 141(ab)
Vasodilatory capacity, changes, acetazolamide-induced, cerebrovascular disease, 1371
Ventilation/perfusion imaging
combined with stress testing, emergency department patients, 1265(ab)
diagnosis of pulmonary embolus, 1262(ab)
helical CT comparison, pulmonary embolism patients, 592(ab)
high-resolution CT concordance, diagnosis of pulmonary embolism, 1267(ab)

lung
peripheral pulmonary artery stenosis, 1251(ab)
rapid 3D nonlinear, 900(ab)
observer variability, accuracy of different criteria and, 739
prediction of ventilation heterogeneity, children with cystic fibrosis, 1271(ab)
regional, quantification with PET, 1982
regional ratios, measured with radionuclide techniques, 920(ab)
SPECT acquisition in, 1265(ab)
^{99m}Tc MAA and DTPA, silent pulmonary thromboembolism in children, 1261(ab)
Ventilation, high-volume
microvascular permeability lung changes during, rat, 1274(ab)
vs spontaneous breathing, lung injury in rats, 1275(ab)
Verapamil, effects on ^{99m}Tc N-NOET uptake, normal or ischemic canine myocardium, 981
Vesicoureteral reflux
cause of pyelonephritis, cystography for detection, children, 1256(ab)
radionuclide cystography, repeat bladder filling in, 1252(ab)

W

World Federation of Nuclear Medicine and Biology (WFNMB), 13N(5)
international focus, 32N(1)

Y

Yttrium-86
PET imaging with, quantitation by background subtraction, 939(ab)
pharmacokinetics and biodistribution, ovarian cancer model, 1148
2D PET, uniformity and quantitative accuracy, 965(ab)
Yttrium-90
antibodies labeled with, ^{111}In as chemical and biological surrogate for, 1155(ab)
colloid for chronic synovitis of hemophilia, 1481(ab)
colloidal solution of, brain tumors, 871(ab)
dosimetry, ovarian cancer model, 1148
glass microsphere, unresectable metastatic colorectal cancer to liver, 1475(ab)
lanreotide therapy, urinary excretion of, 1466(ab)
monoclonal antibodies labeled with, PET, xenograft-bearing nude mice, 1663
radiopharmaceutical preparation of, 1150(ab)
radioprotection against, measurements or Monte Carlo calculations, 1169(ab)
Yttrium-90 DOTA-hLL2, radioimmunotherapy, non-Hodgkin's lymphoma, 77
Yttrium-90 DOTA, humanized anti-CD22 IgG, non-Hodgkin's lymphoma, 2000
Yttrium-90 ibritumomab tiuxetan, safety data, 50N(6)
Yttrium-90 lanreotide
intrahepatic artery infusions, neuroendocrine tumors, 445(ab)
treatment, metastatic sites of neuroendocrine tumors, 1465(ab)
Yttrium-90 microspheres, in hepatic tumors, 34N(5)
Yttrium-90 octreotide
inhomogeneous radioactivity uptake, renal cortex, dosimetric consequences, 330(ab)
therapy, phase-1 study, neuroendocrine tumors, 443(ab)
treatment, effects of amino acids and, 1464(ab)
Yttrium-90 oxine-ethiodol, liver cancer, 48N(7)
Yttrium-90 SMT487, targeted radiotherapy, in neuroendocrine tumors, 1556